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Foreword
In each year's calendar of scientific events related to drug abuse,
the Annual Scientific Meeting of the Committee on Problems of
Drug Dependence, Inc., is an occasion of outstanding importance.
The membership of the CPDD represents a broad spectrum of exper-
tise that includes pharmacology, clinical medicine, psychiatry,
public health, chemistry, and the social sciences. The Committee
maintains liaison with Government regulatory and research agencies,
with the pharmaceutical industry, with national and international
agencies that are interested in drug dependence and abuse, and with
educational and treatment facilities.
The proceedings of each annual CPDD meeting are a comprehensive
gathering of reports on current research in all aspects of drug
abuse and drug dependence. Topics presented in Problems of Drug
Dependence, 1980 include the effects of drugs on the central ner-
vous system, their pharmacological action, biological disposition,
safety, abuse potential, and clinical usefulness. Annual progress
reports of NIDA-supported dependence studies of new compounds are
included, in addition to the 40 papers presented and 6 papers read
by title at the 42nd Annual Scientific Meeting in Hyannis, Massa-
chusetts, on June 18-20, 1980. There is also an extensive index.
Some of the papers have been condensed by the authors to meet space
limitations of this volume.
In the belief that readers with widely diverse interests will find
this timely review of value, the National Institute on Drug Abuse
is pleased, for the second year, to publish in its Research Mono-
graph series the Proceedings of the Annual Scientific Meeting of
the Committee on Problems of Drug Dependence, Inc.
William Pollin, M.D.
Director
National Institute on Drug Abuse
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Dynorphin
Nathan B. Eddy Memorial Award Lecture
A. Goldstein
It is indeed a very great honor to be chosen as recipient of the
1980 Nathan B. Eddy Memorial Award. Dr. Eddy was one of the truly
great pioneers in the field of opiabe research and, in more ways
than one, my own research owes inspiration to what he contributed
to our field. I have stood here so often before, on the platform
at previous meetings of CPDD, presenting some research finding,
while Dr. Eddy -- right there in the second row -- listened and
took notes. I can remember if one said anything at all that lacked
sufficient experimental evidence or was too speculative, he would
look up suddenly, then scribble more vigorously in his notebook.
And afterwards, in corridor discussion , one would have to defend
one's conclusions against his sharp and perceptive criticisms.
It has been said that if we accomplish anything at all in science,
it is because we can stand on the shoulders of giants. Besides Dr.
Eddy, there have been other giants in our field -- some of them in
this room today -- upon whose shoulders I was lucky enough to
stand. This Committee on Problems of Drug Dependence has played a
role of extraordinary importance in nurturing the environment in
which fruitful concepts and hypotheses about the opiates could
develop. Since I was a product and a beneficiary of that environ-
ment, the occasion of this award seems an appropriate time, and
this meeting an appropriate place, to acknowledge that debt.
Another major influenza in stimulating my early research in the
opiate field was Vincent Dole. His conviction that opiate addic-
tion was fundamentally a biochemical disorder -- a "metabolic
disease"-- had a very great influence on me in the late 1960's.
My clinical interest in heroin addiction was a direct outcome of
what Dr. Dole was saying and doing. But more than that, his view
of the disorder encouraged me to seek the molecular mechanisms of
opiate action, and consequently to develop, in 1971, the concep-
tual approach and practical technique for identifying the opiate
receptors (Goldstein 1971).
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In late 1974 and early 1975, Terenius and Wahlstrom (1974) and the
Aberdeen group (Hughes, 1975) reported that the opiate receptors
really did have endogenous ligands which could be extracted from
brain. Then, at the May 1975 International Narcotic Research
Conference, when the structures of the endogenous ligands from
brain were still unknown, my group reported our discovery of opioid
activity in pituitary extracts. Our first paper (Teschemacher et
al., 1975) described a material from fresh bovine pituitary
glands which had all the properties later shown to characterize
lipotropin- (61-91) , now known as -endorphin. Indeed, when later
in 1975, the sequence of methionine-enkephalin, reported by Hughes
and Kosterlitz and their colleagues (Hughes et al., 1975), proved
to be identical to the sequence 61-65 of -lipotropin, my group, in
collaboration with Dr. C.H. Li, immediately demontrated the
opioid activity of -endorphin (Cox et al., 1976). Simultane-
ously, Smyth's group (Bradbury et al., 1976) published essentially
the same finding.
Our second paper (Cox et al., 1975) dealt with an opioid peptide
obtained from a crude porcine ACTH extract. Its properties were
clearly different from those of -endorphin or any fragment of
lipotropin. It was much more basic, its apparent molecular weight
was only about half as great , its naloxone-reversible inhibitory
effect in the guinea myenteric plexus preparation could not be
washed out as quickly, and its biologic activity was more easily
destroyed by trypsin. Most important of all, its biologic activity
was completely resistant to cyanogen bromide -- a reagent that
attacks methionine residues -- whereas the activity of every
opioid peptide containing mathionine-enkephalin is destroyed by
this reagent. The cyanogen branide result suggested the possi-
bility that this nor- -endorphin-like "slow-reversing endorphin"
might contain leucine-enkephalin, and this turned out to be the
case.
We took a long tine to isolate enough of the new endorphin for
partial sequencing. Fortunately, Drs. Leroy Hood and Michael
Hunkapiller, at Caltech, were perfecting their microsequencing
technology at the same time. When we finally obtained two micro-
grams in a state suitable for sequencing, they had reached the
point where this amount was sufficient. The first 13 residues are
now know with certainty (Goldstein et al., 1979), but there is
some doubt about the next four (we think there are seventeen in
all) . Fortunataly, all the potency of the natural peptide -- and
an extraordinary potency it is -- was displayed by the synthetic
tridecapeptide.
The natural peptide was named dynorphin in recognition of its great
potency (Creek prefix dyn = power). Indeed, dynorphin is in a
class by itself. For example, in the guinea pig myenteric plexus
preparation it is fully 50 times more potent, on a molar basis,
than -endorphin, 190 times more potent than normorphine and 700
times more potent than leucine-enkephalin.
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By removing one residue at a time from the carboxy terminal of
dynorphin-(1-13), my colleague Charles Chavkin was able to ascer-
tain which residues were critically important for the potency,
using the myenteric plexus preparation as an assay.
possible fragments in which the amino terminal Tyr1
All 12
remained
intact were prepared and purified to homogeneity. The results can
be summarized as follows: 1) The -COOH of Lys13 is not required,
as the methyl ester is fully active, and COOH-terminally extended
of Lys13
peptides(like natural dynorphin) retain full potency. 2) Removal
causes a loss of potency but this has been show to be due
to interference by the negatively charged free -COOH on Leu12, and
removal of Leu12 restores potency to nearly that of dynorphin-(1-
13). 3) There are twocritically important basic residues, removal
of which causes major loss of potency; these are Lys11 and Arg7.
Our present picture of the dynorphin receptor is shown in figure 1.
The important point here is that the "alkaloid pocket," occupied by
Tyr-Gly-Gly-Phe, or even the "leucine-enkephalin pocket" occupied
by Tyr-Gly-Gly-Phe-Leu, represents only a small part of the exten-
sive recognition site in this opiate receptor.
The high potency of dynorphin-(1-13) is not restricted to the
guinea pig myenteric plexus preparation, but two properties of the
peptide make it difficult to assess potency accurately in membrane
Fig. 1. Hypothetical model of the dynorphin receptor,
showing the "alkaloid pocket," which accommodates Tyr-
Gly-Gly-Phe, the anionic site accommodating the proto-
nated terminal amino group, and a postulatad H bond
involving the phenolic OH group. There are two addi-
tional anionic sites, critically placed to accommodate
Arg7 and Lys11.
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radioreceptor binding assays. Most important, this peptide (and
natural dynorphin too) is "sticky", i.e., it is adsorbed very
rapidly to glass and plastic surfaces, to the matrix of chromato-
graphic media, and to biological membranes. If a "sticky" peptide
is not vary potent, there is no problem, because relatively high
concentrations will be used, and the adsorptiw losses will be only
a small fraction of the total. However, when a "sticky" peptide is
vary potent, like dynorphin, the major fraction of what is present
may be lost by adsorption. This is illustrated in figure 2. The
radioreceptor binding assay was carried out with neuroblastoma X
glioma NG-108-15 cell membranes, well washed, with 3H-D-Ala2-D-
Leu5-enkephalin as radioligand. At the end of the usual one-hour
incubation at 23º, the amount of dynorphin-(1-13) free in the
aqueous medium was measured by radioimmunoaassay (see below). The
log dose response curve at the right is based on the added
(nominal) concentrations, that at the left upon the measured
(actual) free concentrations. It is evident that the true IC50
(about 200 pM) qualifies the peptide as at least as potent here as
in the myenteric plexus preparation.
Fig. 2. Radioreceptor binding assay with NG-108-15 cell
membranes, showing, at left, the true potency of dynor-
phin-(1-13), based on radioimmunoassay of free peptide
in the supernatant solution, and at right, the apparent
potency based on total added peptide. Most of the added
dynorphin-(1-13) is adsorbed nonspecifically to mem-
branes or to tube walls.
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In order to learn about the distribution of natural dynorphin, it
was essential to develop a good radioimmunoassay (RIA). One of the
rabbits immunized with dynorphin-(1-13) coupled to thyroglobulin
produced a wry sensitive and highly specific antiserum, as illus-
trated in figure 3. We can detect a few fmol of dynorphin-(1-13),
the IC50 is 50 pM final concentration in the 0.3-ml incubation
mixture, and the specificity is outstandingly good, in that
leucine enkephalin is not recognised even at 10 million times the
IC50 of dynorphin-(1-13). Another opioid peptide that contains
leucine endephalin -- -neo-endorphin --
10-4%. Finally, this antiserum,
crossreacts only at about
"Lucia," is indifferent to Tyr1
and also to Lys13, and therefore should recognize both COOH-
terminally and NH2-terminally extended dynorphin pepdides.
Fig. 3. Radioimmunoassay of dynorphin-(1-13) with
"Lucia" antiserum. 125I-labelled dynorphin-(1-13) was
displaced by various concentrations of nonradicactive
dynorphin-(1-13), at left. These are final concentra-
tions in 0.3-ml incubation mixture. Low crossreactivity
with related peptides is shown in curves at right. There
was no detectable crossreactivity with -andorphin (not
shown).
Figure 4 shows an assay of an extract of rat pituitary posterior
lobe after removal of intermediate lobe tissue. The upper graph
shows the parallelism of extract and standard curves, the lower
graph shows the loss of immunoreactivity after treatment with
5
Fig. 4. Dynorphin immunoreactivity in rat pituitary
posterior lobe. Top = pituitary extract (right) and
dynorphin-(1-13) standard (left). Bottom = pituitary
extract treated with papain and with heat-inactivated
papain ("control").
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papain, thus demonstating the peptides nature of the dynorphin
immunoreactivity. In the pituitary, dynorphin is primarily a pars
nervosa peptide.
Gel permeation chromatography in 4 M guanidine hydrochloride re-
veals the presence of two immunoreactive peaks from porcine pitu-
itary posterior lobe. A major peak co-elutes with an -endorphin
marker (MW 1.7 K) , a minor peak co-elutes with a -endorphin marker
(MW 3.4 K) . Similar results are obtained with rat posterior lobe.
Rat brain contains two very similar peaks to those in pituitary,
and also peaks of larger molecular weight, which could be precursor
("pro-dynorphin") peptides.
Rat brain contains immunoreactive dynorphin in many regions, and
the concentration is especially high in spinal cord. The material
in spinal cord does not seem to have a supra-spinal origin, since
immunoreactivity does not decrease below the level of a transec-
tion. My colleague, Dr. Brian M. Cox, has identified inmunoreac-
tive dynorphin in rabbit dorsal root ganglia. Dr. Stanley Watson,
using "Lucia" antiserum and immunohistochemical technique, has
found immunoreactive dynorphin in large cells of rat supra-optic
nucleus, and also in both the myenteric plexus and the submacous
plexus of guinea pig ileum. An interesting question is whether any
or all "leucine-enkephalin" previously localized by immunohisto-
chemistry may in fact 12 dynorphin , since some leucine-enkephalin
antisera do recognize dynorphin-(1-13). In the pars nervosa of rat
pituitary, we have made measurements with sufficiently specific
antisera to be certain that in this tissue, leucine-enkephalin and
immunoreactive dynorphin are both present in about equal amounts.
But we do not yet know if leucine-enkephalin can arise from
dynorphin, as seems to be suggested by the Arg6-Arg7 pair, since
double basic resides are often signals for peptide processing.
Dynorphin is in some ways the long-sought counterpart of -en-
dorphin, namely, a long peptide that attains leucine-enkephalin
instead of methionine-enkephalin at its NH2-terminus. Although
studies with naloxone blockade indicate many highly significant
functions of endorphins, no function has yet been associated with
any particular endorphin . The most important research challenge
of the coming years is certainly to find out which endorphin does
what. Only then will we uderstand the physiologic role of
dynorphin and how it relates to the roles of the other opioid
peptides.
In summary, dynorphin is a very potent opioid neuropeptide with
wide distribution in the central and peripheral nervous systems
and in pituitary. The function of dynorphin have not yet been
studied at all. It is appealing to imagine that opiate addiction
is associated with disturbed regulation of an endogenous opioid,
as I first proposed at a 1973 symposium (Goldstein, 1975). Perhaps
this new endorphin will shed light on the problem of opiate
dependence.
7
For the convenience of those who are interested in the historical
record, I include below, in addition to the references cited in
the text, a chronological annotated bibliography on dynorphin.
All the research described here was supported by grants DA-1199,
DA-7063, and DA-0054 from the National Institute on Drug Abuse.
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gan, B.A. and Morris, H.R. Identification of two related pentapep
tides from the brain with potent opiate agonist activity. Nature
(London) 258: 577-579, 1975.
Terenius, L. and Wahlstrom, A. Morphine-like ligand for opiate
receptors in mammalian brain. Acta Pharmacol Toxicol. 35: 55-59,
1974.
Teschemacher, H., Opheim, K.E., Cox, B.M. and Goldstein, A. A
peptide-like substance from pituitary that acts like morphine. 1.
Isolation. Life Sci 16: 1771-1775, 1975.
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DYNOPHIN: Chronological summary, to June 1980
The discovery of opioid activity in pituitary peptides was
first reported at the Airlie House meeting of the International
Narcotic Research Club in May 1975.
H. Teschemacher, K.E. Opheim, B.M. Cox, A. Goldstein. A
peptide-like substance from pituitary that acts like morphine. 1.
Isolation. Life Sci. 16:1771-1776, 1975.
-- The properties of this substance, extracted from fresh
bovine pituitary glands, were those later found to characterize
beta-endorphin (see Cox et al., 1976, above).
B.M. Cox, K. Opheim, H. Teschemacher, A. Goldstein. A
peptide-like substance from pituitary that acts like morphine. 2.
Purification and properties. Life Sci. 16:1777-1782, 1975.
-- The properties of this substance, obtained from a basic
extract of porcine pituitary (crude ACTH), were very different
from the substance described above. The differences from
endorphin and all -endorphin fragments ware the subject of
further publications -- some of which are listed below -- as the
material was purified.
S. Gentleman, M. Ross, L.I. Lowney, B.M. Cox, A. Goldstein.
Pituitary endorphins. In Opiates and Endogenous Opioid Peptides,
H.W. Kosterlitz, Ed., Elsevier/North Holland, Amsterdam, 1976, pp.
27-34.
M. Ross, T.P. Su, B.M. Cox, A. Goldstein. Brain endorphins.
In Opiates and Endogenous Opioid Peptides, H.W. Kosterlitz, Ed.,
Elsevier/North Holland, Amsterdam, 1976, pp. 35-40.
-- These two papers describe further the properties of the
non endorphin opioid peptide in pituitary, and demonstrate its
presence also in brain. Outstanding characteristics were : (1) its
strong basicity, which could only be accounted for by Arg residues;
(2) its resistance to cyanogen bromide treatment, indicating it
does not contain a critical Met residue, and suggesting, there-
fore, that it might contain Leu-enkephalin; (3) its sensitivity to
tryptic digestion, which was greater than that of -endorphin; (4)
its apparent molecular weight, only about half that of -endor-
phin; (5) the slow reversal of its activity in the myenteric plexus
preparation upon washing.
B.M. Cox, S. Gentlemen, T.P. Su, A. Goldstein. Further
characterization of morphine-like peptides (endorphins) from
pituitary. Brain Res. 115:285-296, 1976.
-- Further purification, confirmation of the strong basicity,
and indication that the non- -LPH endorphin is degraded by brain
membranes.
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L.I. Lowney, S.B. Gentleman, A. Goldstein. A pituitary
endorphin with novel properties. Life Sci. 24:2377-2384, 1979.
-- "Slow-reversing endorphin", purified further but still not
to homogeneity. Demonstration of predominance of this material in
posterior (neurointermediate) lobe of beef pituitary.
A. Goldstein, S. Tachiban, L.I. Lowney, M. Hunkapiller, L.
Hood. Dynorphin-(1-13), an extraordinarily potent opioid peptide.
Proc. Nat. Acad. Sci. USA 76:6666-6670, 1979.
-- Sequence through 13 residues (YGGFLRRIRPKLK), demonstra-
tion that synthetic dynorphin-(1-13) is about as potent as natural
dynorphin - in myenteric plexus preparation 190 times normor-
phine, 50 times -endorphin. Information about bahavioral effects
in rats, and rapid degradation in contact with brain membranes or
in vivo.
V.E. Ghazacossian, C. Chavkin, A. Goldstein. A specific
radioimmnoassay for the novel opioid peptide dynorphin. Life
Sci. 26:75-86, 1980.
-- Sensitive RIA (IC50 17 fmol per assay tube), no cross-
reactivity with Leu-enkephalin at 20 million times the concen-
tration. Major losses of dynorphin-(1-13) by adsorption to glass
and plastic surfaces.
A. Goldstein, V.E. Ghazarossian. Immunoreactive dynorphin in
pituitary and brain. Proc. Nat. Acad. Sci. USA In press, 1980.
-- Application of the RIA to determination of immunoreactive
dynorphin in rat, porcine, and bovine pituitary, and in rat brain
and spinal cord. Immunoreactive dynorphin is concentrated pri-
marily in parsnervosa of pituitary. It is also widely distributed
throughout the central nervous system.
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Increasing Life Span; Changing
Disease Patterns; Changing Life
Styles: The Role of Government
J. L. Steinfeld
As you meet this year to discuss problems of drug de-
pendence, I thought it might be useful to review briefly
the changing health problems in the United States.
As the nation was born, the major health problems were
yellow fever, smallpox, scurvy, dysentery, malaria,
puerperal fever and childhood diseases occurring in
epidemics. The United States, through first the Marine
Hospital Service and later the United States Public
Health Service, played a major role in improving nutri-
tion, food and water supplies, sanitation, excretion
disposal, and discovering and implementing immuniza-
tion practices.
If we are not to repeat history, we must be familiar
with it. The Commissioned Corps of the PHS, threatened
with extinction just a decade ago for having outlived
its usefulness, is thriving again with the National
Health Service Corps, Center for Disease Control,
National Institutes of Health, and Alcohol, Drug Abuse,
and Mental Health Administration among other units.
A similar period in the preceding century was tumul-
tuous just prior to and during the Civil War, when
marine health and hospital officers were appointed
politically by local Customs officials from the
Treasury Department, and the physicians so appointed
were accused of performing faulty examinations on
Union soldiers and others, thus permitting escape from
military duty for payment of legal tender at the time.
Following the Civil War, during which the Marine
Hospital System was neglected, Congress, after a
national study debated many recommendations and then
in 1870, federalized the Marine Hospital System and
set up a para-military organization for the Marine
Hospital Service with physicians appointed to a uni-
formed service after passing a competitive qualifying
11
examination, with a Surgeon General as its Chief.
President Ulysses S. Grant appointed Dr. John M.
Woodworth, hero of General Sherman's march through
the South, as the first Surgeon General. I want to
emphasize that it was over a century ago that the U.S.
saw the ending of a politically appointed national
health corps, and the beginning of a quasi-independent
professional group of health officials. There was
another rupture following World War I, again politi-
cally inspired, which led to the creation of the
Veterans Administration Hospital and health disability
programs.
The Public Health Service's job was clearly cut out
for it after the Civil War -- as U.S. citizens moved
westward to the Pacific and the country absorbed many
thousands of immigrants. Health status in the United
States improved slowly, such that a child born around
the turn of the century (1900) could expect to live
47 years. Currently the expectation at birth is 73
years. Most of this increase in longevity occurred
between 1900 and 1950, resulting from decreased child-
hood deaths from infections and parasitic diseases.
Since 1950 approximately five years have been added
to life expectancy at birth and some of this recent
increase results not only from antibiotics and im-
proved technology other than drugs, but also results
from a decreased death rate from cardiovascular dis-
orders including hypertension and stroke in middle
age (particularly true since 1966).
Life expectancy in the United States is not the highest
in the industrialized world, but is respectable. The
period 1975-1980 provides some fascinating vital sta-
tistics. There are 105 male babies born for every
100 female babies. By age 20-24, the ratio is 100
to 100 and that male increase in mortality is deter-
mined more by life style characteristics than suscept-
ibility to disease; i.e., males have higher mortality
from accidents, including automobile accidents,
suicides, homicides, and accidental drug overdoses.
By age 65 there are 79 men living for every 100 women
and by age 85, there are only 47 men for every 100
women!! A male born in 1976 could expect to live 69
years and female 76 years.
Among young adults, violent deaths account for 75% of
deaths among the 15-24 year age group. One half of all
deaths from ages 5 to 14 years and 25 to 34 years are
the result of violence.
With an increasing life span, no longer dominated by
infectious diseases and epidemics, heart diseases
and cancer account for 60% of all deaths over age 35,
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followed by a rising toll from chronic pulmonary
diseases.
What do all these dry statistics have to do with drug
dependence? I have been speaking of quantity of life--
not quality of life. Certainly, government programs
of the past century including immunization, sanitation,
regulation of water and food and drug supplies have
contributed significantly to the increased quantity
of life we enjoy. And, government has been successful
in these programs because the average citizen could
remain relatively passive. Of course, he and his
family had to be immunized, the citizen had to support
water and sewer systems through taxation, as well as
food, drug, and occupational and environmental types
of regulation. But it was not necessary for the citi-
zen to undertake a life-long life style of exercising
regularly, eating an appropriate diet, drinking alcohol
in moderation or not at all and never driving when
drunk, avoiding smoking by never starting or quitting
if an individual had started, not abusing drugs, etc.
In addition to the spectacular hard drug abuse by the
young -- which may be associated with criminal be-
havior -- there is to my mind an equally spectacular
drug abuse by young, middle aged, and old alike in
the field of tobacco, alcohol, and prescription and
mood-altering drugs. As I reviewed the proceedings
of your meetings of the past few years, it occurred
to me that you should include tobacco as an appropriate
subject to study and for an entire section or session
at each of your annual meetings. Tobacco and other
substances of abuse are inextricably intertwined;
certainly, if the executive committees and program
committees had individuals knowledgeable about tobacco
use and abuse, then the sessions would follow. The
tobacco and health field has been relatively neglected
from the point of view of behavioral scientists; but
in terms of overall public health problems, it cer-
tainly is as worthy of study by your group as is heroin
or opium or marijuana. Clearly, our attitudes, mores.
and concerns about the social acceptability of ciga-
rette, pipe, and cigar smoking pervade the scientific
world.
Saturday, June 14, 1980, the New York Times had an edi-
torial complaining that unprecedented supplies of heroin
were on their way to the United States while the Federal
Government had cut funds for drug treatment programs and
needed to get its drug policies in order.
Sunday, June 15, 1980, the Richmond Times Dispatch had
an editorial on "Marijuana Hazards" pointing out that
two national experts, who earlier dismissed warnings
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about marijuana, now have joined a growing group of
physicians and scientists who believe marijuana poses
significant hazards to health.
The Richmond newspapers do not agree that smoking
cigarettes presents health hazards sufficient for
editorial comment. Perhaps that is appropriate, since
Virginia (after North Carolina) produces more tobacco
than any other state. From newspapers, television,
radio, the halls of Congress in Washington, of state
and even local legislatures, it is clear that our
nation is concerned about heroin, other hard drugs, and
marijuana, and our nation is willing to support bio-
logical, chemical, and sociophysiological studies on
these drugs.
ADDITIONAL DATA ON CIGARETTE SMOKING
Approximately 53 million Americans are regular smokers
while over thirty million have quit. Over 90% of
cigarettes now have filter tips, compared with approxi-
mately 1% thirty years ago. In 1980 the average tar
level as determined by the FTC is less than 15 mg
compared with the 25-37 mg tar cigarette of the 1920s,
1930s, and 1940s. The nicotine level is approximately
0.8 - 1.2 mg per cigarette now compared to 2.0 to 2.7
mg nicotine 30 years ago. Nicotine may be the addict-
ing chemical in the cigarette, but additional data
will be necessary to prove the point. These recent
data on relatively low tar and nicotine content ciga-
rettes are for the first quarter of 1980, but give no
information on carbon monoxide, HCN, nitrosamines, or
other toxic or potential toxic compounds in cigarette
smoke. Moreover, the data are for machine-smoked
cigarettes in which the machine takes one 35 ml puff
lasting two seconds per minute. An individual who
takes bigger puffs or puffs more frequently, and
inhales deeply and smokes to a shorter butt length
may, in fact, switch as he is advised to do from a high
tar, high nicotine cigarette to a low tar, low nico-
tine cigarette, and harm himself in the process, if he
alters the way he smokes.
MORTALITY AND MORBIDITY FROM CIGARETTE SMOKING
There is a 70% excess mortality for all U.S. current
male cigarette smokers.
Mortality ratios increase with the amount smoked (2
packs/day leads to an increased mortality ratio of
2.0 rather than 1.7). Mortality ratios increase with
length of time smoked, age at which smoking began,
and increase with depth of inhalation. For the ex-
smoker mortality rates approach that of the non-smoker
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by 7 to 10 years after quitting smoking and are essen-
tially similar to that of the non-smoker after 15 years.
Cigarette smokers have a higher likelihood of develop-
ing either fatal or non-fatal myocardial infarction.
Cigarette smokers have a higher incidence of being
dead on arrival following a heart attack. Cigarette
smokers have more aortic atherosclerosis, more athero-
sclerotic vascular diseases, and more arteriosclerotic
aortic aneurysms. Women smokers also on the pill
(birth control pills) have a marked synergism in their
susceptibility, both to myocardial infarction and to
subarachnoid hemorrhages.
Both men and women smokers have a higher incidence of
cancer of the lung, oropharynx, larynx, esophagus,
urinary bladder, and pancreas than do non-smokers. There
is a dose response relationship between cancer develop-
ment, tar content of cigarettes, years smoked, age
smoking began, depth of inhalation, and certain types
of occupations as well. Since women tended to smoke
filter cigarettes, with lower tar and nicotine content,
and since they appeared to smoke in what we described
10 years ago (for those who couldn't quit) as a less
hazardous way of smoking -- fewer puffs, less inhala-
tion, and leaving a bigger cigarette butt -- it had been
thought that with women smoking the less hazardous prod-
uct in a less hazardous way, perhaps their cancer
incidence would be low. On the contrary -- over the
past 5 to 10 years the rate of increase of lung cancer
in women who smoke in this country shows a slope as
steep as that for the lung cancer epidemic that occurred
in men in the 1930s, 1940s, and 1950s and is now contin-
uing in men, but at a less rapid rate of increase.
One can speculate that the female lung may be more
susceptible to tobacco carcinogenesis. A few
scientists are speculating that the female lung and
trachea and bronchial tree is smaller than the male
and may receive proportionately more of the carcino-
gens. But whatever the theory, there is an epidemic
of lung cancer among smoking women.
Chronic obstructive pulmonary disease (COPD) in the
elderly is extensively associated with long-term ciga-
rette smoking. COPD incidence in both men and women
is rising rapidly and has the beginning characteristics
of the cigarette-induced lung cancer epidemic. Stop-
ping smoking improves symptoms, but there is no evi-
dence of anatomical healing of the lung.
15
In addition to these major diseases, smokers have
significantly more disability days, more days of
hospitalization without overt cancer, heart disease or
COPD, than do non-smokers.
Among the highest risk group is the cigarette smoking
pregnant female -- who even with low tar, low nicotine
filter tip cigarettes continues:
to have babies who weigh an average 200 grams
less and are shorter than non-smokers'babies,
to have a higher placental to birth weight,
to have a statistically significant higher
spontaneous abortion rate,
to have higher perinatal mortality (as high as
100% greater for a high parity, public hospital
status woman with previous low weight births,
and/or anemia, if she is a heavy smoker). Peri-
natal mortality is approximately 10% higher in
upper socioeconomic classes in women with few
children, good nutrition, and good obstetrical
care.
Clearly, what has been advertised as the less hazard-
ous cigarette of the late 70s is still hazardous.
Smoking in this country appears to be class related as
has been clearly demonstrated in the United Kingdom.
However, young girls are beginning to smoke at rates
equal to those of young boys in the 9 to 17 year group.
THE QUIT RATE
Many Americans have received and acted on the health
message that physicians and scientists have communi-
cated to the American people.
Smoking Statistics in the United States
White male 51.5% smokers in 1965 to 36.3% smokers in 1979
Black male 60.8% smokers in 1965 to 42 % smokers in 1979
White female  34.2% smokers in 1965 to 28.2% smokers in 1979
Black female  34.4% smokers in 1965 to 28.9% smokers in 1979
Current data in the United States shows smoking among
adults at 32.3% overall, the lowest level in 45 years.
In contrast, in the depression year of 1935, Fortune
magazine estimated 37.3% of all adults smoked.
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WHAT IS THE ROLE OF GOVERNMENT?
Certainly, if tobacco-containing cigarettes were de-
veloped by a major pharmaceutical manufacturer today
as a vehicle for delivering nicotine or carbon monoxide
or some other chemical to the human lung, it is un-
likely that tobacco-containing cigarettes would be
approved by the FDA.
As matters stand, cigarettes are neither a food nor a
drug and are not subject to regulation by an govern-
mental department, except with respect to advertising,
through the FTC.
My own view is that the government's role is to educate
children and adults about tobacco's hazards, and further,
to do research on the pathophysiology of the multiple
disease processes caused by the over 4800 different
chemicals identified in cigarette smoke.
Where people in a work setting wish pure air, it seems
to me a cooperative arrangement between non-smoking
employees, smoking employees, and/or employer should
be worked out. Failing this, government may need to
step in to protect the rights of the non-smoker, assum-
ing, of course, appropriate legislation is on the
books.
THE ROLE OF PRIVATE GROUPS OF RESEARCH SCIENTISTS
The use or abuse of hard drugs including excess acute
alcohol ingestion leads to immediate and frightening
effects, especially when violent crimes become part
of the drug scene. I am concerned about heroin, opium,
cocaine, marijuana, alcohol, the amphetamines, and
related drugs, just as you are. I am concerned about
the wrecked young lives and the enormous cost to
society.
While the number of heroin and opium abusers is far
fewer than the 5% of our population estimated to be
alcoholics, I remain puzzled why cigarette smoking,
which every year causes 225,000 excess deaths from
cardiovascular diseases, 102,000 excess deaths from
cancer and 19,000 excess deaths from pulmonary disease
(not to mention deaths from fires accidentally set by
burning cigarettes)-- I repeat -- I remain puzzled
why more behavioral scientists are not interested in
this phenomenon. Is it because cigarette smoking was
socially acceptable just a few years ago? Is it be-
cause most of you are ex-smokers, or still smoke, or
because your boss or your spouse or your parents smoke?
Is it because there is no career path for behavioral
scientists interested in the tobacco problem?
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I think all of the above may be true. Very few
dollars are available from the National Institutes
of Health, the United States Government, The Depart-
ment of Health and Human Services, the Office on
Smoking and Health, National Institute of Mental Health,
or any other governmental agency to study this problem
in a comprehensive manner and with support reasonably
well guaranteed over a long period of time assuming
the work is well done.
Perhaps a group such as yours with support from a wide
variety of sources can provide the stimulus -- act
as the catalyst for improving both the quantity and
quality of research in the behavioral sciences regard-
ing smoking as a form of drug dependence. I know your
response -- there aren't any good ideas. My response
would be to point to a number of major scientific
fields where significant available research support
stimulated research, such as in cancer chemotherapy.
The exploding existing field of psychopharmacology may
be similar, although the ideas may have preceded the
funds. If scientists don't ask. the questions, it's
unlikely they'll find the answers.
In the last few years, the National Cancer Institute,
Office on Smoking and Health, and American Cancer Society
convened groups to review the latest data on behav-
ioral aspects of tobacco related research and all are
in agreement that the field is underpopulated and
needs nurture from senior scientists and organizations
concerned with both health research and education.
SUMMARY
Much progress has been achieved over the past twenty
years in informing the American people of the hazards
of cigarette smoking. Over thirty million Americans
have quit smoking cigarettes; many have quit as a re-
sult of social pressure-- cigarette smoking becoming
less socially acceptable. The average cigarette has
less than half as much tar and less than half as much
nicotine as its predecessor cigarettes a quarter
century ago. Moreover, most American cigarettes today
are filtered.
We still do not know why people begin or why they
continue to smoke. I would urge the Committee on
Problems of Drug Dependence to add tobacco -- as you've
added alcohol -- to your agenda for research, for
cooperative studies, and for an annual update. You
should examine and speculate upon the reasons why
53,000,000 Americans' dependence on tobacco has
attracted so little attention from scientists with
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knowledge and expertise such as yours. And when you
have the answers, I hope you will utilize those
answers to attract more research and appropriate
action to our number one public health problem and our
number one drug dependence problem.
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Governmental Control of
Individual Behavior—
Philosophical and Practical
Considerations
H. Kalant
THE UNIVERSALITY OF RESTRICTIONS
Since the Second World War, perhaps more than at any other time in
our history, our society has engaged in continuous and often heated
debate about the right of governments to restrict individual free-
dom in matters of taste, beliefs, personal practises, and choice of
pleasures and entertainments. This is well illustrated by, though
by no means restricted to, the use of cannabis, cocaine and other
drugs. The arguments about these are reminiscent of the debates
about alcohol half a century ago. Then, as now, the fundamental
legal and philosophical issue has been to what degree a government
has the right or justification to limit the freedom of individual
citizens to live their private lives as they wish.
It is a fact of life that all societies impose many kinds of res-
triction on the freedom of individual citizens. In contemporary
industrialized societies, in which the debate is perhaps the most
vocal and audible, we tend to think in terms of restrictions im-
posed by governments. Indeed, restrictions are imposed by all lev-
els of government, and in all spheres of human activity. In the
United States and Canada, for example, the federal governments re-
strict our freedom to spend our personal income as we choose, by
levying income taxes which they redirect to various social purposes
with which we may or may not agree. The military draft restricts
our freedom to serve or not serve in the armed forces as we might
choose. The criminal code determines whether we will or will not
have the freedom to read certain books or magazines, view certain
films, and use certain drugs for pleasure as distinct from medical
therapy. At the state or provincial level, governments determine
how rapidly or slowly we may drive our cars on the highway, what
forms of education our children may get, whether we must or must
not join a collective bargaining unit, and so forth. At the munici-
pal level, local governments determine in what areas of the city we
may build, and whether we may do so in the style and for the purpose
that we choose, whether we may or may not shop on Sunday, how we may
dress in certain locations and at certain times, and so forth. The
list is endless. There is a tendency for us to feel that this re-
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presents a progressively greater modern invasion by government into
the freedom of the individual, and many people long for the earlier
days in which our forebears supposedly lived according to their own
ideals and wishes, and in which their homes were their castles.
Unfortunately this nostalgic yearning for freer days of yore is
based on a delusion. Earlier, and even primitive, societies have,
or had, equivalent restrictions imposed by the society upon the in-
dividual, even though these restrictions were of a different nature.
In our own society, one does not have to look back too many decades
or centuries to see such astonishing examples as obligatory Sunday
closure of all businesses, the prohibition of contraception, and
even the prohibition of bathtubs and bathing of the whole body in
the nude except for medical reasons. In primitive societies, the
restrictions are probably even greater in importance because the
range of possible activities is much smaller, and each prohibition
weighs more heavily. The descriptions given by anthropologists
reveal the gravity with which religious taboos and tribal rituals
were enforced.
One must conclude, therefore, that restriction of individual free-
dom is part of the price for living in an society. In order that
a large number of people may live together in reasonable coopera-
tion and harmony, enjoying the benefits of mutual help and protec-
tion, it seems necessary for each member of the group to give up
certain freedoms for the sake of maintaining the necessary unity.
Our society is probably in many senses more free than most others
in human history. Nevertheless, the restrictions on individual
behavior are real enough to warrant some examination of the basis
on which they are formulated. Moreover, some of them are now re-
sented by enough people to warrant consideration of their purpose
and validity.
REASONS FOR UNIVERSALITY OF RESTRICTIONS
Though they may seem at times to be arbitrary and capricious, limi-
tations imposed by a society upon the behavior of its individual
members are usually not deliberately malicious. Of course, one
must exclude from this statement the cruel and perverse limitations
that have sometimes been imposed by despots. In the remarks that
follow, the assumption is made that we are referring to a funda-
mentally democratic society.
Social restrictions on individual behavior usually represent an
attempt to achieve the greatest common good, as this is perceived
at the time the rules are made. In earlier days, when travel and
communications were far below their present levels and xenophobia
was the norm, homogeneity of any given society was evidently a
highly desirable attribute. The more values, beliefs and customs
that people shared, the easier it was for them to accept and co-
operate with each other. Therefore, the Sunday blue laws were ac-
cepted by most people in North America as a perfectly justifiable
and reasonable means of ensuring universal adherence to the pre-
dominant puritanical version of Christianity. In our own time,
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obligatory chlorination or fluoridation of municipal water supplies
is seen by most citizens not as an infringement of personal freedom
to drink water of a different taste, whether contaminated or other-
wise, but as a reasonable means of serving the common good by mini-
mizing the health costs of typhoid fever, dysentery, and dental
caries.
In general, it is probably fair to say that such social restrictions
of individual behavior are conscious or unconscious weighings of the
individual’s freedom versus the interests of the larger group. In
general, they depend upon an explicit or implicit weighing of the
costs versus the benefits of any given behavior to the individual
and to the society at large.
COSTS AND BENEFITS OF DRUG USE AND DRUG CONTROL MEASURES
The question of drug control measures offers a good example of the
various considerations that go into the formulation of social poli-
cies with respect to individual behavior. They illustrate very well
the scope and complexity of the cost-benefit analysis that must ul-
timately serve as the justification for any specific policy. It is
useful to analyze the nature of the costs and benefits that must be
weighed.
In the case of licit drugs used for medical or other therapeutic
purposes, the nature of the costs and benefits, and the balance
that is drawn between them, are relatively simple. The major bene-
fit is obviously the relief of disease and suffering, though one
must not ignore the significant economic benefit that comes from
the creation of a pharmaceutical industry
profit, and taxation revenue.
which provides employment,
The major costs can be identified as
the risk of iatrogenic disease created by
and the economic burden to
improper use of the drugs,
the individual and to the society, as a
result of widespread and sometimes unnecessary use of newer and more
expensive agents.
When we consider the nonmedical use of licit and socially approved
substances, such as alcohol, caffeine, and tobacco, the spectrum of
costs and benefits is rather different. The most important benefit
is individual pleasure, although this can often be a socially shared
pleasure which reinforces group values and traditions. This is
particularly true of the long established role of alcohol in the
social practices and traditions of our society. A very important
additional benefit is the large economic contribution made by the
production, distribution and taxation of these commodities. The
costs are most typically seen or incurred at high levels of use,
and are of three major types. The first category includes the
consequences of acute excess, such as alcohol-related motor vehicle
accidents, violence, rowdiness, and other behaviors which infringe
upon the rights and tranquility of other people. The second broad
category includes the harmful effects of such agents upon the health
of the user. Alcohol-related diseases of the liver, nervous system,
or cardiovascular system, and bronchopulmonary disease caused by
heavy smoking, are examples of major costs to the individual, the
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family and society at large, in the form of both personal suffer-
ing and economic costs to the health care system. A third category
of costs, both social and economic, is represented by lost produc-
tivity, disruption of families and associated welfare costs, an
the creation of special problem groups such as the skidrow cultures
in many large cities.
In relation to the nonmedical use of illicit drugs, certain addi-
tional factors must be considered. The spectrum of "benefits" be-
comes much more variably defined, and depends much more on whose
point of view is reflected in the definition. For example, the
euphoria induced by amphetamine, or the alterations of perception
produced by LSD, are perceived by the users as novel, interesting,
and hence desirable, while to the general public all such drug use
appears bad - at best escapism, or at worst dehumanizing. The life
style of the chronic heavy user of cannabis is often represented by
the user as relaxed and more human by virtue of its avoidance of the
competitiveness of conventional society; in contrast, the same user
is often seen by the majority of the public as devoid of ambition,
shiftless, and irresponsible. In general, the heavy users of such
drugs perceive the effects as beneficial in providing interest and
solace to their lives, while society at large sees the drug use as
a threat to its values. In addition, a major cost of such drug use
arises from its illegal status, and consists not only of the econo-
mic cost of law enforcement measures against the use and sale of the
drugs, and the loss of currency from the country for the illict im-
portation of some of them, but also the human costs to users who are
convicted and imprisoned on charges of possession or trafficking.
It is worth noting here that the possible conventional therapeutic
benefits of a drug are quite irrelevant to the legal status of its
non-medical use. For example, the possible value of cannabis as an
anti-nauseant agent, or in the treatment of wide-angle glaucoma,
has no real bearing on the cost-benefit balance concerning legal
controls of the non-medical use of cannabis for personal pleasure.
This is readily apparent from our attitudes and practices with res-
pect to opiates. The therapeutic use of morphine is perfectly le-
gal, while trafficking and possession for non-medical use are il-
legal. In fact, the prohibition of manufacture and importation of
heroin for therapeutic use, in an effort to decrease availability
for non-medical use, is seen by many physicians as a glaring ano-
maly that illustrates the fallacy of confusing the two.
RELATION TO LEVELS AND DISTRIBUTION OF CONSUMPTION
In general, the perceived benefits of the use of licit drugs, and
even those of illicit ones, tend to occur at the relatively low
levels of use that are characteristic of the occasional or social
user. In contrast, the harmful effects on health and behavior, and
most of the economic costs, tend to occur in association with heavy
use.
There is now a considerable body of evidence to demonstrate that
the range of levels of drug use by individual users in a population
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follows a unimodal distribution-of-consumption curve that does not
differentiate, by any sharp inflection, between the normal and ab-
normal, light and heavy, social and addicted users. Rather, there
is a single continuous smooth transition between a majority of
light users and a minority of very heavy users, The levels of ha-
zard associated with the various risks mentioned above tend to rise
progressively with increasing average daily individual consumption.
Consequently, government interventions which are aimed at reducing
individual and social hazard by decreasing the levels of drug con-
sumption tend to affect both light and heavy users alike.
This is illustrated well by the effects of price manipulations and
of changes in legal status that have been tried at various times in
various countries. For example, when alcohol was rationed strictly
in France under the German occupation, the death rate from alcoholic
cirrhosis in Paris fell rapidly and drastically, only to rise equal-
ly rapidly after liberation in 1944. The enactment of prohibition
in the United States began with a variety of legal restrictions
imposed by the States and by the Federal government on interstate
commerce in alcohol in 1916, and continued with the constitutional
amendment enacted in 1921. These measures were followed by an
abrupt and rapid fall in the death rate from alcoholic cirrhosis
in the United States. Following repeal in 1932 the death rate did
not rise nearly as rapidly as it had fallen, because the United
States was now in the depth of the Great Depression, and the cost
of alcohol relative to average individual earning capacity had risen
sharply. Similar studies from Canada have shown a similar marked
effect of price interventions on the death rate from liver cirrho-
sis, and in Trinidad, price changes had equally striking effects on
the rate of alcohol-related road vehicle accidents.
It is clear, therefore, that government interventions can effec-
tively modify individual behavior with respect to alcohol and drugs,
even the behavior of those whom we would consider to be addicted and
at maximum risk of the health hazards associated with addiction.
The questions that must be asked are not whether such interventions
can work, but rather, at what cost, for whose benefit, by what
methods, and to what degree? The objective of such interventions
is obviously to keep the level of use low enough to minimize the
individual and social costs of drug use, while either maximizing
the pleasure or interfering with it as little as possible. However,
a further objective should be to keep the cost of the intervention
itself as low as possible.
BALANCING COSTS AND BENEFITS
The task of balancing the costs versus the benefits is considerably
more complex than might at first appear. It actually involves at
least three different types of cost-benefit accounting. The first
is a balancing of the costs versus the benefits of drug use at any
given average level of use by the whole population. How much plea-
sure from drug use is worth how much risk of physical or social
harm to the heavy users, or of health and economic costs to the
community at large? The second cost-benefit accounting must be
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applied to the various types of governmental intervention or con-
trol measure which might be applied. For example, deliberate price
manipulation by elevation of taxes on alcohol or tobacco is most
likely to decrease the level of use sharply if the prices are raised
drastically. But the same intervention may result in a net fall in
revenue to the government if it is too effective. The third and
most difficult type of cost-benefit accounting involves a comparison
of the costs and benefits of uncontrolled use with the costs and
benefits of the control measures taken to prevent this. The dif-
ficulty here lies in the fact that one is not comparing the costs
and benefits of the control measures against the costs and benefits
of the actual level of use found while these measures are in force,
but rather, one must compare the costs and benefits of the control
measures with those of the situation that would probably exist if
the control measures were not in place. Experience shows, for ex-
ample, that reduction of the legal drinking age is associated with
a large increase in the level of consumption of alcohol by teenagers,
and a disproportionate increase in the number of alcohol-related
traffic accidents among this age group. A particularly vexing pro-
blem is to assess how much increase in teenage drinking, drunkenness,
and drinking-driving accidents, is an acceptable price to pay for
the legal and philosophical consistency that someone who is old
enough to be conscripted for military service or to vote should also
be entitled to drink legally.
INPUTS TO DECISION-MAKING
It will be obvious from the examples given above that the drawing
of such a cost-benefit balance involves at least three different
types of input. The first and in some ways easiest input is that
of accurate factual information. Objective research can demonstrate
what the consequences of a given level of intake of a particular drug
may be, and also what individual and social consequences may follow
from a particular social policy. Disagreement among scientists at
this level are, on the whole, found at the fringes of knowledge, at
which facts are still not yet firmly established. Such differences
of opinion concerning actual fact are relatively easy to identify,
and the methods for resolving them are part of the objective equip-
ment of science.
The second type of input is the estimation of probability of oc-
currence of any particular type of consequence at any given level
of drug intake, or similarly the estimation of probability of oc-
currence of any particular individual or social consequence of a
particular policy option. Here, the reliability of estimates rests
upon the degree of expertise and impartiality of the experts making
them. In general, this is recognized as another part of the func-
tion of the expert. Subjective feelings, wishes and biases may all
influence the estimate of probability, but scientists by training
should be relatively capable of separating their personal prefer-
ences from their estimates of probability.
The third type of input is totally different in nature, and consists
of the value judgment concerning the relative weights to be attached
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to the different costs and benefits. Clearly, the importance of
any particular consequence depends on the scale of values of the
individual making the judgment. This is easily grasped by compari-
son with similar problems in other fields. Two internationally ac-
claimed experts in nuclear physics can disagree radically concern-
ing the desirability or undesirability of a particular nuclear arms
program or nuclear energy program. The difference does not depend
upon substantive disagreement concerning the nature of radiation
effects, or the probabilities of their occurrence at any given level
of radiation, but upon such considerations as whether it is better
to be dead than red or better to be red than dead.
When one reaches this level of evaluation, dependent upon the re-
ligious, philosophical and cultural backgrounds of the people making
the judgments, it is apparent that an expert in nuclear physics, or
an expert in psychopharmacology, has no particular claim to moral
superiority over the ordinary citizen. When it comes to making a
value judgment concerning the future nature and course of our so-
ciety, every citizen is entitled to the same consideration with
respect to his or her scale of values. The expert is expert only
in matters of scientific fact and probability estimate. Once he
has explained the facts and probabilities, his personal preferences
and values have no more weight or authority than those of every
other citizen.
Since the government represents the ordinary citizens in a demo-
cracy, it is not surprising to find that governments tend to fol-
low, rather than lead, public attitudes and opinions in matters
which are heavily dependent upon moral, religious, and cultural
values. In matters such as drug control legislation and its en-
forcement, governments and political parties are as divided within
themselves as the general public is. This is not necessarily an
unhealthy state of affairs, because it puts the onus clearly back
where it belongs, on the shoulders of the public at large. Our
function as scientists is to explain, but it is the function of
the public to decide on its values.
When viewed in this light, the role of government intervention in
individual behavior is really that of codifying and formalizing the
beliefs and values of the constituents whom the government repre-
sents. In drug controls, as in any other matter within the purview
of government, it is unrealistic to hope for unanimity. That some
measures are unpopular with some segments of the citizenry is almost
inevitable. Under these circumstances, drug control measures are
philosophically no more unjust than any other legislation which does
not have the unanimous backing of the entire population. If the
citizenry at large wish that a certain field of human activity
should lie entirely within individual discretion, or conversely that
it be subject to governmental intervention for the common good, it
is the responsibility of the citizens to make that known to their
elected representatives. Viewed in this light, the role of personal
choice is not merely to use or not use a drug, but to participate
in choosing the type of society we wish to live in.
AUTHOR: H. Kalant, M.D., Ph.D., Department of Phamacology, University of Toronto,
Toronto, Canada M5S 1A8; Addiction Research Foundation of Ontario, Toronto, Canada M5S 2S1
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Compliance and Enforcement
Programs of the Drug
Enforcement Administration
R. W. Buzzeo
It is indeed a pleasure and an honor to be with you at this your
42nd Annual Scientific Meeting of the Committee on Problems of
Drug Dependence, Inc., and to represent Mr. Peter B. Bensinger,
Administrator of the Drug Enforcement Administration,
I want to emphasize that DEA considers it absolutely essential to
establish and maintain a close relationship with organizations
such as this. The membership which you represent forms a vital
partnership with DEA in monitoring over 600,000 registrants, both
practitioner and nonpractitioner.
Our sincere desire is to remain approachable and responsive to
the needs of these many registrants. Little progress would be
made if the DEA were to remain aloof, issuing edicts, regulations
and policies from Washington. We need to monitor the registrants
and we need to work closely with all groups in preventing diver-
sion. We must understand that enforcement or medical programs
going off in separate directions is a simplistic approach -- we
need to work together in addressing a common problem.
I would like to highlight briefly with you today the Drug
Enforcement Administration and its Compliance and Enforcement
Programs, which include DEA activities in State-Federal coopera-
tion and with professional licensing boards, and then close
with a major problem which faces this country.
The DEA is the lead Federal law enforcement agency charged with
combatting drug abuse and the drug traffic. We have both an
enforcement and a prevention responsibility.
The Controlled Substances Act of 1970, which we enforce, is
designed to improve the administration and regulation of manu-
facturing, distribution, and the dispensing of controlled
substances by providing a "closed" system for legitimate
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handlers of these drugs. The idea of a closed system, through
which flow 20,000 brand named products controlled under our
current law, is to reduce the widespread diversion of these drugs
from legitimate channels into the illicit market.
Often the public associates DEA with its better known role of
criminal drug investigation. The resultant arrests and seizures
of illicit drugs make daily headlines around the nation.
Perhaps less colorful, but no less important, is our compliance
work in which we enforce those portions of the Controlled
Substances Act that apply to the manufacturers, distributors,
prescribers, and dispensers.
The DEA has about 4,200 employees worldwide -- most of them
operating under five regional offices in the United States.
Approximately 2,000 of our employees are Special Agents, and
about 200 are Compliance Investigators. These 200 investigators,
working closely with 7,000 State investigators, are responsible
for monitoring a market which, for comparison, is reached by some
26,000 medical service representatives of the pharmaceutical
industry.
DEA's regulatory mission is performed by its Office of Compliance
and Regulatory Affairs. Under it, we carry out such major
responsibilities as registration, import and export monitoring,
voluntary compliance, scheduling, quotas, regulatory investiga-
tions, State assistance programs, pharmacy theft prevention,
DAWN, and the ARCOS system, which helps us spot problems and abuses
in the distribution of controlled substances.
Our Compliance Program is concerned with the registrant who
criminally diverts controlled substances into the illicit market.
Although these are in the minority, the damage resulting to our
society from such diversion can be most serious. These criminal
diverters are no better than the individual who deals in heroin;
even worse, since they have abused the trust placed in them by
society.
Diversion has been reduced at the manufacturer/distributor level
as a direct result of regulatory requirements under the Controlled
Substances Act and Federal and State efforts. I am sorry to say
the same results have not been achieved at the practitioner level,
which includes physicians, pharmacies, researchers, hospitals, and
clinics. Currently, the sources of diversion at this level are
forged prescriptions, indiscriminate prescribing, thefts, and
illegal sales. We estimate that 300 million dosage units are
diverted annually, with 70 to 90 percent coming from the retail
(level. Primary responsibility at this level falls to, the States
under the Controlled Substances Act which requires DEA to register
every professional who possesses a valid State license unless
he has. a drug felony conviction or materially falsifies his
registration application.
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It is entirely true that only a minority of practitioners are
deliberately engaged in drug diversion; however, this minority
can, and does, create serious drug problems in many parts of the
country. In light of this problem, DEA embarked on a program
called "Operation Script," a cooperative effort which combines
the resources of both DEA and State drug agencies, which targeted
94 preselected pharmacies (44) and physicians (50) in 22 States
for extensive investigation.
This increase in effort has focused DEA technical, investigative
and legal expertise against preselected retail violators to
produce high impact investigations.
This increase in effort will be valuable in:
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
decreasing diversion,
demonstrating the Federal Government's concern,
increasing public awareness of the diversion and abuse
of legitimately manufactured controlled substances,
encouraging States to address practitioner diversion,
demonstrating the need for additional and continuing
Diversion Investigative Units (DIU's),
giving impetus to potential Federal legislation,
supporting possible FDA actions regarding indications
and uses of controlled substances,
obtaining information which may be utilized in
decreasing quotas and/or restricting imports.
At this point, indictments have been returned in seven of these
cases and fifteen more are pending. Eight convictions have
already been obtained for the illegal sale of controlled substances.
These eight (two pharmacists and six physicians) were responsible
for an estimated diversion of 15.4 million d.u. per year.
Clearly, with 600,000 practitioners and only 2,000 agents/inves-
tigators, we must concentrate our efforts on practitioners who
are strongly suspected of criminality.
For example, in FY '79, as part of our regular Compliance and
Enforcement Investigative Program we were able to conduct only
129 practitioner complaint investigations (62 pharmacists,
42 practitioners and 25 others), while DEA arrested 4,900
nonprofessionals.
As part of our State assistance, we have developed a State
criminal investigation operation aimed at prosecuting willful
retail registrant diverters. We call it the Diversion
Investigative Unit Program. DEA supports these State-run,
State-manned units by providing 18- to 24-month seed funding,
regulatory training, a full-time DEA representative working in
the unit and investigative support. In addition to the DEA
representative, the unit and its overseeing policy board are
composed of personnel from the State's various regulatory
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boards and its law enforcement agencies. This blend of expertise
and the flexibility provided have had a beneficial impact in
the nineteen States (Massachusetts, New Hampshire, New Jersey,
North Carolina, Georgia, Hawaii, Washington, Oklahoma, Michigan,
Pennsylvania, Nevada, Illinois, Texas, California, Alabama,
Maine, Arkansas, Utah, New Mexico and the District of Columbia)
where the units now exist. Perhaps the best measure of the DIU
Program's success has been the willingness of State governments
to continue these units with State funding.
Since the program's inception in 1972, these DIU's have accounted
for approximately 3,000 arrests. In Calendar Year '79, these
units made 450 arrests, including 170 registrants and removed
750,000 dosage units of controlled substances from the illicit
market.
A spin-off of the DIU Program is our application of computer
technology to identify problem drugs and problem registrants for
investigation. In a pilot program in San Francisco, we utilized
our Drug Abuse Warning Network (DAWN) to identify legitimate
drugs appearing most frequently in the hands of abusers and our
Automation of Reports and Consolidated Orders System (ARCOS) to
pinpoint registrants excessively purchasing these drugs. This
project, in conjunction with the California DIU, resulted in the
criminal indictment of nine physicians and civil actions directed
toward 21 pharmacies, with administrative actions against an
additional 10 physicians and 16 pharmacies.
Additional progress in curbing diversion at the retail level has
been made with the development and implementation of a program to
address pharmacy thefts. Thefts from pharmacies and practitioners
accounted for the loss of over 34 million (out of 43 million)
dosage units of controlled substances in 1978, and in 1979 a
projected 40 million (out of 52 million) dosage units. I might
add that retail pharmacies are subjected to theft more than any
other pharmaceutical business category. In the first six months
of 1979, 73.5 percent of all thefts reported to DEA were reported
by pharmacies. During this same time period 64.4 percent of all
controlled substances diverted by theft were stolen from pharmacies.
In order to assist pharmacists who are concerned about this
alarming increase in pharmacy thefts, the DEA initiated a Pharmacy
Theft Prevention (PTP) Program which is available to all commu-
nities. DEA's PTP Program is a community action approach to
pharmacy theft.
The nucleus of a PTP Program is the leadership in a community.
These leaders form an executive committee which includes repre-
sentatives from the police department, DEA and the professional
associations.
The DEA currently has eleven active PTP cities and three that
are in the developmental stages. The active programs are:
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Philadelphia Pennsylvania; Milwaukee, Wisconsin; Nashville,
Tennessee; Johnson County Kansas
Seattle, Washington; San Diego,
; Dallas, Texas; Denver, Colorado;
California; Rhode Island State;
Utah State; and Clark County, Nevada. Programs are developing
in Louisville, Kentucky; San Juan, Puerto Rico; and Pittsburgh,
Pennsylvania.
In addition, DEA has been working with the various medical
associations in developing prescribing guidelines that provide
and establish acceptable professional responses to guard against
contribution to drug abuse through indiscriminate prescribing
of drugs or the acquiescence by practitioners to unwarranted
demands of some patients. These guidelines will also work to
ensure that multiple prescription orders are not being obtained
by the patient from different physicians, that prescriptions
only provide enough of a drug to carry the patient to his next
scheduled appointment, and that prescriptions are alteration-
proof.
While progress is being made, the curbing of retail diversion in
the future will require substantial increases in State and
professional monitoring of practitioners in order to identify
the problem areas and to develop solutions.
Before I discuss a major area of concern, I first wish to address
some additional items of interest --
Dextropropoxyphene
Pursuant to a recent UN decision to add dextropropoxyphene to
Schedule II, the DEA has determined that the placing of bulk
dextropropoxyphene into Schedule II and the leaving of all dosage
units in Schedule IV will meet our international obligation as
required by the Single Convention and our domestic needs. In
addition, a recent recommendation by FDA that propoxyphene be
classified as a narcotic will require practitioners using dextro-
propoxyphene in maintenance or detoxification programs to register
as NTP's.
Clandestine Laboratories
Another area of interest is DEA's Clandestine Laboratory seizures.
In 1979, 237 labs were seized in the U.S. This includes 10
amphetamine producing labs; 137 methamphetamine and 53 PCP labs.
Already for the first quarter of 1980, 74 labs have been seized.
This figure is 31 percent of all labs removed last year.
International Diversion
Another major drug abuse concern of the DEA is the diversion of
legitimate pharmaceuticals from international commerce. Many of
the manufacturers of pharmaceuticals are located in Europe, where
regulatory controls are quite different from those of the
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United States. Several drugs, such as methaqualone, secobarbital
and methamphetamine, which are tightly controlled in the U.S.
because of high abuse levels, have not historically been considered
a problem in some European countries and therefore have not
been or have only recently been controlled. These conditions
afford drug traffickers opportunity for diversion. Using various
means of ordering and employing complex shipping routes, drug
traffickers are diverting large quantities of drugs of abuse.
In response to this growing U.S. and potential worldwide problem,
the DEA has initiated a program in cooperation with host govern-
ments to establish a voluntary program of soliciting cooperation
from various manufacturers and pharmaceutical firms in Europe.
Firms are encouraged to watch for and report unusual or suspicious
orders from customers, requests for unusual or suspicious labeling
or shipping instructions, and excessive orders.
It appears the long-range solution to this problem of drug diversion
from legitimate sources will require the enactment of additional
legal controls over nonnarcotic controlled substances. Addition-
ally, it is necessary to ensure the application of adequate
criminal or civil penalties to those firms or individuals that
violate legal requirements.
Only through extensive international cooperation and sharing of
information can countries effectively curtail the illegal interna-
tional movement of abusable pharmaceuticals.
Southwest Asian Heroin
In many respects, DEA has seen considerable progress in its efforts,
but the instabilities of the governments of Southwest Asia are
having a dramatic adverse impact on the dimensions of the world
drug situation. This area -- Iran, Afghanistan, and Pakistan -- is
capable of producing many times over the amount of opium needed to
satisfy world demand. This gives us cause for concern. The con-
sequences of excessive opium production there have already been
experienced in Europe, and now are being felt in the United States
as well.
It is estimated that in 1978 Afghanistan produced 300 metric tons
of opium and Pakistan produced approximately 400 metric tons, for
a regional total of about 700 metric tons. Iran cannot be included
in the 1978 total because at that time opium cultivation in Iran
was legal and controlled. In 1979, however, opium production in
all three of these countries in Southwest Asia is believed to have
increased to a maximum of 1,600 metric tons.
We estimate a regional consumption of 1,000 metric tons of opium,
leaving 60 metric tons of heroin available for worldwide distribu-
tion from this one area of the world.
Of course, these are "guesstimates." As you can well imagine,
intelligence-gathering in that part of the world is, at best, very
difficult. Our agents stationed abroad are our primary intelligence
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source. However, DEA has had to close its offices in Iran and
Afghanistan. Our efforts in Pakistan have been disrupted exten-
sively, and still have not returned to the levels of previous years.
Foreign governments are often a secondary intelligence source,
but we do not have ongoing enforcement and intelligence exchange
in Iran and Afghanistan, and these countries have lost a number
of their career drug law enforcement officials.
The high quality and availability of Southwest Asian heroin has
made it a very marketable commodity. By mid-1977, West Germany
was inundated with this high-quality Southwest Asian heroin. The
problem has since spread to other West European markets which
traditionally have been and continue to be outlets for Southeast
Asian heroin. Despite sincere attempts by European governments to
control the narcotics addiction problem, the situation has
continued to worsen.
Throughout 1979, Western Europe served as a "sponge," absorbing
the increased Southwest Asian heroin production. Approximately
2.5 metric tons of heroin were consumed in Western Europe that
year. By way of contrast, a recent intelligence study estimates
that in 1978 0.6-0.8 metric tons of Southwest Asian heroin,
representing 17 percent of the total market, entered the
United States. I expect that proportion to have doubled during
1979.
Although the heroin picture in Western Europe may be stabilizing,
the situation still is not good. Drug-overdose deaths in
West Germany, for example, are almost double those of this country
and yet their population is one-fourth of ours. In West Germany,
street-level purity is currently between 20 and 40 percent and
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prices in some European cities have dropped to as low as
25,000-$35,000 per kilogram. According to our latest figures,
that same kilogram would sell for about six times as much in
New York City.
DEA intelligence reflects that some Iranian citizens, unable to
move cash out of that country because of the currency regulations,
have "converted" their cash to narcotics and have smuggled their
assets out in that fashion. The profit motive has enticed numerous
black, Hispanic, Italian, Iranian and other traffickers to enter
the Southwest Asian heroin trade in the United States. Although
at present this trade is best characterized as fragmented, there
are indications that in the future it will be dominated increas-
ingly by cohesive criminal groups.
Over the past two years, there has been a rising number of seizures
and resulting investigations. During 1977 and 1978, small
quantities of Southwest Asian heroin appeared in the U.S. and
were confined to the New York/Washington, D. C. corridor. Since
then, undercover purchases of Southwest Asian heroin also have
been made in Chicago, Detroit, San Francisco and Los Angeles.
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Seizures of heroin in this quantity and purity have not been
experienced in several years.
Given the magnitude of recent developments, the question then
becomes, "What plans are there for coping with this new presence
and accelerating problem?" Unfortunately, there are no easy
answers.
The United States Government has developed initiatives to attack
the Southwest Asian heroin problem. The Administration is making
the Southwest Asian heroin effort a high priority and is coordi-
nating efforts of the Departments of Justice, State, Treasury,
Defense, and Health and Human Services.
The Department of State is seeking international cooperation, not
only through contacts with individual nations, but also by raising
the issue in international forums such as NATO. We are accelerating
the enforcement activities of the U.S. Customs Service and DEA
both in the U.S. and abroad. Additionally, New York, Philadelphia,
Boston, Newark, Baltimore and Washington are being designated
target cities where major efforts are needed most to fight the
flow of Southwest Asian heroin. The State and local law enforce-
ment agencies are being involved in the antiheroin effort to the
maximum extent. As you can see, the Drug Enforcement Administra-
tion is involved in the forefront of this action plan.
On February 28, 1980, President Carter and Attorney General
Civiletti hosted approximately 120 law enforcement officials
including all State attorneys general and several police chiefs-
and prosecutors. At this meeting, a five-point program to
address the threat of Southwest Asian heroin was discussed with
these enforcement officials and their cooperation and participa-
tion were encouraged.
Both Attorney General Civiletti and Mr. Bensinger have met with the
Italian Prime Minister and Minister of the Interior of the Federal
Republic of Germany to discuss mutual concerns regarding the
Southwest Asian heroin problem. We intend to continue to assist
foreign law enforcement agencies with support services directed
at identifying and immobilizing major drug trafficking networks.
In all cases, our preference is to work as close to the source as
possible; but, in the case of Southwest Asia, that door has
virtually been slammed shut. Consequently, we have accelerated
our efforts as close to the source as we can get -- through our
agents and country attaches stationed along the transshipment and
destination corridor in Western Europe.
DEA has recently established a Special Action Office/Southwest
Asian Heroin to meet the imposing threat of renewed heroin
production, transshipment and trafficking in and from Europe, the
Middle East, and parts of Southwest Asia's opium producing countries.
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SAO/SWA will address this serious situation on both the European
and North American continents in a coordinated, directed,
high-priority enforcement effort.
All of these actions are designed to counter the increasing
availability that could cause Southwest Asian heroin to reach
epidemic proportions. We believe that for the present our initial
measures will blunt this threat to the best extent possible.
In closing, let me leave you with the following thoughts. The DEA
is committed to preventing diversion. However, you, too, must be
conscious of your responsibilities in the fight against drug
diversion and abuse.
I am confident that the application of your know-how and resources
to the abuse problem will have significant results. The urgent
need to effectively curtail drug abuse and prevent diversion cannot
be overemphasized. DEA has assigned the problem a high national
priority. You can help by giving your utmost attention to the
abuse of controlled substances.
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Reinforcing Properties of
Buprenorphine: A Behavioral
Analysis
N. K. Mello, M. P. Bree, and J. H. Mendelson
Buprenorphine, a partial agonist of the morphine type, is a congener
of the narcotic agonist etorphine, and the antagonist, diprenor-
phine (Lewis 1974). Buprenorphine has morphine-like analgesic,
subjective and physiological effects and its analgesic potency is
estimated to be 25 to 40 times that of morphine (Cowan et al. 1977,
Jasinski et al. 1978, Houde 1979). However, buprenorphine does
not produce significant physical dependence in man (Jasinski et al.
1978, Mello & Mendelson 1980). The antagonistic potency of bupre-
norphine is equivalent to that of naloxone but it has a longer
duration of antagonistic action, comparable to that of naltrexone
(Jasinski et al. 1978).
Buprenorphine (8 mg/day) significantly suppressed heroin self-
administration (21 to 40.5 mg/day) by heroin addicts over 10 days
(P < .001) in comparison to buprenorphine placebo (Mello & Mendel-
son 1980). Placebo control subjects took between 93 and 100 percent
of all the heroin available. Subjects liked buprenorphine and said
they would prefer it to methadone or naltrexone. In view of bupre-
norphine's safety, efficacy, and acceptability to heroin addicts,
it should be an effective pharmacotherapy for heroin addiction.
This study examines the potential abuse liability of buprenorphine
in a primate drug self-administration model. This model has proved
useful for the preclinical assessment of drug abuse liability and
it is generally agreed that most drugs abused by man are also self-
administered by monkey (Schuster & Johanson 1974, Thompson & Unna
1977, Griffiths et al. 1980). This report is the first of a series
of studies that examine the conditions under which buprenorphine
is reinforcing, i.e. will maintain operant behavior leading to its
intravenous administration in monkey. Woods (1977) has shown that
substitution of buprenorphine (.0001-.10 mg/kg/inj) for codeine
(.3 mg/kg/inj) maintains responding on an FR 30 schedule of rein-
forcement, but response rates were lower than for codeine, morphine
or heroin. Evaluation of relative reinforcing efficacy is difficult
because of the problems involved in equating effective dose levels
per injection across drugs.
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METHODS
Subjects were 5 adolescent male rhesus monkeys (Macaca mulatta)
weighing 5.5 to 8.2 kg. Four monkeys had a long history of mor-
phine self-administration. Two were drug free and one had been
maintained on cocaine (100 mcg/kg/inj) prior to buprenorphine self-
administration. Monkey A319 had no previous drug self-administra-
tion history.
Monkeys worked at an operant task for food (1 gm banana pellet)
and drug injections and were maintained at ad lib weight throughout
the study. After training on a food administration task, each
monkey was surgically implanted with a chronic double lumen catheter
to permit intravenous drug self-administration. Details of the
surgical procedures and operant apparatus have been published pre-
viously (Mello & Mendelson 1978).
Four periods of food availability, drug availability and time outs
occurred each day. A one-hour food session was followed by a 1-
hour drug session and 2 hours of time out (when responses had no
programmed consequences). Experiments continued 24 hours a day,
7 days a week. The conditions of food and drug availability and
time out periods each were associated with a different color stimu-
lus light (S+) projected on a translucent response key on an oper-
ant panel. When saline was substituted for buprenorphine in control
studies, saline was also associated with a distinctive colored
stimulus light. Food and drug self-administration were maintained
under a second order schedule of reinforcement {FR 3 (VR 16: S)}.
An average of 16 responses on a variable ratio schedule (VR 16)
produced a brief stimulus light (S+) of the appropriate color.
However, a drug injection or a food pellet was delivered only after
a fixed ratio of 3 (FR 3) of the VR 16 response requirements had
been completed. Consequently, each food pellet or drug injection
required an average of 48 responses. Second order schedules were
used to minimize the possible disruptive effects of drug infusions
on operant responding.
Each of 5 buprenorphine doses (.005, .01, .03, .05, .10 mg/kg/inj)
was available for 60 consecutive drug sessions over 15 days.
Buprenorphine doses were presented in an ascending order. However,
the entire dose range was not completed by all monkeys. Buprenor-
phine hydrochloride solutions were diluted to the appropriate con-
centration for individual monkeys and doses are expressed in terms
of salts. The upper limit of this dose range was determined in
part by the solubility characteristics of buprenorphine.
The drug naive monkey and the drug free monkeys with a morphine
self-administration history were given access to buprenorphine
upon recovery from surgical implantation of an intravenous catheter.
Buprenorphine was immediately substituted for cocaine without an
intervening saline period. Each monkey began to work for buprenor-
phine on the same second order schedule of reinforcement previously
required for food and cocaine self-administration.
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After completion of the buprenorphine dose series, saline was sub-
stituted for buprenorphine, and monkeys were observed for signs
of opiate withdrawal. Saline and food self-administration patterns
were studied over 15 or more days.
RESULTS AND DISCUSSION
All monkeys self-administered buprenorphine over the range of doses
studied irrespective of their previous drug history. Increases in
the dose of buprenorphine per injection resulted in dose-related
increases in the total amount of buprenorphine self-administered
that day. Abrupt discontinuation of buprenorphine infusions did
not result in discernible withdrawal signs. Monkeys consistently
self-administered significantly more buprenorphine than saline.
The effects of buprenorphine on food self-administration were in-
consistent, but there were no significant changes in body weight
as a function of chronic buprenorphine self-administration.
FIGURE 1
Figure 1 shows buprenorphine self-administration (mg/kg) and injec-
tions per day over 3 doses of buprenorphine (.005, .01, .05 mg/kg
/inj) by a drug naive monkey. Each data point is the mean (± S.E.)
of 60 drug sessions over 15 consecutive days. There was a signi-
ficant increase (p < .001) in the daily dose of buprenorphine at
each increase in the buprenorphine dose per injection. The number
of injections per day also increased as the dose per injection in-
creased. Injections per day of .01 mg/kg/inj were significantly
higher (p < .005) than injections per day at a dose of .005 mg/kg
/inj. Despite a tenfold increase in the dose per injection, the
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number of injections at .05 mg/kg/inj was greater than at .005 mg/
kg/inj of buprenorphine.
Since the analgesic potency of buprenorphine is estimated to be
between 25 and 40 times more than that of morphine, .20 mg/kg/day
of buprenorphine is roughly equivalent to between 5 and 8 mg/kg of
morphine; .60 mg/kg/day of buprenorphine is equivalent to between
15 and 24 mg/kg of morphine; and 2.55 mg/kg/day of buprenorphine
is equivalent to between 63 and 102 mg/kg of morphine (cf. Figure 1).
Cumulative records of responding for buprenorphine on a FR 3
(VR 16:S) sechdule of reinforcement by the drug naive monkey are
shown in Figure 2. A high steady rate of responding, (between
2 and 2.5 responses per second) was maintained across a tenfold
increase in the buprenorphine dose per injection. Even at very
high doses of buprenorphine, there was no evidence of sedation.
As cumulative records at doses of .05 mg/kg/inj indicate, self-
administration of 1 mg/kg of buprenorphine, the equivalent of 25
to 40 mg of morphine, did not suppress response rates.
Since this monkey was drug naive, his performance cannot be attri-
buted to generalization from previous drug self-administration
experience. He learned to self-administer buprenorphine very
rapidly. He took 29 buprenorphine injections on the first day
of exposure to a low dose of buprenorphine (.005 mg/kg/inj) and
reached the final second order schedule requirement within 8
sessions on the first 2 days of buprenorphine exposure. In our
experience, acquisition of morphine self-administration by naive
monkeys on a VR 32 schedule of reinforcement required 3 to 4 weeks
FIGURE 2
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and codeine acquisition by naive monkeys on a FR 30 schedule of
reinforcement required almost 3 weeks (Woods 1977). The rapid
acquisition of buprenorphine self-administration on a second order
schedule is consistent with the interpretation that this drug is
highly reinforcing in monkey.
Drug experienced monkeys also showed progressive increases in
buprenorphine self-administration as the dose of buprenorphine
per injection was increased. Data for 4 drug experienced monkeys
are shown in Table 1. Three monkeys each took significantly
more buprenorphine at doses of .03, .05 and .10 mg/kg/inj than at
a low dose of .01 mg/kg/inj. Monkey A105 averaged a maximum of
2.95 mg/kg/day of buprenorphine at the highest dose level which is
approximately equivalent to 72 to 166 mg/kg/day of morphine. In
comparison to the lowest dose studied, injections per day remained
stable, or increased significantly (p < .05, .01) as the dose per
injection increased. One monkey (B205) did not show significant
changes in buprenorphine self-administration across the range of
doses studied. He took about .158 mg/kg/day,which is approximately
equivalent to 3.9 to 6.3 mg/kg/day of morphine.
Table 1
BUPRENORPHINE SELF-ADMINISTRATION (mg/kg) OVER 60 SESSIONS ( ± S.E.)
MONKEY BUPRENORPHINE DOSE PER INJECTION (mg/kg)
.005 .01 .03 .05 .10
DRUG NAIVE
A-319 .20 .60* 2.55*†
(±.03) (±.04) (±.17)
MORPHINE HISTORY
1-187 .16 .16 .72*
(±.02) (±.04) (±.13)
B-205 .13 .17 .14 .24 .11
(±.03) (±.02) (±.05) (±.09) ±.04)
A-105 .19 .57** 1.44**† 2.95**†
(±.02) (±.07) (±.13) (±.24)
B-255 .09 .43** .62** .94**†
(±.01) (±.03) (±.06) (±.09)
* Different from intake at .005 mg/kg/injection (p < .001)
** Different from intake at .01 mg/kg/injection (P < .001)
† Different from immediately preceeding value (p < .01 - .001)
Figure 3 shows illustrative data for the substitution of saline
for buprenorphine for one monkey (B255) that took moderate bupren-
orphine doses. The range of the average number of buprenorphine
injections taken across the dose range studied is shown at the
right. This is a somewhat typical saline extinction curve insofar
as high rates of saline maintained responding occurred during the
first 10 days followed by a gradual decrease in saline injections.
The number of saline injections taken during the first 10 days of
saline substitution was significantly greater than during the
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last 10 days (p < .001). Buprenorphine at all doses per injection
maintained self-administration behavior significantly above the
last 10 days of saline (p < .001).
FIGURE 3
SALINE SUBSTITUTION FOR BUPRENORPHlNE
No discernible withdrawal signs or weight loss were observed in any
monkey following prolonged buprenorphine self-administration. With-
drawal ratings were completed 3 times each day for 30 days in saline
substitution trials and when a catheter became occluded. An absence
of withdrawal signs after antagonist challenge in buprenorphine-
maintained monkeys has been consistently reported (Cowan et al.
1977).
CONCLUSIONS
Buprenorphine is a positive reinforcer in rhesus monkey and main-
tains behavior leading to its administration on second order sched-
ules of reinforcement, It appears comparable to morphine in re-
inforcing efficacy. These data are consistent with clinical studies
of reactions to buprenorphine by heroin addicts (Jasinski et al.
1978). Addicts' reports of "liking" buprenorphine and its rein-
forcing properties in monkey, suggest that buprenorphine, like
morphine, may have some abuse potential in man.
The abuse potential of any drug must be balanced against its safety
and efficacy relative to other available compounds. In contrast
to morphine or methadone, buprenorphine has been shown to produce
minimal physical dependence in man. Its antagonistic properties
virtually preclude overdose. Buprenorphine maintenance effectively
reduces heroin self-administration by heroin addicts (Mello & Men-
delson 1980) and it appears to offer some advantages as an anal-
gesic (Houde 1979). Moreover, buprenorphine's agonistic properties
could be advantageous if it were used as a pharmacotherapy for
heroin addiction and as an analgesic for patients suffering from
chronic pain.
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Correlations Among Certain
Behavioral, Physiological, and
Biochemical Effects of Narcotic
Agonists
J. H. Woods, J. L. Katz, A. M. Young, F. Medzihradsky,
and C. B. Smith
INTRODUCTION
Types of narcotic agonists nay be differentiated behaviorally
according to their actions in various preparations. Morphine-
liKe drugs ("mu" agonists) produce analgesia in rodents (Tyers,
1980) and are capable of suppressing completely the signs of
deprivation-induced abstinence in morphine dependent rhesus
monkeys (e.g., Deneau and Seevers, 1963). Additionally, these
compounds share common interoceptive stimuli; rhesus monkeys
trained to discriminate codeine or etorpnine from saline make
drug-appropriate responses to other morphine-1iKe drugs out not to
behaviorally active drugs from other pharmacological classes
(Woods et al., 1979a; Herling and Woods, in press). Moreover, a
wide variety of morphine-like drugs maintain drug-reinforced
responding in rhesus monkeys (Woods, 1977; Woods et al., in press;
Young and Woods, in press).
Similar to mu agonists, ethylketazocine-like drugs ("kappa"
agonists) produce analgesia in rodents (Tyers, 1980; Woods et
al., 1978); however, these agonists fail to either precipitate or
suppress abstinence in morphine-dependent rhesus monkeys (Woods
et al., 1978; 1979b). These drugs also snare common intero-
ceptive stimuli that are distinct from those of "mu" agonists;
rhesus monkeys trained to discriminate ethylKetazocine from saline
make drug-appropriate responses to ethylketazocine-like drugs out
not to other behaviorally active drugs including mu agonists (Hein
et al., in press; Woods et al., 1979a). In rhesus monkeys
trained to self-administer codeine, kappa agonists (i.e., those
that share ethylKetazocine's discriminative and direct effects)
fail to maintain drug-reinforced responding (Woods et al., 1978;
1979a).
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Thus, these types of narcotic agonists may be differentiated
from each other on the basis of their actions in morphine-
dependent monkeys, in monkeys trained to discriminate these
agonists from saline, and in maintaining drug-reinforced
responding. Mu and Kappa agonists also have characteristic
actions upon two smooth muscle preparations, the isolated guinea-
pig ileum and the mouse vas deferens (e.g., Kosterlitz and
Waterfield, 1975). In both preparations, these agonists inhibit
the electrically-induced twitch, and their effects are reversed by
narcotic antagonists. Similarly, both types of narcotic agonists
displace radiolabelled narcotics from binding sites in brain
(Hutchinson, et al., 1975).
A number of investigators have noted the similarity of potencies
across these preparations (Creese and Snyder, 1975; Hutchinson et
al., 1975; Kosterlitz and Waterfield, 1975; Lord et al., 1978).
The present study extends further the comparison of effects of
narcotic agonists across a wider range of mu agonists and among
some additional preparations. We nave compared across prepa-
rations a group of Kappa agonists that have been well identified
and characterized behaviorally, allowing the evaluation of certain
empirical generalizations about these classes of narcotic agonists
and the identification of compounds that deviate significantly
from the common spectra of action.
MATERIALS AND METHODS
Mouse vas deferens, Male, albino Swiss-Webster mice, weighing
between 25 and 30 g, were sacrificed by decapitation. The vasa
deferentia were removed, and 1.5 cm segments were suspended in
organ baths which contained a modified Krebs' physiological
buffer. The buffer contained the following: NaCl, 118mM; KCl,
4.75 mM; CaCl2, 2.54 mM; MgS04, 1.19 mM; KH2P04, 1.19 mM;
glucose, 11 mM; NaHC03, 25 mM; hexamethonium bromide, 0.07 mM;
pargyline, 0.3 mM; tyrosine, 0.2 mM; ascorbic acid, 0.1 mM; and
disodium edetate, 0.03 mM. The buffer was saturated with 95%
02-5% CO2 and Kept at 37°C. The segments were attached to a
strain gauge transaucer and suspended between two platinum
electrodes. After a 15-minute equilibration period, the segments
were stimulated once every ten seconds with pairs of pulses of 1
msec duration, 1 msec apart, and at supramaximal voltage. The
segments were stimulated for 30 min or until a stable twitch
height was achieved. Cumulative concentration-response curves were
determined for the various drugs by increasing the concentration
of the drug my three-fold increments until a maximum response was
obtained. EC 50 values were calculated by probit analysis.
Guinea-pig ileum, The isolated guinea-pig ileum was prepared as
described by Paton (1957). Segments of ileum were suspended in a
Kreos physiological buffer at 37°C, saturated with 95% 02-5%
CO2. The composition of the buffer was the same as described
for the vas deferens preparation except that it contained
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pyrillamine maleate, 0.125 mM, and did not contain the pargyline,
tyrosine, ascorbic acid, or disodium edetate. Tissues were
equilibrated for 30-40 minutes with washes every 10 min. After
the equilibration period, cumulative concentration-response
relationships were determined for the various drugs. EC 50
values were calculated by probit analysis.
3H-Etorphine binding to rat brain membranes Male Sprague-
Dawley rats, weighing approximately 200 g, were decapitated and
the brains were excised at 4°C. The brains were homogenized in
50 mM Tris HCl buffer, pH 7.4, and centrifuged for 15 min at
20,000 x g. The pellet obtained was resuspended in cold buffer
(1:100) and either frozen or used for the binding assay. The
assay mixture consisted of 400 ul of the membrane suspension, 50
ul of H20 or 1.6 M NaCl, 50 ul of either dextrorphan,
levorphanol, or the narcotic drug under investigation and 25 ul
of [15,16(n)-3H]etorphine (specific activity, 31 Ci/mmole,
Amersham). The final concentrations of NaCl, dextrorphan,
levorphanol, and etorphine in the medium were 1.5 x 10-1 M, 6 x
10-7 M, 6 x 10-7M and 3 x 10-9 M, respectively. Incubations
were carried out for a period of 15 min at which time the labelled
etorphine was added. After a further incubation for 30 min, the
tubes were placed on ice and their contents were filtered through
Whatman GF/C filters previously washed in H20. The samples on
the filter were washed with 3 x 4 ml of ice-cold 50 mM Tris HCl,
pH 7.4. Subsequently, the filters were placed in counting vials
with 1 ml absolute ethanol and 10 ml of a dioxane-xylene-
naphthalene scintillation mixture, and the vials were counted in a
liquid scintillation spectrometer. Tne binding of 3H-etorphine
in the presence of a given drug was related to the maximum
stereospecific etorphine binding, obtained as the difference
between binding in the presence of excess dextrorphan and
levorphanol. The EC 50 values were obtained graphically from
log-probit plots of the binding data. Each drug was investigated
at 5 or more concentrations, run in duplicate. In order to
determine the sodium response ratio, the receptor assay was
carried out both in the absence and presence of 150 mM NaCl in the
medium. The sodium response ratio for a given drug was expressed
as the ratio of EC 50 values obtained under those two experimental
conditions.
Morphine-dependent rhesus monkey, Groups of rhesus monkeys were
trained to routinely receive morphine injections and were
maintained on a regular schedule of injections (3 mg/kg q 6 hr)
that produces physical dependence in this species (Seevers and
Deneau, 1963). After at least three months stabilization on the
above schedule, morphine injections were periodically withheld,
which was followed by the development of withdrawal signs.
Fourteen hours after the last morphine injection, when abstinence
signs are approximately half of the maximal severity, new
compounds were tested for their ability to relieve the abstinence
signs. Generally, morphine-like agonists suppress the abstinence
signs whereas narcotic antagonists exacerbate those signs. In
contrast to the morphine-like agonists, drugs identified as Kappa
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agonists neither suppress nor exacerbate abstinence signs.
Rather, these compounds at suitable doses produce a unique
constellation of signs of sedation (Woods et al., 1979b). For
further details of the procedure, and details on the grading of
the various signs, see Deneau and Seevers (1963) and Villarreal
(1973).
Drug self-administration, Rhesus monkeys were surgically
prepared with chronic indwelling venous catheters and fitted with
stainless steel harnesses which were connected by a jointed hollow
arm to the back of the experimental cubicles. The catheter passed
out the back of the monkey through the arm and to an infusion
pump. Mounted on the front panel of the cubicle were one green and
two red stimulus lights and two response keys. Experimental
conditions and data collection were arranged by a digital
computer.
Experimental sessions were conducted twice per day, during which
pressing the right-hand key in the presence of the right stimulus
light intermittently produced intravenous infusions of codeine
phosphate (0.32 mg/kg) according to a schedule of one injection
per 30 responses . Following each injection was a 600-sec period
during which responses were ineffective and all lights were out.
Sessions ended after 130 min or 13 injections, whichever came
first. Different doses of test compounds were substituted for
codeine on every fourth session. For further details of the
apparatus or procedure see Deneau et al., (1969) and Woods (1977,
1980).
Drugs. The following were used: meperidine hydrochloride (v),
fentanyl citrate (b), levorphanol hydrochloride (c), morphine
sulphate (d), sufentanil citrate (f), etorphine hydrochloride (a),
d-propoxyphene hydrochloride (w), dl-propoxyphene hydrochloride
(e), ethylketazocine methane sulfonate (p), ketazocine methane
sulfonate (q), methadone hydrochloride, ketobemidone
hydrochloride, heroin hydrochloride, azidomorphine hydrochloride,
UM 909: 2-(2-methyl-3-furylmethyl)-2'-hydroxy-alpha-
5,9-dimethyl-6,7-nenzomorphan methane sulfonate (r), UM 911:
2-(3-methylfurfuryl)-2'-hydroxy-alpha-5,9-dimethyl-6,7-
benzomorphan methane sulfonate (s), UM 983: N-(alpha-pyridyl),
n-(l-beta-phenylethyl-4-piperidyl) ethylcarbamate hydrocnloride,
UM 1070: ( ± )-5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-6,7-
benzomorphan hydrochloride (1R/S,, 5R/S, 9R/S, 2"R/S) (t), UM
1072: ( ± )-5,9-alpha-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-
6,7-benzomorphan hydrochloride (1R/S, 5R/S, 9R/S, 2"R/S) (u), UM
1 1 1 2 : 2-cyclopropylmethyl-10- m-hydroxy-phenyl-trans-
decahydroisoquinoline, UM 1113: 2-cyclopropylmethyl-10- m -
hydroxy-phenyl-6-methyl-trans-decahydroisoquinoline, UM 1124: 1
m-[2-(cyclopropylmethyl)-1,2,3,4,4a,5,6,7,8,8a-decanydro-4a-
isoquinolyl] phenol succinic acid salt, UM 1160: Structure
not disclosed, UM 1167: (-)-17-cyclopropylmethyl-7,7-dimethyl-
3-hydroxy-6,8-dioxamorphinan d-tartrate methanolate (g), UM
1169: Structure not disclosed (h), UM 1170: 4-beta-(m-methoxy-
phenyl)-1,3-dimethyl-4 alpha-piperidinol proprionate hydrochloride
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(x), UM 1173: dl-(1-(2- dimethylamino)ethyl)-6,7-dihydro-3-
methyl-4-oxo-6-phenylindole-2-carboxylic  acid ethyl ester (E)
oxime, UM 1213: L-tyrosyl-D-alanylglycyl-L-N-alpha ethylphenyl-
alanine amide acetate (k), UM 1220: N-(2-methoxyetnyl)-
norketobemidone oxalate (l), UM 1233: N-(2-ethoxyethyl)-
norketooemidone oxalate (n), UM 1238: Structure not disclosed (o).
The letters following the drug names are used to designate
compounds in Figure 1 and 2.
RESULTS AND DISCUSSION
Narcotic agonists which act upon mu receptors have been
differentiated from those which act upon kappa receptors by
comparing their relative potencies upon the isolated, electrically
stimulated guinea-pig ileum and mouse vas deferens preparations
(Hutchinson et al., 1975; Lord et al., 1978). Mu agonists were
reported to be equipotent upon the two preparations, whereas kappa
agonists were found to be more potent in suppressing the twitch of
the ileum than in suppressing the twitch of the mouse vas
deferens. The present study reevaluated the potencies of standard
kappa agonists as well as certain mu agonists upon the two
preparations and extends the number of mu agonists previously
evaluated. Mu and Kappa agonists were identified by their
behavioral actions as described above. The majority of the mu
agonists were found to be roughly equipotent upon the two
preparations (Table 1). Relative potencies upon the ileum when
compared to the vas deferens ranged from one half as potent for
UM 1167 and UM 1169 to slightly more than 4 times more potent for
UM 1176. However, three mu agonists were much more potent upon
the guinea-pig ileum than upon the mouse vas deferens, namely
etorphine, fentanyl, and sufentanil. Sufentanil was remarkable in
that it was found to be approximately 8 million times more potent
upon the ileum than upon the vas deferens which suggests that this
drug either interacts with a unique receptor in the ileum or that
it possesses physical properties such as a very high degree of
lipid solubility which increases its affinity for the mu receptor
in situ. In contrast, UM 1170 is much more potent upon the
mouse vas deferens than upon the guinea-pig ileum.
Kappa agonists also varied greatly in their relative potencies
upon the two preparations. Ketazocine, UM 1070, and UM 1072 were
approximately equipotent upon the two preparations. However,
UM 909 and UM 911 were much less potent upon the ileum than upon
the vas deferens. Only ethylketazocine was found to be more
potent upon the ileum than upon the mouse vas deferens. Thus, tne
present observations fail to support the contention that mu
agonists are equipotent upon the two preparations whereas kappa
agonists are more potent upon the ileum than upon the vas
deferens. These observations suggest further either that narcotic
agonists act upon a heterogeneous population of receptors in the
two preparations or that individual drugs possess physical
characteristics which alter markedly the manner in which they
interact with one or more receptor type in each of the
preparations.
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TABLE 1
Potencies of "mu" and "kappa" agonists
on the mouse vas deferens and guinea-pig ileum
"Mu" Agonists
Sufentanil
Fentanyl
Etorphine
UM 1176
Meperidine
Morphine
UM 1238
UM 1177
UM 1213
UM 1220
UM 1167
UM 1169
UM 1170
"Kappa" Agonists
Mouse
vas deferens
EC 50
4.43 x 10-9
3.71 x 10-8
6.81 x 10-11
7.97 x 10-7
2.79 x 10-6
1.83 x 10-8
7.28 x 10-8
6.22 x 10-7
1.09 x 10-8
3.19 x 10-7
8.68 x 10-10
8.38 x 10-7
7.78 x 10-8
Ethyl-
ketazocine 1.56 x 10-9
UM 1070 5.88 x 10-10
UM 1072 2.58 x 10-9
Ketazocine 1.18 x 10-9
UM 909 6.17 x 10-8
UM 911 1.21 x 10-8
Guinea-pig
ileum
EC 50
5.86 x 10-16
1.34 x 10-10
4.76 x 10-13
1.86 x 10-7
9.75 x 10-7
1.05 x 10-8
6.12 x 10-8
5.54 x 10-7
1.01 x 10-8
3.87 x 10-7
1.74 x 10-9
1.86 x 10-6
3.08 x 10-4
1.49 x 10-10
6.50 x 10-10
3.30 x 10-9
1.58 x 10-9
1.90 x 10-6
3.90 x 10-7
Ratio EC 50's
MVD/GPI
8,000,OOO
276.9
142.9
4.3
2.9
1.7
1.2
1.1
1.1
0.8
0.5
0.5
0.0003
10.5
0.9
0.8
0.7
0.03
0.03
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The relationship between potencies of narcotic agonists upon
the two physiological preparations and potencies in displacing
3H-etorphine from opiate receptors on membranes isolated from
rat cerebrum has been evaluated for mu and kappa agonists.
Several investigators have compared the agonistic activity of
opiates in the two preparations with displacement of various
radiolabelled agonists and antagonists from rat brain membranes.
Creese and Snyder (1975) found a high correlation between activity
upon the guinea-pig ileum and activity in displacing 3H-naloxone
from rat brain membranes especially in the presence of sodium.
Hutchinson et al. (1975) found a stronger relationship between
displacement of 3H-dihydromorphine from rat brain membranes and
activity in the mouse vas deferens than between displacement and
activity in the guinea-pig ileum. Finally, Kosterlitz and Leslie
(1978) found a good correlation between displacement or
3H-naloxone from rat brain membranes and from membranes
isolated from the guinea-pig ileum and suggested that kappa
agonists are less susceptible to the sodium effect than are mu
agonists.
In the present studies a strong correlation was found between the
EC 50's for the displacement of 3H-etorphine from rat brain
membranes and EC 50's upon the mouse vas deferens for the mu
agonists. This correlation improved slightly when etorphine was
excluded from the analysis. For displacement in the presence of
sodium the correlation coefficient was 0.8559 and the slope of the
regression line was 0.9879 which indicates equal potencies in the
two preparations. In the absence of sodium the correlation
coefficient was 0.9174 and the slope of the regression line was
0.8448. A relatively good correlation also exists between EC 50's
for displacement and EC 50's upon the guinea-pig ileum if one
excludes etorphine, fentanyl, and sufentanil from the analysis. In
the absence of sodium, the correlation coefficient was 0.8838 and
the slope was 0.8830. When etorphine, fentanyl, and sufentanil
were added to the analysis, a lower correlation was found between
potency on the ileum and displacement of 3H-etorpine either in
the presence or absence of sodium (Figure 1). Low correlations
were also found between EC 50's for kappa agonists in either
preparation and displacement of 3H-etorphine from membranes
isolated from rat cerebrum. It is possible that higher
correlations will be found between the physiological effects of
the various agonists and displacement of labelled ligands other
than etorphine. The fact that etorphine is a mu agonist and that
the correlations for mu agonists improve with the exclusion or
etorphine supports this suggestion.
Correlations among effects of mu and kappa agonists upon mouse vas
deferens or guinea-pig ileum and the 14-hr withdrawn monkey are
shown in Figure 2. Drugs identified as kappa agonists do not
suppress abstinence signs in the monkey; however, these compounds
produce other overt effects including ataxia with marked body sag,
dozing, and pronounced mydriasis. These effects can be antagonized
by naloxone (Woods et al., 1978) indicating that, although they
are different from those of morphine, they are narcotic effects.
49
339-844 0 - 81 - 5
FIGURE 1
INHIBITION OF ELECTRICALLY INDUCED TWITCH LOG EC 50
Correlations among effects of mu-type and kappa-type agonists
upon tritiated etorphine bound to membranes from rat cerebrum.
Abscissae: Log molar EC 50 for inhibition of electrically in-
duced twitch of either mouse vas deferens (left panels or guinea-
pig ileum (right panels). Ordinates: Log molar EC 50 for dis-
placement of 3H-etorphine from membranes of rat cerebrum. Upper
panels: mu-type agonists; lower panels: kappa-type agonists.
Lower case letters adjacent to points refer to drugs as coded in
the Drugs section above. Solid straight lines were fitted to the
points by the method of least squares. Broken lines indicate
identical molar concentrations.
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FIGURE 2
Correlations among effects of mu and kappa agonists upon smooth
muscle preparations and 14-hr withdrawn rhesus monkeys. Abscis-
sae: log dose, in mg/kg, that produced complete suppression of
abstinence (upper panels) or log dose, in mg/kg, that produced
an intermediate grade of sedation (lower panels). Ordinates:
log EC 50 for inhibition of electrically induced twitch of the
mouse vas deferens (left panels) or guinea-pig ileum (right
panels). Lower case letters adjacent to points refer to drugs
coded in the Drugs section. Straight lines were fitted to the
points by the method of least squares linear regression.
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Since the kappa agonists do not suppress abstinence, correlated
here with effects on the physiological preparations are their
sedative effects. Generally, correlations among the effects in
smooth muscle with the in vivo effects were quite high for
either guinea-pig ileum or mouse vas deferens. Most noticable
were the differences in slopes of the regression lines that
depended more on the particular physiological preparation than on
the type of agonist or the type of behavioral effect observed. A
similar relationship between slopes was obtained when effects on
the two physiological preparations were correlated with analgesic
effects obtained in mouse hot-plate tests (not shown). Thus,
while relative potency in the mouse vas deferens underestimated
relative potency in vivo. relative potency in the guinea-pig
ileum overestimated relative potency in vivo.
Two mu-type agonists ( d-, propoxyphene and UM 1233) snowed an
unusual effect in the mouse vas deferens (Woods et al., this
volume). These drugs suppressed abstinence signs in the 14-hr
withdrawn monkey and inhibited the electrically driven guinea-pig
ileum. In the mouse vas deferens, however, at suitable
concentrations these drugs enhanced the magnitude of the twitch.
Naltrexone further enhanced the increases in response magnitude
produced by these compounds, suggesting a narcotic component to
their actions that opposed the increased twitch. Indeed, at low
concentrations, one of the drugs (UM 1233) produced a small
inhibition of the twitch that was completely antagonized by
naltrexone. Thus, while appearing to be morphine-like in the
rhesus monkey, these compounds have other interesting, possibly
noradrenergic, effects that obscure their narcotic actions in the
mouse vas deferens.
The behavioral effects of the mu and kappa agonists obtained in
the 14-hr withdrawn rhesus monkey were also correlated with the EC
50's obtained for the compounds in displacing tritiated etorphine
bound to membrane preparations from rat cerebrum in the absence or
sodium. While relatively better correlations were obtained with
kappa-type than mu-type agonists (0.9417 vs. 0.7656, respec-
tively), the slope for the regression line was relatively more
steep for the mu-type agonists (mu: 0.65; kappa: 0.43). These
differences in slope were not merely due to differences in the
particular behavioral measures used for mu- and kappa-type drugs
since they were consistent with the different slopes obtained when
etorphine displacement EC 50's were correlated with analgesic ED
50's obtained in mouse hot-plate tests (not shown). Thus of the
seven identified kappa-type agonists there was little difference
in their potencies in displacing tritiated etorphine. In
contrast, of the fifteen mu-type agonists studied there was a
relatively wider range of potencies in displacing tritiated
etorphine that approximated the range of potencies obtained
in vivo.
Two compounds that were effective in suppressing abstinence signs
in the 14-hr withdrawn rhesus monkey (meperidine and a meperidine
analogue, UM 1170) were ineffective in displacing tritiated
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etorphine in concentrations up to 2 x 10-6M (Medzihradsky,
unpublished data; Swain et al., 1979). Both of these compounds
were also effective inhibitors of the electrically driven guinea-
pig ileum and mouse vas deferens (see above). A third compound
(UM 1213), while displacing etorphine with a relatively high
potency, suppressed abstinence in the monkey with a relatively low
potency. This compound is a synthetic peptide with opiate-like
effects (Woods et al., this volume). Its low in vivo potency
is probably a result of the high degree of degradation of the
compound before it reaches its site of action.
The potencies of mu agonists in suppressing abstinence in the
14-hr withdrawn rhesus monkey were also correlated with their
potencies in maintaining drug-reinforced responding (Figure 3).
The correlation between the mu agonists in exerting these
in vivo effects in the rhesus monkey was 0.8704; the slope of
the regression line was 0.77, suggesting a relatively good
agreement between the relative potencies of the mu agonists in
exerting these effects. Two interesting exceptions to this high
correlation were noted. First, the regression line did not fit
the points for very potent compounds such as etorpnine and
sufentanil as well as it did points for less potent compounds.
This disparity in the relative potencies of these compounds was
also found in the comparisons of the effects of etorphine and
sufentanil across the in vitro smooth muscle and binding
preparations. Second, two compounds, UM 1167 and UM 1170, that
were effective in suppressing abstinence in the 14-hr withdrawn
monkey did not maintain drug-reinforced responding by the monkey
(Swain et al., 1979; Woods et al., this volume). Interestingly,
UM 1170 did not displace tritiated etorphine at concentrations up
to 2 x 10-6 M.
SUMMARY
Relative potencies of Kappa and mu agonists on guinea-pig ileum
compared to mouse vas deferens varied across a considerable range.
In contrast to earlier reports (e.g. Hutchinson et al., 1975;
Lord et al., 1978), the present differences in potency failed to
distinguish between kappa and mu agonists, suggesting that
distinctions between agonist types on the basis of their relative
effects in these two preparations are unlikely to be general-
izable. It remains possible that differences between this and
previous studies may be due to differences in strain of subject,
to minor differences in procedure, or to differences in the
particular compounds studied. The study of a wider range of both
mu and kappa agonists will provide further information on whether
mu and Kappa agonists can be distinguished according to relative
effects in these two preparations. Identification of additional
compounds possessing kappa-like activity will be very useful.
In contrast to the correlation among effects in vas deferens and
ileum, correlations among effects in either of these preparations
with displacement of bound etorphine did distinguish between mu
and kappa agonists. Slopes of regression lines for mu agonists
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FIGURE 3
Correlations among doses of mu-type agonists that maintained
maximal rates of responding under a fixed-ratio schedule of drug
injection and that completely suppressed abstinence in the 14-hr
withdrawn rhesus monkey. Abscissae: dose, in mg/kg on a log
scale, that produced complete suppression of morphine abstinence
on the Seevers scale; Ordinates: dose, in mg/kg on a tog scale,
that maintained maximal rates of responding under a fixed-ratio
schedule of intravenous drug injection in rhesus monkeys condi-
tioned to self-administer codeine. A straight line was fitted
to the points by the method of least squares.
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were generally steeper than slopes for kappa agonists. This
distinction was particularly clear in correlations of etorphine
displacement and effects in the mouse vas deferens. With exclusion
of exceptional compounds, slopes of lines fitted to mu and Kappa
agonists in the guinea-pig ileum were also distinctive.
Correlations among effects in vas deferens or ileum with effects
in the 14-hr withdrawn rhesus monkey showed an interesting
differentiation between smooth muscle preparations but not agonist
types. While all correlations were generally nigh, the slopes of
regression lines in comparisons of in vivo effects with effects
in ileum were steeper than with effects in vas deferens,
indicating that effects in ileum overestimate while effects in vas
deferens underestimate in vivo potency.
The displacement of etorphine and in vivo effects were also
highly correlated, with some interesting exceptions. Noteworthy
were meperidine and the meperidine analogue UM 1170. These
compounds suppress abstinence in the withdrawn monkey but do not
displace etorphine, suggesting that the narcotic actions of these
compounds are mediated by distinctive recognition sites.
An important property of mu agonists is that they suppress
abstinence in the morphine-dependent monkey. These effects were
very closely correlated with the reinforcing effects of those
drugs. In contrast, Kappa agonists neither suppress morphine
abstinence nor maintain self administration. To the extent that
the reinforcing effects are critical to the abuse liability of a
compound, the kappa agonists may be a significant step towards
compounds that are more useful analgesics.
The effects of narcotics have been studied in a variety of
experimental preparations and many of their effects are highly
correlated. An interdisciplinary approach comparing various
effects of narcotics offers an approach that naturally
highlights common characteristics of compounds. Possibly more
important, the approach also delineates distinct types of
narcotic agonists and individual compounds with unusual spectra
of activity.
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Comparative Studies of the
Pharmacological Effects of the
d-and l-Isomers of Codeine
T. T. Chau and L. S. Harris
Opiates are known for their stereospecificity. The l-isomers are
for example active as analgesics whereas the d-congeners are de-
void of analgesic properties. Based upon these properties, first
Goldstein et al., 1971, then other investigators have demonstrated
the stereospecific binding of opiates and attempted to correlate
such binding with specific opiate effects.
In our studies, the analgesic, antitussive, cardiovascular and
binding properties of l-codeine were compared with those of d-
codeine. An attempt was also made to demonstrate that the sup-
pression of the cough reflex was mediated through receptors dif-
ferent from "opioid receptors."
METHODS
1. Antinociceptive effects of d- and l-codeine
The analgesic effects of l-codeine phosphate and d-codeine HBr,
2H20 were assessed in the mouse tail-flick test as described by
D'Amour and Smith (1941) and in the hot plate test as described
by Eddy and Leimbach (1953). Each mouse served as its own control.
The antinociception response was calculated as % MPE (percent
maximum possible effectiveness).
% MPE = Test - Control
Cut off - Control
x 100
The cut off time was 10 sec. in the tail-flick test and 30 sec. in
the hot plate test. The drugs were given either S.C. or p.o.
After the time of peak effect had been established for the tail-
flick, all observations were then made at that time (20 min. post
injection). The Litchfield-Wilcoxon method gave the ED50 and the
95% confidence limits (Litchfield and Wilcoxon, 1949).
58
2. Effects on cough reflex, blood pressure and heart rate
Cats weighing 3 to 4 kg were anesthetized with sodium pentobar-
bital 35 mg/kg i.p. The cough reflex was initiated by manual
stimulation of the pharynx or lower part of the trachea with a
probe through a small slit made in the trachea. The respira-
tion rate, normal amplitude and the amplitude produced by the
cough reflex were measured by a pneumograph and recorded on a
polygraph. The control cough amplitude was initiated several
times prior to the i.v. injection of the drug into the femoral
vein. A decrease of the cough amplitude upon drug administra-
tion at different time points was defined as percent inhibition
of the cough reflex. Different doses of each isomer were given
and 3 cats were used for each dose. The Litchfield-Wilcoxon
method gave the ED50 expressed as base and the 95% confidence
limits.
The blood pressure was monitored via the femoral artery and the
EKG leads gave the heart rate.
In other studies naloxone was given prior to d- or l-codeine but
after the control cough had been obtained.
3. Inhibition of the stereospecific binding of 3H-dihydromorphine
Several concentrations of d- or l-codeine ranging from 10-l0 M to
10-4 M were added to whole-mouse-brain homogenates and tested for
their inhibitory effects on 2.2 x 10-9 M 3H-dihydromorphine
stereospecific binding. The experiments were carried out as
described by Pert and Snyder (1973).
RESULTS AND DISCUSSION
1. Analgesic effects
The antinociceptive effects of l-codeine phosphate were summarized
in Table I.
d-Codeine HBr, 2H20 did not show any significant analgesic effect
up to 100 mg/kg S.C. or p.o. in the tail-flick test. Hyper-
excitability was observed at low doses (10 mg/kg). Convulsions
were caused at higher doses and 100 mg/kg was lethal to all mice.
In the hot plate test, the mice were particularly sensitive to
the heat stimulus. No analgesia was observed from 10 to 75 mg/kg
S.C. or p.o., the latter dose being lethal to all mice tested.
Hyperalgesia at low doses and convulsions at higher doses were
obtained with d-codeine.
Thus, in the antinociceptive test procedures, l-codeine was active
whereas d-codeine had no analgesic effect up to lethal doses.
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TABLE I
Antinociceptive Effects of l-Codeine in Mice
Test
Procedure
Route of
Administration
ED50 mg/kg and
95% C.L.a
Tail-Flickb s.c.
N = 6 p.o.
Hot Plateb s.c.
N = 6 p.o.
4.09 (2.01 - 8.34)
13.41 (6.91 - 26.0)
20.66 (11.52 - 37.08)
20.47 (14.63 - 28.67)
a Expressed as codeine phosphate
b The mice were tested 20 min. after injections of l-codeine
phosphate.
2. Effects on cough reflex
The antitussive effects of l-codeine were summarized in Table II.
TABLE II
Antitussive Properties of l-Codeine Phosphate in the Cat
% Inhibition Time of
Dose mg/kg, i.v. the Cough Reflex Maximum Effect
.25 15 30 min.
.3 53 3 min.
.5 82 6 min.
1.0 93 3 min.
ED50 of l-codeine base = .27 mg/kg (.14 - .47 mg/kg)
a. N = 3 per dose
b. Cats anesthetized with pentobarbital 35 mg/kg, i.p.
c. Cough reflex initiated by stimulation of the pharynx
with a blunt-tipped probe
d. Recovery within 30 min. at .25 and .3 mg/kg
e. Recovery within 1 or 2 hours at .5 and 1.0 mg/kg
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None of the doses changed the respiration rate or the amplitude
of the normal respiration.
When 1 mg/kg naloxone HCl was given 4 or 5 min prior to the ED84
dose of l-codeine base (0.54 mg/kg), the antitussive effect of
l-codeine was still observed in 2 cats tested. The cough reflex
was still inhibited by 88% and by 84% in the 2 cats. Naloxone
by itself did not interfere with the cough.
The antitussive effects of d-codeine HBr, 2H20 were shown in
Table III. In one cat, 3 mg/kg, and in another cat, 4 mg/kg of
d-codeine HBr, 2H20 somewhat decreased the respiration which
became irregular, rapid but shallow for 4-5 min during which time
the cough reflex could be still initiated. As with l-codeine,
the ED84 dose of d-codeine (2.5 mg/kg) was not antagonized by 1
mg/kg naloxone given 5 min before.
TABLE III
Antitussive Properties of d-Codeine HBr, 2H2O in the Cat
% Inhibition of Time of
Dose mg/kg, i.v. the Cough Reflex Maximum Effects
1 4 3 min.
2 40 6 min.
3 60 6 min.
4 95 6 min.
ED50 of d-codeine base = 1.61 mg/kg (.98 - 2.65 mg/kg)
a. N = 3 per dose
b. Cats anesthetized with pentobarbital 35 mg/kg, i.p.
c. Cough reflex initiated by stimulation of the pharynx
with a blunt-tipped probe
d. Recovery within 30 min. at 1, 2, 3 mg and within 90 min.
at 4 mg.
Thus, in our experiments, l-codeine and d-codeine showed good
antitussive effects by decreasing the amplitude of the cough in
a dose related manner, l-codeine being six times more potent than
d-codeine. Their effects appeared to be mediated through recep-
tors which were not sensitive to naloxone, since naloxone failed
to prevent the antitussive effects of the 2 isomers.
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3. Cardiovascular effects
l-Codeine phosphate, at the highest dose tested (1 mg/kg) caused
a transient decrease in the blood pressure (20% decrease) in 2
out of 3 cats tested. In general, however, no significant cardio-
vascular effect was observed with l-codeine in the cats.
The cardiovascular effects of d-codeine were more pronounced, due
probably to the higher doses which were given to the cats, as shown
in Table IV.
TABLE IV
Cardiovascular Effects of d-Codeine HBr, 2H2O in the Cat
Dose Mean Heart Recovery Time
mg/kg, i.v. B.P. Rate (min.)
1.0 No Effect No Effect
2.0a 30% Decrease 20% Decrease 30
3.0a 64% Decrease 20% Decrease 40
4.0b 65% Decrease 22% Decrease 45
a. Effect in one out of
b. Effect in two out of
Three cats per dose
three cats
three cats
The hypotensive effects of the ED84 of l or d-codeine were not
prevented by 1 mg/kg of naloxone. The blood pressure was still
decreased by 18% with 0.54 mg/kg l-codeine base and by 30% with
2.5 mg/kg d-codeine base.
4. Inhibition of the stereospecific binding of 3H-dihydromorphine
The concentration of l-codeine which inhibited the SSB of 2.2 x
10-9 M 3H-dihydromorphine by 50% (IC50) was 1.6 x 10
-5M (1.2 x
10-5- 2 x 10-5M).
to 10-4
The d-isomer was inactive in this test up
M. Although high-concentrations of l-codeine were required
to displace 3H-dihydromorphine from its specific binding sites,
the stereospecificity of the 2 optic isomers could be still observed
here. Enzymatic conversion of l-codeine to a more active metabo-
lite (Adler, 1963) may explain the discrepancies between its in
vivo analgesic effects and its in vitro binding properties. d-
Codeine did not show any antinociceptive effect in our studies and
did not bind to specific opiate receptors as expected.
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In summary we have shown the stereospecific properties of the d-
and l-isomers of codeine with respect to their binding properties
and analgesic effects, The antitussive effects of the 2 isomers
did not appear to be mediated by the classical opiate receptors
as demonstrated by the lack of naloxone antagonism.
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WHO’s Response to International
Drug Control Treaties
I. Khan
I should like to review briefly the activities undertaken by
WHO since I last reported to you in Philadelphia June 1979:
1. SCHEDULING ACTIVITIES
WHO's recommendations to the Secretary-General of the UN
regarding the control status of eight substances were
reviewed by the 6th Special Session of the UN Commission on
Narcotic Drugs in February 1980 in Vienna. Tilidine and
Sufentanil were placed in schedule I of the 1961 Convention
while Dextropropoxyphene was placed in schedule II of the
same Convention.
The Commission agreed with the recommendations of WHO that
Phencyclidine continue to be controlled under schedule II of
the 1971 Convention as it is needed in veterinary practices.
It was also decided that three analogues of PCP (TEP, PHP or
PCPY and PCE) be controlled under schedule I and
Mecloqualone under schedule II of the 1971 Convention.
In September 1980, WHO plans to review the status of a group
of 9 substances (anorectics). These are:
Phentermine
Chlorphentermine
Chlortermine
Benzphetamine
Mazindol
Fenfluramine
Amfepramone
Phenmetrazine
Phendimetrazine
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Phenmetrazine and Amfepramone are already controlled under
schedule II and IV respectively of the 1971 Convention.
2. TECHNICAL COOPERATION WITH DEVELOPING COUNTRIES IN THE
IMPLEMENTATION OF THE INTERNATIONAL DRUG CONTROL TREATIES
2.1 In the past, WHO has collaborated with a number of
industrialized countries where data was made available to take
scheduling decisions to control narcotic drugs under the
earlier treaties. The 1971 Convention deals with psychotropic
substances which are widely used in large doses for a long
period of time and for ill-defined symptoms and disease
entities. Many of these substances have been available on
the market before the 1971 Convention was enforced in
August 1976 or even formulated. Thus, data on the therapeutic
usefulness of these substances and on their producing public
health and social problems and the extent is needed. WHO is
concerned and wishes to promote the active participation of
its Member States, in particular the developing countries,
in its programme on the implementation of the international
drug control treaties.
2.2 Information on the needs of developing countries have
been obtained through two WHO travelling seminars in the USSP.
on the "Safe Use of Psychotropic and Narcotic Substances,"
when participants from 35 countries were present as well as
a large number of Soviet officials and international and
non-governmental organizations.
In 1979, a WHO staff member visited four countries within its
four regions (AFRO, SEARO, EURO and PAHO) for discussions
with officials responsible for the implementation of the
international drug control treaties, members of the health
profession and scientific community as well as those
responsible for the trade and industry of drugs with
dependence liability. These four countries have already
ratified the 1971 Convention. In connexion with these visits,
three reports on the "National Response to the Convention on
Psychotropic Substances, 1971," by Finland (MNH/79.25),
Thailand (MNH/79.36) and Madagascar (MNH/79.42), are
available and a report on Argentina is in preparation.
2.3 NEED FOR DEVELOPMENT OF GUIDELINES FOR THE IMPLEMENT-
ATION OF THE INTERNATIONAL DRUG CONTROL TREATIES
WHO has already identified a number of activities which
require the development of guidelines to be considered by
Member States, where needed. Some of these are:
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1. Development of guidelines for carrying out research,
registration and re-registration of psychotropic substances
with dependence liability with special reference to drugs
modifying driving.
2. Need to limit and/or reduce the number of psychotropic
substances linked to a clear policy on the availability of
defined psychotropic drugs for the control of major
neuropsychiatric disorders.
3. Mechanisms involving members of the various health
professions in decision making to schedule drugs and their
subsequent prescription control.
4. Development of drug utilization and drug monitoring
systems for early identification of harm produced by
psychotropic drugs and to take remedial steps.
5. Development of WHO guidelines for exemption of
preparations containing more than one controlled psychotropic
substance from certain control measures under article 3 of
the 1971 Convention. Since the 1971 Convention allows
parties to use their discretion and grant exemption, a need
has been felt for WHO guidelines to be considered by
countries while granting exemptions.
The report of the Director-General of WHO, (EB65.21)
proposing the development of these guidelines was discussed
at the 65th Session of the Executive Board in January 1980,
and endorsed in its Resolution EB65.R7. Similarly, while
considering the above documents, the 6th Special Session of
the UN Commission on Narcotic Drugs which met in Vienna in
February 1980, also endorsed the development of guidelines.
The 33rd World Health Assembly also endorsed this in a
resolution WHA33/27 of 23 May 1980.
I have observed during the last four years that the CPDD is
becoming more and more involved in the subject of drug abuse,
going further away from laboratory investigations in the
field.
I should, therefore, like to request the Committee to consider
collaborating with WHO in the development of these guide-
lines, as deemed fit.
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3. A WHO Expert Committee on the Implementation of the
Convention on Psychotropic Substances, 1971, will be held
in Geneva to review methodology for assessing public health
and social problems associated with drug abuse. The report
of this Committee will be of assistance in identifying the
harm caused by psychotropic substances, vis-a-vis their
therapeutic benefit.
The Government of Finland has offered support to WHO in
developing guidelines to assess the public health problems
associated with the use of psychotropic substances.
WHO is planning to hold a Workshop in Finland in June 1981
in which 12 experts from developing countries will be
invited to participate together with other resource persons.
I would welcome a contribution from the CPDD to this
meeting by deputing an expert.
AUTHOR
Inayat Khan, Ph.D.
Senior Medical Officer
Division of Mental Health
WHO
Switzerland
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Potent Analgetics Derived From
9-Nor-9
Hydroxyhexahydrocannabinol
M. R. Johnson, T. H. Althuis, J. S. Bindra, C. A. Harbert,
L. S. Melvin, and G. M. Milne
SUMMARY
Based on the report of morphine-like analgetic activity of 9-nor-
9 -hydroxyhexahydrocannabinol (HHC), we undertook a study of struc-
tural modifications of the C-3 side chain of HHC to optimize the
analgetic activity. We ultimately examined four distinct classes
of side chains: (1) alkyl (la-lc), (2) arylalkyl (ld-lh), (3) al-
koxy (li-lj) and (4) arylalkyloxy (lk-lo). Three of these deriva-
tives (1b, 1f, 1l) possessed analgetic activity 10X morphine. These
studies demonstrate that the C-3 side chain of HHC can be modified
in a structure-dependent fashion to yield potent, nonopioid anal-
getics. In addition, the effect of the 1 methyl-4-phenylbutyloxy
side chain is unique among the side chains examined.
INTRODUCTION
In 1974, May and Wilson postulated that the analgetic activity of
- and -THC was due to their 11-hydroxy metabolites. They sup-
ported this conclusion by the observation that the 9-nor derivatives,
which cannot be transformed into the 11-hydroxy metabolites, lack
significant analgetic activity but exhibit dog ataxia and cardio-
vascular profiles nearly identical to - and -THC. During these
studies (-)-9-nor-9 -hydroxyhexahydrocannabinol (HHC) was prepared
and found to be analgetic with activity in the mouse hot plate test
nearly equal to that of morphine. We report here on our study of
structural modifications of the C-3 side chain of HHC; the objective
was to determine if a further increase in analgetic activity was
possible by structural alteration of the side chain.
METHODS
Subjects
Mice used in most of the studies were Charles River males, Swiss CD
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Reprinted with permission from R.W. Wilson and E.L. May, J Med Chem, 17, 475 (1974).
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strain (17-21 g). Mice in the 2-phenyl-4-benzoquinone abdominal
stretching experiment were Carworth males, albino CF-1 strain, weigh-
ing 11-15 g. Rats were Charles River males, Sprague-Dawley CD strain
weighing 180-200 g unless otherwise noted.
Materials
-Tetrahydrocannabinoid ( -THC) was supplied courtesy of Ms.
Jacqueline R. Porter of NIDA. The side chain derivatives la-lo were
synthesized by the Fahrenholtz (1967) procedure beginning with the
appropriately substituted resorcinol. Pentazocine was graciously
donated by Winthrop Laboratories. Morphine sulfate was purchased
from Mallinckrodt Laboratories.
Routes of administration varied and are noted in the various indi-
vidual studies. The compounds used in this study were dissolved
and administered to rodents in a vehicle consisting of 5 percent
ethanol, 5 percent Emulphor-620 and 90 percent saline. Solution
concentrations were varied to allow a constant injection volume of
10 ml/kg of mouse and 5 ml/kg of rat.
Statistics
Data were calculated as the "% maximal possible effect," or % MPE
as previously described (Milne et al. 1980)..
Tests of Analgesia
The tail-flick, tail-pinch, flinch jump and blockade of abdominal
stretching after phenylbenzoquinone (PBQ test) tests were conducted
according to previously published procedures (Milne et al. 1980).
The method used for the mouse hot-plate test was modified after
Woolfe and McDonald (1944).
RESULTS AND DISCUSSION
The finding of May and Wilson that analgetic activity was a disso-
ciable feature of the cannabinoid molecule encouraged us to examine
the effect of structural modifications at other positions of the
cannabinoid molecule to more fully understand the optimum structural
requirements for analgesia. One area that looked particularly at-
tractive was the modification of the n-amyl C-3 side chain, since
Adams and his co-workers (1949) demonstrated quite early that struc-
tural alterations of the C-3 side chain of synthetic 6a,10a-tetra-
hydrocannabinols markedly altered biological potency (Mechoulam et
al. 1976). However, since many of the biological effects measured
in these early studies were non-analgetic, we set out to carefully
determine specific structure-analgetic activity relationships. Our
search led us ultimately to examine four distinct classes of side
chains which are summarized in table I along with their analgetic
activity: (1) alkyl (la-lc), (2) arylalkyl (1d-1h), (3) alkoxy
(li-lj) and (4) arylalkyloxy (lk-lo).
Initially, we examined the effect of the alkyl derivatives lb and
lc, side chains previously used in the 6a,10a-, -THC
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TABLE I. ANALGETIC DATA (PBQ TEST)
Compound
(-) -THC
Analgetic MPE50 (mg/kg)
a
9.1
(5.4-12.3)
1a -CH2CH2CH2CH2CH3
1b
-CH-CH-CH2Ch2CH2CH2CH3
CH 3CH 3
1c -C-CH2Ch2CH2CH2CH2CH3
CH3 CH3
1d -CH2CH2C6H5
1e -CH-CH2CH2C6H5
C H 3
1f -CH-CH2CH2CH2C6H5
C H 3
1g -CH-CH2CH2CH2-4-C5H5N
CH 3
1h -CH-CH2CH2CH2CH2C6H5
C H 3
li -O-c-C6H11
1j -O-CH-CH2CH2CH2CH2CH3
CH 3
1k -O-CH-CH2CH2C6H5
CH 3
1l -O-CH-CH2CH2CH2C6H5
C H 3
1m -CH-CH2CH2OC6H5
C H 3
1n -CH-CH2CH2CH2-O-C6H5
CH3
1o -CH-CH2-O-CH2CH2C6H5
CH3
0.63
(0.26-0.97)
0.08
(.06- .09)
0.06
(.04- .08)
>10
b
4.66
(3.06-6.41)
0.06
(0.03-0.12)
0.22
(0.09-0.54)
0.35
(0.1-0.56)
<10C
0.17
(0.13-0.23)
0.23
(0.13-0.33)
0.07
(0.03-0.12)
0.23
(0.1-0.41)
0.38
(0.18-0.51)
1.28
(0.54-1.85)
(a) 0.3 hr. post. dose, s.c.
(b) 27% protection at 10 mg/kg, s.c.
(c) 75% protection at 10 mg/kg, s.c.
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(Mechoulam, 1973; Mechoulam et al. 1976; Loev et al. 1973), and in
the nabilone (Stark and Archer 1975) and nabitan (Pars et al. 1976)
series. The use of a side chain branched at the benzylic position,
such as lb and lc, considerably increased biological activity rela-
tive to the n-amyl side chain presumably, in part, due to a lessen-
ing of metabolic inactivation through benzylic oxidation. Side
chain c has the further advantage that it does not introduce the
additional diastereoisomers present in b. As can be seen in table
I, both lb and lc exhibited analgetic activity considerably greater
than HHC and -THC.
Having demonstrated that it was possible to considerably increase
the analgetic potency of HHC, we next turned our attention to aralkyl
substituted derivatives in order to determine the effect of a pendant
phenyl ring on analgetic activity (previously studied in the nabitan
series by Winn et al. 1976). The unbranched phenethyl side chain
(ld), which has the approximate extended chain length as n-amyl, had
weak analgetic activity. However, the branched three, four and five
carbon homologs exhibited potent, structure dependent analgetic ac-
tivity with a maximum response at four linear carbon atoms (lf ). The
heteroaromatic 4-pyridyl derivative lg, while somewhat less potent
than lf, retained analgetic activity. Molecular models show that lf
and lg have approximately the same extended side chain length as lb
and lc.
Previous studies in the 6a,10a-THC series have shown that an oxygen
atom directly attached to the phenolic ring has a seemingly variable
effect on biological activity. Thus, while unbranched ether side
chains were reported to decrease activity (Mechoulam 1973), branched
ether side chains exhibited a small increase in activity relative to
their carbon isomers (Loev et al. 1973). These early studies did
not address the effect these side chains had on analgetic activity,
however, and furthermore, simultaneous changes in the C-ring and
side chain have been shown to produce non-predictable SAR (Loev et
al. 1973). Therefore, we reinvestigated this parameter to specif-
ically assess the effect of an oxygen atom on analgetic activity in
the HHC series. While the cyclohexyl derivative li retained some
analgetic activity, the 2-heptyloxy derivative lj possesses potent
(2-3x morphine) analgetic activity. This finding encouraged us to
pursue further the effect of a heteroatom in the C-3 side chain.
Introduction of oxygen in the aralkyl derivative le yielded lk which
was 20 times more potent than le. Increasing the chain length by
one carbon yielded 1l which was fully as potent as lf and lc. Since
the extended chain length of 1l is greater than lc and lf, this find-
ing indicated that the oxygen atom itself and not just chain length
affected analgetic activity. Furthermore, when the oxygen atom is
not directly attached to the phenolic ring of HHC, it generally be-
haves as a carbon unit. Thus, ln and lo more closely resemble lh
than 1l. However, lm does resemble its isomer lk rather than lf
Since many classes of "false" positive analgetics are active in the
writhing assay, we selected a potent member of each side chain class
to more fully evaluate analgesia across a broad range of stringent
assays. Table II summarizes our results with lb, lf, lJ, 1l and ln
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versus the opiate agonist morphine, the mixed agonist-antagonist
pentazocine, aspirin, -THC and HHC (la). As is evident from table
II, unlike -THC, aspirin and pentazocine, these new derivatives
exhibit potent, efficacious analgesia across a broad battery of
tests and most closely resemble the opiate agonists in this respect.
Even the potent analgetic la loses considerable efficacy in these
more stringent tests of intrinsic analgetic activity.
We have shown that the C-3 side chain of HHC can be modified in a
structure-dependent fashion to yield derivatives that produce potent
analgesia in animals, previously characteristic only of the opiate
analgetic class. In addition, we have shown that the effect of the
placement of an oxygen atom directly attached to the aromatic ring
of HHC is unique.
TABLE II. COMPARATIVE DOSES PRODUCING 50 PERCENT OF THE
MAXIMUN POSSIBLE ANALGETIC EFFECT
Compound
MPE50 (mg/kg, s.c.) at Time of Estimated Peak Activity (95%
Copfidence Limits)
PBQ Writhinga Tail Flickb Hot Plateb Rat Tail Pinchc Flinch Jumpc
Morphinea
(-)- -THC
0.9
(0.4-1.3)
Pentazocinea >56 >56
Aspirin (p.o.) >100
1a
1b
1f
1j
1l
1n
9.1
(5.4-12.3)
7.4
(1.3-13)
123
(106-132)
0.63
(0.26-0.97)
0.06
(.06-.09)
0.06
(0.03-0.12)
0.17
(0.13-0.23)
0. 07
(0.04-0.12)
0.38
(0.18-0.51)
5.72 4.23 4.77 10.3
(2.73-10.59) (1.98-7.02) (3.5-5.8) (6.6-13.8)
55
(32.4-218.2)
>56
9.1
(5.1.20)
3. 0
(2.2-3.9)
0.25
(18-.3?)
N.T.
.33
(.16-.48)
0.8
(.007-4.1)
>100
>56
>100
34.4 70.5
(15.6-173) (49.7-149.8)
.32-.56 N.T.
.55
(.32-1.7)
.56-1.0
.46
(.23-.83)
10
~133 83
(47.8-1217.3)
>100
.49
(.13-.84)
.65
(.39-.96)
.38
(.20-.58)
N.T.
>100
36.4
(33.3-40.0)
0.39
(.31-.47)
0.47
(.31-.66)
N.T.
.38
(.33-.45)
(1.4-13.8)
(a) Values at 0.3 hr post dose
(b) Values at 1 hr post dose
(c) Values at 2 hr post dose
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Preclinical Pharmacology of
Doxpicodin, a New Analgesic
S. E. Smits, R. Nickander, R. N. Booher, D. M.
Zimmerman, D. T. Wong, M. D. Hynes, and A. Pohland
INTRODUCTION
Doxpicodin is a new analgesic which appears to exert its action
through opiate-like receptors but is structurally different from
other known analgesics. Doxpicodin is one member of a series of
substituted 1,3-dioxanes whose synthesis and structure activity
relationships have been previously reported (Booher et al. 1977).
It produces an analgesic effect with a wide margin of safety in
rodents and has demonstrated low physical dependence liability in
monkeys. This paper reports the results of the preclinical
studies on doxpicodin, a compound which is currently undergoing
clinical evaluation.
DOXPICODIN
MATERIALS AND METHODS
Acetic Acid-Induced Mouse Writhing Analgesic Test. Fasted male
Cox standard albino mice (Laboratory Supply Co., Mooresville, IN)
weighing 20-22 gm were used. This method was similar to that
previously described (Nickander et al. 1977).
Rat Tail Heat Analgesic Test. Fasted female Cox Sprague-Dawley
rats (Laboratory Supply Co., Mooresville, IN) weighing 60-80 g
were used in this test, which has been described earlier
(Nickander et al. 1977; Robins, 1955).
Narcotic Antagonist Measures in Rats. The ability of the test
compounds to reduce or antagonize the analgesic effect of morphine
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was measured in the rat tail heat analgesic test (Zimmerman et al.
1977).
Affinity for Opiate Receptors of Rat Brain. Interaction of the
compounds with opiate receptors of rat brain homogenates was
measured by assaying the displacement of 3H-naloxone and
3H-dihydromorphine from specifically bound sites as described
before (Wong and Horng, 1973). IC5O's were determined as the
oncentration at which a compound displaces 50 percent of bound
3H-ligand.
Respiratory Depressant Measures in Conscious Rats. Experiments
were conducted on male Sprague-Dawley rats weighing 300-325 g and
fasted overnight. A carotid arterial cannula was permanently
implanted by a method modified from Popovic and Popovic (1960). A
cannula of PE60 medical grade tubing beveled bluntly from both
sides was inserted into the carotid artery to a length of 22 to 25
mm. The exteriorized end of the cannula was plugged with a metal
pin. A leather harness surrounded the chest and shoulders with
openings for the forelegs, head, and trunk; and each animal was
secured in a Stoelting holder.
On the day of test, 3 days after surgery, the rat was placed in an
animal holder. After a 30-minute stabilization period a sample of
0.7 - 0.8 ml of blood was drawn anaerobically into a tuberculin
syringe whose dead space had been filled with heparin. Blood gas
values were determined within 10-15 minutes. The first blood
sample was considered the "control" (pre-drug) and additional
samples were drawn 30, 60, 120, 180 and 300 minutes after drug
administration. The samples were analyzed on an Instrumentation
Laboratory 513 pH/Blood Gas Analyzer that measured pH, pCO2 and
pO2 directly.
Acute Toxicity and Its Antagonism by Naloxone in Mice. Mice were
treated subcutaneously with either saline (10 ml/kg) or naloxone
(10 mg/kg, s.c.) and a simultaneous dose of doxpicodin. There were
10-20 mice at each dose level. The number of mice dead at 7 hours
was recorded. The LD5O's and 95 percent confidence limits were
calculated for both experiments according to the method of
Litchfield and Wilcoxin (1949).
Mouse Withdrawal Jumping Procedure. Mice with free access to food
and water were used. A chronic injection schedule was employed to
induce physical dependence. The test compounds were administered
subcutaneously at two different dose levels to look for a dose-
response relationship. Injections were given at 8:00 a.m., 10:30
a.m., 1:OO p.m. and 3:30 p.m. The low-dose group received 32 mg/kg
at each injection on the first and second days and 64 mg/kg on the
third and fourth days. On the fifth day the mice received 32 mg/kg
at 8:00 a.m. The high-dose group received double the amount of
compound that the low-dose group received. The total doses
achieved are indicated in RESULTS. Beginning one hour after the
8:00 a.m. treatment on the fifth day the mice were injected
intraperitoneally with naloxone (100 mg/kg), immediately placed
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individually into plexiglass cylinders, and the number of jumps
was determined for 10 minutes.
RESULTS
Mouse Writhing Analgesic Test. Doxpicodin inhibited acetic acid-
induced writhing in mice following both oral and subcutaneous
administration. The ED5O's compared to standard analgesics are
shown in Table 1.
Doxpicodin's ED50 of 1.8 mg/kg S.C. was similar to that of
meperidine and was 3 times that of morphine. Following oral
administration, doxpicodin's activity was comparable to that of
codeine and exhibited a p.o. to s.c. ratio of approximately 5
which was similar to that seen with codeine.
TABLE 1
ANALGESIC ACTIVITY OF DOXPICODIN IN THE MOUSE WRITHING TEST
*ED5O's (95 PERCENT C.L.)
COMPOUND OR TREATMENT SUBCUTANEOUS ORAL
DOXPICODIN 1.8 (1.2 - 2.7) 9.2 (6.8 - 12.6)
MORPHINE 0.64 (0.49 - 0.89) 3.9 (2.9 - 5.3)
CODEINE 2.3 (0.62 - 8.5) 12.6 (9.3 - 16.9)
MEPERIDINE 2.8 (2.3 - 3.10 16.4 (13.5 - 19.9)
PENTAZOCINE 2.0 (1.4 - 2.9) 46.0 (38.0 - 56.0)
*THE ED50 VALUE, DETERMINED AT THE PEAK TIME, IS THE DOSE (mg/kg) Required
FOR A 50 PERCENT REDUCTION IN THE FREQUENCY OF WRITHINGS.
The duration of effects of doxpicodin (s.c. and p.o.) compared to
meperidine (s.c.) and codeine (p.o.) are shown in Figure 1.
FIGURE 1
DURATION OF ACTION OF DOXPICODIN IN THE MOUSE WRITHING TEST
Following subcutaneous administration, doxpicodin and meperidine
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showed rapid onsets of action and comparable short durations. The
duration of action of doxpicodin was prolonged following oral
administration while its potency was equivalent to that of
codeine. The analgesic effects of doxpicodin in the mouse
writhing test were blocked by the narcotic antagonist naloxone.
Rat Tail Heat Analgesic Test. Doxpicodin produced analgesia in
rats as evidenced by prolongation of heat reaction times. Dose-
response comparisons of doxpicodin, morphine, and meperidine
following S.C. administration in the rat tail heat test are shown
in Figure 2.
FIGURE 2
COMPARATIVE DOSE EFFECTS OF DOXPICODIN IN THE RAT TAIL HEAT TEST
Doxpicodin is equivalent in potency to meperidine and 1/3 as
potent as morphine. Doxpicodin was nearly 1/2 as potent by the
p.o. route compared to the subcutaneous route (Figure 2). The
dose-effect of doxpicodin compared to codeine following p.o.
administration is also shown in Figure 2. Doxpicodin appears to
be significantly more active than codeine. The analgesic effects
of doxpicodin in the rat rail heat test were also blocked by
naloxone.
FIGURE 3
DURATION OF ACTION OF DOXPICODIN IN THE RAT TAIL HEAT TEST
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The time effects of doxpicodin in the rat tail heat test are shown
in Figure 3. Doxpicodin's peak effect by the S.C. route is similar
to that of meperidine, however, doxpicodin appears to have a longer
duration of action. Following p.o. administration a dose of 35
mg/kg of doxpicodin produced significantly greater analgesia than
50 mg/kg, p.o. of codeine and had a longer duration of action.
Narcotic Antagonist Measures in Rats. The ability of doxpicodin to
reduce or antagonize the analgesic effect of morphine was examined
in the rat tail heat analgesic test. Doxpicodin failed to reduce
the analgesic action of morphine but did show additive effects.
Opiate Receptor Binding. Receptor affinities of doxpicodin, as
measured by its inhibition of 3H-naloxone and 3H-dihydro-
morphine binding to rat brain synaptic membranes, are shown in
Table 2. Doxpicodin with an IC50 of 1.7 x 10
-6M is far less
potent than morphine but comparable to meperidine in competing for
3H-dihydromorphine binding sites. The displacement of
3H-naloxone by doxpicodin (IC50 = 5 x 10
-6M) though weak is
reduced approximately 5-fold in the presence of sodium.
TABLE 2
INHIBITION OF 3H-NALOXONE AND
3H-DIHYDROMORPHINE BINDING BY DOXPICODIN
3H-LIGAND
N A C L
ADDED
IC50* (M)
DOXPICODIN MORPHINE MEPERIDINE
3H-DIHYDROMORPHINE 1.7 x 10-6 1.5 x 10-9 2 x 10-6
3H-NALOXONE 5 x 10-6 5.2 x 10-9
3H-NALOXONE + 23 x 10-6 230 x 10-9
*CONCENTRATION OF COMPOUND AT 50 PERCENT INHIBITION.
Respiratory Depressant Measures in Conscious Rats. The respira-
tory depressant effects of doxpicodin as measured by arterial blood
pCO2, pO2 and pH have been evaluated in conscious rats and
compared to that of morphine. The subcutaneous dose-effect of
morphine and doxpicodin on arterial blood pCO2 are shown in
Figure 4. The effects were compared 120 min after treatment, a
time at which both compounds were near maximum effect. For both
morphine and doxpicodin, there was an initial dose-related increase
in pCO2 followed by an apparent plateau with increasing dose.
During the initial dose-related phase morphine was approximately 4
times as potent as doxpicodin. However, the maximum achievable
depressant effect for morphine, as indicated by increases in
pCO2, was at least twice that observed with doxpicodin. In
accord with these results, administration of morphine and
doxpicodin produced dose-related decreases in pO2 and pH. The
maximum achievable decreases with morphine were again twice that of
doxpicodin. The effects on blood pCO2, pO2 and pH by both
morphine and doxpicodin were reversed by naloxone.
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FIGURE 4
DOSE EFFECT OF DOXPICODIN AND MORPHINE ON
ARTERIAL BLOOD PCO2 IN RATS
Acute Toxicity Measures in Mice. The subcutaneous LD50 (95
percent Confidence Limits) of doxpicodin in mice was found to be
1420 (1297 - 1555) mg/kg. Simultaneous treatment with naloxone
significantly reduced the acute toxicity of doxpicodin resulting
in a LD50 value of 1840 (1688 - 2006) mg/kg. Using the ED50
from the mouse writhing assay, doxpicodin has a margin of safety
greater than 750.
Physical Dependence Measures in Mice and Monkeys. The ability of
doxpicodin to produce physical dependence following chronic
subcutaneous administration in mice was estimated using the mouse
withdrawal jumping test and compared to those of codeine and
pentazocine. The results of this test are presented in Table 3.
The maximum doses used for codeine and pentazocine were limited
because of toxicity. The jumping activity due to doxpicodin was
less than or equal to that of pentazocine and considerably less
than that seen with codeine.
TABLE 3
EFFECT OF DOXPICODIN IN THE MOUSE WITHDRAWAL JUMPING TEST
TOTAL DOSE JUMPS/MOUSE
COMPOUND MG/KG,  s.c. N (MEAN ± S.E.)
SALINE 30 3.5 ± 1.0
DOXPICODIN 800 15 5.1 ± 2.5
1600 20 11.6 ± 4.1*
PENTAZOCINE 800 15 9.5 ± 2.9
1088 15 13.6 ± 3.1*
CODEINE 800 15 25.3 ± 4.9*
1280 17 36.9 ± 4.4*
JUMPING(%)
>1
43
33
50
64
67
100
100
JUMPING(%)
>10
20
20
35
47
60
80
94
*SIGNIFICANTLY GREATER THAN CONTROL (P < 0.05).
The physical dependence liability of doxpicodin in monkeys was
assessed at the University of Michigan and the Medical College of
Virginia under the auspices of the Committee on Problems of Drug
Dependence. In the single dose suppression test doses as high as
75 mg/kg failed to alter the withdrawal syndrome (Swan et al. 1977;
Aceto et al. 1977). In the test for primary physical dependence,
doxpicodin administered every 6 hr at a maximum dose of 150
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mg/kg s.c. No withdrawal signs were apparent either after abrupt
withdrawal or when given a naloxone challenge (Aceto et al. 1977).
CONCLUSIONS
In rodents doxpicodin exhibits analgesic activity comparable to
that seen with meperidine and codeine and appears to exert this
effect by an action at the opiate receptor. Acute toxicity
measures in rodents indicate a wide margin of safety, a result
supported by the demonstration of limited respiratory depression in
conscious rats. Doxpicodin's low physical dependence liability
novel structure,and encouraging pharmacological profile suggest it
may be a safe and useful analgesic in man.
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Pharmacologic Effects of
N-Allylnormetazocine (SKF-10047)
E. T. lwamoto
INTRODUCTION
N-allylnormetazocine (SKF-10047; Win-19,631) possesses potent
psychotomimetic activity in man (Keats and Telford 1964) and also
is an effective antagonist of meperidine analgesia in the rat
having little or no detectable antinociceptive properties itself
(Archer et al. 1964; Pearl and Harris 1966). In the chronic
spinal dog, SKP-10047 caused mydriasis, tachypnea, tachycardia
and mania, effects which were quite unlike those induced by
morphine or ketocyclazocine; Martin and coworkers (1976) then
proposed that the pharmacologic effects of SKF-10047 culminate
from opiate action at a putative opioid receptor and not from
µ (morphine) or (ketocyclazocine) opioid receptors.
The bizarre behavior -- consisting of mild ataxia, lateral head
movements, pivoting of hindpaws and walking backwards (Schneider
1968; Buckett and Shaw 1975) and peculiar circular movements
turning to one direction only (Ahtee and Kääariäiren 1973) --
induced by cyclazocine in the rat is purportedly caused by its
activity, activity which is also shared by other opioids such as
nalorphine, levallorphan and pentazocine in addition to SKP-10047.
Recently, in novel environment, SKF-10047 and cyclazocine both
caused circling, rearing and side-to-side head movements in addi-
tion to increasing the seizure threshold in rats (Cowan et al.
1979).
It was reported that SKF-10047 potently displaced radiolabelled
phencyclidine bound specifically to a saturable class of binding
sites in rat brain membrane preparations (Zukin and Zukin 1979),
although the data have been contested (Maayani and Weinstein 1980).
In any event, the finding is significant in that chronic abuse of
phencyclidine in man resembles schizophrenia with symptoms in-
cluding auditory hallucination, inappropriate affect, and agita-
tion. Thus, the psychotomimetic activity induced by the putative
a opioid agonists might arise from receptor activation of an
appropriate "psychotomimetic" receptor. One possible common
underlying mechanism of action in PCP-induced and SKP-10047-
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induced hallucinations in man and the bizarre motor effects in
rats and dogs may be an excess of central dopaminergic receptor
activities. For example, it has been noted that acute amphet-
amine overdose resembles part of the acute schizophrenia syndrome.
In addition, Martin has shown that some signs induced by SKF-
10047 in the dog were mimicked by the dopaminergic agonist,
apomorphine. The following study was designed to characterize
some of the pharmacologic effects of N-allylnormetazocine in the
rat with respect to central dopaminergic mediation.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 250 to 450 g at the time of the
experiments were housed in the testing room under automatically
controlled conditions. Locomotor activity in the horizontal
plane was recorded by an activity monitor equipped with two arrays
(X,Y) of 15 infrared beams (Opto-Varimex-ATT, Columbus Instruments,
OH) and assessed between 1100 and 1800 hours. Antinociception
was measured by the hotplate method of Eddy and Leimbach (1953)
as modified by O’Callaghan and Holtzman (1975); the surface temp-
erature was maintained at 49.5 ± 0.1°C. The nociceptive endpoints
were a licking of the hindfeet, jumping onto the cylinder rim or
a lifting of one of the hindfeet for greater than 2 seconds.
Test latencies no greater than 45 seconds were subtracted by the
control response latency, an average of three predrug trials, to
give "change in latency." The drugs used were: SKF-10047 and
ketocyclazocine methanesulfonate (generous gifts from Sterling-
Winthrop Research Institute, Rensselaer, NY); spiperone (gift
from Janssen Pharmaceutics, Beerse, Belgium); clonidine hydro-
chloride (gift from Boehringer Ingelheim Ltd., Ridgefield, CO);
apomorphine hydrochloride (Sigma); naltrexone hydrochloride (gift
from Endo Laboratories, Inc., Garden City, NY).
6-Hydroxydopamine Lesions
Separate groups of animals were lesioned with 4 µg of 6-hydroxy-
dopamine (6-OHDA) injected into the right substantia nigra as
described previously (Iwamoto et al. 1976) and used in the circling
behavior experiments after three weeks.
RESULTS
Locomotor Behavior
Locomotor activity was stimulated up to 120 minutes after 10 mg/
kg of SKF-10047 (Fig. 1). Other behaviors observed after SKF-
10047 were sniffing and alternating backward locomotion. A
heroic dose of naltrexone, 20 mg/kg s.c., given at -15 minutes
significantly decreased locomotor activity induced by 10 mg/kg S.C.
of SKF-10047. Thirty minute pretreatment with 0.15 mg/kg S.C. of
spiperone strongly inhibited SKF-10047-induced locomotion by
over 94 percent; this dose of spiperone did not produce cata-
leptic behavior. Clonidine administration, 0.1 mg/kg s.c.,
diminished the SKF-10047-induced locomotor response by 67 percent
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FIGURE 1
MINUTES AFTER INJECTION
FIGURE 2
MINUTES AFTER INJECTION
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between 10 to 60 minutes after injection. Similarly, 0.1 mg/kg S.C.
of apomorphine significantly reduced the SKF-10047-induced loco-
motor activity by 54 percent (Fig. 1).
Antinociception
SKF-10047 did not produce analgesia as assessed by the 49.5°C
hotplate in agreement with previous reports (Fig. 3). Also in
keeping with past data, 2 mg/kg of either morphine or ketocycla-
zocine produced potent antinociception on the "warm" hotplate.
Significantly, 1.5 mg/kg S.C. of SKF-10047 antagonized the
analgesic effects of both morphine and ketocyclazocine (Fig. 2).
Circling Behavior
In the unilateral 6-OHDA-lesion - circling behavior model, in
which ipsilateral intracaudate dopamine levels are diminished by
almost 80 percent 28 days after lesioning, d-amphetamine-induced
dopamine release in the intact striatum causes circling behavior
towards, or ipsilateral to, the lesion. In contrast, direct
stimulation of supersensitive dopamine receptors in the lesioned
striatum after apomorphine injection causes contralateral
circling behavior (Fig. 3).
FIGURE 3
Using the circling model, SKF-10047 administration of 6-OHDA-
lesioned rats caused high intensities of ipsilateral circling
behavior that was not antagonized by 10 mg/kg naltrexone pre-
treatment (Fig. 4).
In similarity to the effects of SKF-10047 on spontaneous activity,
the SKF-10047-induced circling behavior was antagonized by the
putative dopamine receptor blocker, spiperone, at the 0.15 and
0.05 mg/kg doses, but not at 0.01 mg/kg S.C. (Fig. 4).
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FIGURE 4
These results demonstrate clearly that SKF-10047 increases spon-
taneous locomotor activity and causes ipsilateral circling
behavior, both of which are not easily antagonized by naltrexone,
but which are significantly diminished by the dopamine receptor
blocker, spiperone. The data from 6-OHDA circling behavior model
suggests that SKF-10047 indirectly activates the intact dopamin-
ergic mesostriatal pathway, perhaps by blocking reuptake of
dopamine, by releasing dopamine as after amphetamine to cause
the observed ipsilateral turning behavior, or by stimulating the
mesostriatal path at the level of the cell bodies directly. The
fact that a putative dopamine receptor blocker, spiperone, was
able to antagonize the locomotor activity and circling behavior
induced by SKF-10047, supports the hypotheses that SKF-10047
increases the activity within dopaminergic neurons. Thus, both
SKF-10047 and morphine (Iwamoto et al. 1976) induce ipsilateral
circling behavior, although the present data illustrate that the
SKF-10047 compound is much more potent than morphine in this
regard.
Stimulation of presynaptic dopamine receptors after 0.1 mg/kg of
apomorphine causes an inhibition of nerve impulse flow within
the pathway (Bunney et al. 1973). Thus, if locomotor activity
induced by SKF-10047 depended upon neuronal transmission through
dopaminergic pathways, it can be expected that inhibition of
transmission after presynaptic dopamine receptor stimulation
would diminish locomotion; this, in fact, was observed as pre-
sented in Figure 1. In addition, a role for noradrenaline
cannot be excluded since clonidine also blocked SKF-10047-
induced locomotor behavior. However, separate experiments not
illustrated showed that brain levels of morphine 30 minutes
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after 2 mg/kg s.c. morphine sulfate are decreased by 49 percent
by 0.1 mg/kg clonidine; whether clonidine also diminished brain
levels of SKF-10047 is not known at this time. Finally, the
fact that SKF-10047 antagonized both morphine-induced and keto-
cyclazocine-induced antinociception would suggest that SKF-10047,
in addition to its known properties as a µ opioid receptor
antagonist, also possesses antagonist actions at the putative
opioid receptor.
In conclusion, the present data indicate that opioid-induced
hypermotility may originate from a opioid receptor interaction
and may also depend upon the integrity of central dopamine-
containing systems since SKF-10047-induced locomotion can be
disrupted by both presynaptic and postsynaptic inhibitors of
dopamine transmission.
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Clonidine vs. Methadone for
Opiate Detoxification: Double-
Blind Outpatient Trials
A. M. Washton and R. B. Resnick
INTRODUCTION
Stemming from earlier demonstrations that a single dose of cloni-
dine reduces signs and symptom of opiate withdrawal (Gold et al.,
1978; Washton et al., 1980a) open clinical trials have shown that
clonidine can be used safely and effectively for the clinical man-
agement of opiate detoxification in both inpatient (Gold et al.,
1980) and outpatient (Washton et al., 1980a; 1980b) settings. For
example, we reported that following abrupt temination of 5 to 40
mg chronic methadone, 31 of 43 patients or 72 percent were able
to remain opiate free on clonidine for the 10 days necessary to
initiate opiate antagonist treatment with naltrexone (Washton et
al., 1980b). Our studies further indicated that to achieve safe
and effective control of withdrawal symptom with clonidine on an
outpatient basis, the clonidine dose regimen must be individual-
ized and titrated according to each patient's symptoms and blood
pressure because of varying sensitivity to clonidine's antiwith-
drawal, sedative, and hypotensive effects.
These clinical studies indicated that clonidine might be a poten-
tially valuable pharmacologic aid in addiction treatment, particu-
larly since it is the only nonopiate medication shown to have
specific and significant antiwithdrawal effects. It has been sug-
gested that clonidine might even be superior to conventional meth-
adone detoxification procedures (Gold et al., 1980) but thus far
no controlled clinical investigations have been carried. out.
We have now conducted a randomized double-blind placebo-controlled
study comparing clonidine and methadone detoxification procedures.
SUBJECTS AND METHOD
The subjects were 26 opiate-dependent outpatient volunteers who
showed no evidence of serious medical or psychiatric illness and
gave informed consent to participate in the study after receiving
a full explanation of the experimental procedures. They ranged in
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age from 22 to 49 years (mean 31 years) with addiction histories
of 3 months to 25 years (man 10 years). Twenty-two subjects were
males and 4 were females. Eighteen subjects were white, 5 were
black, and 3 were Hispanic. All knew that they would be detoxi-
fied with either clonidine or methadone and that they would be
randomly assigned to one or the other treatment on a double-blind
basis with an equal probability of receiving either treatment.
Nineteen of the 26 subjects were enrolled in a methadone mainten-
ance treatmant program for at least 6 months before entering the
study and were receiving a daily methadone dose of 15 to 30 mg.
The remaining 7 subjects were using illicit opiates (heroin and/or
methadone) and not enrolled in any treatment program upon admis-
sion to our outpatient clinic. These subjects were stabilized on
a daily methadone dose of 15 to 30 mg for at least 3 weeks before
entering the study. When the detoxification procedures were in-
itiated, 18 subjects were receiving 20 mg methadone, 3 were receiv-
ing 30 mg, 3 were receiving 15 mg, and 2 were receiving 25 mg.
Upon entering the study, subjects were randomly assigned to the
clonidine or methadone detoxification procedure. The procedures
were conducted under double-blind placebo-controlled conditions in
which all subjects received both liquid medication (methadone or
placebo) and tablet medication (clonidine or placebo) on each
study day. In the clonidine procedure, patients received active
clonidine and placebo methadone. In the methadone procedure, pat-
ients received placebo clonidine and active methadone, A compari-
son of the subjects assigned to the clonidine and methadone groups
indicated that the randomization process yielded compararable sub-
ject samples with respect to several relevant psychosocial, demo-
graphic, and drug use variables.
The clonidine detoxification procedure consisted of abrupt discon-
tinuation of active methadone and simultaneous introduction of
active clonidine. The methadone detoxification procedure consisted
of meththadone dose reductions of 1 mg per day until a zero dose was
reached, with simultaneous administration of placebo clonidine.
Clonidine dose regimens were individualized on a double-blind
basis according to dosing methods described previously (Washton
et al., 1980b). The initial clonidine dose regimen consisted of
0.1 mg every 4 to 6 hours as needed for withdrawal discomfort.
The total daily dose was then increased, as needed, by 0.1 mg or
0.2 mg increments on succeeding days in an attempt to minimize
withdraw discomfort without generating untoward side effects.
In some cases, clonidine doses were held steady or decreased to
compensate for sedation and/or hypotension. The total daily clon-
idine dose did not exceed 1.2 mg on any given day. Most subjects
received night-time sedative medication to alleviate insomnia.
At each clinic visit (3 to 5 times per week) subjects met with the
investigators for review of withdrawal symptoms, medication effects,
and compliance with suggested clonidine dose regimens. Neither
the subjects nor investigators were told whether the subject had
been assigned to the clonidine or methadone procedure. Blood
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pressure and pulse rate were recorded at each clinic visit, but by
someone other than the investigators, because clonidine's observ-
able effects on these measures would violate the double-blind,
Subjects were free to terminate their participation in the study
at any time and be restabilized on methadone.
The datum of primary interest in this study was a comparison of
detoxification success rates with the clonidine and methadone pro-
cedures. "Detoxification success" was operationally defined as
completion of a 10–day opiate-free period following discontinua-
tion of active methadone. Opiate-free status was evaluated by
laboratory analysis of supervised urine samples and additionally,
in subjects who desired naltrexone treatment, by a naloxone chal-
lenge of 2.0 mg i.v. which served as the necessary screening pro-
cedure before starting naltrexone.
Since the methadone detoxification procedure was conducted at a
fixed rate of 1 mg per day, the number of days from initiation
of the procedure to zero dose varied according to the subject's
starting methadone dose, with a subsequent fixed 10-day post-
methadone period required to complete the detoxification procedure.
Thus, for subjects on a 20 mg starting dose, completion of the
procedure required 30 days. In order to maintain double-blind
conditions, the length of the clonidine procedure was extended to
be identical with that of the methadone procedure and, therefore,
was also determined by starting methadone dose plus 10 additional
days. Although all clonidine subjects could potentially achieve
the 10-day post-methadone criterion by day 10 of the study, ir-
respective of starting methadone dose, the medications were con-
tinued according to protocol until the defined study endpoint.
All subjects were informed that completion of the study procedures
with a 10-day opiate-free period would be a necessary prerequisite
to any post-detoxification treatment with or without naltrexone.
RESULTS
Table 1 presents a group comparison of detoxification success
rates in terms of subjects' ability to achieve a 10-day opiate-
free period following discontinuation of active methadone. For the
clonidine procedure, the data represent subjects' status on day 10
and for the methadone procedure they represent subjects' status at
the defined endpoint of the study which, in most cases, was day 30.
These data show an overall success rate of 38% for the subject
sample as a whole, with no statistically significant difference
between the clonidine and methadone procedures. Examination of
individual-subject data revealed no association between ability to
detoxify and subject's age, years addicted, employment status, or
starting methadone dose.
Two of the 4 clonidine subjects who achieved the opiate-free cri-
terion by day 10 subsequently relapsed to opiate use before com-
pletion of the double-blind procedure on day 30. Eleven of the 3
methadone subjects reached a zero methadone dose, although 5 of the
11 subsequently relapsed to opiate use during the final 10-day
post-methadone period.
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TABLE 1
SUCCESS IN ACHIEVING 10 DAYS OPIATE-FREE
(N=26)
Successful Unsuccessful
%  ( N ) % (N)
TOTAL SUBJECT SAMPLE (N=26) 38% (10) 62% (16)
Clonidine Procedure (N=13) 31% ( 4) 69% ( 9)
Methadone Procedure (N=13) 46% ( 6) 54% ( 7)
Chi–square test: p > .05.
Consistent with our previous findings (Washton et al., 1980a;
1980b), patients given the active clonidine treatment found that
it relieved a substantial portion of their withdrawal discomfort.
Lethargy and sluggishness were the most consistent complaints.
During induction onto clonidine, patients occasionally experienced
transitory episodes of mild dizziness or lightheadedness which
tended to abate with continued clonidine administration over the
course of several days.
Methadone subjects assumed that they were receiving the active
clonidine treatment because they attributed the relative absence
of withdrawal symptoms during most of the detoxification procedure
to effectiveness of the placebo tablets. Clonidine subjects, on
the other hand, reported sedative effects not reported by those on
the placebo tablets. Thus, although doubleblind conditions could
not be strictly maintained, all subjects were operating under the
assumption that they were receiving the active clonidine treatment.
Of the 8 subjects who were opiate-free at completion of the study,
6 began treatment with naltrexone and 2 elected to continue in
drug-free treatment without naltrexone. Of the 18 subjects who
failed to complete detoxification, 17 were restabilized on meth-
adone and 1 was lost to follow-up.
The slightly lower success of the clonidine procedure did not ap-
pear to be due to less effective control of withdrawal discomfort.
The major syptomatic complaints were identical for both subject
groups (i.e., lethargy, restlessness, and insomnia) and subjective
ratings of symptom severity were indistinguishable as well. More-
over, most subjects who discontinued their detoxification attempt
felt that it was not primarily a result of physical withdrawal
discomfort. Of the 18 subjects who discontinued, 8 stated that
they returned to opiates in response to some form of psychological
stress (e.g., relationship problems, job pressures, dysphoric feel-
ing state) and 6 subjects attributed their relapse to an uncon-
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trollable craving for opiates that was not associated with an
identifiable precipitating event. Four subjects, 2 in the cloni-
dine group and 2 in the methadone group, felt that physical with-
drawal discomfort was the primary reason for discontinuing their
detoxification attempt. Thus, the present observations appear to
indicate that the clonidine and methadone procedures generated
roughly equivalent levels of withdrawal symptomatology.
There was a noticeable difference between groups, however, with
respect to the point at which withdrawal symptoms emerged. Cloni-
dine subjects reported symptoms during the first week of the study
whereas methadone subjects reported symptoms during the final
week. In both cases, the emergence of symptoms followed discon-
tinuation of active methadone.
DISCUSSION
Our findings indicate that the clonidine and methadone detoxifica-
tion procedures employed in this study were of comparable efficacy
in helping patients achieve a 10-day opiate-free period. There
was no statistically significant difference between the two pro-
cedures in terms of detoxification success rates, although success
with the clonidine procedure was slightly lower than that of the
methadone procedure.
It appears that the clonidine detoxification procedure was select-
ively disadvantaged in the current protocol by having to artifi-
cially extend the length of the procedure simply to maintain double-
blind conditions. In our open studies (Washton et al., 1980a;
1980b), patients found clonidine to be a highly desirable treat-
ment primarily because it allowed them to detoxify in the shortest
possible time. Within only 10 days after discontinuing methadone,
patients were able to begin naltrexone or drug-free treatment.
Knowing that the detoxification would be completed within such
a short period of time seemed to help them endure withdrawal dis-
comfort and control urges to use opiates. By contrast, in the
present study, the detoxification procedure was considerably
longer and, in most cases, lasted 30 days, Since clonidine sub-
jects became symptomatic during the first week of the study, a
30-day period was perceived as a rather long period of time to en-
dure even mild withdrawal discomfort without giving in to urges and
cravings for opiates. The long time period from onset of withdrawal
symptoms to completion of the detoxification procedure actively dis-
ouraged patients from continuing in the study despite our intensive
efforts at fostering their retention. In the methadone procedure,
on the other hand, patients became symptomatic only toward the end
of the procedure and, similar to patients in open clonidine treat-
ment, knowing that completion of the detoxification was almost at
hand, helped them to persevere.
Thus, clonidine might be maximally efficacious when used as a
rapid detoxification treatment. A more appropriate test of its
efficacy would be a double-blind comparison of clonidine vs. pla-
cebo for 10 days following abrupt discontinuation of low-dose
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methadone. Another possibility would be an open parallel-groups
study where subjects are randomly assigned to either a 10-day
clonidine detoxification procedure or a gradual methadone dose
reduction procedure similar to that employed in the present study.
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Clinical Utility of Clonidine in
Opiate Withdrawal
M. S. Gold, A. L. C. Pottash, I. Extein, and A. Stoll
INTRODUCTION
We have reported that a single dose of 5 ug/kg of clonidine but not
placebo caused a rapid and significant decrease in acute opiate
withdrawal signs and symptoms inpatients addicted to methadone,
other synthetic opiates, and heroin (1-3). These initial studies
suggested a new use for clonidine as a nonopiate treatment for
rapid opiate detoxification (4). In addition these studies with
the alpha-2 adrenergic agonist clonidine which reduces brain nor-
epinephrine activity support a noradrenergic hyperactivity hypo-
thesis for opiate withdrawal (5).
While our previous inpatient studies (1-3) offered considerable
Promise they were complicated by the small number of patients
studied. We now have given clonidine acutely in a dose of 6 ug/kg
and chronically in a dose of 17 ug/kg/day in an inpatient setting
to 100 opiate addicts after withdrawal from 10-80 mg of chronic
methadone treatment.
SUBJECTS AND METHODS
Subjects were patients who had been addicted to opiates for up
to fifteen years. They all expressed interest in discontinuing
methadone and gave informed consent to a study which required an
abrupt withdrawal from methadone three days after admission to the
Evaluation and Research Unit and at least 36 hours with no opiate
administration. All patients had previous unsuccessful attempts at
detoxifying from opiates. All had objective signs of opiate with-
drawal. Patients were observed for the presence or absence of with-
drawal signs and symptoms by a research nurse clinician every hour
from 8:00 a.m. while the patients were at bed rest during the day
of clonidine administration (1). The nurse rated twenty-one items,
associated with withdrawal (1) as present or absent, the total
score being added to give a measure of withdrawal severity. The
symptoms and signs were opiate craving, anxiety, yawning, perspira-
tion, lacrimation, rhinorrhea, yen sleep, mydriasis, goose flesh,
tremors, hot and cold flashes, aching bones and muscles, anorexia,
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increased blood pressure, insomnia, increased temperature, increas-
ed respiratory rate and depth, increased pulse rate, restlessness,
nausea and vomiting, and diarrhea. After the first day of clonidine
administration, the patients were administered clonidine 17 ug/kg/day
in divided doses and rated three times a day before clonidine ad-
ministration for opiate withdrawal symptoms by a research nurse
clinician. In addition, all patients completed self-rating analog
scales. These analog rating scales were utilized to assess for
changes in nervousness, being high, unpleasantness, energy, irrita-
bility, fear and anger. They were completed every hour from 9:00
a.m. during three times a day prior to clonidine administration. On
the first day, the patients took 6 ug/kg of clonidine or placebo
orally in matching vehicles to demonstrate the effect of clonidine
on opiate withdrawal signs and symptoms and to assess the changes
in blood pressure produced by this dose of clonidine. After the
initial clonidine and placebo administration, patients without pre-
cipitous blood pressure declines were given clonidine 17 ug/kg/day
for at least nine days. Clonidine dose was gradually decreased to
zero by day fourteen. Naloxone (1.2 mg) was given intravenously to
assess for Naltraxone readiness. All patients were excluded who had
a previous history of cardiac arrhythmias, hypotension, vasomotor
instability, psychiatric illness or hospitalization (6).
RESULTS
Acute First Dose Study
The number of opiate withdrawal signs increased during the baseline
period. Clonidine 6 ug/kg produced a rapid and significant decrease
in opiate withdrawal signs and symptoms to 0.9±0.5 at 120 minutes
(paired t test p<0.01). Opiate withdrawal ratings remained un-
changed for an additional 240 minutes. Systolic and diastolic
blood pressure was significantly reduced at 120 minutes after
clonidine administration (p<0.01). Blood pressure was not signif-
icantly changed over the next 240 minutes. Relief of subjective
and objective distress was significant.
On self-rating analog scales where 70 is the highest score, there
were significant (p<0.01) decreases in self-rated nervousness,
irritability, "uninvolved" and "angry" scales at 120 minutes. There
were no significant changes noted in self-rating analog scales for
energy or feeling "high." Placebo had no significant effects on any
of the above measurements or ratings. The effect of clonidine was
not significantly different for those patients addicted to low or
moderate doses of methadone.
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Figure 1
All 100 patients were continued on clonidine in an inpatient hospi-
tal setting. None of the patients chose a return to methadone after
their first dose of clonidine. On the first day of clonidine ad-
ministration, the patients were given 6 ug/kg as a test dose and
then 6 ug/kg at bedtime. Thereafter, 17 ug/kg/day of clonidine was
given in divided doses of 7 ug/kg at 8:00 a.m. and 3 ug/kg at 4:00
p.m. and 7 ug/kg at 11:00 p.m. Each day vital signs and nurses' ab-
stinence ratings and self-ratings were done as described previously
(l-3). Clonidine doses were withheld in some cases due to severe
hypotension. Additional clonidine was given, if needed. There were
no significant changes in the abstinence ratings during this ten-day
inpatient trial. The majority of patients, however, complained of
difficulty in falling asleep. Dry mouth, sluggishness, depression
and occasional bone pain were more infrequent complaints. Systolic
and diastolic blood pressure remained significantly decreased
throughout the nine days of 17 ug/kg of clonidine administration.
There were no significant increases or decreases in self-rated ner-
vousness, irritability, uninvolved, angry, fear, "high" or energy.
Clonidine dose was decreased to compensate for oversedation or hypo-
tension. On days 11,12,13 the clonidine dose was decreased by 50%.
On day 14, the patients received no clonidine whatsoever. None of the
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339-844 0 - 81 - 8
Figure 2
patients showed any increase in opiate withdrawal signs or symptoms
or had the emergence of clonidine withdrawal symptoms using this
protocol. One patient eloped from the hospital on day 5 of the
study. On day all patients were given Naloxoma (1.2 mg) intra-
venously to assess for residual opiates or dependence. All Naloxone
test responses were negative. Ninety-nine of the 100 patients com-
pleted the 14-day inpatient study and were Naltrexon–ready.
DISCUSSION
As compared to our previous studies (1-4) the data reported here
were not confounded by small sample size, difficulties in compli-
ance and other drug use. All patients in this study were success-
fully detoxified from chronic methadone addiction in an inpatient
setting and all but one were fourteen or more days without any
opiate administration at the time of discharge from the hospital.
This detoxification success rate is much greater than our experience
or data reported in the literature for methadone detoxification
groups. Clonidine could be given in high enough doses to reverse
all opiate withdrawal signs and the resultant significant and poten-
tially serious decreases in systolic and diastolic blood pressure
were successfully managed in the hospital. Finally, the risk of
illicit drug adding to the hypotensive effects of clonidine
was prevented in this inpatient study.
In this inpatient detoxification study, we have shown that clonidine
is a safe and effective non-opiate treatment for opiate withdrawal
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which suppresses the symptoms and sighs of opiate withdrawal as well
as the affective changes associated with opiate withdrawal. Affects
associated with withdrawal such as anxiety, irritability and anger
were rapidly reduced after clonidine administration. Clonidine is
therefore extremely useful as a noneuphorogenic treatment for detox-
ification. Some of the advantages of clonidine detoxification are
listed in Table 1. This 14-day inpatient clonidine detoxification
protocol could be useful in the treatment of selected opiate addicts.
For example, clonidine detoxification could be linked to maintenance
on long acting opiate antagonists such as Naltrexone. Clonidine,
being a nonopiate, allows the patient to abruptly discontinue opiate
administration and opiate-free long enough to initiate maintenance
treatment with Naltrexone. Clonidine detoxification my allow the
detoxification of patients maintained on methadone who have had pre-
vious unsuccessful attempts to detoxify due to the norbidity of cur-
rent slow detoxification practices. Clonidine is also potentially
useful in the treatmant of iatrogenic addictions and the protracted
abstinence syndrome where the risk of exposure toopiates might be
reduced. Clonidine appears most useful in the treatment of working
patients, iatrogenic addictions, nondrug-using methadone maintenance
patients, patients with family and work support systems who are also
good candidates for Naltrexone.
Table 1
1. Rapid
2. Nonopiate
3. Noneuphoria-producing
4. High success of inpatient detoxification
5. High success of Naltrexone induction
6. Provide drug-free or Naltrexone alternative to methadone main-
tenance, for:
a. Iatrogenic addictions
b. Pill, cough medicine, "nonstreet" opiate addiction
c. Suburban addict with no previous exposure to clinic-
related drug abuse and crime
7. Ideally suited for the working addict
8. Enhance the role of M.D. and M.D.-patient relationship
9. Define and limit the role of maintenance methadone
In summary, the effects of clonidine on opiate withdrawal in man
(1-4,9) and rodent (5,7,8) provide pharmacogical support for a
noradrenergic hyperactivity hypothesis for opiate withdrawal and
suggest that clonidine reverses opiate withdrawal by replacing
opiate-mediated inhibition with alpha--2 adrenergic and opiate re
ceptors, my become activated in opiate withdrawal-related panic
states and possibly naturally occurring panic states.
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Clonidine Hydrochloride
Detoxification From Methadone
Treatments: The Value of
Naltrexone Aftercare
R. A. Rawson, A. M. Washton, R. B. Resnick, and
F. S. Tennant, Jr.
At the past two meetings of the Committee on Problems of Drug
Dependence, data have been presented which indicate that
clonidine hydrochloride can be effective in alleviating opiate
withdrawal symptoms (Gold, Redmond and Kleber, 1978a; Washton,
Resnick, and Rawson, 1980a). These presentations and a number of
recently published reports (Gold, Redmond and Kleber, 1978b;
Washton, Resnick and Rawson, 1980b) have aroused substantial
public interest in developing clonidine as a treatment for
relieving opiate withdrawal symptoms. Although the extent of
clonidine's clinical usefulness has not yet been determined, it is
already apparent that clonidine is uniquely suited for one purpose
which no other opiate detoxification agent can adequately address.
Since it is not an opiate, clonidine is precisely the type of drug
needed for the rapid detoxification of patients from opiates prior
to their induction onto the narcotic antagonist, naltrexone.
A review of the work on naltrexone indicates that one of the
limiting factors in the use of the drug has been the inability of
patients to become sufficiently opiate free prior to induction
onto the medication. In addition, some of the high early dropout
rates from naltrexone treatment may have been due to patient
discomfort from mild precipitated withdrawal symptoms resulting
from incomplete prenaltrexone detoxification.
If clonidine can be developed as a viable prenaltrexone
detoxification agent, the usefulness of naltrexone treatment may
be greatly enhanced. This possibility is supported by data
presented in the Washton and Resnick paper in this volune, which
indicates that 72 percent of the methadone maintenance patients
detoxified with clonidine successfully were inducted onto
naltrexone. This is a substantial improvement over prior
prenaltrexone detoxification methods. For example, in Leo
Hollister's summary of the National Research Council Committee
on Clinical Evaluation of Narcotic Antagonists, only 21 percent of
those methadone maintenance patients who volunteered for naltrexone
treatment took an initial dose of the medication.
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The efficacy of clonidine to relieve opiate withdrawal symptoms
to such a degree that the transition from methadone to naltrexone
is accomplishable raises a further question. If clonidine can
relieve withdrawal symptoms to such a degree that patients can
achieve the 10-day opiate-free period necessary to start naltrexone,
is it possible that the methadone to drug free transition can be
made without the intermediate step of naltrexone treatment? If
opiate withdrawal symptoms can be relieved substantially during
the initial postmethadone period, the naltrexone step may be
unnecessary in progressing from methadone treatment to drug free
status.
The purpose of this study is to evaluate the usefulness of
naltrexone aftercare following clonidine detoxification from
methadone maintenance treatment. This paper contains data from
a collaborative study between New York Medical College and
Community Health Projects in West Covina, California.
METHOD
Subjects and Setting
Subjects were selected from two methadone maintenance clinic
populations. Subjects in the clonidine/naltrexone group were
selected from volunteers at the New York Medical College Division
of Drug Abuse Research and Treatment. Subjects in the clonidine
only group were selected from volunteers at the Community Health
Projects clinics located in the San Gabriel Valley, 30 miles east
of Los Angeles. All subjects had at least a two-year history of
opiate use and were over 18 years of age.
Obviously, the results of the clonidine only versus clonidine/
naltrexone group comparison must be interpreted cautiously in view
of the corresponding California - New York difference. However,
two considerations mitigate the importance of the location
difference. First, as can be seen from Table 1, there were no
significant differences between the subject samples on a variety
of important demographic, psychosocial and drug history variables.
Second, the senior author (Rawson) was involved with the
coordination of the study in both sites. All data collection
instruments and clonidine treatment procedures were identical for
subjects in both groups. All subjects entering treatment in both
groups sought out treatment due to their desire to detoxify with
clonidine. Most of the subjects had never heard of naltrexone
and many in the clonidine/naltrexone group were initially sceptical
of the need for naltrexone aftercare.
Procedure
At the time of the intake interview, demographic, psychosocial
and drug history data were collected from all subjects. In a
subsequent interview with the study coordinator (Rawson) a
description of the clonidine detoxification program was presented
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to each subject and the clonidine informed consent forms were
signed. In addition, subjects in the clonidine/naltrexone group
were presented information about naltrexone and required to sign
a naltrexone informed consent form. Subjects in the clonidine/
naltrexone group were informed of the necessity of achieving a
10-day opiate-free period in order to start naltrexone with no
precipitated withdrawal symptoms. Subjects in the clonidine only
group were informed that the 10-day opiate-free period was
extremely important if they were to successfully accomplish their
detoxification from methadone and achieve opiate abstinence.
Subjects were subsequently treated in an identical manner throughout
the clonidine detoxification procedure.
The detoxification was initiated with an abrupt switch from
methadone to clonidine. The dose was adjusted for each patient
so as to maximize therapeutic benefit and minimize the occurrence
of adverse side effects such as sedation and orthostatic
hypotension. Similar amounts of clonidine were used for subjects
in both groups. Ten days after opiates were discontinued, a
naloxone challenge of 1.2 mg was administered to confirm opiate-
free status. For subjects in the clonidine/naltrexone group, a
negative naloxone challenge also provided the necessary screening
procedure to determine readiness for naltrexone induction. On
the day following the naloxone challenge clonidine doses were
gradually reduced by 0.1 or 0.2 mg decrements per day until a
zero dose was reached. While on clonidine, subjects were seen
5 days per week for a recording of withdrawal symptom ratings,
blood pressure, medication adjustments and a self-report of drug
use.
At the completion of their detoxification, subjects in the clonidine
only group were encouraged to stay in drug free psychotherapy
offered at the same facility or accept referrals to a residential
program. Subjects in the clonidine/naltrexone group were encouraged
to stay in postdetoxification treatment with naltrexone which
required three clinic visits per week. Naltrexone treatment
consists of 100 mg doses of naltrexone on Monday and Wednesday and
a 150 mg dose on Friday. None of the subjects at either facility
were engaged in counseling or psychotherapy during the
detoxification period.
RESULTS AND DISCUSSION
The primary question addressed by this study is whether
naltrexone aftercare facilitates the success of clonidine
detoxification from methadone maintenance. "Detoxification
Success" is operationally defined by the following criteria:
1. The completion of a 10-day opiate-free period following
discontinuation of methadone; and
2. The opiate use status of subjects 30 days postmethadone.
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Clonidine Detoxification Period (last day of methadone to day 10
postmethadone)
Table 2 presents a group comparison of "success rates" of subjects
regarding their ability to achieve a 10-day opiate-free period
following the discontinuation of methadone maintenance treatment.
As can be seen from this table, 9 of 12, or 75 percent of those
subjects in the clonidine/naltrexone group achieved the 10-day
opiate-free criterion, while only 3 of 12 or 25 percent of the
clonidine only group were successful (X2 = 6.0, df=1, P<.05).
These data suggest that the availability of naltrexone on day
10 postmethadone affects the success of a clonidine detoxification
procedure on days 1-9 postmethadone. One explanation for this
finding is that although both groups of subjects were nearly
identical on a broad range of pretreatment variables, it is
possible that the clonidine was simply less effective in relieving
the withdrawal symptoms of subjects in the clonidine only group.
This explanation appears unlikely since the symptoms rating data
collected from subjects were extremely similar at both facilities.
Specifically, subjects in both groups found clonidine to be:
extremely useful in relieving physical and autonomic signs of
withdrawal; moderately useful in relieving anxiety, restlessness
and insomnia; and not useful in relieving anergia. Other
evidence to suggest that clonidine was successful in reducing the
severity of withdrawal symptoms was that few of the subjects in
either group prematurely terminated their detoxification due to
unacceptable levels of withdrawal discomfort. Table 3 lists the
reasons given by the 12 subjects who discontinued their
detoxification when asked why they had decided to stop. As is
shown in this table, most of the subjects experienced extreme
opiate craving as well as problems at work and at home, but few
of the subjects reported that unacceptably high levels of
withdrawal symptoms were instrumental in the discontinuation of
their detoxification.
The differential efficacy of the clonidine detoxification
procedure between the two groups of subjects does not appear to
have been a result of differential symptom relief; rather, it
appears to have been the result of different subject attitudes
toward their detoxification. Subjects in the clonidine/naltrexone
group perceived the clonidine detoxification as a transitional
treatment with a specific goal. Naltrexone induction on day
10 postmethadone was perceived as a clear endpoint to the
detoxification. Subjects in this group frequently expressed the
feeling that they had "made it" when they started naltrexone and
many reported feeling relief that once on naltrexone they no
longer had to struggle with the urges and cravings to use opiates.
It appeared that if the clonidine procedure was perceived by
subjects as being for a specific number of days with a clear goal
and endpoint such as starting naltrexone, most of them could
exert sufficient control to abstain from opiate use for the 10
days post methadone.
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Subjects in the clonidine only group did not appear to view the
detoxification process as having a clear endpoint. Although they
were told that a 10-day opiate-free period was necessary, 9 of
12 were not able to achieve this 10-day abstinence period. As
previously noted the return to opiate use was not attributed to
withdrawal symptom relief but rather to an inability of subjects
to resist opiate urges and cravings.
Postdetoxification Period (Day 10 to Day 30 postmethadone)
Table 4 presents the opiate use status of subjects in the two
groups on day 30 postmethadone. As shown in the table, 7 of 12
of the clonidine/naltrexone group subjects were on naltrexone
and/or opiate free on day 30, while only 2 of the 12 clonidine
only group subjects were opiate free (X2 =  4.42, df=1, P<.05).
These data strongly support the contention that naltrexone can
be extremely useful in preventing readdiction to opiates during
the initial postmethadone period. Additionally, these data
should serve as a caution to those who may have unrealistic
expectations about the role of clonidine in addiction treatment.
Patient anecdotal reports and symptom rating scores strongly
suggest that clonidine will provide substantial relief from
opiate withdrawal symptoms. However, for patients who do find
clonidine useful, it is useful only as part of a comprehensive
treatment plan with a clearly defined aftercare program. The
expectation that several weeks of clonidine treatment will
provide a sufficient postmethadone treatment is not supported.
It is clear that during the initial postmethadone period patients
are extremely vulnerable to readdiction even with the benefit
provided by clonidine.
SUMMARY
From the data collected in this collaborative New York Medical
College - Community Health Projects study, the following conclusions
are possible.
1. Based upon subject reports and symptom rating data,
clonidine hydrochloride provided substantial relief from
opiate withdrawal symptoms. The degree of symptom-relief
and the cluster of symptoms most improved appeared similar
for both groups of subjects.
2. The availability of naltrexone aftercare significantly
increased the success rates of subjects in achieving a 10-
day opiate-free period following the discontinuation of
methadone.
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3.
4.
5.
The relapse to opiate use during the clonidine detoxification
period was reported by most subjects to be the result of
extreme opiate craving brought on by environmental and
psychosocial variables, rather than a response to severe
withdrawal symptoms.
The induction onto naltrexone provided a tangible endpoint
to the detoxification process. Subjects who viewed the
detoxification process in this manner appeared to be better
able to control their impulses to use opiates.
The availability of naltrexone aftercare significantly
improved the 30-day postmethadone followup results. A
significantly higher percentage of those subjects in the
naltrexone group were opiate free at the 30-day followup
point than were subjects for whom naltrexone was not available.
TABLE 1
PRETREATMENT SUBJECT CHARACTERISTICS
Mean Age
Mean Years Addicted
Male/Female Ratio
Anglo/Black or Hispanic
Mean Methadone Maintenance Dose
Mean Methadone Dose When
Switched to Clonidine
Percent Employed
Percent in a Relationship
Percent Who Bad Used Illicit
Opiates During Month Prior to
Detoxification
Clonidine Only Clonidine/
Group Naltrexone Group
31
9.7
11/1
9/3
44 mgs.
22.3
58%
90%
30
10.1
10/2
7/5
41 mgs.
20
50%
75%
66% 58%
TABLE 2
SUBJECTS SUCCESSFULLY ACHIEVING
TEN DAYS OPIATE FREE
Number Number
Successful Unsuccessful
Clonidine Only Group 3
Clonidine/Naltrexone Group 9
X2 = 6.0, DF = 1, P<.05
9
3
106
TABLE 3
REASONS CITED FOR RETURN TO OPIATE USE*
Number of Subjects
Reporting Problem
Extreme Craving for Opiates
Coping with Employment-Related Stress
Coping with Family/Interpersonal
Problems
Relief from Depression
Relief from Boredom
"Someone Came By With Heroin"
Relief from Withdrawal-Related Insomnia
Relief from Withdrawal/Clonidine Related
Anergia
Relief from All Other Withdrawal Symptoms
7
5
7
3
3
2
2
2
1
*Some Subjects Cited More Than One Reason
TABLE 4
SUBJECT STATUS 30 DAYS POSTMETHADONE
Clonidine Only Clonidine/
Status Group Naltrexone Group
Opiate Free, In Postdetoxification
Treatment (includes naltrexone) 0 6
Opiate Free, Not In Treatment 2 1
Returned to Methadone Maintenance 5 3
Using Illicit Opiates 5 2
Total 12 12
Summary*
Opiate Free 2 7
Not Opiate Free 10 5
* x2 = 4.42, DF = 1, P<.05
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Psychotherapy and Naltrexone in
Opioid Dependence
R. B. Resnick, A. M. Washton, N. Stone-Washton
An issue of current importance to psychiatry is the efficacy of
psychotherapy and phamacotherapy in comparison to one another and
in combination. In addiction treatment, the importance of individ-
ual counseling for the successful use of opioid antagonists such
as naltrexone has often been suggested but as yet there is insuffi-
cient data to support this contention. Furthermore, naltrexone ef-
ficacy studies have not controlled for the type or degree of pat-
ients' involvement in interpersonal aspects of treatment. The
present pilot study evaluated the effectiveness of naltrexone in
conjunction with a high intervention treatment that included indi-
vidual counseling as compared with a low intervention treatment
that excluded such counseling.
METHOD
Sixty-six opioid-dependent volunteers were randomly assigned at
intake to either a low intervention (N=31) or high intervention
(N=35) treatment group. All subjects were over 18 years of age,
had been addicted to opiates for at least one year, were free of
serious medical and psychiatric illness and signed an informed
consent. An attempt was made to match the two groups for level of
opioid dependence immediately prior to entering the study and num-
ber of subjects who entered the study from long-term methadone
maintenance as compared with those who entered with dependence on
illicit opioids (street addicts). All subjects were new admis-
sions to the treatment unit since it was felt that a prior treat-
ment history at this facility would confound their assignment to
groups.
Because naltrexone treatment has been limited by high drop-out
rates before subjects even received the first naltrexone dose, sub-
jects were assigned to their treatment group prior to detoxifica-
tion in order to assess whether the intervention level would af-
fect naltrexone induction rates. The detoxification period also
seemed to be an opportune time to initiate a therapeutic relation-
ship with subjects in the high intervention group.
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All subjects were offered identical medical and nursing services
which included detoxification from opioids followed by maintenance
on naltrexone requiring three clinic visits per week. Each high
intervention subject was additionally offered regularly scheduled
psychotherapy sessions with an experienced therapist who closely
monitored the patients' clinical course and was available to pro-
vide a variety of services. The therapy included supportive, dir-
ective and insight-oriented techniques, depending on the orienta-
tion of the therapist, the needs of the patient, and what seemed
to be most helpful at a particular point in time. In addition to
offering at least one scheduled therapy session each week, the
therapist maintained a high level of availability to assist with
problems that my have emerged between the scheduled sessions.
Therapists encouraged patients to contact them at the clinic or at
home if there was a need for services outside the scheduled visits.
Subjects were telephoned by therapists whenever they failed to ap-
pear for a scheduled clinic visit. In general, therapists made an
active attempt to provide patients with continuing emotional sup-
port and develop a strong therapeutic alliance.
Low intervention subjects were assigned a case manager who provid-
ed only concrete services, referral to outside agencies, or crises
intervention. The case managers were instructed to avoid engaging
patients in a therapeutic relationship, i.e., no attempt was made
to encourage discussions about personal problems or to contact sub-
jects when a clinic visit was missed, Low intervention subjects
requesting psychotherapy were referred to community agencies or
private practitioners who could provide such services. In all
cases an attempt was made to service the needs of low intervention
subjects without promoting a close personal bond between the sub-
ject and staff members.
The frequency and duration of contacts with the staff were recorded
for each subject. The contacts were classified as either: (1) Med-
ical/Data Collection contacts, or, (2) counseling contacts. Con-
tacts with the physician that primarily addressed medication is-
sues, physical examinations and symptoms or with the project co-
ordinator for obtaining data on mod or psychosocial functioning
were designated Medical/Data Collection contacts. Contacts with
the therapist, case manager or nurse that primarily concerned other
issues were designated Counseling. For high intervention subjects
counseling included formal therapy sessions as well as telephone
and other contacts that provided advice, encouragement, or support
on an informal basis. For low intervention subjects, Counsel-
ing contacts consisted of discussion about referrals to outside
agencies or time spent providing crisis intervention.
Outcome evaluations were made with respect to: 1) detoxification
success rates; 2) naltrexone retention rates, and 3) opiate use
status at three and six months following the first naltrexone dose.
RESULTS
Table 1 shows that before entering the study the high and low in-
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tervention subjects were comparable with respect to several key
demographic, psychosocial, and drug use variables,
TABLE 1
DEMOGRAPHIC AND DRUG HISTORY VARIABLES FOR
HIGH vs. LOW INTERVENTION GROUPS
High Low
Intervention Intervention
(N=35) (N=31)
Sex
Male 66% 71%
Female 34% 29%
Ethnicity
black 26% 29%
Hispanic 8%
66%
3%
white 68%
% Employed 49% 52%
% in significant interpersonal
relationship 66% 76%
Mean Age (years) 28.5 29.8
Years Addicted 7.8 9.0
Longest Opiate-Free Period 8 months 13 months
Longest Period Employed 3.3 years 3.3 years
Level of Dependence
Street Addictson Heroin $67/day $55/day
Street Addicts on Methadone 36 mg 38  mg
Methadone Maint. Patients 30 mg 41 mg
The contact time data shown in Figure 1 indicates that although
both groups received almost the same amount of time over medical
issues and data collection, the high intervention group spent sig-
nificantly more time with their therapist discussing interpersonal
problem and issues concerning psychosocial functioning. Counsel-
ing contact time for high intervention subjects averaged about 70
minutes per week throughout the study. For low intervention sub-
jects counseling time averaged less than 20 minutes per week during
detoxification and then dropped to less than half that time until
treatment termination. For both high and low intervention groups
there was an average of 45 minutes per week in Medical/Data Col-
lection contacts during the early phase of treatment, when all sub-
jects were seen for 10-15 minutes 3-5 times a week for symptom re-
view and medication adjustments.
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FIGURE 1
MEAN WEEKLY CONTACT TIME BETWEEN THE SUBJECTS AND STAFF FOR
HIGH vs. LOW INTERVENTION GROUPS
During Detoxification and
1st Two Weeks on Naltrexone Week Three to Termination
FIGURE 2
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Figure 2 compares detoxification success rates (i.e., naltrexone
induction rates) for the high and low intervention subjects. High
intervention subjects showed greater detoxification success rates
than low intervention subjects (73 percent vs. 57 percent) al-
though this difference was not statistically significant (> .05).
Table 2 compares time on naltrexone for the two treatment groups.
High intervention subjects tended to remain on naltrexone for a
longer period of time and this finding was statistically signifi-
cant for subjects who detoxified from illicit opioids but not for
those who entered the study from methadone maintenance. Illicit
opioid users who received the high intervention treatment remained
on naltrexone an average of 9.3 weeks and as long as 26 weeks,
whereas those who received the low intervention treatment remained
on naltrexone an average of only 2.1 weeks and no longer than 7
weeks. These findings are also depicted graphically in Figure 3
which shows attrition rate curves for the two groups over the
first 26 weeks.
The bar graph in Figure 4 shows the percentage of subjects still
opiate-free at three and six months after starting naltrexone and
indicates a greater likelihood of opiate-free status for subjects
in high intervention treatment: 73 percent vs 40 percent at 3
months and 54 percent vs. 40 percent at six months follow-up, Of
those patients who were opioid dependent at follow-up, 70 percent
from the high intervention group had entered methadone maintenance
treatment and 30 percent were using illicit opioids, whereas only
33 percent from the low intervention group had entered methadone
maintenance and the remaining 67 percent were using illicit drugs.
TABLE 2
TIME ON NALTREXONE (WEEKS)
Total Sample
From
Methadone
Maintenance (N=18)
From
Illicit Opioids
(N=19)
High Low
Intervention Intervention
(N=22) (N=15)
Mean 8.0 3.6
Range 1-26 1-12
Mean 6.5 4.1
Range 2-18 1-12
Mean 9.3* 2.1
Range 1-26 1-7
* p < .05
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339-844 0 - 81 - 9
FIGURE 3
NALTREXONE ATTRITION RATES FOR WEEKS 1 to 26
(6 MOS.) FOR HIGH vs. LOW INTERVENTION GROUPS
FIGURE 4
FOLLOW-UP AT THREE AND SIX MONTHS AFTER FIRST NALTREXONE DOSE FOR
HIGH AND LOW INTERVENTION GROUPS
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DISCUSSION
We anticipated numerous problems in controlling the level of staff
intervention in a therapeutically oriented clinic that requires fre-
quent visits for medication. Specifically, we expected difficulty
in limiting the services provided to low intervention subjects for
two reasons: 1) all patients in the study were required to attend
the clinic three times per week for medication and therefore would
have frequent contact with the clinic staff; and 2) therapists as-
signed to case managers for low intervention patients would have
difficulty in limiting service delivery since this would be con-
trary to their training and philosophy.
The present study shows that it was possible to control the amount
and type of services rendered to patients by the therapists who
participated in the study. However, it was very difficult for the
majority of nursing and counseling staff not involved in the study
to limit contacts with low intervention patients, my of whom re-
ceived considerable unplanned and unrecorded intervention that my
have had a significant impact upon treatment outcome.
The amount of time in Medical/Data Collection contacts was rather
high during the early phases of treatment, although there was no
difference between the two treatment groups. During these "medi-
cal" contacts there was substantial encouragement and emotional
support given to the patients which may have obscured differences
in detoxification success rates between the high and low interven-
tion groups.
An additional factor which may have reduced outcome differences
between the two treatment groups is that three of the six subjects
in the low intervention group who were opiate-free at six months
follow-up had been receiving regularly scheduled psychotherapy at
other facilities.
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Type of Pre-Treatment Income
and Response to Treatment in
Methadone Maintenance
A. T. McLellan, J. C. Ball, L. Rosen, and C. P. O’Brien
INTRODUCTION
Among the major goals of psychiatric treatment in general, and drug
abuse rehabilitation in particular, is the development of the
patient's ability to support himself in a socially desirable manner.
Operationally, this means reducing dependence on public assistance
and illegal income, while increasing employment earnings. This
goal, in particular, may be central to the overall rehabilitation
effort and the maintenance of treatment gains in the areas of drug
abuse and psychosocial adjustment.
It must be admitted that treatments for drug abuse have had limited
success in achieving the goal of patient self-support (Savage and
Simpson 1977; Veterans Administration 1979; Sells and Simpson 1976).
However, given the variations within the drug-abusing population,
it is possible that treatment programs which are only moderately
effective with the total population, might be particularly success-
ful (or unsuccessful) with specific subgroups of the population.
In this regard, we felt that the amount and sources of patient's
pre-treatment income might serve as predictors of post-treatment
adjustment in the area of self-support. Specifically, we had no-
ticed three distinctly different sources of income within our patient
population: earnings from employment, money from public assistance
or other support agencies, and illegal income. We were, therefore,
interested in the relationships between these three sources of
income within the population and the extent to which these relation-
ships changed following drug abuse treatment.
METHOD
Subjects - Subjects were 165 male narcotic-dependent veterans ad-
mitted to the methadone maintenance program of the Drug Dependence
Treatment Service (DDTS) at the Philadelphia VA Medical Center.
This sample included all patients who were admitted during the
period July 1, 1978 to June 30, 1979 and who remained in treat-
ment for at least one month.
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Data Collection Instrument - The instrument used to provide both
the admission and six-month data was the Addiction Severity Index
(ASI) which is described in detail in another article within this
volume (Veterans Administration 1979).
Procedure
We initially focused on those questions from the admission ASI which
identified the amount and sources of the patient's net income during
the 30 days prior to the start of treatment. It should be noted
that these responses were self-reports, and while some of the figures
were estimates, validity checks were built into the ASI and we have
found this self-report data to be generally quite accurate (Ball
1972; McLellan and Druley 1977). An examination of the data sug-
gested that the sources of monthly income could be condensed into
three categories: employment, support, and illegal.
Employment income was defined as the net cash value of salaries
earned from full or parttime work from either regular or unreported
"odd jobs." Unemployment compensation was not included. Eighty-
nine patients (54 percent) reported some income from employment at
the time of admission.
Support income was defined as the total value of monies derived
from public assistance (DPA), Social Security, pension, health bene-
fit plan, and from family or friends. Only cash income was in-
cluded, thus room and board were not considered in this total.
Ninety-five patients (58 percent) reported some income from support
sources (generally DPA) at the time of admission.
Illegal income was estimated as the net worth of cash and goods re-
ceived from criminal activity. The majority of illegal income was
derived from burglaries, theft, robbery, or drug sales. Eighty-
three patients (50 percent) reported some income from illegal
activity.
Twenty-one patients (12 percent) reported income from only one of
these sources, 66 (40 percent) reported two sources, and 44 (27
percent) reported three sources of income. The mean income for the
total population during the month preceding admission was $510
(S.D.=640) with an average of $230 (S.D.=612) from illegal sources,
$206 (S.D.=418) from employment, and $74 (S.D.=216) from social sup-
port. However, the population mean and standard deviations for each
of these sources indicated considerable population variance in the
amount and sources of income, suggesting that the population might
be comprised of several distinct subgroups having more homogeneous
types of income.
The admission income data indicated that 43 patients had had virtu-
ally no income during the month preceding drug treatment, due to
hospitalization or incarceration. An inspection of the individual
income data on the remaining patients suggested that most subjects
received the majority of their monthly income from one of the three
major income sources. We therefore attempted to divide the remain-
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 ing patients based on the source of at least 45 percent of their
total monthly income. This division resulted in 30 patients who
received at least 45 percent of their monthly income from employ-
ment, 42 who received primarily support, and 36 patients who re-
ported primarily illegal income. An additional group of 14 patients
comprised a heterogenous group of subjects who did not fit into the
prior categories for various reasons. Thus, in the remainder of
the paper we will focus upon the main income groups since they pre-
sented the clearest income picture and were representative of three
basic economic subtypes within the population.
The admission status of each of the three main income groups is
shown in table 1 in terms of demographic, background and treatment
history measures. Although the groups were rather similar with re-
gard to several of the demographic and educational variables, there
were clear differences among them in most of the comparison items.
It is important to note that the total monthly incomes within each
of the three groups were approximately normally distributed with
small standard deviations, thus quite representative of the income
patterns of the individuals within each group.
RESULTS
Population Change - The pre-post comparisons (paired t-test) for
the three major groups, as well as the total population (N=165)
are summarized in table 2. The table presents mean values for each
of the major groups on the ASI problem severity ratings, the days of
patient-reported problems, and the amounts of the three income
sources. The comparisons for the total population are presented
in the last columns of table 2, and as can be seen, there were sig-
nificant reductions in problem severity in the areas of drug abuse
(p < .01) , employment, and criminality (p < .05) . The subjective
reports of the patients also showed a significant (p < .01) reduc-
tion in the average number of days of drug use, from 20 in the month
prior to admission to 13 in the month prior to follow-up. Similar
reductions in "problem days" are seen in all areas, significantly
so in the areas of unemployment and family and social problems.
Finally, an examination of the population income figures indicates
a considerable increase (57 percent) in the total income from em-
ployment.
Changes in Income Groups - The pre-post comparisons for the three
major groups in the present study reveal the disparity of posttreat-
ment change within the population. While these three groups were
roughly alike in terms of their patterns of pretreatment problem
severity, only the Employment and Illegal groups showed evidence of
significant improvement by the time of follow-up. Both the Employ-
ment and Illegal groups reported significantly fewer days of drug
use and unemployment, as well as fewer days of family and social
problems. Significantly fewer criminal acts were shown by the
Illegal group, and fewer days of psychological problems were re-
ported by the Employment group. The improvement for these groups
was most evident in the significant reduction of illegal income
with corresponding increases in employment earnings.
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The performance of the Support group stands in marked contrast to
the results for the other two groups. The patients in the Support
group showed little criminal activity or illegal income at either
comparison point, but they also showed little evidence of employment
or income from earnings. In addition, there were no significant
changes shown in the other indicants of psychosocial adjustment.
Thus, methadone maintenance was not associated with posttreatment
improvement in any area for this group.
DISCUSSION
From a clinical perspective, two points were evident from the data.
First, specific improvement in the area of patient self-support was
highly related to general improvement in personal and psychosocial
adjustment. While it was not possible to determine the causal agent
in this relationship, the initial reduction of illicit drug use may
have made increased employment and decreased criminality possible.
It seems likely, however, that the maintenance of reduced drug use
and increased psychosocial adjustment may have relied heavily upon
the development of adequate and stable source of employment.
A second point which was clear from the data was that patients' pre-
treatment source of income was a powerful predictor of treatment
benefit. With regard to the actual outcomes of the study groups,
the results were somewhat surprising. The exceptional improvement
shown by the Illegal group was gratifying considering the reluctance
on the part of many programs to accept criminal justice system re-
ferrals. The absolute lack of improvement in the Support group
stands in direct contrast to the results for the Employment and
Illegal groups. We were struck by the stability of the Support
group over time, the increase in support income from admission to
follow-up, and the general absence of employment or illegal income
in the majority of these patients at both admission and follow-up.
The subjects in this group may be characterized as the "lethargic"
patients who apparently have little involvement with active pursuit
of income from either employment or illegal sources. It is important
to note that the poor employment record of this group was apparently
not due to more physical disability nor to less education and tech-
nical training (see table 1). Rather, these data suggest that many
of the patients in the Support group may be characterologically de-
pendent upon government sources of income, as well as physically de-
pendent upon opiates. This characterological or institutional de-
pendence may be a major reason why the Support group showed no evi-
dence of improvement in any area. It may be that these patients
require a program of intensive vocational and motivational develop-
ment as an adjunct to existing methadone maintenance. Regardless
of the potential reasons for their performance, it seems clear that
the program of methadone maintenance and counseling which was associ-
ated with significant improvement in the majority of this population
was not effective with this particular group of patients. It re-
mains to be seen if these results are generalizable to other drug
abuse treatment programs and to nonaddict populations. Nonetheless,
the methodology presented here is relevant to the evaluation of drug
abuse treatments, and the results may be useful in the clinical
management of other rehabilitation programs.
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TABLE 1
DRUG
ADMISSION STATUS OF 165 METHADONE MAINTENANCE PATIENTS
VARIABLE
N
MEAN AGE
% BLACK
YRS. EDUC.
MOS. TECH. TRNG.
% W/SKILL OR TRADE
% MARRIED/COHABIT
MEAN # PREVIOUS
TREATMENTS
ALCOHOL
PSYCH.
% W/PHYSICAL
DISABILITY
% GENERALLY EMPL.
PAST 3 YRS.
% ARRESTED
MAJOR CRIMES
MEAN TOTAL ARRESTS
INCOME PREVIOUS MONTH
EARNINGS
SUPPORT
ILLEGAL
TOTAL
EMP.
30
28
47
10.5
5
68
37
SUPP. ILLEGAL TOTAL
42 36 165
29 28 28
62 48 52
11 11 11
3.5 3 3
71 73 70
40 38 39
2.5 6.5
1 2.5
.5 1.0
3 5
40 7
11 6.5
3 1.5
3
1
.5
3
34
14
4
3.5
1.5
1.0
4
29
10.5
3.5
516 58 194 206
41 187 71 74
181 41 623 230
738 286 888 510
SIG
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+ = p < .05
* = p < .01
SEVERITY RATINGS
0-9
TABLE 2
PRE-POST TREATMENT COMPARISONS
EMPLOYMENT SUPPORT ILLEGAL TOTAL1
30
P R E POST PRE
Abuse
Medical
Emp/Sup
Emp/Sup
Legal
Psych
6.0
3.0
3.0
5.0
4.0
4.5
4.0
3.0
3.0
4.5
2.5*
2.5*
7.0
4.0
5.5
5.0
3.0
5.5
PROBLEM DAYS
PAST MONTH
Used Drugs 23 11*
Med. Probs. 4 3
Days   Unemp. 15 8+
Fam/Soc Probs. 11 8
Crime Days 6 3
Psych Probs. 6 2+
21
6
19
4
4
6
INCOME PAST MONTH
Earnings 516 631* 58
Support 41 30 187
Illegal 181 116+ 41
TOTAL 738 777+ 286
42
6.0 6.0
3.5 3.5
5.5
4.5
5.0
6.0
2.5 6.5
5.0 3.0
3.5*
3.0
4.0*
4.0+
3.5*
3.0
6.6
3.5
5.5
5.5
4.5
4.0
5.0*
3.0
4.5+
4.5+
3.0
3.5
17 24
4 5
15 14
4
6
11
6 4
13*
10+
8*
6*
3
20
5
16
12
7
6
13*
4
11+
7+
4
5
64 194
201
440 623
71
305 888
501* 206 341*
44 74 68
247* 230 112*
792+ 510 521
‘Results for the Jail (N=19), Hospital (N=24), and Other (N=14) group comparisons are presented in the text.
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PRE POSTPOST
4
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Certain Types of Substance
Abuse Patients Do Better in
Certain Kinds of Treatments:
Evidence for Patient-Program
Matching
A. T. McLellan, C. P. O’Brien, L. Luborsky, K. A. Druley,
and G. E. Woody
INTRODUCTION
Recently, there have been criticisms of treatment effectiveness in
the mental health field, especially the available treatments for
the substance abuse disorders of alcoholism and drug addiction
(Cummings 1979). The results of several treatment evaluation studies
in substance abuse have contributed to this view (Edwards et al.
1977; Armor 1978; Bale et al. 1980). These studies have concluded
that while there is evidence that substance abuse treatments are
generally more effective than no treatment, there is no indication
that different types of treatments produce significantly different
outcomes, or that these particular types of treatment are diffen-
tially effective with specific types of patients.
The present paper reports evidence of significant differences in
outcome among six treatment programs, and evidence for differential
effectiveness of these treatment programs with various types of
substance abuse patients. This evidence results from a cooperative,
Veterans Administration study of substance abuse treatment effective-
ness in a population of approximately 1000 male, veteran alcoholics
and drug addicts from the Philadelphia region. The design of the
study has been described previously (McLellan et al. 1980), and we
have shown greater improvement and better outcomes in the treated
groups than in a slightly treated control group (McLellan et al.
under review). Thus, the purpose of this paper is to examine the
issue of patient-program matching and to offer some methodological
explanations for the lack of differential treatment effects in pre-
vious evaluations.
METHOD
Treatment Programs - The substance abuse treatment network of the
Veterans Administration in the Philadelphia area consists of 4 in-
patient (2 alcohol, 1 drug, 1 combined) programs at the Coatesville
VA Medical Center, plus outpatient alcohol and drug abuse clier
at the Philadelphia VA Medical Center. This treatment network has
enjoyed cooperative referral arrangements since 1975. Once admitted
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to substance abuse treatment at either hospital within the network,
patients were assigned to one of the six rehabilitation programs on
the basis of their personal requests, the clinical judgment of the
admitting staff, administrative considerations such as bed census
or patient visit criteria, and simple chance.
Subjects - All male veterans who presented for alcohol or drug abuse
treatment at either the Coatesville or Philadelphia VA Medical Cen-
ters during 1978 were eligible for the study. There were no sig-
nificant differences in demographic or background characteristics
between patients in the two hospitals, and approximately 90 percent
of all subjects were Philadelphia residents. There were no treatment
admission criteria other than eligibility for veterans’ benefits.
We initially evaluated 1035 male veterans who were admitted to al-
cohol (N=671) or drug abuse (N=364) rehabilitation programs at the
Coatesville or Philadelphia VA Medical Centers during 1978. Since
the aims of the study were confined to patients who had been effec-
tively engaged in the treatment process, we did not follow patients
who dropped out of treatment prior to 5 inpatient days or 5 out-
patient visits. We were able to contact approximately 85 percent
of the remaining 879 patients six months after admission to treat-
ment, and complete data were therefore available on 742 subjects
(460 alcoholics and 282 drug addicts).
All followup evaluations were done through ASI interviews between
an independent research technician and the patient, either in per-
son or over the phone. While much of the data is self-reported,
the ASI has built-in validity checks and we have found this self-
report data to be reliable and generally accurate (Ball 1972).
PROCEDURE
Developing Appropriate and Reliable Measures of Outcome - We felt
it was important to develop general measures of outcome since
assessments based solely on single item criteria (e.g., days of
drug use) offer meager and inherently unreliable (Nunnally 1967)
estimates of posttreatment status. We therefore constructed com-
posite outcome measures based on combinations of objective items
from each of the ASI areas. Several of the objective items within
each ASI area were intercorrelated to eliminate unrelated items,
and the remaining items were standardized, summed, and tested for
conjoint reliability using Cronbach's formula (Cronbach and Farby
1970). In this manner seven composite criteria were constructed
from sets of the ASI objective items, producing highly reliable
(.73 or higher) general measures of outcome in areas which are com-
monly affected by alcohol and drug abuse treatments.
Assessing the Role of Patient Factors and Treatment Program in
Determining Outcome - We were primarily interested in whether some
programs had shown better posttreatment outcomes than others, and
whether certain "types" of patients appeared to have better out-
comes in certain programs. However, we knew that the treatment
programs and the patients in them were quite different at the out-
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set of treatment, thus it would not be meaningful to compare outcome
results directly. We, therefore, required a statistical procedure
which would allow us to account for this pretreatment variation
and still detect outcome differences among programs and among
patient-program combinations. To this end we employed the stepwise
multiple regression procedure (Cohen and Cohen 1975).
The multiple regression analysis permitted us to sequentially enter
independent (predictor) variables which we considered important in
determining outcome as measured by each of our composite scores.
For each of these independent variables the regression analysis
performed two important functions. First, it tested whether the
specific independent variable explained a significant (p < .01)
proportion of outcome variance. Stated differently, the procedure
was able to determine if patients who differed on demographic, ad-
mission status or during-treatment variables (e.g., age, race, years
drinking, ASI psychological severity score), had significantly dif-
ferent scores on the outcome measure. Secondly, the regression pro-
cedure removed that portion of outcome variance accounted for by
all of these variables. In this manner, it was possible to adjust
(control) for pre-existing differences in demographic and admission
status factors before testing for significant effects due to treat-
ment programs and patient-program matches.
Four demographic variables were entered first (Age, Race, Education,
Number of Previous Treatments), followed by the pre-treatment ASI
severity scores (depicting the admission status of the patients)
and then the during-treatment measures of days-in-treatment and
type of discharge. Therefore, the criterion measures were adjusted
for differences in each of these variables prior to tests for dif-
ferences among programs and patient-by-program interactions.
RESULTS
Initial Findings for Alcoholics and Drug Addicts Examined Separately -
Regression analyses were calculated separately for the alcoholic
(N=460) and drug addict (N=282) samples on each of the seven outcome
criteria. An examination of the overall results indicated that the
majority of variables which were significant (p < .01) determinants
of outcome were demographic or admission status variables. Dis-
appointingly, there was virtually no evidence of significant patient
characteristic-by-treatment program interactions in either sample.
In short, these initial findings were quite comparable to results
of previous national reports showing no differences in outcome among
different treatments or among different patient-program combinations.
However, the results did show a clear and significant (p < .01) re-
lationship between the outcome measures and the patients' pretreat-
ment ASI psychological severity score. The correlations between
admission psychological severity and the six-month outcome measures
were calculated for both the Alcoholic and Drug Addict samples.
Significant relations were seen on 5 of the 7 measures for the
alcoholics, and on 4 of the 7 criteria for the drug addicts. In
every case, greater pretreatment psychological severity was related
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to poorer six-month outcome, and this variable alone accounted for
an average of 10 percent of the outcome variance.
The strength and pervasiveness of these relationships in the present
data suggested the possibility of further dividing the Alcoholic
and Drug Addict samples into LOW, MID, and HIGH groups, based upon
their pretreatment psychological severity scores, under the assump-
tion that qualitatively different results might appear. Thus the
regression analyses were repeated and were calculated separately
for each of these six groups.
Interpretation of Regression Analyses - Since seven regression
analyses were computed for each of these six groups, there were
obviously a large number of individual predictors for specific
criteria. In order to present these results in a clear and inter-
pretable fashion, we have summarized the data for all regressions
in the two LOW groups in table 1, for the two HIGH groups in table 2
and for the two MID groups in table 3. In these tables the left
hand margin indicates the category of independent (predictor)
variables and the order in which they were entered into the equations.
Findings for the Six Groups - When the Alcoholic and Drug Addict
samples were divided into groups based upon the psychological sev-
erity measure, several specific relationships emerged which had been
masked in the ungrouped analyses. For example, the regression re-
sults for the LOW groups were generally similar to the results for
the ungrouped data. That is, greater amounts of treatment were
associated with better outcomes, but there were no significant dif-
ferences in outcome between the different programs, and only a few
significant patient-program matches. However, an examination of
the outcome results (McLellan et al. under review) indicated that
these LOW group patients showed the best posttreatment status and
the most significant amount of improvement on virtually all mea-
sures. These data lead us to conclude that the LOW severity patients
have the best treatment prognosis generally, and appear to improve
significantly in any of the treatment programs to which they are
assigned. The admission characteristics of these patients and the
type of improvement shown are suggestive of the small group of al-
coholic patients described in the Rand Study (Armor et al. 1978)
who were able to return to "social drinking" following treatment.
It may be that non-abstinent goals are possible for some members
of this more intact group of patients. From a practical perspective
we have recommended that the majority of these LOW severity patients
be treated in an outpatient setting since this is the most economi-
cal, and seemingly equally effective alternative. Despite this
general conclusion, the data indicate (consistent with our clini-
cal experience) that even with the generally favorable prognosis
for this group, patients with significant family and/or employment
problems should be treated in an inpatient setting.
The results of our analyses in the HIGH groups also showed few
significant differences in outcome among programs and no significant
patient-program matches. However, unlike the LOW groups the HIGH
severity patients did not show better outcome with more treatment.
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We have previously reported (Gottheil et al. 1980) on this growing
proportion of psychiatrically ill substance abusers, and have dis-
cussed the special problems involved in treating them, within either
psychiatric or substance abuse programs. The present data, our
earlier reports, and our clinical experience indicate that none
of the programs currently available within our treatment network
are effective with these individuals. Interestingly, although treat-
ment outcome could not realistically be called satisfactory, the
Methadone Maintenance Program appeared to have the most positive
impact on the HIGH severity drug patients, possibly due to the regu-
latory and weak anti-psychotic effects of the methadone (McLellan
et al. 1979). In view of these results! we have recommended the
formation of a special, inpatient psychiatric-substance abuse ward,
staffed and run by psychiatrists and psychiatric personnel. It is
hoped that by focusing primarily upon the psychiatric aspects of
these individuals' addiction syndromes, it will be possible to con-
trol their substance abuse.
Once the HIGH and LOW groups (which comprised approximately 40 per-
cent of the total population) were separated from the remaining
(MID) population it was possible to discern significant differences
in outcome associated with specific treatments, and especially
associated with specific patient-program matches. For example, MID
patients (alcoholics and drug addicts) with more severe family and/
or employment problems had poorer outcomes in outpatient treatment.
These findings are consistent with our clinical experience and sug-
gest that while severe alcohol or drug use, and even medical or
legal problems, may be dealt with effectively in an outpatient set-
ting, family and employment problems appear to be clear contrain-
dications for outpatient treatment. Finally, two of the inpatient
alcohol abuse treatment programs showed evidence of poorer outcomes
with clients having more serious legal problems. We have suggested
that these clients be transferred to the Combined Treatment Program
or (in some cases) the Alcohol Outpatient Program which did not
show poorer outcome with these patients.
Clinical Implications - The present data, and other reports (McLellan
et al. 1980; McLellan et al. this volume) indicate the importance
of making independent pretreatment assessments of patient status
in several areas commonly affected by addiction. These addiction-
related problem severity measures were the most significant predic-
tors of outcome in all groups. The fact that patients with greater
pretreatment psychological severity showed the poorest outcome is
not surprising. What is remarkable is that alcohol and drug abuse
severity were not generally important in predicting outcome. In
fact, pretreatment psychological severity was a better predictor of
posttreatment drinking than pretreatment drinking. This finding
in particular suggests why previous predictive studies which have
used brief data collection instruments concentrating on demographic
and substance abuse variables have not demonstrated meaningful out-
come prediction.
Finally, the demonstration of significant differences in outcome
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as a function of interactions between patient factors and treatment
programs suggests that different forms of substance abuse treatment,
like other medical treatments, have specific as well as general
effects. Further, the data illustrate how the specific effects of
the treatment programs may combine with the particular treatment
needs of the patient to produce favorable outcomes, as well as clear
contraindications. We were gratified that the patient, treatment,
and patient-by-treatment factors which were statistically significant
in the analyses also made conceptual and clinical sense. These
factors which were statistically significant predictors of outcome
in the present study will be utilized as determinants of treatment
assignment in the next stage of our project (McLellan et al. 1980).
Thus, we will be able to determine if these factors can be of prac-
tical value in producing improved treatment effectiveness for the
six-program treatment network.
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Type of Variable
DEMOGRAPHIC
ADMISSION
SEVERITY
DURING TREATMENT
TREATMENT PROGRAM
INTERACTIONS
Table 1
OUTCOME PREDICTORS IN LOW SEVERITY PATIENTS
ALCOHOLICS DRUG ADDICTS
N=102 N=68
Variable R
1 Variable R
1
# Prior Trts. .32
Medical Severity .33 Drug Use Sev. .30
Employ. Severity .28 Employ Sev. .30
 Days in Trt. -.20 Days in Trt. -.28
i
Legal Sev. X FIDD .28 Emp. Sev X MM .28
MEAN OUTCOME VARIANCE EXPLAINED 34% 32%
Table 2
OUTCOME PREDICTORS IN HIGH SEVERITY PATIENTS
ALCOHOLICS DRUG ADDICTS
Type of Variable
N=82 N=53
Variable R 1 Variable R 1
DEMOGRAPHIC Age .30
ADMISSION SEVERITY Drug Use Sev. -.26
DURING TREATMENT
TREATMENT PROGRAM COMB .36 COMB
AOP
.44
.37
INTERACTIONS
MEAN OUTCOME VARIANCE EXPLAINED 48% 54%
1
Mean correlation between predictor and the seven outcome criteria
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339-844 0 - 81 - 10
Type of Variable
DEMOGRAPHIC
ADMISSION SEVERITY
DURING TREATMENT
TREATMENT PROGRAM
INTERACTIONS
TABLE 3
OUTCOME PREDICTORS IN PATIENTS WITH MID-LEVEL
PSYCHOLOGICAL SEVERITY
ALCOHOLICS DRUG ADDICTS
N=276 N=161
Variable Rl Variable Rl
Age .38 Race .37
# Prior Trts. .34 Age -.27
Family Sev. .28 Employ. Sev. .36
Legal Sev. .26
Days in Trt. -.38 Days in Trt. -.35
Type Disch. -.26 Type Disch. -.27
FIDD .25 COMB .33
Legal Sev. X FIDD .31 Fam. Sev. X MM .37
Emp. Sev. X AOP .30 Emp. Sev. X MM .34
Legal Sev. X ATU .28 Med. Sev. X DAR .30
Age X COMB .25 Drug Sev. X COMB .28
Fam. Sev. X AOP .24
Fam. Sev. X ATU .24
MEAN OUTCOME VARIANCE EXPLAINED 44% 48%
1Mean correlation between predictor and the seven outcome criteria
A Quantitative Evaluation of Fetal
Growth Failure in a Drug-Abusing
Population
R. J. Wapner, J. Fitzsimmons, R. D. Ross, M. E. Rudrauff,
A. B. Kurtz, and L. P. Finnegan
An association between maternal drug abuse during pregnancy and
low birth weight infants is known. A significant proportion of
these low birth weight infants are felt to be small for gesta-
tional age (SGA). The growth pattern and possible etiologies of
growth failure in these fetuses have not been well documented.
In order to study fetal growth, ultrasonic scans were performed
on 99 patients of The Family Center Program at Jefferson between
1/1/78 and 12/31/79. Biparietal diameters (BPD), head circum-
ferences, abdominal circumferences, and total intrauterine volumes
(TIUV) were measured. At delivery, weight, height, head circus-
ference and gestational age by Dubowitz score of each newborn was
recorded. Infants whose weight fell below the tenth percentile
for gestational age were considered to be SGA. By this criterion,
13 infants had growth retardation.
Of the scans performed on infants who at birth were determined to
be adequate for gestational age, all showed TIUV's and BPD's in
the normal range. However, 11 of the 13 SGA infants had BPD's
more than two stardard deviations below the mean, and 11 of 13
had total intrauterine volumes in the abnormal range: i.e. more
than one standard deviation below mean. These findings were
evident as early as mid-second trimester, and were shown to per-
sist through the third trimester in patients having serial scans.
The ratio of head to body circumferences approaches one in both
the sonographic and postpartum measurements in these SGA infants.
Both the early evidence by sonography of altered fetal growth, and
the symmetric nature of the deficit indicate an early onset type
of growth retardation. This is in contrast to the more common
late onset, asymmetric form seen typically with "supply-line"
defects secondary to placental insufficiency.
The incidence of growth retardation in the subgroup of patients
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abusing pentazocine was statistically higher (p < .01) than that
expected in the total population. Mothers using methadone did
not demonstrate a significantly increased incidence of SGA infants.
Pentazocine-abusing mothers constituted only 9.1 percent of Family
Center patients, while their infants represented 53.8 percent of
growth retarded infants in the study.
The early onset, symmetric form of growth retardation found in
these patients is typical of a direct, teratogenic drug effect
on the early developing fetus. This effect is most marked in
patients abusing pentazocine.
AUTHORS
Ronald J. Wapner, M.D.
Jack Fitzsimmons, M.D.
R. Douglas Ross, M.D.
Martha E. Rudrauff, M.A.
Alfred B. Kurtz, M.D.
Loretta P. Finnegan, M.D.
Family Center Program
Jefferson Medical College of
the Thomas Jefferson University
1025 Walnut Street
Philadelphia, Pa. 19107
132
Alcohol Tolerance Development
in Humans: Tests of the Learning
Hypothesis
R. E. Mann and M. Vogel-Sprott
Tolerance to alcohol may be defined as a reduction in response to
a given dose of alcohol after repeated administrations. A great
deal of research has been devoted to the study of this phenomenon
(1), but studies of tolerance development in humans who are not
alcoholic have been few, perhaps because such studies were thought
to expose participants to the risk of developing dependence on
alcohol. However, recent studies suggest that tolerance develop-
ment can be studied safely in human social drinkers (2,3). As well,
similarities between learning and some forms of tolerance to drugs
have been described (4,5,6,7,8). This paper reports two studies
designed to test the hypothesis that tolerance to alcohol in human
social drinkers may be subject to the laws of instrumental learning.
EXPERIMENT 1
Animal research has shown that the development of tolerance on
behavioral measures is often dependent upon the reinforcement con-
tingencies which maintain those behaviors. Specifically, tolerance
seems most likely to occur when the initial effects of a drug act
to reduce the amount of reinforcement received by the organism, a
principle first described by Schuster and his coworkers (4).
Recent human studies suggest a parallel between animal and human
research in this respect; tolerance developed on a paper and pencil
coding task where intrinsic reinforcement contingencies were operat-
ing (2,3), but not on a pursuit rotor task where no reinforcement
was available (3,9). The first experiment tested the prediction,
derived from the learning hypothesis, that tolerance to the effects
of alcohol on pursuit rotor performance would develop when rein-
forcement for nonimpaired performance was provided.
Eight male undergraduate volunteers were randomly assigned to
either an alcohol (A) or placebo (P) group (n=4 per group). After
predrug training (36 50-sec. trials on the Pursuit Rotor over two
days) the subjects attended four drinking sessions, separated by a
mean of 3.3 days. In each drinking session group A subjects re-
ceived alcohol (.88 ml 96 percent alc/Kg body weight) while group
P subjects received a placebo beverage. Pre and postdrug pursuit
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rotor tests, alcohol administration, and blood alcohol content
(bac) measures followed a standardized schedule in each drinking
session (3,10).
The pursuit rotor task used was basically identical to that used
in the alcohol studies in which no tolerance development was
observed (3,9). Thus, subjects tracked a light source moving in
a square pattern with a photosensitive hand-held stylus. The
speed of the rotor was 30 r.p.m. and a test on the task consisted
of two 50-second trials separated by a 30-second intertrial
interval. The subject's score on a test was his average time on
target during the two 50-second trials. This study modified the
task by introducing reinforcement for performance. The reinforce-
ment provided consisted of augmented auditory feedback, posttrial
performance information, and monetary reinforcement. Further
details on reinforcement procedures can be found in (10). Blood
alcohol levels were obtained with a Omicron Intoxilyzer.
The drug-free performance of subjects in groups A and P did not
differ significantly during the practice period. Their initial
drug-free tests, which preceded alcohol tests on each session, also
did not differ. Thus the drug-free performance of the two groups
was essentially equal throughout the entire experiment. Examination
of bac readings from group A revealed a typical bac curve, and no
differences over sessions were observed.
The differences between a subject's drug-free score on a session
and each of his five subsequent alcohol tests in that session were
calculated to provide measures of change in performance. A negative
difference thus obtained indicated that performance under alcohol
was poorer, or impaired, relative to the subject's nondrug state.
Variance analysis of the pursuit rotor difference scores (2 groups
X 4 sessions X 5 trials) revealed a significant groups X sessions
interaction (F=3.989, df=3/18, p<.05), presented in table 1. On
the first session the two groups were clearly different, with group
TABLE 1
Mean Change (in Seconds) from Daily Drug-Free Baseline - Experiment 1
Drinking Sessions
Groups 1 2 3 4
Group P 1.28 -.97 1.83 -.13
Group A -2.52* -2.26 2.16 .42
*for p<.05 on a two-tailed t-test, an absolute
difference of 2.45 between groups is required (11).
A showing a strong performance deficit. However, by the final
session the groups did not differ, due to the fact that group A no
longer displayed impairment.
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EXPERIMENT 2
The results of the first experiment support the learning hypothesis,
in that tolerance developed to the impairing effects of alcohol with
the appropriate reinforcement conditions. The results of other
studies show no tolerance on this task (3,9); the suggestion is
that the difference in tolerance development between the first
experiment and other studies was due to the differences in rein-
forcement contingencies. However, this comparison is between
separate experiments, and interpretation must be tentative. For
this reason, an additional study was designed to replicate the
first study and include a group of alcohol subjects not given
reinforcement. This second study also served to test an additional
prediction concerning the loss of tolerance. Specifically, if the
acquisition of tolerance observed in this paradigm is an instrumental
learned response, then withdrawal of reinforcement from subjects
showing tolerance should result in extinction, or a return of
impaired performance.
Twelve male undergraduate volunteers were randomly assigned to one
of three groups. Two alcohol groups and one placebo group were
employed. One alcohol group (n=4) received reinforcement (AR),
the second alcohol group (n=4) did not receive reinforcement (ANR)
and the third group was a placebo group (n=4) which received rein-
forcement (P). The subjects attended two predrug practice sessions
followed by six drinking sessions. The drinking sessions were a
mean of 4.01 days apart. The pursuit rotor and intoxilyzer employed
in this study were identical to those employed in the first exper-
iment.
The procedures for reinforcement administration to the AR and P
groups in the two practice sessions and the first four drinking
sessions were identical to those for the A and P groups in the first
experiment. In the final two drinking sessions, the extinction
hypothesis was tested by withholding all reinforcement contingencies
from these groups. Thus, the auditory feedback was withdrawn, no
posttrial performance information was given, and subjects could not
earn any more money for nonimpaired performance. Subjects in the
ANR group did not receive any of the reinforcement conditions at
any point in the study. Testing schedules, the dose of alcohol or
placebo, and drinking schedules in all sessions were identical to
those used in the first study.
The drug-free baseline measures of performance from the drinking
sessions showed no differences between groups or over sessions,
indicating that drug-free performance remained stable and comparable
throughout the experiment. Bac measures showed a typical bac curve,
consistent over sessions with no differences between AR and ANR
groups.
Each of the five postdrug measures of performance in each session
for each subject was expressed as a difference from that subject's
baseline score in that session. Variance analysis of these data
(3 groups X 6 sessions X 5 trials) revealed a significant inter-
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action of groups and sessions (F=3.777, df=10/45, p<.01), presented
in table 2. On the first two sessions, the two alcohol groups
TABLE 2
Mean Change (in Seconds) from Daily Drug-Free Baseline-Experiment 2
Drinking Sessions
3. 6Groups 1 2 4 5
Group P 1.08a .45a .20a .53a -2.43 1.20a
Group AR -2.28b -2.54b -.89a -.33a -4.06 -5.53ab
Group ANR -2.52b -2.30b -3.86b -3.62b -3.22 -3.31b
For p<.05 on a two-tailed t-test, an absolute difference
between groups of 2.06 is required (11).
a - Differs from Group ANR, p<.05
b - Differs from Group P, p<.05
showed significant impairment relative to the placebo group, and
did not differ from each other. On sessions three and four,
however, the reinforced alcohol group showed tolerance, in that it
did not differ from the placebo group, while the nonreinforced
alcohol group remained significantly impaired relative to the
placebo and reinforced alcohol group. Finally, on sessions five
and six when reinforcement was withdrawn, the reinforced alcohol
group showed a decline in performance which resulted in significant
impairment relative to both of the other groups on session six.
DISCUSSION
The results of both studies agree with the predictions based upon
an instrumental learning hypothesis of alcohol tolerance. Tolerance
to the impairing effects of alcohol developed when appropriate
reinforcement contingencies were in place, did not occur when
reinforcement contingencies were not present, and disappeared
(showed extinction) when reinforcement contingencies were withdrawn
from tolerant subjects. These results are not predicted by metabolic,
biochemical, or physiological theories of tolerance which emphasize
chronic administration, and the results occurred under conditions
which should minimize the effects of nonlearning variables (i.e.,
low doses, separation of testing sessions). The conclusion
suggested by these findings is that there exists at least one form
of tolerance to alcohol which is a learned response, and which
might complement other forms of tolerance.
The learning hypothesis of tolerance is useful in that it generates
some very specific predictions about tolerance acquisition, the
amount of tolerance displayed in a situation, and the loss of
tolerance. For example, although it appears that tolerance can
be acquired very quickly under appropriate environmental conditions,
tolerance may also disappear by means of a very simple change in
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those conditions. Thus, further testing of the learning hypothesis
may have some important applied and forensic implications, as well
as being of theoretical interest.
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The New Mixed Agonist-
Antagonist Analgesics,
Nalbuphine and Butorphanol, vs.
Pentazocine: Relapse and
Substitution in Morphine-Addict
Rats
G. F. Steinfels, G. A. Young, and N. Khazan
INTRODUCTION
The therapeutic efficacy of the narcotic drugs in the treatment of
cough, pain, and diarrhea is unsurpassed by drugs of other pharma-
cological classes. While these effects have been known and util-
ized over many centuries, the euphoric and other psychological
properties of narcotics have made them prime candidates for abuse.
This has prompted researchers over the past several decades to
search for compounds that possess similar therapeutic efficacies
to that of a narcotic such as morphine but devoid of the side
effects and abuse potentials. One general class of narcotic com-
pounds that has resulted from this intensive search is the mixed
agonist-antagonist analgesics. Three of these compounds, being
pentazocine, nalbuphine, and butorphanol, were of special interest
to us in our ongoing studies on narcotics since each is currently
available for therapeutic use as a potent analgesic.
We speculated that tendencies of morphine postaddict rats to re-
lapse to self-administration of such compounds might provide di-
tional information for the assessment of degree of abuse potential
for at least two reasons. First, the morphine postaddict rats
would have a history of drug self-administration but would be
neither tolerant to nor physically dependent on a narcotic. Thus,
no precipitation of withdrawal would occur if these rats were given
the opportunity to relapse to the self-administrationof these
mixed agonist-antagonists. This is in contrast to a direct substi-
tution procedure in which a mixed agonist-antagonist would presuma-
bly precipitate abstinence in morphine-dependent rats. Second, one
would not have to contend with problems of training the postaddict
rats to self-administer the drugs, because each rat would already
have established a history of self-administration. Thus, any
possible reinforcing properties of a mixed agonist-antagonist
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would be disclosed in a morphine postaddict rat. Therefore, the
tendencies of morphine postaddict rats to relapse to the self-
administration of pentazocine, nalbuphine, and butorphanol were
comparatively studied.
METHODS
Adult female Sprague-Dawley rats were prepared with chronic EEG
and temporalis EMG electrodes (Khazan et al. 1967, Khazan 1975).
Stainless steel screws which served as bipolar cortical electrodes
were implanted over the frontal (2 mm anterior and 2 mm lateral to
bregma) and the ipsilateral parietal cortex (3 mm posterior and
2 mm lateral to bregma). For drug injections, a silicone rubber
cannula was implanted into the right external jugular vein (Weeks
1962). Each rat was maintained in an individual cage that was
equipped with a response lever, a swivel cable connector for EEG
and EMS recordings, and a feed-through cannula for drug administra-
tion. EEG and EMG activities were recordedon a Grass model 7D
polygraph . The EEG was filtered to pass frequencies between land
30 Hz.
Forty rats were first made tolerant to and physically dependent on
morphine by a series of electronically-controlled automatic iv in-
jections. During the first day, the rats received 1.25 mg/kg/hr
of morphine sulfate. The dose was increased to 2.5, 5.0, 10.0 and
20.0 mg/kg/hr on successive days. The rats were then trained to
lever press on a fixed ratio (FR) schedule of reinforcement to
receive morphine (10 mg/kg/injection over 3 sec). A FR of one
lever press was initially required per injection, which was gradu-
ally increased to FR-20. After one week of stabilized responding
for morphine, the rats were divided into two main groups. In one
of these groups each rat was removed from the experimental cage
and allowed to withdraw from morphine in the home cage for two
weeks. Each rat was then returned to the experimental cage and
given the opportunity to reestablish self-administration of mor-
phine (10 mg/kg/injection), pentazocine (1 mg/kg/injection), nal-
buphine (5 mg/kg/injection), butorphanol (0.5 mg/kg/injections), or
0.9% saline. In the second of morphine-dependent rats
pentazocine, nalbuphine, butorphanol at the above doses, or nal-
oxone (0.5 mg/kg/injection) or mathadone (2 mg/kg/injection) was
directly substituted for morphine.
The study of REM sleep distributions during self-maintained de-
pendence on narcotics in the rat has elucidated similarities and
differences in pharmacodynamic profiles among narcotics (Moreton
et al. 1976, Young et al. 1979a). Also, the relative degree of
REM sleep suppression has proven to be a reliable indicator of
severity of withdrawal from narcotics (Young et al. 1977, 1979b),
andbehavioral states of sleep, REM sleep, and wakefulness were
identified by the corresponding changes in gross behavior and in
EEG and EMG recordings (Khazan et al. 1967, Khazan and Weeks 1968,
Moreton et al. 1976). Thus, REM sleep times per 24 hours and REM
sleep distributions were also assessed in the present study.
Occurrences of lever presses and injections were recorded on the
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polygraph as well as on an Esterline-Angus event recorder.
RESULTS
When morphine postaddict rats were given the opportunity to relapse
to the self-administration of morphine, the man daily number of
self-injections gradually increased over days and was stabilized
within a week (Figure 1). The patterns of mean daily number of
self-injections during relapse to the self-administration of penta-
zocine, butorphanol, and nalbuphine were similar to that for mor-
phine. In contrast, when morphine postaddict rats self-adminis-
tered saline, the mean total number of self-injections was very
high on the first day and steadily decreased over the seven days
of relapse studied.
FIGURE 1
Mean daily number of self-injections are shown over
seven days of relapse to the self-administration of
morphine, pentuzocine, butorphanol, nalbuphine, and
saline.
Upon stabilization of drug self-administration (i.e., on the
seventh day of relapse in a moqhine postaddict rat relapsing to
morphine self-administration) the characteristic pattern of self-
injections and distribution of REM sleep episodes seen earlier
(Khazan and Weeks 1968) is presented in the top row of Figure 2.
This individual rat, for example, took single injections of mor-
phine (10 mg/kg/injection) at intervals of about 2 hours. Each
morphine self-injection usually suppressed occurrences of REM
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sleep for 30 min or more, after which they reappeared and persisted
until immediately before each subsequent morphine self-injection.
Furthermore, Figure 2 also sham that patterns of self-injections
and distribution of REM sleep episodes on the seventh day of relapse
to self-administration of pentazocine, butorphanol, and nalbuphine
in morphine postaddict rats were similar to those during relapse to
morphine . Single and, occasionally, multiple self-injections were
relatively equally spaced, and REN sleep occurrences were also
suppressed for about 30 min or more after self-injections.
FIGURE 2
REM sleep distributions for individual rats during the
seventh day of relapse. Data are shown during relapse
to the self-administration of morphine, pentazocine,
butorphanol, and nalbuphine. Self-injections are
indicated by the filled arrows.
Grouped data during the seventh day of relapse to narcotic self-
administration in morphine postaddict rats and during the first day
of subsequent saline substitution are shown in Figure 3. During
the seventh day of self-administration mean daily numbers of self-
injections were similar at the dose levels used for morphine, penta-
zocine, butaphanol, and nalbuphine. During the first day of sub-
Sequent saline substitution mean daily numbers of self-injections
increased for all four drugs. Furthemore, during relapse the mean
daily REM sleep time in min was on the lower edge of control values
for all four drugs. However, during the first day of subsequent
saline substitution the mean total amount of REM sleep was sup-
pressed with morphine and pentazocine but not with butorphanol and
nalbuphine.
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FIGURE 3
Grouped data during the seventh day of relapse to
narcotic self-administration in morphine postaddict
rats and during the first day of subsequent saline
substitution. Mean daily numbers ± s.e.m. of self-
injections and mean daily times in min of REM sleep
are shown for morphine, pentazocine, buturphanol, and
nalbuphine.
During stabilized self-maintained dependence on morphine the substi-
tution of methadone (2 mg/kg/injection) for morphine supported de-
pendence. When pentazocine, butorphanol, nalbuphine, or naloxone
was substituted for morphine, occurrences of REM sleep were severely
supressed . As expected, the rats also exhibited signs of absti-
nence such as diarrhea, "wet-dog" shakes, and abdominal stretching.
The effects of naloxone substitutionwere similar to those of the
three mixed agonist-antagonists.
DISCUSSION
Morphine postaddict rats relapsed to the self-administration of
morphine, pantazocine, butorphanol, and nalbuphine. Relapse to
morphine self-administration in postaddict rats has been previously
demonstrated (Weeks and Collins 1968, Moreton et al. 1975, Young
et al. 1975). Several characteristics of relapse to self-adminis-
tration of pentazocine, butorphanol, and nalbuphine in the present
studywere similar to those with morphine. All of these drugs were
self-administered periodically and self-injections of each usually
suppressed occurrences of REM sleep for 30 min or more. When
saline was substituted for each of these drugs, self-injections
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greatly increased in number. All of the above observations suggest
that the drug-seeking by the rat was eminent for the four narcotics
studied.
When saline was substituted for the respective narcotic, occur-
rences of REM sleep were severely suppressedduring abstinence from
morphine and pentazocine. However, REM sleep suppression was not ob-
served during abstinence from butorphanol and nalbuphine. Further-
more, abstinence from morphine and pentazocine was associated with
behavioral symtoms such as diarrhea, "wet-dog" shakes, and irri-
tability, while abstinence from butorphanol and nalbuphine was not.
These findings suggest that there was considerable physical depen-
dence in rats dependent on morphine and pentazocine, but relatively
little physical dependence on butorphanol and nalbuphine. Thus,
the above data also seem to differntiate between drugs which in-
duce both psychological and physical dependence such as morphine
and pentazocine, and drugs which produce a similar psychological
dependence with apparently minimal physical dependence such as
butorphanol and nalbuphine. While differences in degree of physi-
cal dependence were disclosed between morphine and pentazocine on
the one hand and butorphanol and nalbuphine on the other hand, drug-
seeking behavior for all four compounds was found to be similar.
Finally, pentazocine, butorphanol, and nalbuphine did not substi-
tute for morphine during self-maintained dependence, since absti-
nence was precipitated in all three cases. since these mixed
agonist-antagonists did not support dependence in the "substitution"
procedure it was assumed that each drug possesses a relatively low
abuse potential. However, for all three mixed agonist-antagonists
in morphine postaddict rats, relapse to self-administration was
established in a manner similar to morphine. Therefore, our
findings showed that butorphanol and nalbuphine demonstrated addic-
tion liability in the relapsing morphine postaddict rat. However-,
this addiction liability appeared to consist of more psychological
dependence than physical dependence in contrast to the addiction
produced by morphine.
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Effects of Route of
Administration on Methadone
Disposition in the Rat
B. Ziring, L. Brown, and M. J. Kreek
The long-acting narcotic, dl-methadone, has been used since 1964
for the chronic treatment of patients addicted to heroin (Dole et
al. 1966). Clinical experience with over 85,000 patients main-
tained on daily oral doses of methadone has shown that this method
of treatment is effective. Despite the effectiveness of orally
administered methadone in the treatment of addiction, the analgesic
properties of methadone have been shown to be reduced when the drug
is administered by the oral, rather than a parenteral route of
administration (Beaver et al. 1967). Studies have shown that when.
methadone is administered orally on a chronic basis in the rat,
measurable plasma levels of drug are achieved with apparent
terminal half-life similar to that observed following subcutaneous
administration (Kreek 1979). Also, it has been shown that estrogen
and alcohol both interact with methadone following oral administra-
tion in ways that significantly alter overall methadone disposition
(Kreek et al. 1980; Wendell et al. 1979). Yet, experimentally
demonstable tolerance and dependence could not be developed in
rats given orally administered doses of methadone, nor could with-
drawal be induced through the administration of the narcotic antag-
onist, naloxone (Harris et al. 1978).
This study was undertaken to compare the distribution of methadone
plus metabolites (measured as total radioactivity from methadone),
when the drug was administered by the oral, subcutaneous and intra-
venous routes. This information complements previous methadone
disposition studies (Adler and Eisenbrandt 1949; Elliot et al. 1949;
Way et al. 1949; Misra et al. 1973). It was hoped that information
from these studies could provide insight into the kinetics and, thus,
possibly action of methadone in the rat model following each route
of administration as well as to delineate to what extent orally
administered methadone should be active in the rat.
METHODS AND MATERIALS
Male Sprague-Bawley rats weighing 150 to 200 g were obtained from
Charles River Breeder (Wilmington, MA). The animals received Purina
Lab Chow and water ad libitmn and were kept in a temperature
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controlled room With a conventional day-night lighting schedule.
The rats were divided into two study groups, receiving either acute
or chronic treatment. An acute treatment group received a single
tracer dose of 14C radiolabeled dl-methadone HCl (1.3 mg free base;
3.125 µCi) by the oral, subcutaneous or intravenous route of admin-
istration. The 14C dl-methadone, labeled in the 2-carbon position,
was obtained from California Bionuclear Corporation (Sun Valley, CA)
and demostrated to be radiochemically pure (>95 percent) by thin
layer chromatography with zonal scanning. A second, chronic treat-
ment group was formed. One-third of this group received chronic
pretreatment which consisted of 2 weeks of oral administration of
dl-methadone HCl (1.15 mg free base initially increased to 1.3 mg
free base after week one) to achieve a final dose of 5 mg/kg rat
weight/day. This Was followed by the administration of a single
oral dose of l4C dl-methadone. The remaining two-thirds of the
chronic treatment group received pretreatment with dl-methadone
administered by the subcutaneous route in the same dosages as given
to animals treated by the oral route. After two weeks of pretreat-
ment, half of these rats received a single tracer dose of
methadone administered by the subcutaneous route and the other half
by an intravenous injection into the tail vein of each animal. All
rats in the chronic treatment group received l4C dl-methadone HCl
in the same dosage as rats in the acute treatment group (1.3 mg
free base; 3.125 µCi).
Three to five animals Were studied at each time point by each route
of administration following both acute and chronic methadone admin-
istration. Rats Were kept in metabolic cages for collection of
urine until time of sacrifice 30 minutes to 24 hours after the
single tracer dose administration. Animals were sacrificed by
anesthesia.
exsaguination through the inferior vena cava following light ether
Half of the total volume of blood Was centrifuged to
obtain plasma; and the other half was analyzed as whole blood.
Organs were removed, Weighed and frozen in physiological saline
solution.
Each organ was homogenized using a Polytron PCU-2-110(Brinkmann
Instrmnents, Westbury, NY). Two-hundred fifty µl aliquots of each
homogenate were taken in triplicate, dried at 37° C in combustible
capsules and radioactivity was recovered by oxidation using a
TriCarb 306 Sample Oxidizer(Packard Instrument Co., Downers Grove,
IL). Radioactivity Was measured by liquid scintillation counting
(Packard TriCarb Model C2425), and appropriate quench corrections
were made.
Thin layer chromatography with zonal scanning using methods pre-
viously described from this laboratory was carried out to determine
relative amounts of unchanged methadone and metabolites in liver and
brain at the one-hour time point following both oral and intravenous
tracer dose administration in the chronic treatment group (Kreek et
al. 1978).
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RESULTS
The results of this study may be divided into two parts. The con-
centrations and total amount of radioactivity from methadone, thus
including both methadone and its metabolites in various organs and
tissues, may be compared with respect to the route of administration,
and the relative amounts of drug in different organs within a given
treatment group may be assessed.
Methadone and metabolites, measured as total radioactivity in tissue
homogenates, were found to be present in all organs studied at all
time points between 30 minutes and 24 hours. As shown in Table 1,
the route of administration had only a small effect on the total
radioactivity from methadone recovered over the calculated 23-hour
(1 hour to 24 hours after tracer dose administration) period in the
liver and whole blood of rats in the acute treatment group. Oral
Table 1
Total amounts of methadone and its metabolites in organ
during 24-hour interval following drug administration
(ng equivalent/organ/24 hours)a
Acute Chronic
Whole Ng Eqb
po sc i v po sc iv
7420 8060 9050 6271 7876 7799
Blood Ratio- 0.819 0.891 1 0.804 1.010 1
Liver Ng Eq 100500 101360 92410 121143 65768 69370
Ratio 1.088 1.097 1 1.746 0.948 1
Brain Ng Eq 290
Ratio 0.372
Lung
Kidney
Ng Eq
Ratio
Ng Eq
Ratio
Spleen Ng Eq
Ratio
1510
0.139
2830
0.309
290
0.106
970
1.253
11910
1.098
10700
1.169
2560
0.942
770 212
1 0.310
10850 1553
1 0.192
9150 2196
1 0.313
2710 340
l 0.121
718 684
1.050 1
9035 8092
1.117 1
6869 7026
0.978 1
2441 2818
0.866 1
Testes Ng Eq 580 7070 5440 531 5389 5434
Ratio 0.107 1.299 1 0.098 0.992 1
Adrenals Ng Eq 60 270 200 53 167 179
Ratio 0.277 1.322 1 0.296 0.933 1
a Time points: Chronic = 60m, 90m, 3h, 6h, 24h;
Acute = 60m, 3h, 6h, 24h
b po ratio = po/iv
SC ratio = sc/iv
iv set to equal 1.0
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administration of tracer dose did result in reduced radioactivity
recovered in other organs. Brain, kidney and adrenals of rats
receiving an oral dose contain approximately 30 percent of the
radioactivity found in these organs in rats receiving an intra-
venous dose. Lung, kidney and spleen of rats receiving an acute
oral dose contain approximately 10 percent of the radioactivity
found in these organs in rats receiving an intravenous dose.
Similar results are found for rats receiving chronic methadone
pretreatment with one exception; livers of rats receiving chronic
Oral pretreatment contain substantially more radioactivity from
methadone than livers of rats receiving chronic pretreatment by
either parenteral route.
Figures 1-3 show total content of methadone and metabolites (measured
as radioactivity and expressed as nanogram equivalents of methadone/
organ) at specific time points following radiolabeled dose adminis-
tration by the oral, subcutaneous or intravenous route of administra-
tion. Naive rats received a single radiolabeled dose of methadone
(5 mg free base/kg body weight). Each point represents mean value
(± SEM) for all animals studied at each time point (number of animals,
3-5 at each time point). These figures show that the reduced amounts
of radioactivity from methadone that were observed in the organs and
tissues of rats receiving an oral radiolabeled dose (Table 1)
resulted from reduced amounts in these organs at the early time
points. At 24 hours following radiolabeled dose administration,
route of administration does not significantly affect amount of radio-
activity recovered in any organ except the testes in the acute treat-
ment group.
The mean terminal half-life (3-24 hours) of total radioactivity was
calculated for all of the, organs and tissues studied in the chronic
treatment group. Table 2 shows that mean terminal half-life for all
organs of rats receiving an oral radiolabeled dose is longer than the
mean terminal half-life for organs of rats receiving a radiolabeled
dose by either parenteral route. However, the difference in overall
organ disappearance rates for total radioactivity from methadone is
due to very slow disappearance of compounds (or persistence of com-
pounds) in the brain, whole blood, adrenals and testes.
Table 2
Mean apparent terminal half-life (3-24 hours) of total
radioactivity including methadone and metabolites in
chronically treated rats
All organs
Liver, Lung
Kidney, Spleen
Whole Blood,
Brain, Testes,
Adrenals
Oral Subcutaneous Intravenous
14.2 hours 7.7 hours 7.0 hours
(± 2.2 SEM) (± 1.7 SEM) (±1.0 SEM)
7.6 hours 5.72 hours 8.30 hours
(± 0.3 SEM) (± 1.14 SEM) (± 1.69 SEM)
19.5 hours 9.73 hours 5.66 hours
(± 1.5 SEM) (± 3.02 SEM) (± 1.01 SEM)
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Figures 1-3. Total amounts of methadone and metabolites in organs over a 24-hour
interval following radiolabeled dose administration
DISCUSSION
The results of this study expand upon and reinforce previous studies
of the effect of route of administration on methadone disposition
in the rat. Specifically, this study protocol allows the direct
comparison of data from rats receiving an oral, subcutaneous or an
intravenous dose of methadone and also analysis of the effect of
route of administration on the distribution of methadone and
metabolites to organs not previously studied in this manner.
Methadone administered to the rat clearly is extensively metabolized,
but also stored and concentrated in major organs. Although the levels
of methadone and metabolites observed in many organs are sharply
reduced When the drug is administered by way of the oral route, high
levels of total radioactivity from methadone are observed in the
liver and blood following oral administration which are similar to
levels observed in rats receiving treatment by the parenteral routes.
In rats receiving a single radiolabeled dose of dl-methadane follow-
ing tracer dose administration, livers were shown to contain 87 per-
cent of the amount of unchanged methadone found in rats receiving
methadone by the intravenous mute. Thus, route of administration
ties little difference on either the amounts of unchanged methadone
or metabolized methadone found in the liver. However, in the chronic
treatment group, at the one-hour time point following tracer dose
administration, brains of rats receiving methadone by the oral route
contain only 3 percent of the amount of unchanged methadone found in
brain of rats receiving methadone by the intravenous mute. These
highly significant differences may explain the differences in acute
analgesia observed both in rats and in man when methadone is given
by the oral as opposed to the intravenous route of administration.
The data from this study, combined with previous data from this
laboratory concerning long-tern Persistence of dl-methadone in
tissues (Harte et al. 1976), show that a measurable mount of
unchanged methadone could be present in the brain for at least 24
hours. This amount of active narcotic may be sufficient to develop
a degree of tolerance in the rat, albeit insufficient to produce
symptoms of tolerance and physical dependence measurable by current-
ly available, well-tested and validated methods. The estimated total
binding capacity of specific opiate receptors in the brain is very
low. Thus, even small amounts of active narcotic available to
critical receptor sites may bind to a physiologically, if not pharma-
cologically, significant percentage of sites (Snyder et al. 1974).
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Androgenic-Like Effects of
Morphine in the Male Rat
T. J. Cicero, E. R. Meyer, S. M. Gabriel, and C. E. Wilcox
INTRODUCTION
Narcotics produce dose-dependent decreases in serum luteinizing hor-
mone (LH) levels in the male and female of several species (Bruni et
al. 1977; Cicero et al. 1977a; 1977b; Mirin et al. 1976; Muraki et
al. 1977; Pang et al. 1977;). This effect appears to be due to a
direct action of the narcotics on the hypothalamus, presumably by an
inhibition of the release of L&releasing hormone (LH-RH) (Rotsztejn
et al. 1978); furthermore, it has been established that the LH-de-
pleting effects of the narcotics are mediated by specific opiate re-
ceptors (Cicero 1977; Cicero et al. 1977a; 1977b; Pang et al. 1977;
Rotsztejn et al. 1978).
The existence of opiate receptors in the hypothalamus mediating the
effects of narcotics on the hypothalamic-pituitary-LH axis suggests
that there may be endogenous opioids which normally play an inhibi-
tory role with respect to the secretion of LH. Support for this hy-
pothesis has been provided by several groups of investigators who
have shown that narcotic antagonists, such as naloxone, significant-
ly increase serum LH levels after their administration to male and
female rodents and humans (Blank et al. 1979; Bruni et al. 1977;
Cicero et al. 1979; 1980; Meites et al. 1979; Mendelson et al. 1979).
Moreover, we have reported that naloxone blocks testosterone's nega-
tive feedback control of the hypothalamic-pituitary-LH axis in the
male rat (Cicero et al. 1979). These results, coupled with the ob-
servation that certain endogenously occurring opioid peptides (e.g.,
methionine-enkephalin) also depresss serum LH levels (Bruni et al.
1977; Meites et al. 1979), give strong support to the hypothesis
that opioid-containing neural elements are intimately involved in
the neuroendocrine control of reproductive endocrinology.
If, as suggested by the preceding studies, an endogenous opioid is
involved in regulating activity in the hypothalamic-pituitary-LH
axis, and in mediating the negative feedback control of this axis
exerted by testosterone, then it should follow that morphine and re-
lated narcotics should mimic the acute and chronic effects of tes-
tosterone on the hypothalamic-pituitary-LH axis. However, it would
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be expected that this androgen-like activity should be confined to
the hypothalamus since narcotics do not apparently exert any impor-
tant effects on the pituitary (Cicero et al. 1977a; 1977b; Pang et
al. 1977), whereas testosterone has activity at both sites (Bogdanove
et al. 1975; Damassa et al. 1976). The present studies were carried
out to examine these possibilities.
METHODS
Testosterone-Like Effects of Morphine——Acute Studies
To determine whether morphine, like testosterone, acutely depressed
serum LH levels in the castrated male rat, Sprague-Dawley-derived
male rats were injected either with testosterone (500 µg/rat) or
morphine (5 mg/kg) 48 hours after castration. They were then killed
at intervals after drug administration and LH levels were determined
as described elsewhere (Niswender et al. 1969). On the basis of
these time-course studies, the interval at which peak depressions in
LH occurred (24 hours for testosterone and 30 minutes for morphine)
was used to construct dose-response curves for each test drug.
Testosterone-Like Effects of Morphine——Chronic Studies
To examine whether testosterone would reverse the long-term postcas-
trational changes in hypothalamic LH-RH content, LH concentrations
in the pituitary and serum LH levels, groups of rats were castrated
or shamoperated and immediately thereafter were injected, subcuta-
neously, with testosterone (500 µg/rat) or sesame seed oil; these
injections were continued for 14 days, and groups of rats were killed
at 3, 7, 10 and 14 days. Blood was collected from the decapitated
carcasses for determining serum LH levels (see above). In addition,
the anterior lobe of the pituitary and the brains were obtained.
The pituitaries were homogenized in phosphosaline (pH=7.4) and LH
levels were determined by radioimmunoassay (Niswender et al. 1969).
Hypothalami were dissected from the brains at -20°C and were homog-
enized in 2 ml 0.2N acetic:absolute ethanol (1:1, V/V). They were
then centrifuged, and LH-RH content was determined in dilutions of
the supernatant fluids by a double-antibody radioimmuoassay de-
scribed elsewhere (Nett et al. 1973).
To examine whether morphine, like testosterone, would reverse the
changes induced by castration, groups of rats were castrated or
sham-operated and were then implanted with morphine pellets, con-
taining 75 mg morphine base, or placebo pellets, containing lactose,
on a regimen described elsewhere (Cicero et al. 1977b). This pro-
cedure results in relatively constant serum and brain levels of nor-
phine for an extended period (Hipps et al. 1976). Rats were killed
3, 7 and 10 days later. Serum and pituitary LH levels and hypotha-
lamic-LH-RH content were determined as described above. A 10-day
treatment interval was used in these studies, as opposed to the 14-
day treatment interval in the case of the testosterone-replacement
experiments, to avoid the possible development of tolerance to mor-
phine which develops 13 to 17 days after treatment on this regimen
(Cicero et al. 1977b).
153
RESULTS
Acute Testosterone-Like Effects of Morphine
Single injections of testosterone (500 µg/rat) in the 48-hour cas-
trated animal produced a time-dependent drop in serum LH with the
maximum level of depression occurring 24 hours after the injection.
Moreover, as shown in table 1, there was an excellent dose-response
relationship between the dose of testosterone injected and reductions
in serum LH 24 hours after its injection. Morphine (5 mg/kg) also
acutely depressed serum LH in the 48-hour castrate. LH levels were
significantly depressed within 10 minutes after the injection of the
narcotic, and the lowest level of depression (approximately 65 per-
cent with respect to controls) occurred 30 minutes after the injec-
tion. Thereafter, LH levels slowly returned to control values.
These time intervals correspond quite closely to peak brain and serum
morphine levels (Hipps et al. 1976). The dose-effect curve for mor-
phine-induced depressions in serum LH is also shown in table 1.
There was an excellent dose-response relationship with essentially
linear decreases in LH up to a dose of 4.0 mg/kg when LH levels were
reduced to approximately 1/3 of control levels. Higher doses of
morphine produced no further decrease in serum LH levels.
Table 1
The effects of testosterone and morphine on serum LH levels in the
castrated (48 hr) male rat. Values are means (±SEM) of 8 animals
in each group. *p<.05 when compared to control.
Serum LH (ng/ml)
Dose (ug/rat) Testosterone Dose (mg/kg) Morphine
Control 765 (±85) Control 646 (±37)
40 680 (±72) 0.5 505 (±41)*
80 675 (±68) 1.0 475 (±18)*
160 619 (±80)* 2.5 346 (±21)*
320 425 (±46)* 4.0 250 (±26)*
640 155 (±26)* 5.0 218 (± 7)*
1000 148 (±28)* 10.0 220 (±11)*
Testosterone and Morphine Reversal of Postcastrational changes in
LH and LH-RH in Serum, Pituitary and Hypothalamus
Following castration in the male rat, serum LH levels rise 10 to
20-fold within 24 hours and remain elevated at this level for ap-
proximately 5 days (Badger et al. 1978). Between days 5 to 10 a
doubling of LH levels occurs which then persists for weeks or months.
This "two-stage" effect of castration is also reflected in pituitary
LH and hypothalamic-LH-FH content. During stage 1 (days 1-5), there
is little change in pituitary LH or LH-RH in the hypothalamus. Dur-
ing stage 2 (>5 days) there is a substantial increase in pituitary
LH levels (2 to 3-fold) and a corresponding decrease (approximately
75 percent) in hypothalamic LH-RH. We found that daily injections
of testosterone reversed all of the changes occurring during stages
154
1 and 2 of castration (data not shown). The effects of morphine
and testosterone on the postcastrational changes in hypothalamic
LH-RH content are shown in table 2. As can be seen, morphine was
just as effective as testosterone in preventing the fall in hypo-
thalamic-LH-RH content which occurred during the second stage of
castration. Morphine also suppressed the postcastrational increase
in serum LH during stage 1 but was relatively ineffective in stage
2 (data not shown). Moreover, morphine did not reverse the increase
in pituitary LH observed during the second stage of castration (data
not shown). Thus, testosterone reversed all of the postcastrational
changes occurring in the hypothalamus, pituitary and blood whereas
morphine selectively reversed only those changes occurring in the
hypothalamus.
Table 2
The effects of testosterone and morphine on hypothalamic LH-RH lev-
els (ng/hypothalamus) in castrated or sham-operated male rats. Val-
ues are means (±SEM) of 8 to 10 animals in each group. *p<.05 when
compared to sham.
Days
3 7 10 14
Sham 1.90 1.98
(±.15) (±.22)
Castrate 1.86 1.05*
(±.17) (±.11)
Castrate+Testosterone 2.05 2.52
(±.15) (±.20)
Castrate+Morphine 2.08 2.15
(±.26) (±.18)
2.10 2.05
(±.46) (±.25)
0.76* 0.53*
(±.09) (±.08)
2.16 2.42
(±.25) (±.31)
2.32
(±.56)
DISCUSSION
The results of previous studies have indicated that endogenous opi-
oid peptides participate in regulating activity in the hypothalamic-
pituitary-LH axis and participate in testosterone's negative feed-
back control of this axis (Blank et al. 1979; Bruni et al. 1977;
Cicero et al. 1979; 1980; Meites et al. 1979; Mendelson et al. 1970;
Mirin et al. 1976). More recent studies (Cicero et al. 1979; 1980)
have further indicated that an opioid-containing cell represents a
bridge between the effects of testosterone on the hypothalamus and
the ultimate inhibition of LH-RH containing cells. Whether this
opioid-containing system is the final link, impinging directly upon
LH-RH containing neurons, or is simply part of a complex neural
chain is at present unknown.
If the assumption outlined above is correct, then it would follow
that opioids should mimic the effects of testosterone in the castrat-
ed animal. Our results indicate that acute morphine administration
depresses serum LH in the short-term castrated male rat (48 hours)
to the same extent as testosterone. As a second prediction derived
from the hypothesis that opioid-containing cells serve as a neuronal
pathway mediating testosterone's effects, it would also be expected
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that morphine should reverse the long-term testosterone-dependent
postcastrational changes in the hypothalamic-pituitary-LH axis.
However, one would expect distinct differences between the two com-
pounds. Specifically, since morphine exerts only hypothalamic ef-
fects within the hypothalamic-pituitary-LH axis (Cicero 1977; Cicero
et al. 1977a; 1977b; Pang et al. 1977; Rotsztejn et al. 1978), and
testosterone exerts effects at both the hypothalamic and pituitary
level (Bogdanove et al. 1975; Damassa et al. 1976), it would be pre-
dieted that morphine should reverse only those postcastrational
changes in this axis which are in some way mediated by alterations
in activity at the level of the hypothalamus. In the present stud-
ies we found that morphine completely prevented the marked reduction
in hypothalamic-LH-RH occurring during stage 2 of castration. Hence,
it appears that morphine exerts rather potent androgen-like effects
on the hypothalamus. In contrast to these observations, however,
morphine was not capable of suppressing the postcastrational changes
in pituitary LH content and blocked increases in serum LH only dur-
ing the initial phases of castration. Indeed, during stage 2 of
castration morphine appeared to exacerbate the effects of castration
on both pituitary LH content and serum LH levels. These observa-
tions are thus consistent with the interpretation that narcotics
exert purely central effects on the hypothalamic-pituitary-LH axis,
whereas testosterone exerts effects at both the hypothalamus and
pituitary to reverse the changes occurring during stages 1 and 2 of
castration.
In summary, the present results further support the concept that
endogenous opioids play au important role in the regulation of the
hypothalamic-pituitary-LH axis and mediate testosterone's negative
feedback control of this axis. Moreover, our results suggest, in
agreement with predictions derived from this hypothesis, that mor-
phine exerts androgen-like effects in the hypothalamus.
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Opiate Inhibition of Sheep
Erythrocyte Binding to T
Lymphocytes: Reversal by
Naloxone and Cyclic Nucleotides
R. J. McDonough, J. J. Madden, H. S. Rosman, A. Falek,
N. K. Wenger, D. A. Shafer, P. J. Bokos, J. C. Kuehnle,
and J. H. Mendelson
The abuse of street opiates causes both pathological and cellular
changes, the etiologies of which are obscure. Spiera et al.
(1974) reported an increase in rheumatoid factor activity titre
in heroin addicts which disappeared after a year in methadone
treatment. This same group (Brown et al. 1974) also found
abnormalities in the humoral and cellular immune systems in
addicts which included hypergammaglobulinemia and an impaired
mitogenic response to phytohemagglutin, pokeweed mitogen and
concanavalin A. At the genetic level, Falek and Hollingsworth
(1980) found a significant increase in chromosome aberrations in
heroin addicts which returned to normal levels after a year in
methadone treatment. The etiology of this increase has been
inferred from the finding that leukocytes from heroin addicts
exhibit a severely reduced capacity to repair DNA damage (Madden
et al. 1979). This reduction in DNA repair should predict for
the addict both an increase in carcinogenesis and in birth de-
fects. In fact, Sadeghi et al. (1978) have reported a 4-fold
increase in bladder cancer in opium addicts, and up to a 20-fold
increase in opium addicts who also smoked tobacco while Wapner
et al. (this volume) have described a fetal heroin syndrome in
children of addicts and former addicts. The cellular mechanisms
by which opiate abuse produces these alterations are at present
obscure.
Several recent investigators have hypothesized that many tissues
outside the neuronal system have opiate receptors which alter
the particular functions of those tissues. Wybran et al. (1979)
demonstrated an in vitro reduction in active T lymphocytes caused
by morphine, met-enkephalin, and dextromoramide but not by
levomoramide, and that this T cell reduction could be reversed
by naloxone. Lopker et al. (1980) reported naloxone-reversible
binding of dihydromorphine to phagocytic leukocytes, while
159
Hazum et al. (1979) showed that lymphocytes bind -endorphin at
a site not inhibited by enkephalins or naloxone. We now report
that both chronic and acute opiate use produce cell-mediated
immunological changes in vivo including a persistent depression
in the percent of total T lymphocytes, and that these changes
can be reversed by (-)-naloxone or cyclic nucleotides in vitro.
METHODS
Peripheral venous blood was collected in heparinized tubes from
control subjects, street opiate addicts entering therapy pro-
grams, and coronary care unit patients receiving intravenous
narcotics for relief of chest pain. Each subject completed an
informed consent document and a medical history form. Lympho-
cytes were collected over Ficoll-Paque, washed twice, diluted
into GIBCO RPMI 1640 - 50% Fetal Calf Serum and counted. Total
T lymphocyte frequencies were determined by the sheep erythrocyte
rosette technique using overnight incubation at 4°C (Palmer et
al., 1978). B lymphocytes were enumerated by binding of Bio-rad
fluorescein-labeled rabbit antibody specific for human IgA, IgG,
and IgM (Palmer et al., 1978). Null lymphocytes were described
as those lymphocytes which were neither T nor B; and, therefore,
% Null = 100 - (%T + %B).
RESULTS
Among 44 street addicts and 28 control subjects from the Atlanta
and Chicago areas, white blood cell counts and % B lymphocytes
did not vary between any of the groups tested (WBC: addict - 7320,
control - 7360; %B cell: addict - 16.3%, control - 17.7%). The
percentage of T lymphocytes, however, was significantly lower in
the addicts than in the controls; 26% vs 69%, respectively (see
Figure 1). Conversely, the addicts had increased Null lympho-
cytes relative to the controls; 57% vs 13%, respectively. Thus,
opiate addicts have decreased ability to form rosettes from
sheep cell erythrocytes, thereby reducing T cell counts and in-
creasing Null cell counts. We hypothesize that the opiate blocks
the sheep erythrocyte binding site on the T lymphocytes.
The suppression of T cell characteristics by long-term opiate
use persists for a significant period of time during detoxifica-
tion. In a program at McLean Hospital, two addicts were studied
longitudinally for 40 days through a protocol of drug-free
detoxification, heroin administration, and a final detoxification
which included administration of naltrexone. After an initial
20 days of drug-free detoxification, these patients demonstrated
a significant depression of % T lymphocytes, no effect on % B
lymphocytes, and a significant increase in null cells (Figure 2).
Five other addicts (X), also tested at 21 days, showed the same
pattern of T cell depression. Administration of 7-14mg heroin,
3 times daily for one week, caused an additional T cell reduction
which continued even after withdrawal from the opiate. Thus,
the T lymphocyte depression was a persistent effect which could
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Figure 1. Histogram of T Lymphocyte % in 44 street opiate
addicts and 28 control subjects. Lymphocytes from addicts ( )
or controls ( ) were incubated overnight with sheep erythro-
cytes in RPMI-1640 + 50% Fetal Calf Serum at 4°. 100 cells from
replicate cultures were scored for rosette formation.
Figure 2. Effect of detoxification and heroin administration
on T lymphocyte %. Two addicts ( and ) were followed
longitudinally during alternating periods of drug-free
detoxification and heroin administration. Five other addicts
( ) were also tested after 20 days of detoxification.
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be measured beyond the time when the drug itself could be detect-
ed in the addict.
The T lymphocyte depression can also be found in patients receiv-
ing an acute dose of opiate prescribed for the relief of pain.
A patient, given 10mg morphine followed by 25mg demerol 24 hr
later, showed a typical pattern of T cell depression within 24
hr of the first opiate dose (Figure 3). The depression persisted
for about a week, before the % T cells returned to normal levels.
These data, and samples from a number of other subjects, suggest
that sheep erythrocyte binding suppression is not rapid as would
be expected if simple opiate-receptor interactions directly
caused the effect. Rather, the suppression required a number of
hours for maximal effect, suggesting a more indirect mechanism
possibly involving membrane rearrangement as, for example, is the
case in phytohemagglutin stimulation of lymphocyte cell division
(Kiefer et al. 1980). In fact, Sharma et al. (1977) have re-
ported similar long-term phenomena in opiate stimulation of
neuroblastoma in which more than 12 hrs are required before in-
creased adenylate cyclase is realized. Thus, T cell depression
can be produced by an acute dose of opiate, but only after a
delay of 12 hrs.
The depression of T lymphocyte % caused by either acute or chronic
use of opiates can be reversed in vitro by (-)-naloxone, an opiate
antagonist, and by cyclic nucleotides (Figure 4). Lymphocytes
from patients who received either a single dose in vivo of
morphine or demerol were incubated in vitro for 1 hr at 25°C with
either 10-6M naloxone, 10-4M adenosine-3':5'-cyclic phosphate
(CAMP), 10-4M dibutyryl CAMP (dBcAMP) or buffer alone. Treatment
with these compounds reversed the opiate-induced T cell depres-
sion (Figure 4), by converting null cells to T cells.
SUMMARY
Acute or chronic use of opiates causes a decrease in T lymphocyte
percent as measured by the sheep erythrocyte rosette assay. The
effect in chronic addicts persists for at least three weeks after
cessation of use, while in acute users the effect reverses more
rapidly. Both naloxone and cyclic adenylate nucleotides can
reverse the T cell depression supporting the hypothesis that T
lymphocytes have membrane opiate receptors analogous to those on
neuronal cells. It is tempting to speculate that the T lymphocyte
depression caused by opiate use indicates an impairment in lympho-
cyte function and immune competence which would explain many
reported physiological deficiencies found in addicts. The cyclic
nucleotide results, for example, suggest that opiates interfere
with the regulation of cyclic nucleotides in the lymphocytes, as
they do in neuronal tissue. Many authors (Parker, 1979) have
described the activation of lymphocyte functions by cyclic
nucleotides so that impairment at this level should have major
consequences for lymphocyte function. Until specific experiments
to quantitate cyclic nucleotide levels and immune competence have
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Figure 3. Longitudinal effect of acute morphine administration
on T lymphocyte %. A patient received 10mg morphine intra-
venously for the relief of chest pain. Blood samples were drawn
pre-injection ( 0 time ) and longitudinally post-injection. The
% T lymphocytes was determined either directly ( ) or after
a 1-hr incubation with 10-6M naloxone at 24°C ( ).
Figure 4. Effect of naloxone or cyclic nucleotides on the T
cell depression caused by a single dose of morphine or demerol.
Two patients were studied pre-injection and 18-20 hr post-
morphine, or demerol, injection. The T cell % was determined
with and without a 1-hr incubation at 24°C with either 10-6M
naloxone, or 10-4M cAMP or dBcAMP. The pre-injection samples
were unaffected by incubation with naloxone or cyclic nucleo-
tides (not shown).
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been completed, however, it is not known whether the blocking of
sheep erythrocyte binding sites by the opiates affects lymphocyte
function. Li et al. (1980) have separated -endorphin binding
activity from analgesic potency in neuronal tissue and it is not
clear which lymphocytic activities, if any, correlate with either
opiate binding and/or loss of E rosette formation. The fact that
both chronic and acute opiate paradigms produce comparable T cell
depressions makes the answer a marked necessity considering the
widespread medicinal use of opiates.
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Intravenous Clonidine Self-
Administration by Rhesus
Monkeys
W. L. Woolverton, W. D. Wessinger, R. L. Balster,
and L. S. Harris
Clonidine has recently been reported to provide dramatic relief
of withdrawal signs and symptoms in human opiate addicts (Gold
et al., 1978, 1980.) Aceto et al. (1979) found that clonidine
partially substituted for morphine in morphine-dependent monkeys.
With these findings in mind, and considering the possibility of
increasing availability of clonidine to the drug abuse popula-
tion, we have evaluated the ability of clonidine to support
intravenous self-administration in rhesus monkeys. Under condi-
tions of limited or unlimited access, clonidine maintained self-
administration above saline levels in both drug-experienced and
drug-naive animals. In addition, continuous unlimited access to
clonidine led to high levels of intake as well as the appearance
of abstinence symptoms shortly after abrupt withdrawal of the
drug. These symptoms were reversible by clonidine administration
and were not precipitated by naloxone.
METHODS
The subjects were 6 male rhesus monkeys. Each monkey was housed
in an individual self-administration cubicle and fitted with a
stainless steel tubular harness and connecting arm. Under
pentobarbital anesthesia the animals were prepared with venous
catheters. The catheter exited through the skin on the back and
connected through the harness and arm to an infusion pump.
Four monkeys were allowed to self-administer cocaine (30µg/kg/
injection) each day for a 2 h experimental session. Ten re-
sponses on a lever were required for a 10 sec injection. When
daily cocaine self-administration was stable, saline or one of
several doses of clonidine (0.3-100µg/kg/injection) was substi-
tuted for cocaine for 6 consecutive sessions. Rates of self-
administration for the last 3 sessions of clonidine availability
were compared to responding during the corresponding sessions of
access to saline. The effects of several doses of clonidine
were replicated in two monkeys.
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Two monkeys have been tested to date under conditions of unlimit-
ed access. Monkey #3018 was drug naive while #3147 had been
used in other self-administration experiments. Experimental
sessions were 23 h long. Beginning at 3:00 p.m. each day, two
red lights were illuminated over each of two levers. Each
left lever press resulted in a 1 ml injection of the drug or
saline vehicle solution. During injections the left lever
lights changed from red to white. Responses on the right lever
produced the same stimulus change over the right lever but no
injection resulted. At 2:00 p.m. the subsequent day the session
was terminated, the data recorded, the equipment checked, the
cages cleaned, and the total food intake over the preceding 23-
hour period determined. After an initial 7 days of access to
saline, several unit doses of clonidine were tested for access
periods that ranged from 10-30 days. During periods of access
to saline that also followed clonidine availability, animals
were observed every 4 h and rated using a withdrawal symptoms
checklist. In addition, one hour prior to the end of session 86,
naloxone (0.1 mg/kg) was administered i.v. to both animals and
the effects were recorded. At the same time point during
sessions 132, 133 and 134, saline or a naloxone challenge dose
of 0.1 or 0.3 mg/kg was administered i.v. in a random fashion
and with observer blind to treatment.
RESULTS
The data for limited access are summarized in table 1. Under
baseline conditions cocaine maintained stable responding above
the range of saline values in all animals. There was, however,
considerable variability between subjects in cocaine intake
per session, with mean values ranging between 56 and 114 injec-
tions per session. Responding for cocaine was relatively evenly
distributed over the session with slightly greater than 50% of
the injections taken in the first half of the session. In con-
trast, when saline was substituted for cocaine, low rates of
responding (<10 injections/session)were usually observed by
sessions 4-6. In addition, responding for saline occurred prin-
cipally in the first part of the session with more than 75% of
the total injections taken in the first half of the session.
TABLE 1
Intravenous Clonidine Self-Administration in Rhesus
Monkeys Under Conditions of Limited Access
Clonidine Injections Per Total Intake No. Self-
Dose Session session) Administered/
(µg/kg/inj) Mean Range
(µg/kg/
Mean Range No. Tested*
Saline 6.3 0-23
0.1 19.3 14-29 1.9 1.4-2.9 1/1
0.3 15.2 3-40 4.6 0.9-12 1/3
1.0 12.1 1-32 12.1 1.0-32 3/5
3.0 11.9 1-38 35.6 3-114 3/5
10 18.1 3-77 181.0 30-770 3/6
30 7.0 0-28 210.0 0-840 1/4
100 19.5 9-34 1950.0 900-3400 1/2
*Number of tests where clonidine range did not overlap with
saline range. Where number tested >4: 1 or 2 animals were
tested twice.
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When clonidine was substituted for cocaine, responding above the
range of saline levels was observed at least at one dose in all
animals. Dose-response curves were somewhat flattened, usually
with less than 30 injections/session taken at any dose at
any time, and typically of the inverted "U" shape usually de-
scribed for drugs that are positive reinforcers. Response rate
maxima occurred at different unit doses in different animals
(0.3-10 µg/kg/injection). Total intake of clonidine ranged
to 3.4 mg/kg/session. The pattern of responding for inter-
mediate doses of clonidine, though often evenly distributed over
the session, was characterized by short bursts of responding
followed by long pauses rather than the evenly spaced responding
that was typical of cocaine self-administration. During periods
of high clonidine intake, ptosis and sedation were observed in
all animals.
TABLE 2
Intravenous Clonidine Self-Administration in Rhesus Monkeys
Under Conditions of Unlimited Access in
Different Phases of the Study
Injections Per Total Intake Incorrect Responses
Monkey Session (µg/kg/day) Per Session
Mean Range Mean
Sessions 1-7 Saline 1.0 ml/inj
3018 21 5-40
3147 125 89-182
Sessions 8-37 Clonidine 1.0 µg/kg/inj
3018 23 5-73 23
3147 205 66-407 205
Sessions 38-76 Clonidine 5.0 µg/kg/inj
3018 80 0-180 400
3147 180 42-411 900
Sessions 68-76* Saline 1.0 ml/inj
3018 88(33) 8-527(98)
3147 53(45) 20-125(73)
Sessions 77-86 Clonidine 5.0 µg/kg/inj
3018 181 84-324 905
3147 221 90-421 1105
Sessions 87-97* Saline 1.0 ml/inj
3018 62(40) 19-289(68)
3147 101(83) 18-277(197)
Sessions 98-107 Clonidine 5.0 µg/kg/inj
3018 248 166-302 1240
3147 447 204-763 2235
Session 108-117 Clonidine 1.0 µg/kg/inj
3018 352 306-411 352
3147 388 157-550 388
Sessions 118-137 Clonidine 10 µg/kg/inj
3018 223 157-339 2230
3147 358 14-877 3580
Sessions 138-147* Saline 1.0 ml/kg
3018 73(55) 33-232(70)
3147 79 (48) 7-356(116)
5
2
2
1
0-13
0-5
*Data in parenthesis excludes extinction burst occurring on the
first day of clonidine withdrawal.
Mean
14
18
Range
0-21
4-22
18 3-87
15 1-50
15
3
0-55
0-19
8 0-43
1 0-5
7 2-16
4 0-21
5
1
0-22
0-5
6 1-16
11 1-38
6 1-14
2 0-6
1-27
0-11
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Table 2 summarizes the results of unlimited access to clonidine
for both subjects. The data are divided into periods of access
to saline and 10-day segments of access to clonidine at various
doses. During the first seven sessions of access to saline, the
drug-experienced animal (#3147) took 125 injections/session
while the drug-naive animal (#3018) averaged about 20 saline
injections/session. During the initial 10 days of access to
1.0 µg/kg/injection clonidine, #3147 increased his rate of self-
administration to 200 injections/session and maintained roughly
this level of intake throughout this period. The second animal
continued to take injections of this dose with the same fre-
quency as he had saline. Total intake ranged between 30-240
µg/kg/session during this period. When the unit dose of clon-
idine was increased to 5 µg/kg/injection, both animals self-
administered the drug at levels that were higher than saline.
Monkey #3147 maintained his roughly 200 injection/session rate,
thus increasing total intake five-fold to 800-1000 µg/kg/session.
Monkey #3018 gradually increased clonidine intake over this
period, often achieving daily intakes greater than 500 µg/kg.
For both animals, as rates of responding for clonidine increased,
the distribution of responding changed from responding primarily
during the day to an even distribution throughout the session.
After a period (session 68-76) of access to saline during which
responding declined to low levels, clonidine was again tested at
several doses. Response rates were generally inversely related
to unit dose. Animals usually averaged 350-400 injections/session
at 1.0 µg/kg/injection. However, rates did not decrease in
proportion to the increase in unit dose and overall intake
increased dramatically at higher doses, often exceeding 2.0
mg/kg/day. After each period of access to saline, animals
promptly resumed clonidine self-administration at or above pre-
vious levels within one session.
For both monkeys, initial high levels of clonidine intake pro-
duced ptosis and general slowing of reactions. Tolerance ap-
peared to develop to this effect within 3-5 days. Food intake
was unaffected by clonidine self-administration and the animals
maintained good health.
When saline was substituted for clonidine (3 times during the
experiment) a number of effects were apparent. During the first
session of saline access, animals typically exhibited high rates
of responding for saline (extinction burst). Saline access was
continued for 9 additional days, and both animals responded at
low levels during the last 8 sessions of each saline access
period. Furthermore, several symptoms of withdrawal were clear-
ly evident by four hours after drug termination and included
restlessness, yawning, bruxism, facial flushing and wet dog
shakes. Withdrawal symptoms that were prominent are summarized
in table 3. Symptoms were most severe 8-12 hours after clonidine
access was terminated and included marked facial flushing,
excessive scratching, lying on side, refusal of preferred food,
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vomiting and masturbation. Normal food intake was often reduced
to less than 50% of control levels, particularly during the second
and third withdrawal periods. Symptoms gradually became less
severe with recovery to normal appearance by 72-96 hours.
TABLE 3
Incidence of Clonidine Withdrawal Symptoms
Sessions Sessions Sessions
Symptom
Monkey
Facial Flushing
Scratching
Lying on Side
Masturbation
Piloerection
Extinction Burst
Salivation
Refused Preferred Food
Yawning
Wet Dog Shakes
Vomitus
68-69 87-88 138-139
3147 3018 3147 3018 3147 3180
X X X X X X
X X
X X
X X
X
X
X
X
X
X X
X X
X X
X X
X X
X X
X X
X X
X X
X X
X
X X
X X
X X
X X
X X
X X
X X
X
X
X
During the second withdrawal period (session 87) clonidine (50
µg/kg) was administered intravenously and reversed the symptoms
noted above. When naloxone (0.1 mg/kg, i.v.) was administered
(session 86), no prominent symptoms were observed in #3147,
though #3018 exhibited a severe reaction about 20 minutes after
naloxone infusion characterized by symptoms observed at the
height of the previous abrupt withdrawal. These symptoms were
reversed by infusion of 50 µg/kg clonidine. However, these
effects could not subsequently be replicated in either animal
when saline, 0.1 and 0.3 mg/kg naloxone were administered on
sessions 132, 133 and 134.
DISCUSSION
Based on the results from these two experiments, a few general
statements can be made regarding intravenous clonidine self-
administration in rhesus monkeys. Under conditions of limited
or unlimited access clonidine was self-administered above saline
levels and, at some unit dose, animals averaged 10-15 injections
per hour. Generally, total intake was in the 0.1-1.0 mg/kg range
though under unlimited access animals sometimes exceeded 5.0 mg/
kg/day, In both situations, responding tended to occur in
periodic bursts, followed by long pauses. Dose-reponses curves
for clonidine were conspicuous in their "flatness." Under
limited access, typical inverted "U" shaped functions were
evident though response rates were not exceptionally high. At
doses above those maintaining maximum rates, rates were gen-
erally inversely related to dose, although at higher unit doses
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responding was not always suppressed. Similarly, with unlimited
access there was generally an inverse relationship between dose
and response rate, though there were clear exceptions to this
rule. Self-administration was somewhat variable in both proce-
dures, with wide ranges of intake and the effects of individual
doses were not always replicable.
Generally, responding was more reliably above saline levels
under conditions of unlimited access. A number of variables may
contribute to this difference. Under conditions of unlimited
access the development of tolerance and physical dependence may
play a role in maintaining more reliable self-administration.
Further, the relatively long duration of action of clonidine may
contribute to the low rates under limited access. In addition,
the low response cost under unlimited access (1 response/injection
rather than 10 responses/injection) may be a contributing behav-
ioral factor. Clonidine self-administration has been reported
in rats as well (Shearman et al. 1977).
Under conditions of unlimited access physical dependence to
clonidine was evidenced by characteristic symptoms of ab-
stinence that were reversible by clonidine administration.
These findings are consistent with those of Meyer et al. (1977)
in rats with a daily clonidine dose of 250-350 µg/kg/day, though
recovery in rats was somewhat more protracted than in the monkey.
A number of the symptoms of clonidine withdrawal were similar to
morphine withdrawal (diarrhea, lying on abdomen, ejaculation,
bruxism). However, the dependence is evidently not of the
morphine type since it could not be precipitated reliably by
naloxone administration. This finding is in agreement with
results of others that naloxone fails to reverse the acute
effects of clonidine (Aghajanian, 1978; Fielding et al., 1978).
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Comparison of Discriminative
and Reinforcing Effects of
Ketamine and Related
Compounds in the Rhesus
Monkey
A. M. Young, S. Herling, G. D. Winger, and J. H. Woods
One prominent behavioral characteristic of the dissociative
anesthetics ketamine and phencyclidine is the ability to serve as
discriminative stimuli. Phencyclidine shares discriminative
properties with several of its structural analogues in rodents
(Shannon, 1979) and with ketamine in pigeons (Herling et al.,
1980). Moreover, a variety of narcotic mixed agonist-antagonists,
such as cyclazocine and SKF 10,047, and dextrorphan, the
dextroisomer of the narcotic levorphanol, share discriminative
effects with phencyclidine and ketamine in these species
(Herling et al., 1980; Holtzman, 1980). The phencyclidine
discriminative stimulus is distinct from that of narcotic
agonists, barbiturates, hallucinogens, and amphetamine in the rat
(Shannon, 1979).
A second behavioral characteristic of ketamine and phencyclidine
is the ability to function as a positive reinforcer (Balster et
al., 1973; Pickens et al., 1973; McCarthy and Harrigan, 1976;
Moreton et al., 1977). However, several drugs that share
discriminative effects with phencyclidine in the rodent and
pigeon, such as SKF 10,047, cyclazocine, and dextrorphan, do not
serve as intravenous reinforcers for monkeys experienced with
codeine (Hoffmeister, 1979; Woods, 1977; Woods et al., 1979). In
order to characterize further the effects of ketamine and other
compounds in the rhesus monkey, we directly compared the
discriminative and reinforcing stimulus functions of ketamine with
those of a variety of other drugs.
METHODS
Subjects. Rhesus monkeys in the self-injection study were
given 75 gm of Purina Monkey chow 45 min prior to each exper-
imental session; monkeys in the discrimination study were reduced
to approximately 85 percent of their free-feeding weights and
provided sufficient Purina Monkey Chow after each session to
maintain their reduced weights. Fresh fruit was provided several
times per week; isoniazid (40 mg/day) on sugar cubes was provided
daily. Water was freely available in individual home cages.
173
Drug Discrimination Studies. Monkeys were trained to
discriminate the subcutaneous injection of ketamine (1.0 - 1.8
mg/kg) under a procedure that has been described in detail
elsewhere (Bertalmio et al., in press). Each monkey was trained
to emit 100 consecutive lever press responses (fixed ratio 100; FR
100) on one of two levers in an experimental cubicle after an
injection of ketamine and the same number of consecutive responses
on the other lever after a sham injection. Completion of each FR
100 was followed by delivery of 3 gm of food. Daily sessions
consisted of two to six discrete FR 100 trials, each separated by
10 min. The appropriate lever for a given trial was determined by
the injection (ketamine or sham) that the animal received 10 min
prior to the start of the trial. An injection of ketamine was
given only once during each experimental session. During the two
trials which followed the ketamine injection, responding on the
ketamine-appropriate lever was reinforced. The two ketamine trials
were preceded by from 0 to 4 sham injection trials.
After ketamine acquired discriminative control of responding,
various drugs were tested for generalization to the ketamine
stimulus. During generalization tests, monkeys received an
increasing cumulative dose of the test drug 10 min prior to the
start of each successive trial during the session. During each
trial, 100 consecutive responses on either the ketamine-
appropriate or the sham-appropriate lever resulted in food
delivery. In general, testing continued until the monkey made 90
percent of its responses during a given trial on the
ketamine-appropriate lever or until the rate of responding was
markedly suppressed.
Intravenous Drug Self-injection Studies. Monkeys were
conditioned to self-inject either codeine or ketamine, and the
ability of test drugs to maintain self-injection behavior was
evaluated under a substitution procedure (Woods, 1980). Monkeys
were prepared with an indwelling siliconized rubber catheter
implanted in a jugular, femoral, or brachial vein. To protect the
catheter, each monkey wore a stainless steel harness (Deneau
et al., 1969) connected to a jointed arm mounted to the back of
the experimental cubicle. The catheter passed through the arm to
an infusion pump. Monkeys lever pressed for intravenous drug
injection during twice daily experimental sessions. During each
session, lever pressing was maintained under a fixed-ratio 30
timeout 600 sec schedule of intravenous injection of either
codeine (0.32 mg/kg /injection) or ketamine (1.0 mg/kg/injection).
Each session terminated after 13 infusions or 130 min, whichever
occurred first. During selected sessions, the maintenance dose of
codeine or ketamine was replaced with saline or selected doses of
test drugs. Two observations of each dose of each test drug were
made in each of three monkeys.
Drugs. Codeine phosphate (S.B. Penick and Co., Lyndhurst, NJ),
ketamine hydrochloride (Parke Davis and Co., Detroit, MI),
phencyclidine hydrochloride (Dr. R. E. Willette, NIDA),
dextrorphan tartrate and levorphanol tartrate (Hoffman-La Roche,
Inc., Nutley, NJ), and SKF 10,047 hydrochloride (N-allyl-
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normetazocine; Dr. A. Jacobson, NIH) were dissolved in 0.9%
sterile saline. Dexoxadrol hydrochloride and levoxadrol hydro-
chloride (The Upjohn Company, Kalamazoo, MI) were dissolved in
sterile water. Ethylketazocine methane sulfonate and cyclazocine
base (Dr. W. Michne, Sterling-Winthrop Research Institute,
Rensselaer, NY) were dissolved in sterile water to which a small
amount of lactic acid was added. If needed, sodium hydroxide was
used to adjust the pH of the solutions to between 3 and 4.
RESULTS
Drug Discrimination Studies. Ketamine acquired discriminative
control over the monkeys' food-maintained lever pressing within 30
to 45 sessions. Ketamine doses of 0.56 to 3.2 mg/kg occasioned
responding primarily on the ketamine-appropriate lever; lower
doses occasioned responding on the sham-appropriate lever (Table
1). Phencyclidine, at doses of 0.1 to 0.32 mg/kg, also occasioned
ketamine-appropriate responding; lower phencyclidine doses
produced only sham-appropriate responding. Dextrorphan and
dexoxadrol also produced dose-related responding on the
ketamine-appropriate lever. Their levoisomers, levorphanol and
levoxadrol, however, did not produce ketamine-appropriate
responses at any dose tested, up to and including doses that
decreased response rates. SKF 10,047 occasioned ketamine-
appropriate responding at doses of 0.32 to 1.8 mg/kg. In contrast,
cyclazocine, ethylketazocine, and codeine did not produce
ketamine-appropriate responding at any dose tested, up to and
including doses that severely suppressed response rates and
precluded the delivery of food pellets.
Self-Self-injection Studies. Self-injection of the test compounds
depended on the compound, its injection dose, and the baseline
drug that maintained responding (Table 2). Codeine, 0.32 mg/kg/
injection, and ketamine, 1.0 mg/kg/injection, maintained FR
component response rates which ranged in individual monkeys from
0.9 to 2.7 and from 1.2 to 4.4 responses/sec, respectively. The
monkeys usually received all 13 available infusions during
maintenance drug sessions. Replacement of the maintenance
drugs with saline for single sessions decreased response rates
to 0.02 - 0.2 responses/sec and the number of injections to
3 - 8.
Ketamine and codeine maintained responding in all monkeys,
independent of the maintenance drug (Table 2). The same doses of
ketamine and codeine maintained maximal response rates for monkeys
self-injecting either maintenance drug. On the other hand,
phencyclidine, dextrorphan, and dexoxadrol maintained responses
leading to their intravenous injection in monkeys experienced in
self-injecting ketamine, but not in monkeys experienced in
injecting codeine. When substituted for ketamine, injections of
0.03 mg/kg phencyclidine, 1.0 mg/kg dextrorphan, and 0.32 mg/kg
dexoxadrol maintained responding leading to 12 or 13 injections
per session, with response rates averaging 52, 50, and 58 percent
of control rates, respectively. Higher and lower doses of each
drug maintained response rates and infusion frequencies little
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TABLE 1
Response generalization to test compounds by rhesus monkeys
trained to discriminate ketamine from salinea
RESPONSES TO KETAMINE LEVER:
DRUG DOSE RANGE LOWEST DOSE NECESSARY MAXIMUM %
Ketamine 0.10-3.2 0.56 100
Phencyclidine 0.01-0.32 0.10 93 - 100
SKF 10,047 0.03-1.8 0.32 99 - 100
Dextrorphan 0.32-5.6 3.2 84 - 100
Levorphanol 0.01-0.32
b 1
Dexoxadrol 0.10-3.2 1.0 98 - 100
Levoxadrol 0.32-17.8 1
Codeine 0.10-1.0 1
Ethyl- 0.0003-0.018 2
ketazocine
Cyclazocine 0.003-0.1 3
aData represent values for one test in each of two monkeys.
bCompounds did not occasion ketamine-appropriate responses at
any dose.
higher than those maintained by saline. The highest phencyclidine
and dextrorphan doses produced ataxia and salivation in all
subjects. When phencyclidine, dextrorphan, or dexoxadrol were
substituted for codeine, however, no injection dose maintained
response rates or injection frequencies higher than those
maintained by saline.
SKF 10,047 did not maintain responding by either ketamine- or
codeine-experienced monkeys. Cyclazocine did not maintain
responding by codeine-experienced monkeys. In ketamine-experienced
monkeys, 0.001 mg/kg cyclazocine injections maintained rates
averaging 10% of those maintained by ketamine. Lower and higher
cyclazocine doses maintained rates no higher than those maintained
by saline. At the highest SKP 10,047 and cyclazocine injection
doses (0.32 and 0.032 mg/kg, respectively) both ketamine- and
codeine-experienced monkeys took only one to three injections and
did not approach the lever during the remainder of the 130 min
experimental session.
DISCUSSION
The dissociative anesthetic ketamine shared interoceptive effects
with an interesting variety of compounds, including phencyclidine,
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TABLE 2
Maximum response rates and injections, expressed as a percent of
control, maintained by test drugs in individual monkeys
experienced in self-injecting codeine or ketaminea
TEST DRUG INJECTION MAINTENANCE DRUG
(range of DOSE CODEINE KETAMINE
injection (mg/kg)
doses, Response Injections Response Injections
mg/kg) rate rate
Codeine 0.32
(0.032-1.0)
Ketamine 1.00
(0.01-3.2)
Phencyclidine 0.03
(0.01-0.10)
Dextrorphan 1.00
(0.01-3.2)
Dexoxadrol 0.32
(0.032-1.0)
Cyclazocine 0.001
(0.0001-0.032)
SKF 10,047 c
(0.01-0.32)
Salined
22b 96b
52 100
87 100
46 92
114 100
117 100
1 27
5 50
12 65
2 15 35 100
2 46
88
41 96
20 42 96
2 54
3 42
8 77
1 19 2 58
1 38 13 88
2 35 13 92
1 35 1 27
2 31 1 38
3 54 3 35
5 50 3 57
(2.2-9.6) (37-62) (2.1-6.3) (43-67)
23 96
77
79
100
100
42 100
52 100
73 100
aControl rates and injections maintained by maintenance drugs
are given in text.
bEntries are data for individual monkeys.
cNo injection dose of SKF 10,047 maintained rates or injection
frequencies higher than those maintained by saline. Data are
for 0.1 mg/kg/injection.
dMean and range of average data for all monkeys studied are
shown.
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dextrorphan, dexoxadrol, and SKF 10,047. In turn, phencyclidine,.
dextrorphan and dexoxadrol were self-administered by monkeys with
recent experience self-administering ketamine. SKF 10,047,
however, was not self-administered by ketamine-experienced
monkeys.
The similarity of the discriminative effects of ketamine with
those of phencyclidine, dextrorphan, and SKF 10,047 in the monkey
agrees with results reported for pigeons and rodents (Herling et
al., 1980; Holtzman, 1980). The results with cyclazocine in the
monkey, however, differ from those reported for other species:
Cyclazocine did not produce ketamine-appropriate responding in
the monkey, but produces phencyclidine- or ketamine-appropriate
responding in rats and pigeons (Holtzman, 1980; Herling et al.,
1980). The lack of ketamine-appropriate responding produced by
codeine, levorphanol, levoxadrol, and ethylketazocine agrees
with data in the pigeon (Herling et al., 1980, unpublished
observations).
Ketamine and codeine served as intravenous reinforcers in all
monkeys, and cyclazocine and SKF 10,047 in none. Phencyclidine,
dextrorphan, and dexoxadrol, however, served as reinforcers in
monkeys experienced with ketamine, but not in monkeys experienced
with codeine. The similarity of the interoceptive effects of
ketamine to those of phencyclidine, dextrorphan, and dexoxadrol in
the monkey may be responsible for the latter three compounds'
capacity to serve as reinforcers in ketamine-experienced monkeys.
It remains to be determined whether recent exposure to ketamine or
longer exposure to phencyclidine, dextrorphan, or dexoxadrol will
increase the reinforcing efficacy of these compounds in codeine-
experienced monkeys. The failure of SKF 10,047 to serve as a
reinforcer in monkeys experienced in self-injecting ketamine, with
which it also shares discriminative effects, emphasizes, however,
that the classification of compounds with respect to their
discriminative similarity to ketamine may not unequivocally
predict their ability to exert other actions characteristic of
ketamine, i.e., to serve as intravenous reinforcers.
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A Pharmacologic Comparison
Between Phencyclidine, Its
Precursor, Metabolites, and a
Quaternary Derivative in the Dog
D. B. Vaupel and E. J. Cone
INTRODUCTION
Studies in the chronic spinal dog have demonstrated that the
effects of single doses of phercyclidine are remarkably similar
to those reported in man, indicating that the dog offers promise
as a valid model to study phencyclioine-type compounds (Jasinski
et al., 1979; Jasinski et al., in press). Further, by compiling
both the physiologic and behavioral effects of drugs to form
pharmacologic profiles in the dog, phencyclidine was clearly
distinguishable from other types of hallucinogens (i.e., LSD,
-tetrahydrocannabinol ard d-amphetamine) except for the hal-
lucinogenic opioid N-allylnormetazocine (SKF 10,047). The pres-
ent investigations evaluated the basic pharmacologic actions of
four compounds structurally related to phercyclidine: 1) 1-(1-
phenylcyclohexyl)piperidine methiodide (PCPMeI), 2) 1-(1-phenyl-
cyclohexyl)-4-hyoroxypiperidins (PCHP), 3) 4-phenyl-4-piperi-
dinocyclohexanol (PPC), and 4) 1-piperidinocyclohexanecarbon
itrile (PCC).
The quaternary analogue of phencyclidine, PCPMeI, was used as a
pharmacologic tool to separate the peripheral and central
actions of phercyclidine, based on a theoretical difficult entry
for PCPMeI into the CNS. Previous metabolic studies in the dog
have demonstrated that phercyclidine is hydroxylated in one of
two positions resulting in the production of PCHP and PPC with
the latter predominating (Core et al., 1980). Aside from the
convulsant properties of the metabolites (Domino, 1978); their
pharmacology has not been studied systematically. Consequently,
the actions of the metabolites were compared to those of phency-
clidine and potency estimates were made when possible. PCC is
the synthetic precursor of phencyclidine, and two reports
(Jasinski et al., 1979) of its effects were presented to the
CPDD last year. In brief, rotarod studies using ataxia in the
mouse were unable to differentiate phencyclidine and PCC, except
on the basis of potency, whereas they were readily differenti-
ated using the rat discriminative stimulus paradigm. As a
result we sought to characterize the pharmacological actions of
PCC in the dog in an attempt to differentiate it from phercycli-
dine and thereby further validate the dog as an animal model for
the study of phercyclidine.
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METHODS
Previous publications (Martin et al., 1978; Vaupel et al., 1977)
have described the methods in detail using the chronic spinal
dog. In the present studies five female chronic spiral dogs
were used in a crossover experiment. Drug and vehicle treat-
ments were incompletely randomized. The hindlimb flexor reflex
was elicited by a pneumatic toe pincher which randomly adminis-
tered either a low (4.5 psi), medium (9 psi) or high (18 psi)
pressure stimulus. Other parameters treasured included respira-
tion, heart rate (measured from an EKG), pupil size, nictitating
membrane width, the skin twitch reflex, temperature, and general
behavioral activity. Nonparametric measures included vocaliza-
tions, stereotypic head and eye movements, attentiveness to
external stimuli, and the presence of both the medial and lateral
canthus reflexes.
Each 100-min experiment was divided into a 30-min control
period, a 40-min i.v. infusion (of drug or vehicle control) into
the cephalic vein, and a 30-min postinfusion period. With the
exception of the flexor reflex, which was evoked at 1 min
intervals, and temperature, which was taken rectally at the
beginning and end of each experiment, measurements were made at
10-min intervals throughout the experiment. Time-action curves
were plotted for each parameter and areas (30-100 min) under the
curves were calculated for statistical comparison using paired
t-tests. A chi square analysis was used to test nonparametric
measures. Results were considered to be significant at the p <
.05 level or higher. Cumulative dose-response curves were pro-
duced by taking that portion of a time-action curve generated
during the infusion and using the four cumulative doses coin-
ciding with the 10, 20, 30, and 40 min times of the infusion with
the corresponding response.
Selection of the 0.5 mg/kg test dose of phercyclidine was based
upon a previous study. The limited quantity of PCPMeI necessi-
tated the use of only a 0.69 mg/kg dose which was equimolar to
phencyclidine. Numerous preliminary experiments were used to
select nonconvulsant doses of PCHP (4 mg/kg), PPC (10 mg/kg), and
PCC (6 mg/kg). The following vehicles were used: 1) saline for
phenyclidine HCl and PCPMeI, 2) double distilled water adjusted
to pH 4 for the free base form of PCC, and 3) a 3:2 ratio of
8.5% lactic acid in in NaOH for the free base forms of PCHP and
PPC. Vehicle control experiments were run for saline and the
lactic acid-NaOH solution.
RESULTS
Phencyclidine and Phencyclidine Methiodide (PCPMeI)
Phencyclidine (0.5 mg/kg) produced its expected characteristic
pharmacologic profile of activity without any convulsant activi-
ty. Compared to saline, phencyclidine (Fig. 1) depressed the
flexor reflex, produced marked increases in heart rate, pupil
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size, the latency of the skin twitch reflex, lacrimation, rhi-
norrhea, and salivation plus a moderate hyperthermia. Under the
influence of phencyclidine the dogs became slightly, but signif-
icantly more restless, which differed from their quiet behavior
observed in the control period. Other behavioral signs compris-
ing the phencyclidine profile were nystagmus, tracking and star-
ing (with staring being predominant), stereotyped head rocking
movements, failure to attend to external stimuli in the labora-
tory and loss of the lateral canthus reflex to gentle touching.
Opisthotonic posturing was not a significant finding in these
experiments. This is in contrast to its development in a prev-
ious study using the same dose. Saline was without effect.
When administered in a dose equimolar to phencyclidine, PCPMeI
was almost inactive. Among the physiologic measures, the only
significant effects of this quaternary amine with respect to
saline were small increases in the latency of the skin twitch
reflex and in the size of the nictitating membrane indicating it
was more relaxed. The analgesic effect of the methiodide com-
pound as assessed by the delay in the onset of the skin twitch
reflex (1.7 sec) was much smaller (p < .05) than the correspond-
ing effect of phencyclidine (5.0 sec) at the 70-min mark of the
experiment. The effects of these two drugs on the nictitating
membrane did not differ from each other. Supplementing the rel-
atively minimal physiologic responses was a complete absence of
behavioral responsiveness to PCPMeI.
The Hydroxylated Metabolites: 1-(1-Phenylcyclohexyl)-4-hydroxy-
piperidine (PCHP) and 4-Phenyl-4-piperidinocyclohexanol (PPC).
The choice of a 4 mg/kg aose of PCHP and a 10 mg/kg dose of PPC
was based on their ability to produce the same degree of mydria-
sis as 0.5 mg/kg of phencyclidine. As illustrated in figure 1,
both metabolites and phencyclidine shared the ability to dilate
pupils, increase body temperature, prolong the latency of the
skin twitch reflex as well as increasing lacrimation, rhinorrhea
and salivation. PCHP, PPC and phercyclidine all retracted the
nictitating membrane slightly, but the effect of phencyclidine
did not attain significance. There were no charges in respira-
tion. Among the other physiologic measures, heart rate showed
the most divergent effects (Fig. 1). Most apparent was the lack
of effect of PPC on heart rate, which contrasted sharply with the
phencyclidine-induced tachycardia. The degree of tachycardia
produced by PCHP occupied an intermediate position with respect
to PPC and phemyclidine. Regression analysis demonstrated that
the flexor reflex elicited by the low pressure stimulus
decreased linearly throughout the infusion and postinfusion
periods with phemyclidine and both metabolites but not with the
saline or lactic acid vehicles (Fig. 1). However, area compari-
sons for these same curves indicated that only the reflex de-
pression produced by PPC differed from control values. when the
flexor reflex was elicited by the medium and high pressure
stimuli, phemyclidine but neither PCHP nor PPC was statistical-
ly effective in producing reflex depression (Fig. 1).
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FIGURE 1
Pharmacologic effects of 1-(1-phenylcyclohexyl)-4-hy-
droxypiperidine (PCHP), 4-phenyl-4-piperidinocyclohex-
anol (PPC), and phencyclidine (PCP) in the chronic
spiral dog. The effects of the lactic acid-NaOH vehic-
le for PCHP and PPC did not differ from those of saline
(PCP vehicle) which are not graphed. Each time-action
curve represents the mean responses of 5 dogs.
With respect to behavior all three drugs made the dogs more
restless. Additional features produced by phencyclidine and
PCHP included nystagmus, staring, stereotypic head movements and
loss of attentiveness. Of these four signs, PPC elicited only
the stereotyped head movements. However, instead of nystagnus,
PPC produced rapid eye movements, a characteristic associated
with amphetamine-like compounds.
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fly selecting corresponding sections of the cumulative dose-
response curves, valid potency estimates (Table 1) were obtained
from parallel-line bioassays for the flexor reflex (low stimu-
lus), pupillary diameter, pulse rate and latency of the skin
twitch reflex. Generally, PCHP was about 1/8 as potent and PPC
approximately 1/20 as potent as phencyclidine.
TABLE 1
Measure: Flexor Pupils Pulse Skin Twitch
Effect: Low Stim Mydriasis Tachycardia Increased
Reflex Latency
Depression
PCHP .15(0-.46) .12(.05-.20) .07(.004-.18) .14(.05-.23)
PPC .04(0-.16) .05(.01-.10) No Effect .06(0-.20)
Relative potencies with their 95% confidence limits in
parentheses were obtained from valid bioassays. Rela-
tive potency is defined as the mg of phencylidine HCl
equivalent to 1 mg of the test compound. Depression of
the flexor reflex and increased latency of the skin
twitch are used as measures of analgesia.
The Precursor: 1-Piperidinocyclohexanecarbonitrile (PCC)
At the end of the PCC infusion significant effects included
tachycardia (163 beats/min), small increases of 35 breaths/min
in respiratory rate and 0.9 mm in pupillary diameter, staring
and head raising. These changes were short-lived as they were
no longer significant at the end of the experiment. Additional-
ly, there were slight, though nonsignificant, increases in lac-
rimation, rhinorrhea, salivation and restlessness. Those
actions which were both qualitatively and quantitatively similar
to PCP were the tachycardia and staring, whereas qualitative
similarities were present as the slight mydriasis and the
increase in secretory activity of the eyes, nose and mouth.
Phencyclidine-like actions which were obvious by their absence
from the PCC data included depression of the flexor reflex, a
prolonged latency of the skin twitch reflex, hyperthermia, ny-
stagmus, stereotype, loss of attentiveness to external stimuli
and the disappearanace of the lateral canthal reflex.
While lacking statistical significance, a number of other
effects produced by PCC were noteworthy insofar as they were not
observed at all with phenyclidine or its metabolites. First,
three dogs developed the stepping reflex or fragmentary stepping
for small periods of time. Second, two animals vomited during
the infusion and another retched. Third, the white portions of
the skin found on the abdomen and on the shaved areas surround-
ing the EKG leads became conspicuously pink during the infusion
of PCC. Upon terminating the infusion the pinkness disappeared.
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DISCUSSION
Con-pared to phercyclidine, intravenously administered PCPMeI was
almost devoid of pharmaccologic activity in the chronic spinal
dog. Similar findings have been reported by Kalir et al.
(1978). Our data suggest that most of the effects of phencycli-
dine orginate at central sites of action. This finding is
limited to the extent that we have not tested higher doses of
PCPMeI to ascertain the relative effectiveness of the blood
brain barrier, nor has the direct central administration of
PCPMeI into the ventricles been attempted in order to reproduce
phencyclidine-like activity.
The hydroxylation of phencyclidine to form less potent metabo-
lites is consistent with established pharmacologic principles.
PPC was less active, being approximately 2 1/2 times less potent
than PCHP. In view of this potency difference it is apparent
that it is more advantageous to detoxification that the dog pro-
duce greater quantities of PPC than PCHP, as shown by Cone et
al. (1980).
Composite pharmacologic profiles were developed for the two mon-
ohydroxylated metabolites of phencyclidine. On the whole, the
profile for PCHP was similar to that of its parent compound and
thus was classified as a phencyclidine-like drug. However, the
qualitative differences between the profiles of phencyclidine
and PPC were numerous enough to conclude that PPC is not primer-
ily a phencyclidine-type compound. Our conclusion that PPC is
pharmacologically different from phencyclidine is in agreement
with the discriminative stimulus studies of Shannon in which
rats trained on phencyclidine did not show stimulus generaliza-
tion to PPC (Jasinski et al., in press).
The precursor of phencyclidine, PCC, failed to reproduce most of
the effects characteristic of phercyclidine, thereby clearly
differentiating it from phencyclidine on the basis of its pro-
file of action. Bailey et al. (1976) have hypothesized that the
toxic properties of PCC, sometimes found as a contaminant in
street phencyclidine, could be attributed to the in vivo genera-
tion of hydrogen cyanide. Several effects observed in this
study lend support to this hypothesis and were consistent with a
low level of cyanide toxicity. These signs, while not patho-
gnomonic, included emesis, rapid heart rate and a flushing of
the skin which we postulated to be due to the hyperoxygenation
of the blood (Chen and Rose, 1952; Hatch, 1977).
In summary, the lack of activity of PCPMeI is suggestive that
phencyclidine acts primarily centrally. PCHP and PPC, the
primary metabolites of phercyclidine, were less potent than
phencyclidine. The pharmacologic profile of PCHP was identical
to that of phencyclidine whereas that of PPC was not. To our
knowledge only a single report of a pure sample of the phency-
clidine precursor PCC has appeared oh the street suggesting that
it has a low level of acceptance as a drug of abuse in man.
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Together the information obtained from the dog, rat and man
argue that the pharmacology of PCC is not rat like that of phency-
clidine and further validates the dog as an effective animal
model to identify phencyclidine-type compounds.
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Phencyclidine Inhibition of
CerebeIIar Purkinje Neurons
J. Marwaha, M. Palmer, B. Hoffer, and R Freedman
Recent Drug Abuse Warning Network statistics indicate that phen-
cyclidine (PCP) is incriminated in 25 percent of all cases of
psychedelic drug abuse. Among its psychotomimetic effects, PCP
profoundly alters normal sensory perception, and the resulting
psychosis closely resembles naturally occurring schizophrenia
(Balster and Pross, 1978). It is postulated that PCP may elicit
these behavioral changes via an interaction with bicgenic amine
transmitters in the brain. There exist few reports of electro-
physiological actions of PCP on identified neurons to test this
hypothesis. Since the rat cerebellum is a brain region where
cell types and pathways can be identified during recording, and
the identity of putative transmitters to various neurons in the
region is well established (Freedman, 1977), we undertook the
study of PCP in this region.
METHODS
Male Sprague-Dawley rats were anesthetized, intubated and placed
in a stereotaxic frame. After appropriate surgery, the brain
surface was covered with agar. Body temperature was maintained
at 37° C. Five-barreled micropipettes were used to record extra-
cellular action potentials of spontaneously active single Purkin-
je neurons and to apply substances at the site of recording.
Some drugs (e.g., GABA and NE) were applied by conventional ion-
tophoresis whilst other drugs (e.g., PCP, ketamine and haloperi-
dol), not sufficiently polar or soluble for microiontophoresis,
were applied by pressure ejection. Both iontophoresis and pres-
sure ejection, used in our laboratory, yield reproducible dose
response relationships.
Extracellular action potentials were amplified, monitored on an
oscilloscope, and converted to constant voltage pulses by a win-
dow discriminator. The pulses were fed to a ratemeter which in-
tegrated them over one-second intervals for display on a strip
chart recorder. Further details of the procedures employed may
be obtained from our previous papers (Marwaha et al. 1980, a,b;
Freedman and Marwaha, 1980).
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RESULTS
PCP and its less potent analog, ketamine reversibly depressed the
firing of Purkinje cells. The EC50’s for the 2 compounds were
3.5 and 18 PSI-sec, respectively. Haloperidol (a butyrophenone
antipsychotic drug), administered intraperitoneally, antagonized
the depressant effects of PCP and ketamine. Since parenteral ad-
ministration of haloperidol could have remote or indirect effects,
the antipsychotic was locally applied. When haloperidol was lo-
cally applied, it also consistently blocked the effects of PCP.
To determine the specificity of the antagonism, inhibitory effects
of PCP were studied before and after administration of alpha-flu-
penthixol (a potent neuroleptic), and beta-flupenthixol (an inac-
tive isomer). Beta-flupenthixol given systemically did not block
PCP-induced inhibitions, whereas alpha-flupenthixol did (Figure 1).
FIGURE 1
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Ratemeter record of PCP actions on a single Purkinje cell. PCP
causes profound inhibition (A), and this inhibition is still pre-
sent when -flupenthixol ( -FPT) is administered intravenously
(B). Inhibitory actions of PCP are blocked 15 min. after admin-
istration of -flupenthixol ( -FPT) intravenously (C). 40 min.
after administration of -FPT, there is complete recovery to the
inhibitory effects of PCP.
We have previously shown that norepinephrine (NE) and GABA also
depress Purkinje neuron discharge. NE responses but not GABA
effects are blocked by antipsychotics (Freedman, 1977). In the
current study, parenterally administered haloperidol blocked the
inhibitory effects of norepinephrine and PCP, but not those of
GABA (Figure 2).
FIGURE 2
Ratemeter record of inhibitory actions of PCP, GABA (G) and nore-
pinephrine (NE) on a single Purkinje cell (A). The inhibitory
actions of PCP and NE, but not those of G are antagonized 45 min.
after administration of haloperidol (B). 90 min. after adminis-
tration of haloperidol, there is complete recovery to the inhibi-
tory actions of PCP and NE (C).
Histofluorescent, ultrastructural and biochemical studies have
shown that intracistemal 6-hydroxydopamine (6-OHDA) treatment
produces a nearly totalandirreversible destructionof cere-
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bellar noradrenergic afferents (Bloom et al. 1969). Interneuronal
excitatory (granule cell-parallel fiber) and inhibitory (basket-
stellate cell) pathways to the Purkinje cell in the cerebellar
cortex can be destroyed by neonatal degranulation with X-irradia-
tion (Woodward et al. 1974). After treatment with 6-OHDA, Purk-
inje cells are no longer depressed by local ejection of PCP
(Figure 3).
FIGURE 3
Effects of PCP (solid line) and NE (dotted line) on P cell dis-
charge after pretreatment with 6-OHDA. Note that there is no
effect of PCP at a dose much higher than that required in normal
rats, whereas a similar ejection of NE induces a maximal depres-
sion. The vertical and horizontal calibrations for this figure
are the same as for Figure 1.
In contrast, Purkinje neurons from neonatally X-irradiated ani-
mals manifest normal responsivity to this substance. The effects
of PCP on spontaneous firing of Purkinje neurons from variously
treated rats are described in Table 1.
TABLE 1
Excite Depress No Effect
Control Bats 2 46 3
6-OHDA Rats 2 2 17
X-Irradiated Rats 1 9 1
X-Irradiated + 6-OHDA Rats 1 0 8
DISCUSSION
This investigationhas shown that PCP inhibits the spontaneous
discharge of Purkinje cells, and its inhibitory effects are
blocked in a rapid, reversible and specific fashion by antipsy-
chotic drugs. Previously, our laboratory (Freedman, 1977) has
shown that neuroleptics specifically block norepinephrine-induced
inhibitions in the cerebellum. Since the effects of PCP and NE,
but not those of GABA were antagonized by antipsychotic drugs,
it may be hypothesized that norepinephrine is involved in the ac-
tions of PCP. Supporting this conjecture, several investigators
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have shown sympathomimetic properties for PCP (Chen et al. 1965;
Smith et al. 1977; Fessler et al. 1979). After neonatal X-irra-
diation which destroys cerebellar interneurons and consequently
parallel fiber excitatory and basket-stellate GABAergic inhibi-
tory pathways, little change is seen in PCP effects. In con-
trast, selective destruction of cerebellar NE-containing affer-
entswith 6-OHDA completely eliminates responses to PCP. Such
findings strongly support the hypothesis that PCP-induced de-
pressions of cerebellar Purkinje neurons are mediated by pre-
synaptic NE release fran noradrenergic fibers synapsing onto
Purkinje neurons.
The finding of a central sympathomimetic effect for a psychoto-
mimetic drug provides further evidence for the participation of
noradrenergic mechanism in the sensory disturbances which accom-
pany psychosis. We have previously shown that NE increases the
sensitivity of Purkinje neurons to afferent climbing and mossy
fiber synaptic input (Freedman, 1977). Neuroleptics, by blocking
the effects of NE, would cause neurons tobeless affected by
their afferent inputs. Our studies do not preclude the interac-
tions of PCP with other transmitter system. These reservations
notwithstanding, however, the fact that the efficacy of PCP and
ketamine in slowing Purkinje discharge parallels their psychoto-
mimetic potency, and that both behavioral and electrophysiological
actions are antagonized by antipsychotics, suggest that the neu-
ronal responses reported here may relate to the sensory and psy-
chotic disturbances produced by these psychotometic drugs.
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The California Registration
System for Habitues to
Schedule II Drugs
F. S. Tennant, Jr.
SUMMARY ABSTRACT
In order to help control abuse and prevent over-prescribing,
California has developed triplicate prescriptions for Schedule
II narcotics as well as a system for physicians to publicly
register patients who are habitues to Schedule II Controlled
Substances. A preliminary evaluation indicates that there is
under-reporting and confusion among physicians about the system,
but it has probably helped control Schedule II narcotic abuse in
California while not depriving patients of needed treatment.
Physicians appear to prescribe Schedule II narcotics for serious
medical conditions but may underprescribe narcotics for some
chronic pain patients and subject others to potential
complications of high, chronic doses of oral narcotics which are
combined with salicylate, acetaminophen, or phenacetin. Despite
some defects, California's system of triplicate prescriptions
and public registration of habitues appears a viable alternative
to the removal of abusable, Schedule II drugs from the commercial
market.
INTRODUCTION
Abuse of prescription drugs is a matter of great concern.1-4 A
major regulatory effort to control abuse of prescription drugs
has been the Comprehensive Drug Abuse Prevention and Control Act
of 1970 which classifies abusable prescription drugs into five
schedules. Drugs in the lower (III, IV, and V) schedules have
fewer prescribing restrictions than those in the upper (I and
II) schedules. Five states, including California, have adopted
a triplicate prescription system for Schedule II narcotics.
With this system the physician and pharmacist each retain a copy
of the prescription and one copy is forwarded to State
authorities to allow monitoring of over-prescribing and
identification of prescription "shopping" by patients.
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California has developed an additional mechanism to reduce abuse
of Schedule II drugs. Any physician prescribing or furnishing
a controlled substance classified in Schedule II to an habitual
user is to report the patient in writing to the Office of the
California Attorney General. Described here is the first study
of this system to determine if physicians use the system
properly and to help assess its effectiveness in controlling
abuse of Schedule II drugs.
DESCRIPTION OF THE REPORT SYSTEM
The report, which the physician files with the State, must
contain the following:
Name of the patient
Address of the patient
Character of the injury or ailment
Quantity and kind of controlled substance used
A statement as to whether or not the patient is an addict
For ease in reporting the above information, the California
Department of Justice has developed a 3" by 5" preprinted,
"patient report card". (Figure 1) This information is then
used to identify patients who go from physician to physician
to obtain Schedule II drugs for non-medical use and to protect
the physician and patient who appropriately use Schedule II
drugs.
METHODS
In 1979 the Bureau of Narcotic Enforcement of the California
Department of Justice granted the author access to data from
the patient report cards submitted by all California physicians
beginning November 1, 1979. All required reporting information
was available except the names of the patients and physicians.
This review covers the 7-month period from November 1, 1979
through June 1980.
RESULTS
A total of 224 patients were registered in this period. Schedule
II narcotics accounted for 167 (74.6 percent) of the cases, and
they were prescribed for medical conditions which are well-
recognized to be associated with severe, chronic pain. (Tables
One and Two) The most common reasons to prescribe narcotics
were carcinoma, arthritis, headaches, lumbo-sacral disease, and
post-traumatic pain. Maximum daily dosages of narcotics
generally appeared to be compatible with mild forms of addiction.5
Only 19 (8.4 percent) of the cases were for habitues to
non-narcotic Schedule II drugs. The most common drugs prescribed
were barbiturates and methylphenidate. Barbiturates were
usually prescribed for insomnia and methylphenidate for
hyperactivity or learning disorder.
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Thirty-eight (17.0 percent) cases did not need to be registered
because they were prescribed codeine compounds, propoxyphene,
diasepam, pentazocine, or another drug which is not in Schedule
II.
DISCUSSION
Findings in this review of limited data indicate under-reporting
and confusion about reporting requirements. Although
approximately 350,000 triplicate prescriptions for Schedule II
narcotics were written in California in this 7-month period,
only 167 patients were classified as habitues to Schedule II
narcotics by physicians and registered with the State. An
additional 57 patients who were prescribed drugs other than
Schedule II narcotics were classified as habitues and registered.
Although the number of habitues to Schedule II drugs in
California is unknown, the number must surely be greater than
the number registered considering that epidemiologic surveys
indicate that 5 to 10 percent of general medical patients
regularly use one or more psychoactive prescriptions drugs.2,6
Many physicians are obviously confused about the California
reporting system. Thirty-eight (38) of the 224 (17.0 percent)
registered persons didn't need to be registered since a Schedule
II controlled substance wasn't prescribed. Very few (19; 8.4
percent) non-narcotic Schedule II habitues were registered. In
California, Schedule 11 non-narcotic drugs do not require a
triplicate prescription in contrast to Schedule II narcotic drugs.
Apparently the fact that Schedule II non-narcotic drugs don't
require a triplicate prescription indicates to the majority of
physicians that registration is not necessary for habitual users.
Some under-reporting may occur because the definition of "habitue"
is not precisely defined in the Uniform Controlled Substances
Act of California; therefore, the physician must determine this.7
Most of the narcotics prescribed to habitues were oxycodone or
codeine compounds which contain the potentially toxic substances
acetaminophen, salicylate, or phenacetin. High doses of these
compounds are of concern due to the potential liver toxicity of
acetaminophen, renal toxicity of phenacetin, and gastrointestinal
bleeding from salicylates.8-11 Plain codeine or another narcotic
in a habitual, high-dose user avoids these potential compli-
cations. The dosage of narcotics did not appear particularly
high in some cases, and the question of adequate pain relief is
suggested since this is a common clinical occurrence.10,12
Despite the problems noted above, it appears that this system
has probably helped control abuse and indiscriminate prescribing
of Schedule II narcotics in California while allowing habitual
use and humanitarian pain relief. Less than 5 percent of
physician arrests for prescribing violations in California
have been for narcotics, while approximately 20 percent have been
for narcotics in the rest of the United States.13 A campaign to
educate physicians about the system could make it much more
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effective and still not deprive of treatment patients who may
benefit from potentially abusable Schedule II drugs. The
California system of triplicate prescriptions plus public
registration of habitues appears, therefore, to be a viable
alternative to the removal of any Schedule II drugs from the
commercial market.
Drug
Oxycodone
Hydromorphone
Meperidine
Methadone
Codeine
Morphine
Levorphanol
Anileridine
TABLE ONE
CASES OF SCHEDULE II NARCOTICS
REGUIRING REGISTRATION
N = 167
Age Mean Maximum
Range Age Daily (Mgs)
Number (Yrs.) (Yr.) Dosage Range
77 26-92 58.0 10-105
33 22-86 50.9 4-40 16.3
18 34-95 59.9 50-800 343.2
17 18-89 48.7 20-120 45.9
11 19-68 34.2 60-900 470.0
9 34-75 51.3 15-720 265.0
1 26 26 2 20.0
1 63 63 50 50.0
Mean Daily
Maximum
Dosage (Mgs)
32.2
TABLE TWO
MEDICAL CONDITIONS REQUIRING REGISTRATION
FOR HABITUATION TO SCHEDULE II NARCOTICS
N = 167
Condition No.
Osteomyelitis 3
Seizure Disorder 2
Biliary Atresia 1
Abdominal Pain 1
Psychologic/Unknown 10
Detoxification 4
Chronic Cystitis 1
Gaucher's Disease 1
Multiple Sclerosis 1
Buerger's Disease 1
Chronic Obstructive Pulmonary Disease 1
Tooth Abscess 1
Carcinoma 49
Lumbo-Sacral Disease 13
Post-Traumatic Pain 16
Headaches 15
Arthritis/Bursitis 19
Post-Surgical Pain 13
Neuropathy/Neuralgia 3
Angina Pectoris 4
Regional Enteritis 2
Chronic Pancreatitis 3
Ulcerative Colitis 1
Inoperable Renal Calculi 1
Total 167
196
FIGURE ONE
THE CALIFORNIA "PATIENT REPORT CARD"
FOR HABITUES TO SCHEDULE II DRUGS
BUREAU OF INVESTIGATION & NARCOTIC ENFORCEMENT
State of California
Mail to: 874 Town & Country Rd., Ste. 110,
Orange, California 92668
Name of Patient
Address
Age
Street
Quantity and Kind of Narcotic
Daily Dosage
City
Diagnosis of Injury or Ailment
Has Patient Previously Used Narcotics? Addicted?
Yes or No Yes or No
Physician's Signature
Address
Street City
Date of Report Fed. Reg. No.
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The Effects of Law Enforcement
Activity on a Population of
Opiate Abusers
C. A. Atkinson
This study examined the effect of police action against heroin
pushers on clients of methadone programs in metropolitan Denver.
On November 10, 1979, twenty suspected drug dealers and buyers
were arrested and another twenty were under investigation in a
vice squad operation in metropolitan Denver. The operation in-
volved an undercover agent who mingled with addicts and bought
opiates over an extended period from dealers, who were later ar-
rested within a 48-hour period. Newspaper reports indicated that
most of those arrested had been selling heroin in the vicinity of
the outpatient clinic operated by Addiction Research and Treatment
Services (ARTS) of the University of Colorado School of Medicine.
Although linked to the clinic by the press, only two of those ar-
rested were known to clinic personnel. In this study we ex-
amined the patterns of opiate use of the clients enrolled in that
clinic as reflected by the presence of opiate metabolites in their
urine samples collected before and after the drug bust. The clini-
cal course of a sample of clients who abused opiates before, but
not after the bust was examined. In addition, urine data from the
other two methadone programs in the city were examined.
Metropolitan Denver has a population of 1.5 million and is approxi-
mately 500 miles from any population center of similar size.
Drugs confiscated in arrests in Denver are analyzed at the Denver
police laboratory. Less than 10% of the drugs analyzed there are
opiates. Approximately half are heroin and half are pharmaceuti-
cals diverted from legal trade by robbery, fraud, or deceit. The
quality of confiscated heroin has been declining during the past
three years and is currently running from 1/2 to 1 1/2% per sample.
The cost of a single balloon or bag of heroin is currently $25.00.
Drugs confiscated outside of Denver are analyzed at the Colorado
Bureau of Investigation laboratory. Opiates, primarily pharma-
ceuticals, form only a small proportion of the samples analyzed.
This research was partially supported by Grant number
5T32 DA 07043 from the U. S. Public Health Service.
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An average of 347 people were receiving methadone at the three
Denver clinics during the nine months covered in this study. ARTS,
the largest of the three and the one linked to those arrested,
averages 221 clients, of whom approximately 62% are treated with
methadone. The remainder either abuse non-opiates or are drug
free. Approximately 53% are Anglo, 28% Hispanic, and 16% black.
The remainder are Native American or Oriental. The median age is
29, with a range of 20 to 60 years. Approximately 70% are males.
The average dose of methadone is 34 mg.
Urine specimens are required once in every seven days from most
of the clients who receive methadone or currently abuse non-
opiates. Clients who have had no dirty urines for six months are
only required to give urine specimens once each month. Additional
specimens may be required at the discretion of the client's coun-
cilor. Urine specimens from the Denver methadone programs are
analyzed at the Colorado Department of Health laboratory. They
are routinely screened for the presence of morphine, dilaudid,
codeine, demerol, oxycodone, and hydrocodone using a combined EMIT
(Enzyme Multiple Immunoassay Technique, The CIVA Co.) and thin
layer chromatography procedure developed at that laboratory
(Wislocki et al. 1974).
FIGURE 1
Figure 1. Number of opiate urine specimens collected at the ARTS
clinic in 15-day periods before and after the November 10th police
operation
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The dramatic decrease in the number of urine samples with detected
opiates collected at the ARTS clinic following the November drug
bust is shown in Figure 1. The number of urines with detected
opiates in the 18 weeks following the police operation was less
than 1/3 that of the preceding 18 weeks. It is interesting to
note that the highest point after the bust is lower than the
lowest point before the bust. The percentage of methadone
clients responsible for opiate urines is shown in Figure 2. It
is clear in these two graphs that fewer clients were using opiates
after the drug bust and those who were using, were using less
often.
FIGURE 2
Figure 2. Percentage of clients responsible for opiate urines
collected at the ARTS clinic shown in 15-day periods
The impact of the police action against drug dealers was clearly
reflected by the decrease in opiate urine samples collected at
the ARTS clinic. We hypothesized that the client population of
another clinic which was not mentioned in the newspapers in con-
nection with the drug bust, but which is within one half mile of
the ARTS clinic, would have been similarly affected, but that the
third clinic, located four miles west, would not have been affec-
ted. We assumed that demonstrating this difference would provide
even stronger evidence of the efficacy of local law enforcement
against pushers in a setting such as Denver's. An interservice
agreement to allow examination of the urine data slips from the
other two clinics was negotiated withthose clinics through the
good offices of the Colorado Department of Health, Alcohol and
Drug Abuse Division. Copies of the urine data slips contain only
numbers and are filed at the state health laboratory. There was
no way in which an urinalysis report could be associated with a
name or other individual identification by the researcher, so
there was no possibility of a breach of confidentiality. The
agreement was cleared by the Division of Methadone Monitoring of
the U.S. Public Health Service.
The population of the eastside clinic, near ARTS, is similar in
composition to that of the ARTS clinic. Approximately 42% are
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Anglo, 23% are black, and 32% are Hispanic. At the clinic on the
west side of Denver 61% are Anglo, 4% are black, and 48% are
Hispanic. The average methadone dose at both clinics is approxi-
mately 35 mg. Most clients are in the 20 - 35 year age range and
66% are males.
To our surprise, urine data from both of the other clinics showed
the same steep decrease in detected opiates following the November
police action. The combined data from all three clinics reflects
the opiate drug use of essentially all of the opiate abusers in
treatment in metropolitan Denver. The number of opiate urines
collected in Denver 18 weeks before and 18 weeks after the
November 10th police operation is presented in Figure 3. The
percentage of methadone clients responsible for the opiate urines
in the same period is shown in Figure 4. Again it is clear that,
for the city as a whole, fewer clients were using opiates and
those who were, were using them less often.
FIGURE 3
Figure 3. Number of urine specimens with opiates collected from
the opiate abusers in methadone treatment programs in Denver be-
fore and after the November 10th police operation
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FIGURE 4
Figure 4. Percentage of clients in methadone programs in Denver
responsible for opiate urines before and after the November 10th
police operation
The urine data from the three clinics present a graphic example
of the effect of heroin supply interdiction by the Denver police,
but we were also interested in the clinical impact on individual
clients. A sample of clients was drawn from the ARTS clinic using
the artitrary criteria of opiate use in November with a minimum
of two opiate urines in the preceding four months and two or less
in the succeeding four months. Clinical records of the 21
clients who met these criteria were reviewed and their counselors
interviewed. One of the 21 was deleted because the opiates he
used had been prescribed for suitable medical reasons and verified.
Of the remaining 20, four have successfully completed detoxifica-
tion from methadone. One of these has left treatment and is
reported by friends still in treatment to be doing well. The
second maintains contact with the clinic and is doing well.
Another developed a serious drinking problem, but is still re-
ceiving counseling and is described as improved. The fourth
expressed concern about his drinking, but left treatment anyway.
Six have shown improvement and are still in treatment. Of these,
three requested increases in their methadone doses shortly after
November 10th. Three clients, who were on high doses of metha-
done (50 - 60 mg.) and had been using heroin frequently, trans-
fered to clinics on the east coast. Seven clients were discharged
as treatment failures. One of the seven was jailed for obtaining
narcotics by fraud while on probation on the same charge. The
rest simply left the program while on moderate doses (20 - 30 mg.)
of methadone. Nineteen of the 20 subjects had illegal non-opiate
drugs detected in their urine samples after November 10th.
A striking aspect of the clinical information is that clinic
personnel were unaware of the radical change in opiate use before
these data were compiled, and there is no mention of the bust or
its effect on individual clients in the 21 surveyed charts, with
the exception of the two who were arrested. Even in those two
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cases the change in the patterns of drug use was not noted. Anec-
dotal reports from the other two clinics in Denver indicated that
the counselors there were also unaware of the change, and some
counselors thought that opiate use might have been increasing in
the first four months of 1980.
There are several possible reasons for the counselors' unawareness
of the pattern of opiate use within the clinics. The heroin
available in Denver is of poor quality and has been in short
supply in recent years. The majority of clients using illegal
opiates were not using them on a daily basis, so cutting off the
the supply did not have a drastic effect on their lives. Most of
the clients who were using heroin also abused other drugs, par-
ticularly benzodiazepines, which probably lessened the impact of
the reduced heroin supply and obscured the change in opiate use
from the counselors' views. The determining factor may have been
that the urinalysis data come to the counselors in batches several
times each week and are difficult to comprehend in this fragmented
form.
The majority of the clients in this population have significant
emotional, interpersonal, and employment problems, which tend to
be the focus of clinical intervention. This emphasis is based on
the assumption that resolving these issues will enable clients to
alter their drug use successively during the course of treatment.
On the other hand, drug use impedes clients' progress in improving
their life situations. It may well be that greater emphasis on
reducing drug use concomitant to resolving emotional, social, and
employment problems would be a more effective approach. Urinaly-
ses are the best evidence of clients' drug use available to the
drug counselor. They provide a valid and reliable check on the
clients' reports of their drug use and can be used in conjunction
with the clinical interview to clarify the pattern and circum-
stances of clients' drug use. Clarification can, in turn, facili-
tate the development of strategies to help the client avoid drug
use in the future.
Supply interdiction is an expensive operation for the police, en-
tailing, as it does, months of undercover work and the expenditure
of cash for drug purchases by agents. But the success of such
action in reducing the quantity of drugs available to abusers in
a situation of relative isolation like Denver's is clearly demon-
strated by the data presented here. Hopefully, recognition of
the efficacy of law enforcement efforts will lead to more rigorous
action against non-opiate dealers as well as heroin dealers in
the future.
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Narcotic Addiction: A Changing
Scene?
D. N. Nurco, I. H. Cisin, and M. B. Baiter
INTRODUCTION
The purpose of this paper is to explore changes in the narcotic
addiction1 scene in an era of rapid social change. The quarter
of a century covered by this study embraces an era in which
major significant changes have occurred in this society.
The Sample and Data
A sample of 499 subjects was selected from a roster of male
narcotic abusers first known to the Baltimore City Police
Department Narcotic Squad between the years 1952-1976, inclusive.
From each year's contribution to the roster, ten whites2 and ten
blacks were selected in a random, stratified manner, and 402
were interviewed. The data to be analyzed were drawn from a
structured interview schedule devised by the project staff; each
interview took approximately three hours and was administered by
a staff member especially trained for this purpose.
In this report, the data3 have been weighted to
differential sampling by year of entry onto the
the total for the population and the totals for
correctly reflect population parameters.
compensate for
roster, so that
various groupings
Although the selection of subjects was based on year of entry
onto the police roster, the information available from the
interviews permitted: (1) confirmation of addiction status; and
(2) reclassification of addicts into incidence cohorts, defined
in terms of the year of onset of narcotic addiction. The present
report is confined to those incidence cohorts for which at least
ten years of data were available from time of onset of addiction
to time of interview. The choice of a ten-year period was felt
to provide sufficient sensitivity to any fluctuation (or lack of
fluctuation) in the behavior of narcotic addicts. A total of 238
narcotic addicts (103 whites and 135 blacks) qualified for analy-
sis in this manner.
* This paper is a brief summary of two longer works, entitled
"Addict Careers: I. A New Typology" and "Addict Careers: III.
Trends Across Time," which will be published in EINSTEIN: The
International Journal of the Addictions, Volume 16, 1981, by
MARCEL DEKKER, INC.
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The incidence cohorts constructed for this report reflect the
trends across time of the characteristics of new recruits into
narcotic addiction. For simplicity, the incidence cohorts have
been grouped into three: pre 1955 (1937-1954); 1955-59; and post
1959 (1960-1966).
TRENDS IN CHARACTERISTICS OF NARCOTIC ADDICTS
Race
The data of the current study, based on and projected to a roster
of all addicts known to the police of Baltimore City over a
quarter of a century, confirm the predominance of blacks in the
addict population. Indeed, when the data are classified according
to the onset of addiction, there is only minor fluctuation in the
black-white ratio over time. During the years 1955-59, there
seems to have been at least a slight increase in white represen-
tation among addicts, but subsequent years showed a slight
decline in the white proportion. Thus, it is appropriate to say
that for every ten men entering addiction at any given time,
seven or eight were likely to be black.
Because of the racial imbalance of the addict population known to
the police, the tables in this report, based on sample weighted
to provide projections to the addict population, are presented
separately for black addicts and white addicts.
Background Characteristics
Although the numbers drawn into the addict population varied
considerably across time, it appears that the appeal of addiction
was essentially to the same population groups during all the
periods studied. There were differences between the background
characteristics of blacks and those of whites who were attracted
into addiction, but within each racial group of addicts separately,
there was little variation in such characteristics across time.
Among the whites in all three periods studied, the median social
status of new addicts fell in the semi-skilled, blue-collar class;
median educational attainment in all three periods involved drop-
out at the junior high school level. Social stability (as reflected
by years of longest residence before finishing high school or
leaving school) showed considerable dispersion among individuals
in all three time periods.)
Among the black addicts, the picture was essentially the same:
no clear trend in the social status of those attracted to
addiction (although the black addicts were consistently drawn
from a lower social class than the whites); a consistent picture
of early drop-out from school; and no clear trend in social
stability.
For both races, the persons who entered addiction later in the
quarter century studied were more likely than those who became
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addicted earlier to have had contacts with juvenile authorities
and to have had acknowledged criminal activity prior to first
narcotic use.
INTRODUCTION TO NARCOTIC USE
In the pre-1955 period, the median age of onset of addiction for
white addicts was just over 18 years; for black addicts, it was
more than a year older. During the 1955-59 period, the onset of
addiction occurred more than a year and a half earlier on the aver-
age; but after 1959, the trend was reversed so that new addicts,
both white and black, showed a median age of onset of 18.0 years.
Not all narcotic addicts are always addicted to heroin. It would
appear that the ready availability of liquid codeine during the
1955-59 period proved remarkably attractive, particularly to white,
addicts. Indeed, among white addicts, liquid codeine was the drug
of choice for the majority of new addicts recruited between 1955-59.
After 1959 liquid codeine and other narcotics became less readily
available (Nurco et al. 1979) and the pattern of drug choice among
white addicts reverted to emphasis on heroin. Among black addicts,
although liquid codeine became considerably more popular beginning
in 1955, its popularity never seriously threatened the predominant
position occupied by heroin.
TRENDS IN NARCOTIC ADDICT CAREERS
All of the addicts in the sample used for this report provided
data covering a ten-year career beginning with the onset of
addiction. Thus it was possible to describe their entrances and
exits to the addict population and their activities during that
ten-year period, even if only a small part of the ten years
involved active addiction.
In order to study these ten-year careers in an orderly and
systematic manner, a typology was constructed around two funda-
mental concepts: 1) commitment to addiction, as reflected in
the proportion of the ten-year period spent actively addicted;
and 2) voluntary abstinence, as reflected by the relative allo-
cation of time to nonaddictive periods in the community and to
periods of time spent incarcerated.
The typology of addict careers presented here is built upon the
concepts of opportunity and motivation to use drugs, i.e.,
characterization depends upon degree of involvement with narcotic
drugs in relation to opportunity for voluntary abstinence. This
typology takes into account the time spent in each of the follow-
ing statuses:
1. Addicted;
2. In the community, not addicted;
3. Incarcerated.
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Emphasis is on the degree of involvement with narcotic addictive
drugs, on opportunity to use such drugs as represented by time in
the community as opposed to jail, and on voluntary abstinence,
Degree of involvement is defined as the proportion of the total
available time (10 years) during which the subject was addicted.
Opportunity to use drugs is defined as the proportion of the base
period (10 years) in which the addict was living in the community
(as contrasted with being incarcerated)--whether using drugs or
not. Voluntary abstinence is defined as the proportion of the
period (10 years) in which the addict was living in the community
but was not addicted. This formulation assumes that the two
variables (opportunity and involvement) are independent at any
level of involvement less than 100 per cent. The independent
contribution of opportunity becomes more apparent at middle or
lower ranges of involvement, where issues of choice become paramount.
Application of these concepts to the data of the present study
yields five clearly distinguishable types:
Type I. Low involvement with narcotic drugs as displayed by those
who used narcotics on a "daily basis" less than 50 per cent of the
time, i.e., less than an aggregate of five years out of the ten;
high opportunity in that they spent no more than two and one-half
years incarcerated; and high voluntary abstinence as demonstrated
by the fact that they were in the community at least seven and one-
half years and chose to be addicted only a relatively small propor-
tion of this time.
Type II. Low involvement (used narcotics less than an aggregate
of five years); low opportunity in that they spent more than two
and one-half years incarcerated; and low voluntary abstinence in
that they had relatively little drug free time in the community.
Type III. Medium involvement, with 50-74 per cent of the ten
years devoted to the addiction; high opportunity, since not more
than two and one-half years of the remaining time was spent
incarcerated; and a median level of voluntary abstinence.
Type IV. Medium involvement, with 50-74 per cent of the total
period devoted to addiction; low to medium opportunity, since
more than two and one-half years were spent incarcerated; and,
therefore, little remaining time for voluntary abstinence.
Type V. Highest involvement, with at least seven and one-half
of the ten years devoted to addiction; therefore, it follows
that opportunity was high and voluntary abstinence was low.
Figure I displays characteristic patterns of movement among the
statuses ON, OFF in the community, and INCARCERATED for the five
types described above. Although it is recognized that no single
case can adequately represent each type because there is consid-
erable variation among the members, the five typical cases
presented in Figure I convey the fundamental characteristics and
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339-844 0 - 81 - 15
FIGURE 1
CHARACTERISTIC ADDICT CAREERS: THE FIRST TEN YEARS
ALLOCATION OF TIME TO THREE ACTIVITIES
ADDICTED
INCARCERATED
IN THE COMMUNITY NOT ADDICTED
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differences among the types in the total ten-year developmental
patterns.
Using this typology to characterize the ten-year careers, what can
be said about trends across time? In other words, what effect do
the ambient conditions related to the starting date of a career
have upon the nature of the career?
Certain characteristics of the addict's careers seem to be reason-
ably stable across time. For example, among black addicts, the
modal career during all time periods is best described as Type V:
virtually uninterrupted addiction during a ten-year period, with
little or no incarceration. This single type characterized 44 per
cent of the black addicts who began their careers before 1955, more
than half of those who began during 1955-59, and over one-third
of those in the subsequent time period.
Among the white addicts, the distribution of career patterns showed
a much less pronounced tendency toward uniformity. In the pre-
1955 period and in the post-1959 period, approximately one-third
of the white addicts displayed a Type I pattern in their ten-year
careers, i.e., they exercised maximum control over their habits,
with a great deal of time abstinent in the community. During the
1955-59 period, the popularity of this type of pattern declined
somewhat.
Some of the trends across time were clearly monotonic. Among
blacks, the popularity of Type III and Type IV patterns increased
steadily across the time periods studied. Among whites, Type II
patterns became considerably more frequent as time went by;
concomitantly, Type IV patterns went steadily downward in relative
frequency. This latter finding suggests that among whites, the
pattern of "confirmed junkie" (Type IV, with much time spent in
addiction, much of the remainder spent incarcerated) was being
replaced by a pattern (Type II) in which less time was spent in
addiction and more time incarcerated.
The remaining career patterns showed quite irregular trends across
time. Among the black addicts, the popularity of Type I and Type
II careers declined in the 1955-59 period and then increased in the
direction of pre-1955 levels. Among whites, Types I and III showed
this same tendency to decline between 1955-59 and then to revert.
The white Type V'S became more frequent during the 1955-59 period
(just as the black Type V's did) and then subsequently declined
in popularity.
In an earlier discussion of career patterns (Nurco et al. 1978),
it was noted that the ready availability of narcotics other than
heroin (particulary liquid codeine) had a marked effect on the
patterning of the habit among white addicts. This fact is drama-
tically illustrated by an analysis of the popularity of heroin
during the ten-year careers. The dominance of heroin was determined
for each addict by calculating what proportion of months of addic-
tion were characterized as heroin-dominated. For black addicts,
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there was not very much variation across time, although there was
some noticeable tendency for heroin to be less dominant during the
1955-59 period. For white addicts, on the other hand, the picture
was completely different. Whites who joined the addict population
prior to 1960 showed a very strong tendency to regard some drug
other than heroin as their dominant drug. After that time, when
liquid codeine became much more difficult to obtain, the pattern
of drug dominance for whites became indistinguishable from that for
blacks, with heroin being overwhelmingly dominant.
To what extent have criminal activities of addicts changed across
time? As a partial answer to this question, we have summarized, for
the three cohorts under discussion, the proportion of their income
that came from illegal sources during their ten-year careers. The
trend shows a slight decline in the importance of illegal income when
one compares the addicts who began their careers in 1955-59 with
those who began earlier, followed by a noticeable increase among
those who began their careers in 1960 and thereafter. In the final
cohort, on the average, about three-fourths of each addict's income
(for both black and white addicts) was derived from illegal sources.
FOOTNOTES
1. Narcotic addicts are defined in this study as persons who have
used opium, its derivatives, or synthetics for non-medical
reasons four or more days a week for at least a month. Onset
of addiction was defined in terms of the first occurrence of
such a period.
2. Only nine whites were available in 1956.
3. All appropriate tables have been deleted from this abbreviated
presentation and appear in the International Journal of the
Addictions, Vol. 16, 6 & 8.
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Relative Analgesic Potency of
Intramuscular Heroin and
Morphine in Cancer Patients
With Postoperative Pain and
Chronic Pain Due to Cancer
R. F. Kaiko, S. L. Wallenstein, A. Rogers, P. Grabinski,
and R. W. Houde
Heroin has been judged to produce more euphoria and less side ef-
fects than morphine (Seevers and Pfeiffer 1936; Ross 1944; Elliot
et al. 1971) and has been used in some countries in controlling
pain in patients with advanced cancer (Twycross 1974; Twycross
1975). While controlled comparisons of intramuscular heroin and
morphine have been carried out in postoperative patients (Reichle
et al. 1962), such assays have not been carried out in patients
with chronic pain due to cancer. Apart from differences in potency
and time action, heroin has been found to be similar to morphine
in most respects, so that the uniqueness of heroin's attributes has
been questioned (Lasagna et al. 1955; Fraser et al. 1961; Martin
and Fraser 1961; Smith and Beecher 1962; Reichle et al. 1962).
The studies reported here are intended to provide estimates of re-
lative analgesic potency and more substantial information as to
whether heroin has any unique attributes in the treatment of cancer
patients with postoperative pain and pain due to advanced disease.
The purpose of the initial study was to determine the relative
analgesic potency of heroin and morphine and to compare side effects
and alterations in various elements of mood of equianalgesic doses
of the two drugs in patients with postoperative pain. In addition,
the concurrent use of categorical (CAT) pain and pain relief scores
with visual analog scales (VAS) was employed for the purpose of
providing infomation as to their relative merits in assays of
analgesic drugs. Preliminary results are also reported for two
additional, but yet incomplete, studies in patients with chronic
pain due to advanced cancer. The first of these studies is in-
tended to provide potency estimates and to compare side effects and
mood changes at equianalgesic doses of heroin and morphine. The
second study in patients with chronic pain is intended to provide
estimates of relative potency of oral as compared to intramuscular-
ly administered heroin.
213
METHODS
Intramuscular doses of heroin hydrochloride of 2 and 4 mg were com-
pared with 8 and 16 mg of morphine sulfate in one series and 4 and
8 mg of heroin compared with 8 and 16 mg of morphine in a second
series of double blind, twin crossover relative analgesic potency
assays in patients with postoperative pain. In a second study,
intramuscular doses of heroin of 4 and 8 mg being compared
with 8 and 16 mg of morphine in a complete crossover assay; and in
a third study, intramcular heroin, 4 and 8 mg, is being compared
to 10 and 20 mg of oral heroin in one series and 20 and 40 mg of
oral heroin in another series of complete crossover assays in
cancer patients with chronic pain due to advanced disease.
The method and design of the assays have been previously described
in detail (Houde et al. 1960; Wallenstein and Houde 1975). The
methods and modifications employed in these particular studies are
briefly described below. Each twin crossover assay consists of a
series of four treatment studies incorporating a lower and upper
dose of the standard and test drug. The ratio of doses of standard
to test drug is varied from study to study. Each patient receives
two doses, a lower dose of one drug and an upper dose of the other.
Each block of four patients is balanced for drug, dose and order,
and the assignment of patients to treatments within the block is
randomized. On completion of each block, a sequential decision-
making process is instituted to determine whether the next block
should incorporate a lower or higher ratio of standard to test
drug. The objective of the process is to obtain as much data as
possible in the equianalgesic effect range of the two drugs. In
the complete crossover assay, each patient receives each of the
four study medications according to a series of randomly chosen
Latin squares.
Patients are selected on the bases of an evaluation of the cause of
pain, the appropriateness of treatment with the study drugs and the
ability of the patient to communicate with the observer. Patients
are seen at hourly intervals and questioned about the severity of
their pains. If the patient requests medication for pain and has
not received an analgesic for at least three hours, and if the pain
is reported as moderate or severe, a study drug is given by the
nurse observer. Observations are then made at one half hour and at
one hour and continued at hourly intervals for six hours or until
pain has returned to the premeditation level. At each observation
time, the patient is questioned as to the severity of pain and the
degree of pain relief according to the standard CAT pain and pain
relief scores, whether or not the pain has been at least half re-
lieved and whether or not the patient considers the drug acceptable.
Volunteered and observed side effects are also recorded.
Patients are also asked to complete VAS and word-pair question-
naires. VAS data are obtained at the same observation times as
CAT data. The patient is asked to mark 100-millimeter scales at
the point on the line which best reflects how he feels between
"Worst I Could Feel" and "Best I Could Feel" for the mod VAS,
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"Least Possible Pain" and 'Worst Possible Pain" for pain VAS and
"No Relief of Pain" and "Complete Relief of Pain" for relief VAS.
The millimeter distance from the origin to the mark is measured
and taken as the VAS score. At the time of drug administration
and at 2 hours after drug, patients are also requested to estimate
various elements of mod by use of a set of 15 contrasting word-
pairs (Lasagna et al. 1955). Patients are instructed to circle
either a neutral, "0", point or a "1", "2" or "3" in the direction
of either word of the pair. Negative feelings are later assigned
negative signs and positive feelings, positive signs. The number
is taken as the mod questionnaire score for each pair of words.
RESULTS AND DISCUSSION
Postoperative pain
The mean age of the study population was 50 years with a range from
19 to 72 years. One hundred of the patients were male and 66 were
female. The site of pain was predominantly abdominal or thoracic.
Study drug was usually administered during the day after surgery
and the following day. Meperidine and levorphanol were the most
common routine postoperative narcotic analgesics. One hundred and
twenty-four patients completed the assay. This included 32 patients
in the lower heroin (2 and 4 mg) series and 92 patients in the
higher (4 and 8 mg) series.
Analyses of variance for twin crossover assays were carried out
with modifications for sequential study design (Finney 1964). The
relative analgesic potency data derived from CAT pain (SPID, sum of
pain intensity differences; PPID, peak pain intensity difference)
and pain relief (TOTPAR, total pain relief; PPR, peak pain relief)
scores are summarized below.
Table 1. Relative Analgesic Potency of Intrarmuscular Heroine vs.
Morphine in Cancer Patients with Postoperative Pain (N, 124)
Analgesic Relative Heroin HCl mg Equivalence to 10
Parameter Potency 95%C.I. Lambda mg Morphine Sulfate (95%C.I.)
TOTPAR 1.9 1.4-2.4 0.44 5.3 (4.1-7.3)
PPR 2.2 1.4-3.1 0.60 4.6 (3.2-7.2)
SPID 1.5 0.7-2.3 0.67 6.5 (4.4-14)
PPID 2.0 1.2-3.1 0.67 4.9 (3.3-8.6)
Relative potency estimates based on peak effects were higher than
those based on total effects, an indication that heroin has a
shorter duration of action than morphine at equianalgesic peak
effects. The use of pain relief data provided more efficient
estimates of relative potency than the use of pain intensity data.
The data show that approximately 5 mg of heroin and 10 mg of
morphine are equianagesic in relieving postoperative pain.
The concurrent use of CAT and VAS scores allowed a comparison in
terns of the statistics generated in the estimation of relative
potency. The use of VAS data provided estimates of relative
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analgesic potency comparable to those provided by the use of CAT
data, but VAS data provided estimates which were more efficient
(lower lambda) and which had consistently narrower confidence
intervals. These differences may result from the fact that VAS
allow the patient to make finer distinctions than CAT scores.
Side effect occurrence after heroin and morphine was dose related
and within a comparable range (table 2). The most common effects
(sleepy, relaxed, dry mouth, groggy, lightheaded, dizzy, nausea,
sweating and weak) were of the highest incidence for both drugs.
The number of particular types of effects exclusive to heroin
outranked those exclusive to morphine (20 vs. 7), but these
particular effects had a very low incidence.
Table 2. Side Effect Occurrence after Intramuscular Heroin and
Morphine in Cancer Patients with Postoperative Pain
Heroin Morphine
Dose 2 mg 4 mg 8 mg 8 mg 16 mg
N(patients, meds.) 18 69 60 73 71
Pts. with side effects. 10 44 44 40 53
% with side effects 56 64 73 55 75
The use of a global VAS mod measurement and the word-pairs allowed
for comparisons of mod effects at equianalgesic effects of heroin
and morphine. No significant differences were observed in the mean
peak VAS mood scores after heroin as compared to morphine at any
level of CAT peak pain relief. Generally, higher mod scores were
associated with greater pain relief. The results of the word-pair
questionnaire (table 3) in terms of the differences between the 2
and 0 hour scores demonstrate that both drugs provide significantly
improved mod. There was a trend, however, for heroin to provide
a smaller increase in scores as compared to morphine at a comparable
decrease in pain intensity. These results must interpreted in
view of the fact that patients were dosed according to the sever-
ity of their pain rather than according to the nature of their mood.
Patients who initially report relatively low mood scores report
positive changes after drug, whereas those patients who initially
report high scores report small or negative changes following drug
(Kaiko et al. 1980).
Chronic Pain
Significantly less pain relief and lower mood scores were observed
in patients with chronic pain as compared to patients with post-
operative pain, indications that patients with chronic-pain are
more tolerant to the effects of both drugs. In addition, prestudy
drug word-pair scores demonstrate significant differences in
various elements of mod as compared to scores in postoperative
patients.
Thirty-six patients with chronic pain have, thus far, completed
the graded dose comparison of heroin and morphine. This study
remains in progress, but preliminary results are consistent with
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Table 3. Differences between 2 and 0 Hour Word-Pair Scores after
Intramuscular Heroin and Morphine in Cancer patients With Post-
operative Pain
Heroin, 4.8 mg Morphine, 11.4 mg
(N, 110) (N, 104)
Word-Pair Mean SE P< Mean SE P<
Shaky-Serene 0.69 0.19 0.001 1.31 0.21 0.001
Restless-Peaceful 0.89 0.20 0.001 1.36 0.22 0.001
Uneasy-At ease 0.99 0.20 0.001 1.16 0.23 0.001
Nervous-Calm 0.63 0.19 0.005 1.01 0.19 0.001
Blue-Cheerful 0.64
Angry-Contented 0.30
sad-Happy 0.59
Alone-Sociable 0.23
Don't care-Interested.. 0.39
Pessimistic-Optimistic. 0.17
Apprehensive-Confident. 0.35
Apathetic-Enthusiastic. 0.24
Heavy-Bouyant 0.51
Lethargic-Peppy 0.21
Serious-Amused 0.01
[Pain Intensity (VAS).. -27
0.15
0.15
0.16
0.22
0.18
0.16
0.19
0.18
0.15
0.13
0.16
2.7
0.001
0.05
0.061
0.3
0.05
0.3
0.1
0.2
0.001
0.2
0.98
0.001
0.67 0.17 0.001
0.42 0.13 0.005
0.68 0.17 0.001
0.56 0.21 0.01
0.11 0.19 0.6
0.26 0.15 0.1
0.64 0.16 0.001
0.57 0.18 0.065
0.55 0.18 0.005
0.09 0.16 0.6
0.40 0.16 0.02
-29 4.6 0.0011
those obtained in postoperative patients. Estimates of relative
analgesic potency are comparable to those obtained in postopera-
tive pain and at a slightly sooner, equianalgesic peak effect,
heroin appears to have a slightly shorter duration of action. The
most common side effects axe shared by both drugs and no signifi-
cant differences are being observed in peak VAS mood scores fol-
lowing heroin as compared to morphine at any degree of CAT peak
pain relief. Changes in word-pair scores between 0 and 2 hours
are, generally, not statistically significant, but changes after
heroin are consistently smaller and primarily negative. The
observation is consistent, however, with the smaller decrease in
pain intensity at 2 hours after heroin as compared to after mor-
phine.
Ten patients have, thus far, completed the comparison of intra-
muscular and oral heroin. This data indicates that equianalgesic
peak effects are not being obtained With the intramuscular to oral
dose ratios of 1/2.5 and 1/5. Although the data is too limited to
provide valid estimates of relative potency, preliminary calcula-
tions suggest that approximately 30 mg of oral heroin is equivalent
to 5 mg of intramuscular drug in terms of total pain relief and
that a considerably higher oral dose would be required to obtain
equianalgesic peak effects. A series incorporating an intramus-
cular to oral dose ratio of 1/10 has been initiated. These pre-
liminary observations are in close agreement With the relative
analgesic potency of oral as compared to intramuscular morphine
(Houde et al. 1965).
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SUMMARY
Heroin hydrochloride is approximately twice as potent as morphine
sulfate, and acts slightly faster but for a shorter duration than
morphine. Although patients With chronic pain due to advanced
cancer differ from cancer patients with postoperative pain in
terms of their degree of tolerance to the analgesic effects of
morphine and heroin and their reports of various elements of mod,
there is, thus far, no indication that heroin has any unique
advantage over morphine in term of side effect occurrence or
effects on mod at equianalgesic doses. Both drugs improve mod
provided they are administered in doses which result in analgesia.
While there appears to be some slight difference in the spectrum
of side effects observed after heroin as compared to morphine,
heroin and morphine share the most common side effects. The
incidence of side effects following both drugs appear to be highest
among those effects which are primarily somatic and undesirable.
The use of visual analog scales concurrent With categorical pain
and pain relief scores provides a means for the finer estimation
of relative analgesic potency and time action.
The results of these studies are in general agreement with those
of other investigators. Where apparent differences exist they can
usually be explained on the bases of differences in methods and
subject populations.
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Human Preference Comparison
of Pentobarbital, Diazepam, and
Placebo
R. R. Griffiths, G. E. Bigelow, and I. Liebson
Increasingly, human experimental methods are being developed to
compare drugs with respect to their efficacy in maintaining drug
self-administration behavior (cf Griffiths et al. 1980). The
studies that have been conducted to date suggest that measures
of the amount of drug self-administration behavior (Schuster
et al. 1971; Griffiths et al. 1979; Bigelow et al. in press)
and behavioral preference measures (Pickens et al. 1977;
Johanson and Uhlenhuth 1978) provide infomation about the
relative reinforcing properties of drugs. In one recent study
(Griffiths et al. 1979) volunteers with histories of sedative
drug abuse were permitted to self-administer orally under
double-blind conditions several doses of pentobarbital, diazepam
and chloropromazine for periods up to 15 consecutive days.
Although all three drugs produced subjective effects and ob-
servable signs of sedative intoxication, the drugs were
associated with different amounts of self-administration.
Chlorpromazine was similar to placebo in that it did not
maintain much self-administration. Both pentobarbital and
diazepam did maintain self-administration with the higher dose
of each associated with higher average levels (ingestions/session)
than the lower dose. The high dose of pentobarbital was
associated with higher average levels and more regular self-
administration than was the high dose of diazepam.
The present double-blind preference comparison of pentobarbital,
diazepam and placebo had several interrelated objectives. First,
the study sought to provide more comparative information about
the relative reinforcing properties, behavioral effects and
subjective effects of pentobarbital and diazepam. Second, the
study was undertaken to examine a totally different measure of
drug self-administration behavior: drug preference. A previous
study (Griffiths et al. 1979) had shown that pentobarbital
maintained higher levels of self-administration than diazepam,
and it was of interest to determine whether a drug preference
measure would provide similar information about the relative
reinforcing properties of these drugs. Such comparisons are
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important to determining both the relative sensitivity of the
behavioral measures and the generality of the observed results.
Third, the present study was designed to permit repeated evalu-
ation of subjective measures of drug effect (e.g., a subject
completed drug liking scale) such that it was possible to
examine the relationship between the subjective measures and the
behavioral preference self-administration measure. This compari-
son is particularly interesting because it provides information
about the commonly held assumption that subjective measures such
as drug "liking" should covary with measures of drug taking.
METHOD
Subjects. Six male volunteers with documented histories of
sedative drug abuse participated. On the basis of physical
examination, history, routine laboratory chemistries and chest
X-ray, participants were found to be without significant medical
or psychiatric disturbance other than their drug abuse. All of
the subjects had histories of abusing both barbiturates and
benzodiazepines. Most subjects reported sporadic (as opposed to
chronic) abuse of high doses of sedative drugs within several
weeks to a month of admission to the research ward.
General procedures. Subjects participated while residing on an
8-bed behavioral pharmacology research ward. Following admission
to the research ward subjects were observed for a three to seven
day period prior to the initiation of the experiment; no subject
showed any clear evidence of clinically significant physical
dependence on sedative drugs as determined by gross clinical
observation and routine monitoring of vital signs. Prior to
research participation subjects were informed that various drugs
would be available for self-administration during the study, and
that these could include the major and minor tranquilizers,
sedatives, stimulants and placebo. Other than this general
information subjects were blind to the type of drug to be
administered.
Daily experimental procedures. Days on which drug administration
was scheduled alternated with drug-free days throughout the
experiment. On drug days subjects were awakened by 8:00 a.m.;
they were permitted to drink fruit juice or coffee in the morning,
but were not permitted to consume milk or any solid food until
12:00 noon. On drug days a single oral dose of drug was dispensed
at 11:00 a.m. according to procedures described Below. Drugs
were administered and evaluated according to double-blind
procedures; neither the subjects nor the staff who dispensed drugs
and rated drug effects knew the identity of test compounds. For
each subject, placebo, 400 mg pentobarbital and 200 mg diazepam
were given an arbitrary letter code (e.g., A, B, C); codes
differed between subjects. On some days (no-choice trials) a
single letter coded compound was scheduled for administration
and the subject was informed of the letter code prior to adminis-
tration. On other days (choice trials) two coded compounds were
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available for administration. Staff informed the subject of the
two letter codes and the subject chose which compound would be
administered. Starting at 1:00 p.m. subjects filled out four
short questionnaires, including a drug-effect scale, a drug-liking
scale, the Profile of Mood States (POMS; McNair et al. 1971), and
a short form of the Addiction Research Center Inventory (ARCI;
Martin et al. 1971). Also at 1:00 p.m. staff completed an
observer-rated drug-effect questionnaire. At 3:00 p.m. and
5:00 p.m. subjects repeated the drug-effect questionnaire and the
drug-liking questionnaire, and the staff repeated the drug-effect
questionnaire.
Sequencing of drug exposure. Before beginning the experiment all
subjects were initially exposed to 100 mg diazepam. The rationale
for scheduling this initial dose was based on a clinical impression
that developed during earlier research, that the effects of initial
exposure to diazepam depended on the recency of prior use. More
specifically, in previous research it seemed that there was
substantial variability across subjects in the magnitude of drug
effect after initial exposure to diazepam, and it seemed that
this variability was reduced with subsequent exposures to diazepam.
After this initial exposure to diazepam, subjects were given three
no-choice trials involving exposure to the three drug conditions
in a random order [placebo (PL); pentobarbital 400 ng (PB400);
diazepam 200 mg (DIA200)]; then subjects were given in a random
order three choice trials involving the three Possible drug
combinations (PL vs PB400; PL vs DIA200; PB400 vs DIA200); the
remainder of the experiment involved simply alternating between
the three randomly sequenced no-choice trials and the three
randomly sequenced choice trials. The total number of experimental
observations was determined by the duration of subject partici-
pation.
Drug dispensing procedures. Commercially available preparations
of diazepam (Valium) and pentobarbital sodium (Nembutal) were
prepared prior to the experimental sessions by crushing and mixing
the drug with approximately 4-12 g unsweetened soft drink mix
(Kool-Aid) and 3-10 mg quinine sulfate. Each drug ingestion
was dispensed from a small medicine cup and nurses were instructed
not to allow the subject to see the powdered drug.
RESULTS
Unsystematic clinical observation revealed that both 400 mg
pentobarbital and 200 mg diazepam produced similar central nervous
system signs typical of sedative drugs, including ataxia and
sedation. Analyses of variance and post hoc t-tests were used to
evaluate drug effects on observer and subject questionnaire
responses. Compared with placebo, pentobarbital and diazepam
both produced increases of similar magnitude in subject and
observer ratings of magnitude of drug effect, and in subject rated
liking of drug effect at 2 hours post administration. Analysis
revealed that for most subjects these measures were significantly
influenced by pharmacological condition, with the two active drug
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conditions differing significantly from placebo but not differing
significantly from one another. There was no consistent pattern
of statistically significant effects of the active drugs relative
to placebo or to one another on the scales of the ARCI and POMS.
Analysis of the subject- and observer-ratings of magnitude of
drug effect as a function of time (2 hours, 4 hours, or 6 hours
after drug administration) revealed a similar time course of
effects for the two active drugs, With the magnitude of drug
effect declining toward placebo values over the 6-hour period.
The results from the choice trials for the six subjects were
relatively consistent. Without exception, subjects chose
pentobarbital over placebo, and diazepam over placebo on all
occasions. In the pentobarbital vs diazepam comparisons, all
six subjects preferred pentobarbital (400 mg) to diazepam (200 mg):
three subjects chose pentobarbital exclusively while the remaining
three subjects chose pentobarhital on 67 percent, 67 percent, and
75 percent of the choice trials. These choice results Were
statistically significant (xr
2 =12.00, p<0.01, Friedman analysis
of variance for ranks); pentobarbital Was consistently preferred
to diazepam, and both these drugs were consistently preferred to
placebo.
DISCUSSION
In the present experiment, pentobarbital (400 mg) and diazepam
(200 mg) produced drug-effect ratings of similar magnitude on
the subject- and observer-rated drug effect questionnaires, While
placebo produced negligible effects. Choice results for the six
subjects were relatively consistent. Without exception, subjects
chose pentobarbital over placebo and diazepam over placebo on all
occasions; in the between-drug comparisons all six subjects
preferred pentobarbital to diazepam.
The present experiment showed that pentobarbital is preferred to
diazepam at doses of the two drugs that produce similar elevations
in ratings of drug-effect and drug-liking. The credibility of
this finding is enhanced by several sources of information that
tend to confirm the general relationship that pentobarbital is a
more efficacious reinforcer than diazepam. First, a previous
inpatient human drug self-administration experiment has shown
that pentobarbital maintains higher levels and more regular self-
administration than diazepam (Griffiths et al. 1979). Second,
studies with rhesus monkeys have shown that pentobarbital is more
effective than diazepam in maintaining intravenous self-adminis-
tration (Yanagita and Takahashi 1973). Third, clinicians familiar
with drug abuse clients estimate that the "euphoria" produced by
pentobarbital is higher than that produced by diazepam (Wesson
and Smith 1977). Finally, epidemiological measures which are
presumed to indicate drug abuse liability uniformly rank
pentobarbital higher than diazepam (Jones 1977; Cooper 1977;
Marks 1978). As a whole, these data suggest that the preference
results observed may reflect a real difference in the reinforcing
properties of pentobarbital and diazepam. This convergence of
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data helps validation an drug self-administration methods and
suggests that such methods my provide information about the
relative reinforcing properties of different drugs.
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Psychophysical Profiles
Differentiate Drugs of Abuse
R. D. Hienz and J. V. Brady
The effects produced by drugs of abuse on complex human perceptual
processes have provided the focus for an expanding research
literature over the past two decades (Hoffer & Osmond, 1967;
Malitz & Kanzler, 1970). Opiates, barbiturates, and
benzodiazepines all produce decrements in visual pattern
recognition (Sambrooks et al., 1977; Ogle et al., 1976; Bartus &
Johnson, 1977; Rothenberg et al., 1977) and critical flicker
fusion (Malitz & Kanzler, 1970; Ogle et al., 1976), and
hallucinogens reportedly impair both auditory and visual
discrimination performances (Key, 1961; Elsmore, 1972; Ferraro &
Grilly, 1973). For the most part, the contribution of changes in
basic sensory functions to such effects has been difficult to
determine since the procedural approaches have encompassed a range
of performance processes which are not readily dissected or
differentiated. Recent developments in the refinement of
psychophysical measurement techniques with laboratory animals
(Blough, 1966; Stebbins, 1970a), however, have provided
methodologies of demonstrated reliability and sensitivity for
quantitative assessment of such sensory changes (Blough, 1957;
Hanson et al., 1964; Myers & Bernstein, 1965; Stebbins, 1970b).
The present report describes the effects of both stimulant and
depressant drugs of abuse upon psychophysical functions in
non-human primates. Specifically, different patterns of
dose-dependent changes in absolute auditory and visual thresholds
and behavioral reaction times are documented following
administration of pentobarbital, diazepam, chlordiazepoxide, and
d-methylamphetamine in laboratory baboons.
Four baboons (Papio anubis), tested in a double-walled sound-
attenuating chamber (IAC 1201-A), were trained on a reaction time
procedure (Moody, 1970; Pfingst et al., 1975a,b) to press and hold
a lever until presentation of a sound burst or light flash
signalled availability of food reward contingent upon lever
release. During auditory testing, 16.0 kHz pure tones were
delivered through an overhead wide-range acoustic driver located
20 cm above ear level. During visual testing, stimuli were
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provided by a slide projector which focused a one-inch
back-lighted circular white patch on the response panel at eye
level through an aperture in an otherwise light-tight chamber
wall. A dimly flashing red cue light became steady contiguous
with a lever press and served as feedback for the lever holding
response. At varying intervals (1.0 to 7.3 sec.) following
initiation of the holding response, a test stimulus (1.5 sec
duration) was presented. Release of the lever in the presence of
the test stimulus defined a correct detection of the stimulus, and
produced a food pellet reward, terminated the test stimulus, and
initiated a 1-sec intertrial interval (ITI). Lever releases prior
to test stimulus onset or following test stimulus offset
reinstated the ITI without food delivery. Reappearance of the
flashing red cue light following the 1-sec ITI signalled
initiation of the next trial. Daily 2 to 2.5 hour experimental
sessions included approximately 500 such discrete reaction time
trials.
Auditory and visual thresholds were determined in separate
sessions by randomly varying the intensity of the test stimuli
from trial-to-trial in accordance with the method of constant
stimuli, and examining detection frequencies at each intensity.
For the auditory modality, four intensity levels 10 dB apart of a
16.0 kHz tone were used, with the lowest level set just below an
animal's estimated threshold. To measure the false alarm, or
"guessing" rate, a series of "catch" trials (i.e., no stimulus
presented) were interspersed among the test trials. For the
visual modality four intensity levels, 0.5 log density units
apart, of the white light were used, with the lowest level set
just below the animal's threshold. Again, "catch" trials with no
light were programmed to occur intermittently. For both
modalities the threshold was corrected for "guessing" by defining
the threshold as that stimulus intensity producing a detection
frequency halfway between the false alarm rate and the 100%
detection point.
Reaction times were measured as elapsed time between signal onset
and lever release. Reaction times to white light and the 16.0 kHz
pure tone produced similar reaction time functions, although the
auditory reaction times were approximately 100 msec faster than
the visual reaction times. Since the drug effects on the reaction
time measure were the same regardless of whether the reaction-time
stimulus was white light or the 16.0 kHz pure tone, only reaction
times to white light are presented.
Drugs were administered intramuscularly (i.m.) immediately before
each experimental session, followed by 15 minutes of dark
adaptation and 15 minutes of "warm-up" on the reaction time task
before threshold determinations were begun. Saline control
sessions requiring return-to-baseline performances occurred
between drug sessions.
Figure 1 shows the dose-dependent effects of diazepam,
pentobarbital, and d-methylamphetamine upon auditory and visual
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thresholds and reaction time. All data points represent average
changes in the indicated function for two animals, and are derived
from 1-hour segments during peak drug action times (i.e., 1 to 2
hours after i.m. injection at the start of each experimental
session). The total range of values obtained from saline control
sessions is shown on the left in each graph. Consistent
elevations in the visual threshold and reaction time were produced
at doses greater than 1.0 mg/kg for diazepam, and greater than 3.2
mg/kg for pentobarbital. Diazepam had a similar effect upon the
auditory threshold, but pentobarbital doses up to 17.0 mg/kg
produced no such changes. d-Methylamphetamine over the dose range
of 0.01 to 0.32 mg/kg produced no changes in either the auditory
threshold or reaction time, though an elevation in the visual
threshold was observed at the highest dose of 0.32 mg/kg. Higher
doses of all three compounds produced disruption of performance.
For diazepam and d-methylamphetamine the next quarter-log dose
step (17.0 and 0.56 mg/kg, respectively) produced complete
cessation of responding. For pentobarbital, the 17.0 mg/kg dose
shown in Figure 1 produced prolonged pauses in performance in one
animal, and at 32.0 mg/kg anesthetic-like effects were observed in
both animals tested.
FIGURE 1 The effects of diazepam, pentobarbital,
and d-methylamphetamine on auditory and visual
thresholds, and reaction time
The consistent pattern of psychophysical change observed with
pentobarbital (elevated visual thresholds but no auditory
threshold elevation) has been systematically observed with one
additional barbiturate, amobarbital, over the same dose range (1.0
to 17.0 mg/kg). Both the visual threshold and reaction time
increased in a dose dependent fashion with significant elevations
following doses of 10.0 mg/kg and 17.0 mg/kg. Over the same dose
range, however, amobarbital did not produce any change in auditory
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thresholds. In contrast, psychophysical determinations over the
same dose range (1.0 to 17 mg/kg) with a second compound in the
benzodiazepine class, chlordiazepoxide, revealed no changes in
either the visual threshold, the auditory threshold, or reaction
time. When chlordiazepoxide was administered at a dose beyond
this comparative range (i.e., 32.0 mg/kg) in one animal, however,
significant elevations in both the auditory threshold and reaction
time were observed without any change in the visual threshold.
Confidence in the validity and reliability of the observed
threshold shifts is based upon the following considerations.
First, reaction time changes with the barbiturate compounds were
observed during both auditory and visual modality determinations
though auditory thresholds did not change. Secondly, calculated
shifts in sensory threshold estimates due to drug-induced
increases in reaction time were negligible compared to the
magnitude of the observed threshold shifts. Finally, control
studies have confirmed that auditory threshold shifts can occur in
the absence of reaction time changes. Temporary acoustic
threshold shifts induced by pre-exposure to 100 dB of broadband
noise for 30-45 minutes elevated auditory thresholds by 15-20 dB.
During this time of peak auditory threshold elevation, reaction
times to the audible stimuli were within normal limits as were all
visual reaction times. These observations indicate that the
reaction time measure and the threshold measure can be considered
to reflect independent functional changes to at least some degree.
The results of these experiments show clearly that drugs of abuse
can be differentiated with respect to their effects on a range of
psychophysical functions. Dose-dependent decrements in visual
thresholds and reaction time in the absence of auditory threshold
shifts were consistently observed within the class of barbiturate
compounds studied. In contrast, the effects produced on these
same psychophysical measures over a comparable dose range by
representative benzodiazepines were differentiated both within and
between drug classes. Diazepam elevated both auditory and visual
thresholds and increased reaction time in a dose-dependent manner,
while chlordiazepoxide over the same dose range (i.e., 1.0 to 17.0
mg/kg) produced no change in either auditory or visual thresholds
or reaction time. Only at the highest doses beyond this range
(i.e., 32.0 mg/kg) did chlordiazepoxide elevate the auditory
threshold and reaction time without effect upon the visual
threshold. Moreover, the unremarkable effects of the prototypical
stimulant d-methylamphetamine, showing no change in auditory
threshold or reaction time and an elevation in the visual
threshold only at the highest dose administered (i.e., 0.32 mg/kg),
clearly contrast with the psychophysical patterns observed with
both the barbiturates and benzodiazepines.
These findings strongly suggest the need for a more extended
analysis of the basic psychophysical effects of pharmacological
agents to determine the extent to which such changes contribute to
the sensory and behavioral dysfunctions associated with drugs of
abuse.
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SUMMARY
Behavioral reaction times and both auditory and visual absolute
thresholds were determined in baboons before and after the
administration of stimulant and depressant drugs of abuse.
Pentobarbital and diazepam increased reaction times and elevated
the visual threshold in a dose-dependent manner. Diazepam also
raised the auditory threshold though pentobarbital did not.
Chlordiazepoxide affected neither sensory thresholds nor reaction
times over the same dose range; d-methylamphetamine elevated the
visual threshold, but did not elevate the auditory threshold or
increase reaction times.
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Abuse Potential of Loperamide:
Adaptation of Established
Evaluative Methods to Volunteer
Subjects
J. H. Jaffe, M. Kanzler, and J. Green
For almost 30 years the assessment of the abuse potential of new
opioid drugs on a depended unique collarboration between the pharma-
ceutical industry, the academic community and the Federal govern-
ment's Addiction Research Center at Lexington, Kentucky. The Com-
mittee on Problems of Drug Dependance (at that time a part of the
National Research Council and chaired, until his death, by Nathan
Eddy) played a vital role in coordinating the movement of new prod-
ucts through the process of data acquisition and evaluation in both
animals and man. The human testing involved the use of Federal
prisoners with a history of opioid addiction who volunteered to be
transferred from various Federal prisons to the Addiction Research
Center. Because prisoner status required a controlled environment,
research designs involving repeated measures could be undertaken
with reasonable assurance that subjects were not simultaneously
using nonprescribed drugs and, in most instances, that the dropout
rate would be low. In 1975, after several years of discussion,
Federal administrators accepted, for all practical purposes, the
viewpoint that prisoners by virtue of being prisoners could not
give a truly informed consent. The last prisoner left Lexington
on December 31, 1976. The use of Federal prisoners was ended --
as was the program for assessment of abuse potential in humans.
The kinds of problems that might arise in attempting to carry out
abuse potential assessments in non-prisoner volunteers were not
clear. When drugs are abused, the dosage involved is often many
fold greater than the recommended therapeutic doses. In order to
test abuse potential before a drug is marketed, it is necessary to
test various doses at levels that are pontentially toxic. Since by
definition the drugs have not been released, there is no "street"
experience to guide the investigator in determining the optimal dos-
age for testing or to advise an Institutional Review Review Board about
expected toxicities or risks. In addition, it is necessary to as-
sume that only a limited subgroup of the population may be vulner-
able to an abuse potential. The best way to be certain that the
drug is tested in vulnerable subjects is to test subjects with a pest
history of opioid abuse or dependence. However, such subjects are
not noted for their reliability in conforming to protocols. It was
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to assess these administrative problems as much as to study the a-
buse potential of loperamide that we undertook the studies to be
described.
Loperamide is a synthetic drug developed by Janssen Pharmaceuticals
that is structurally related to diphenoxylate and to haloperidol.
Studies in rats and mice suggested that it produced CNS actions only
in doses many times higher than those required for anti-peristaltic
actions and that, while it binds to opioid receptors in gut and
brain, it appears to penetrate the CNS poorly (Colpaert et al.
1975; Terenius 1975). In studies at the University of Michigan
and the Medical College of Virginia, parenteral loperamide (dissolved
in propylene glycol) suppressed opioid withdrawal in monkeys and
exhibited other opioid-like effects, but with oral loperamide it
was difficult to establish clear-cut dose-response relationships
(files of Janssen Pharmaceuticals). Subsequently, Yanagita and co-
workers confirmed that loperamide produces opioid-like effects in
monkeys and showed that monkeys would self-administer loperamide
I.V. (Yanagita et al. 1980). On the basis of animal studies, par-
enteral loperamide would be expected to have some opioid-like abuse
potential. However, the commercially available preperation mixed
with magnesium stearate is so insoluble that extraction and paren-
teral administration is exceedingly improbable. Thus, it seemed
that the key question to be answered was whether oral loperamide
produced opioid-like subjective effects (or any subjective effects)
in supratherapeutic dosage.
Our objective, therefore, was to compare the subjective effects of
loperamide with those following a placebo and a threshold dose of
an appropriate criterion drug (codeine) in a manner analogous to
the study of diphenoxylate carried out by Fraser and colleagues
(Fraser et al. 1961) at Lexington in post-addicts.
Study I
Procedures
The first task was to determine an appropriate dose of loperamide
to use in a study of abuse potential. Nine paid volunteers were
recruited. They were not opiate addicts but had prior experience
with other drugs, such as alcohol and marijuana. Subjects partici-
pated three at a time in a "dose run-up" on Mondays, Tuesdays and
Wednesdays for six weks. They remained in the hospital for 25
hours at each drug trial but were on leave from the hospital between
trials. Since preliminary informtion on phamacokinetics of lo-
peramide indicated a t½ of 12 hours, we were obliged to wait at
least 60 hours between tests on the same person. Mindful of this
obligation and in order to minimize the effects of varying day of
the week, each subject was tested whenever possible on the same day
of the week thoughout the study.
Based on data provided by Janssen Pharmaceuticals, we began with a
dose of 12 mg loperamide (6 times the usual therapeutic dose). Our
research committee gave us permission to raise the dose by 6 mg
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increments; however, we were obliged to report on the effects after
each 12 mg increment and to obtain specific permission to raise the
dose to susbsequnt higher levels. During the weeks when loperamide
at 12 mg, 18 mg and 24 mg was being tested against placebo and co-
deine, each subject's morning dose consisted of 12 capsules contain-
ing active drug and/or enough placebo to equal 12 capsules. Lopera-
mide at 30 mg and 36 mg required the subject to ingest 18 capsules;
loperanide 42 mg 48 mg, 24 capsules; and loperamide 52 mg and
60 mg, 30 capsules. Sometime during the study all subjects received
placebo. Eight of the nine subjects had a test dose of codeine sul-
fate (96 mg base) which was about 7 percent less than the 103 mg
codeine base used at Lexington.
To assess the extent and nature of subjective effects of the sub-
stances ingested, we used standard instruments developed at Lexing-
ton--the Addiction Research Center Inventory (ARCI)subscales, Pen-
tobarbital-Chlorpromazine-Alcohol  Group (PCAG) and Morphine-Benze-
drine Group (MBG)--as well as questionnaires asking "Do you feel
the drug; do you like the drug; can you identify the drug?" In
addition, we measured pupillary responses
Results
Table 1 summarizes the data for the doses used, grouped into three
categories: low dose (12, 18, and 24 mg); medium (30, 36, and 42
mg); and high (48, 54, and 60 mg). Despite the absence of systemtic
TABLE l
SUBJECTIVE  POSITIVE RESPONSES TO TREATMENTS--LOPERAMIDE AT THREE
DOSAGE LEVELS, CODEINE AND PLACEBO--STUDY I
Ident. as "Dope"
2 Hrs 4 HrsTreatments
Lopermide
Low(12,18,
24 mg)
Medium(30,
36,42mg)
High(48,
54,60mg)
Codeine
Placebo
N
9
8
9
8
9
Felt Drug
2 Hrs 4 Hrs
6 67%
4 50%
3 33%
6 75%
2 22%
2 22%
4 50%
6 67%
3 38%
2 22%
Liked Drug
2 Hrs 4 Hrs
4 44% 2 22% 0 0% 1 11%
3 38% 3 38% 2 25% 2 25%
0 0% 0 0% 0 0% 1 11%
4 50% 3 38% 2 25% 0 0%
1 11% 0 0% 0 0% 1 11%
assignment of subjects, we felt comfortable in making the general
inference that (1) our subjects were not predominatly placebo re-
actors and (2) they did not express any particular liking for pla-
cebo materials. Our subjects did "feel" our test dose of codeine
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and they did "feel" loperamide at doses in the moderate to high lev-
els but did not particularly like the effects.
On the basis of these findings we decided that 60 mg or 30 capsules
was as highadose as seemed reasonable to administer to subjects
with an established opiate abuse history and to compare with what
we thought to be a threshold dose of codeine.
STUDY II
Procedures
Study II involved a double-blind cross-over design using nine sub-
jects who had been active opiate users and who had been withdrawn
from opiates for varying periods of time. Some had not been depend-
ent for several years, having stopped using opiates long before the
study; others had been withdrawn only within the preceeding two
weeks in our research unit. In contrast to Study I, which permitted
subjects to be on leave between episodes of testing, Study II was
entirely an inpatient investigation and subjects remained as inpa-
tients from at least a day or two prior to their participation in
the study until the day after all three test doses had been given.
Based on pharmacokinetic data from Study I which indicated a t½
of 9 hours (Weintraub et al. 1977) we reduced the minimun interval
between test sessions to 72 hours. The three treatments--lopera-
mide 60 mg, codeine sulfate 120 mg (96 mg base), and placebo--were
given in random order.
Results
In response to the question, "Do you feel the medication?" at the
peak effect for codeine (which occurs at two hours) five of nine
subjects (56%) said they felt the medicine whereas only four of
nine (44%) of the subjects said they felt loperamide. Only one
subject indicated that he felt placebo.
Answers to the question, "Do you like the medication?" were weighted
according to a scoring system based on the Lexington formula which
assigned increasing scores to various degrees of liking (Fraser
et al. 1961). If a subject didn't like the drug at all, the res-
ponse was scored 0; liking slightly, scored 1; liking moderately
scored 2; liking a lot, scored 3. The total score for the group
of nine subjects was 6 at peak (two hours) for the dose of codeine
and 3 at peak (four hours) for loperamide. For placebo, the high-
est total weighted liking score for the nine subjects was only 1.
On the ARCI PCAG subscale (generally measuring sedation), this
group of subjects showed very little change with placebo, modest
increase with loperamide, and a small decrease with the standard
dose of codeine. The "change" scores for each subject for two,
four and six hours were summed (Jasinski et al. 1975) and the sums
were analyzed by a one-way analysis of variance followed by orthog-
onal contrasts in which loperamide and placebo were contrasted
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against codeine. On the PCAG subscale, the changes were not sta-
tistically significant.
Similar analyses of the responses on the MGB subscale of the ARCI
(generally measuring euphoria or stimulation) showed little change
with placebo, a consistent elevation with codeine, and, at the two-
hour point, a decrease with loperamide. While there was virtually
no differerce between loperamide and placebo on this scale, co-
deine differed from both at the .07 level.
Figure 1 shows the pupillary responses for the three standard drugs.
Again, there was virtually no net change in this group with place-
bo. Codeine showed a statistically significant pupillary constric-
tion which, in general, tended to parallel the psychological ef-
fects in terms of time. Here, again, the effects of codeine are
distinct from those of loperamide and placebo (.04 level).
In summary, in terms of responses on the scales validated at Lex-
ington and in terms of pupillary responsed, lopermide at 60 mg
was distinct from codeine and hardly distinct from placebo. Despite
FIGURE 1
Pupillary responses to placebo, codeine (120 mg) and loperamide
(60 mg)--Change from baseline.
this, the subjects taking loperamide did feel some drug effect.
Table 2 summarizes the findings from this study and compares them
236
TABLE 2
LOPERAMIDE STUDY II VS LEXINGTON SUBJECTS--COMPARISON OF RESPONSES
PERTINENT TO ABUSE POTENTIAL
Lexington Psychiatric Institute
103mg 96mg
Codeine Codeine 60 mg
Base Base Loperamide Placebo
Felt drug (at peak) 75% 56% 44% 11%
Identified as dope 33% 44% 11-33%* 11%
(4 hours)
Mean weighted liking 1.2 0.67 0.33 0.11
score (at peak) (2 hours) (2 hours) (4 hours) (4 hours)
*Only one subject called the drug "dope" without qualification.
Two additional subjects refused to choose between dope and another
category, likening the effect to tranquilizer/goofballs/hallucino-
gen/dope combinations
with findings obtained in post-addicts at Lexington. It shows
three parameters: the percentage of subjects who indicated they
"felt" a drug effect: the percentage of subjects who identified the
drug effect as being like "dope"; and the man weighted "liking"
score for the group of subjects studied. The weighted liking score
was based on the procedure developed at Lexington (described above);
the scores for all subjects were summed and divided by the number
of subjects toproduce the mean.
When 140 mg of codeine phosphate (equal to 103 mg of codeine base)
was tested at Lexington, it was felt by 75 percent of ex-addict
subjects but it was identified as "dope" by only 33 percent of such
subjects, indicating, again, that in such subjects who have, on
average, been off opiates for a minimum of a few months, 103 mg of
codeine base is a threshold dose in terms of subjective effects.
The mean weighted liking score for these subjects at Lexington was
1.2, indicating that for most subjects their liking for such dos-
age was, at best, slight.
Table 2 also shows the results from the three drugs given in our
cross-over study with more recently detoxified addicts. Only one
subject (11 percent) felt a drug on placebo, identified placebo as
"dope" and liked it slightly. Our dose of codeine, which was only
96 mg of codeine base, was felt by 56 percent of our subjects and
identified as "dope" by 44 percent. These percentages suggest that
our subjects may have keen slightly less sensitive (or more toler-
ant) but also more discriminating. The mean weighted liking score
for our nine subjects was 0.67 or approximately half that reported
by Lexington. Since only 56 percent even felt this dose of codeine
as a drug, it is not surprising that the average liking score was
lower than that at Lexington.
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After 60 mg of loperamide, 44 percent of the nine subjects indicated
they felt sane drug effect at peak. At that time (approximately
four hours) 11-33 percent of the subjects identified the drug ef-
fect as being like "dope". In the case of codeine there was little
hesitation in describing the effect as like "dope", but only one
subject made such an unequivocal identification after taking lopera-
mide; two others refused to make a clear cut discrimination, indi-
cating that it might be a mixture of dope and tranquilizer, and, in
one case, dope and marijuana. If we count all cases where the word
"dope" was mentioned to any extent, no matter how qualified, we come
up with 33 percent. If we insist that the identification be as un-
equivocal as that observed with codeine, then the figure drops to
11 percent--the same figure obtained with placebo.
The weighted liking score for loperamide was 0.33, about half of
that obtained with our threshold dose of codeine, which, in turn,
was only about half that obtained by a slightly larger dose of co-
deine in addicts who had been detoxified for a longer period at
Lexington.
In summary, our study indicated that 60 mg of loperamide at 15 to
30 times the recommended therapeutic dose in the marketable dosage
form produced a detectable subjective effect in a little less than
half a group of subjects with a known opiate abuse potential, was
liked little or not at all, and was identified as "dope" at a fre-
quency less than that for a threshold dose of oral codeine.
We believed on the basis of these findings that given the social
context in which the drug is likely to be used and sold, the abuse
potential of loperamide was probably low enough so as to make any
formal controls unnecessary. Given this indication of an exceedingly
low abuse potential, it seemed reasonable to allow the market place
to provide further indication as to whether or not the low level
subjective effects produced with supratherapeutic doses of lopera-
mide would be abused. We conceded, however, that the results were
not 100 percent negative. Supratherapeutic doses were not found to
be aversive by all subjects. But we predicted that there would be
little or no abuse of this substance as long as drugs like codeine
in cough medicine, paregoric and diphenoxvlate were available at
much lower costs. At that time (1976) this recommendation was not
accepted by F.D.A. Loperamide was placed in Schedule V of the C.S.A.
PROBLEMS IN THE USE OF NONPRISONER SUBJECTS
We encountered several distinct problems in doing the dose run-up
Study I in normal volunteer subjects--the institutional requirements,
the anxiety of the subjects and the staff, and the real-life circum-
stances from which the subjects came and to which they returned bet-
ween drug trials. Because the drug dosage was raised step wise to
a level which far exceeded the therapeutic dose, the institution's
Review Board required that the subjects be hospitalized--overnight
at least. In addition to the large amount of red tape and/or paper-
work this requirement entailed, formal admission made the subject a
"mental" patient who was "out on pass" between experimental trials.
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The everyday life of the subjects between trials differed widely a-
cross subjects. Some worked at night and might arrive on an experi-
mental morning in a fatigued state and looking forward to a day of
rest. Others might have been affected by pretesting indiscretions
in eating and drinking. In order to control the subject's behavior
on the night before an experimental trial, the subjects were offered
an extra fee if they would come into the hospital the evening before.
Some took advantage of the option but, within the limits of incen-
tives permitted, this approach was not entirely successful.
Problems were not encountered where they had been anticipated--in
keeping subjects occupied. They had access to a color TV, to ping
pong, to an outdoor basketball court, and to a staff-accompanied walk
in the evening. Apparently the experimental day did not tax their
patience unduly. Such would not have been the case if we had re-
quired complete hospitalization for the duration of the study--as
in Study II, where holding the subject in the hospital for the dura-
tion of the study was very difficult. Therefore, despite the vari-
ability introduced by the differences in subjects' real life happen-
ings, the experimental procedure of requiring only twenty-five hours
hospitalization for each trial was probably a satisfactory compromise
with the realities of costs, subject recruitment and adequate control
of experimental variables.
Study II, which required the use of detoxified ex-addicts, posed more
perplexing problems. Was it ethical to administer a drug that might
have opioid-like effects to a former user? How could we be sure
that the subject was fully detoxified? However, the major problems
we encountered as the study unfolded were in recruiting suitable sub-
jects and then dealing with their perception that once we had "in-
vested" in treating their withdrawal, they were under no obligation
to participate in the research. This perception was, of course, not
without basis. As part of our informed consent, we were obliged to
assure potential subjects that a decision not to participate would
not affect their treatment. In some cases, subjects would complete
detoxification, participate in part of the study and then, recog-
nizing our commitment to data acquisition and our investment in them
as individuals, they would seek to renegotiate the fee for partici-
pation.
Despite these problems the study was completed, and the central
question of whether selected studies of abuse potential can be con-
ducted in nonprisoner volunteers can be answered in the affirmative.
The issue of whether it would be possible to test the capacity of an
unmarketed drug to induce physical dependence in supratherapeutic
dosage is unresolved.
EPILOGUE
Recently, at an F.D.A. hearing, Ortho Corporation, which markets lo-
peramide (as Imodium), presented data indicating that after 2 1/2
years of marketing with an estimated 80 million doses prescribed to
more than 3 million patients there have have been no reported overdose
deaths and only one DAWN system equivocal report of use by a drug
abuser. On the basis of these data and the fact that the drug is
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available but uncontrolled in 70 other countries, the F.D.A.'s Advi-
sory Committee has recommended complete decontrol. It is not unfair
to point out that in this situation, as in others, the data from
human testing proved to be a better predictor of abuse potential.
than various animal models.
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Acute Tolerance to Cocaine in
Humans
M. W. Fischman and C. R. Schuster
ABSTRACT
It has been shown that there is a dose-response relationship
between blood levels of intravenously injected cocaine and
magnitude of evoked heart rate (Javaid et al. 1978). This
relationship also holds for inhaled cocaine while plasma levels
are increasing, but the cardiovascular effects of the drug
dissipate more rapidly than cocaine disappears from the plasma.
This suggests that the repeated administration or sustained blood
level of cocaine might produce an acute tolerance. Using an
intranasal route of administration it is possible to maintain
cocaine blood levels for a substantial period of time after heart
rate begins to decrease from its peak levels. If an intravenous
dose is then administered on top of this preexisting blood level,
the effects of this second dose can be compared to the same dose
administered to subjects with no preexisting blood level.
Eight normal adult volunteer subjects were tested according to
this design with intravenous saline and cocaine ranging in dose
from 16 to 48 mg. Each intravenous injection was administered
one hour after inhalation of placebo, when no cocaine plasma
levels were present, or 96 mg, when cocaine plasma levels were
elevated. Cardiovascular effects and verbal report of drug
effects were monitored for eight hours daily. The data suggest
an acute tolerance to the initial effects of cocaine during the
first hour after intravenous drug. When cocaine was intravenously
administered to subjects who previously inhaled 96 mg during the
same experimental session, there was a smaller change in heart
rate, subjective rating, stimulant scale scores on the Addiction
Research Center Inventory, and Arousal and Positive Mood factor
scores on the Profile of Mood Scales than when the intravenous
dose was the only cocaine those subjects received during that
experimental session. No long-term cocaine tolerance was noted.
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A Study of Hospitalized Surgical
Patients on Methadone
Maintenance
T. G. Kantor, R. Cantor, and E. Tom
INTRODUCTION
The study described below addresses itself to the problem of
Methadone Clinic clients who require hospitalization for routine
surgical procedures or for traumatic episodes. Such individuals
would have pain, and, under such circumstances, should be legiti-
mately treated by conventional narcotic medication added to their
maintenance methadone. They may also manipulate the episode to
inappropriately receive incremental doses of narcotics, since
pain is a subjective symptom (Rubenstein et al. 1976).
In either of these two circumstances, it was hypothesized that
due to previously induced tolerance to narcotics, a further
increment in methadone dosage might ensue and that? in the long
run, more far-reaching effects on eventual detoxification and
methadone dosage reduction might conceivably occur.
In order to study this possibility, 25 patients from the Methadone
Clinic at Bellevue Hospital in New York City, who had been hospit-
alized for surgical procedures and traumatic episodes, were
compared with 25 methadone clients from the same hospital facility
matched as to age, sex and length of time in a methadone program.
Since this was a retrospective study, it is recognized that the
control group, by the very fact that they were there to be chosen,
are not strictly a control group with respect to detoxification
and rehabilitation from the program. Hospitalization and treat-
ment of pain with added doses of narcotics may jeopardize the
chance for subjects to have decremental doses of methadone,
eventual detoxification and possible rehabilitation from drug
abuse (Dole at al. 1966).
STUDY POPULATION
Written informed consent was obtained from all 50 study subjects.
As can be seen from Tables I and II, the mean dates for entry into
the methadone program were similar between the hospitalized group
and the control group. Similarly, the mean age and the mean dose
of initial methadone were essentially similar between the two groups.
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TABLE I. NON-HOSPITALIZED PATIENTS
CLIENT SEX STUDY ENTRY AGE AT METHADONE (MGM.) METHADONE (MGM.) NOTE
NO. TO PRESENT END OF DAILY  DOSE AT DAILY DOSE AT
(MONTHS) STUDY TIME OF ENTRY END OF FOLLOW-UP
1 M 74 31 90 70
2 M 69 46 100 100
3 F 5 21 20 40
4 M 42 28 80 80
5 F 12 30 30 30
6 F 53 25 80 80
7 M 14 43 60 70
8 F 69 24 60 80
9 F 18 25 20 60
10 M 9 45 100 100
11 M 16 34 100 70
12 F 74 35 80 80
13 M 24 27 60 60
14 M 60 31 60 70
15 F 61 28 80 80
16 F 37 28 40 5 Left treatment
17 F 75 25 90 60
18 M 18 28 60 35 Transferred
19 F 38 25 80 30
20 F 14 35 70 60
21 M 25 30 50 50
22 M 4 27 20 30
23 F 27 25 100 60
24 F 31 24 40 20 Left treatment
25 M 77 32 80 70
MEAN 27 28 60 6 0
RANGE 4-77 22-46 20-100 5-100
With respect to the hospitalized group, the mean length of hospit-
alization was 9 days and the mean follow period after hospitaliza-
tion to the date of the end of the survey was 20 months. In
addition, the prehospitalization methadone dose of each individual
is noted in a separate column and, following that, the post-hospital-
ization dosage.
Table III depicts the causes for hospitalization of the hospital-
ized group. Following that is a summary in the same Table of the
doses of analgesic received by each of these individuals. The
numerical designation of the subjects in this particular Table is
the same as that of Table II and forms the basis for further data 
analysis below.
RESULTS
It will be noted that there is little essential difference between
the methadone dosage for the hospitalized group and for the non-
hospitalized group after a similar period of followup time and that
the range of dosage is similar between the two groups. In addition,
it is obvious that the hospitalized group were discharged and imme-
diately followed in their respective methadone clinics on doses
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TABLE II. HOSPITALIZED PAIETN
PATIENT SEX SLTUDY ENTRY AGE AT METHADONE (MGM.) METHADONE (MGM.) NO. OF DAYS METHADONE (MGM.)
NO. TO PRESENT DAILY DOSE ON IN HOSPITAL
(MONTHS
STUDY DAILY DOSE ON DAILY DOSE AT
STUDY ADM. TO HOSP. DISCH. FROM HOSP. END OF STUDY
1 F 36 33 70 70 27 50
2 M 60 29 60 60 43 40
3 F 12 29 50 50 10 40
4 M 24 24 70 70 10 70
5 F 24 23 70 70 2 60
6 F 24 25 40 40 12 40
7 F 48 25 60 40 2 50
8 F 6 25 60 60 12 50
9 M 36 37 90 90 29 90
10 F 72 30 60 60 6 5
11 F 72 38 90 90 2 5
12 M 24 39 40 40 7 5
13 F 24 23 40 10 14 15*
14 M 12 27 60 60 5 20
15 F 12 21 50 50 8 40
16 M 48 44 80 80 10
17 F 24 23 50 50 7 10
18 M 36 32 8 0 80 5 100
19 M 72 29 90 90 21 60
20 M 36 32 90 90 18 90
21 M 36 34 80 80 9 50
22 F 24 28 50 50 5 15*
23 M 365 46 80 80 3 80
24 F 60 25 90 70 9 70
25 M 24 36 80 70 3 50
MEAN 39 29 70 70 9 50
RANGE 6-72 21-46 30-90 40-90 2-43 5-100
Terminated * Discharged Died
essentially the same as those on which they entered the hospital.
It is also apparent that irrespective of the entering dosage of
methadone for the hospitalized subjects or the amount of narcotic
analgesics required during their hospitalization, the outcome did
not affect their discharge dosage and subsequent methadone dosage.
DISCUSSION
Several of the hospitalized patients were transferred to other metha-
done clinics and their subsequent course determined by inquiry. In
addition, a number of this group became detoxified and discharged
from the clinic or discharged for administrative reasons. Because
of the nature of the selective process, these resolutions were not
available to the control group and, therefore, conclusions based on
that particular difference are not valid in this study. Changing
conceptions of methadone maintenance dosage may also confound com-
parison between the two groups, since the study subject population
extends from 1972 through 1978. For the same reason, abuse fashions
may have changed in such a way as to further confound such compari-
son. On the other hand, the matching of subjects by age, sex, and
length of residence with the program allows some conceptual com-
parisons between the two groups.
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TABLE IIIa. HOSPITALIZED PATIENTS
DIAGNOSIS NARCOTIC AND ANALGESIC DRUGS IN HOSPITAL
1. Low back pain, post intramedullary fixation DI 50 mgm. X 74
of left femur P 65 mgm. X 16
MO 70 mgm. X 27
2. Ureterits cystical, hydronephrosis, cystoscopy, MO 50 mg. X 16 MI 30 mgm X 6 DI 75 mgm. X 75
bladder biopsy MO 40 mgm. X 15 MI 20 mgm. X 1 DI 100 mgm. X 20
MO 30 mgm. X 2 MI 10 mgm. X 20 DI 50 mgm. X 13
CO 60 mgm. X 8
3. Post vabra pelvic inflammatory disease and non-MO  50 mgm. X 9
specific inflammation of recto-sigmoid of on-
known origin
4. Pancreatitis, appendicitis MO 70 mgm. X 9
AN 650 mgm. X 1
5. Voluntary interruption of pregnancy MI 20 mgm. X 1
MO 70 mgm. X 1
P 65 mgm. X 4
6. Ruptures spleen, raped, pregnant, splenectomy. DI 75 mgm. X 1
culdocentisis MS 4 mgm. X 1
DI 75 mgm. & phenergan X 15
7. R/O ectopic pregnancy, laparoscopy, DSC MI 10 mgm. X 1
MO 60 mgm. X 1
8. Bilateral salpingitis, appendectomy DI 75 mgm. X 5 MI 15 mgm. X 6
AN 650 mgm. X 1 MO 60 mgm. X 10
MI 30 mgm. X 2 P 65 mgm. X 11
9. Chronic active hepatitus, hyperspleenism, DI 100 mgm. X 1 AN 650 mgm. X 2
thrombocytopenia, right mastoidectomy MO 90 mgm. X 28
P 65 mgm. X 17
10. Chronic lymphatic observation of left arm, MO 60 mgm. X 4
cellutis of left hand ASA 650 mgm. X 3
PN 50 mgm. X 3
11. Intrauerine pregnancy, abortion by suction MI 30 mgm. X 1
and curettage MO 90 mgm. X 1
MO 30 mgm. X 1
12. Chronic relal failure, AV fistula of left arm MO 40 mgm. X 3 AC 2 tablets X 3
MO 15 mgm. X 2 CO 30 mgm. X 
MI 15 mgm. X 1
13. Liver abscess. Fitzhugh-Curtis syndrome MI 10 mgm. X 1
MI 30 mgm. X 13
14. Right hernia repair MO 60 mgm. X 4
MI 60 mgm. X 1
D I 75 mgm. X 2
15. Repeat cesarean section MO 50 mgm. X 7 CO 60 mgm. X 4
MI 10 mgm. X 2
DI 75 mgm. X 6
16. Cellulitis abscess dorsum left foot, D I 75 mgm. X 2
debridement MO 80 mgm. X 7
MO 50 mgm. X 2
17. Voluntary interruption of pregnancy MO 50 mgm. X 3
MI 25 mgm. X 1
CO 60 mgm. X ?
18. Fractured rib, pneumothorax MO 80 mgm. X 8
AN 650 mgm. X 1
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TABLE IIIb. HOSPITALIZED PATIENTS
DIAGNOSIS NARCOTIC AND ANALGESIC DRUGS ADMINISTERED IN HOSPITAL
19. Right hydronephrosis secondary to uretero-pelvic MO 90 mgm. X 19 MO 30 mgm. X 18
junction obstruction, status post right nephrectomy MI 40 mgm. X 2 DI 75 mgm. X 3
MI 30 mgm. X 4 DI 50 mgm. X 1
20. Cominuted fracture of fight tibia MS 10 mgm. X 4 MO 60 mgm. X 3
MO 10 mgm. X 8 MO 70 mgm . X 2
MO 5 mgm. X 7 MO 80 mgm. X 3
MO 90 mgm. X 4
21. Right inglnal hernia repair DI 30 mgm X 11
MO 80 mgm. x 7
AN 650 mgm. X 7
22. Mia forcepts delivery, median laceration and MO 50 mgm. X 5
repair p 65 mgm. X 4
CO 60 mgm. X 1
23 Chronic oltitis median of left ear, left MO 80 mgm. X 3
maltoectomy MI 40 mgm. X 1
MO 40 mgm. X 1
24. Cesarean section DI 50 mgm. X 8 P 15 mgm. X 1
DI 75 mgm. X 1 MD 90 mgm. X
DI 100 mgm . X 1
25. Fracture left mandible, closed reuciton MO 80 mgm. X 1
MO 70 mgm. X 1
D I 50 mgm . X 3
MIDICATION CODE
ASA = Aspirin  PO MI = Methadone im MS = Morphine Sulfate IM
CO = Codeine  PO MO = Methadone PO P = Propoxyphene PO
DI = Meperidine IM AC = Aspline 325 mgm. & AN = Acetaminophen PO
Codeine 30 mgm. (combination) PN = Pentazocine PO
In this retrospective study, the house staff, with their attendings
on a teaching service, had little or no guidance as to the manage-
ment of pain under these circumstances. Therefore, there is a
wide spectrum of treatment philosophies represented in terms of
analgetic management. Patients number 1 and 2, for example, were
treated with large amounts of narcotics added to their maintenance
methadone over prolonged hospitalization. On the other hand,
patients number 9 and 19 were also hospitalized over prolonged
periods and received relatively little extra analgetic medication.
In four instances, in short term hospitalization (patients 5, 7,
10, 24), patients in house on oral maintenance methadone had
their doses lowered slightly to "balance" added narcotics. Some-
times this was completely inappropriate, as in patient number 10
who received added aspirin and pentazocine. Two patients (4, 18)
were treated with analgetics other than narcotics, and one patient
(3) received no added analgetics at all although he expressed a
considerable complaint of pain.
Analysis of the data reveals that the mean methadone dosage for
the study patients was 70 mgm. This would be traditionally
considered "high dosage" maintenance. Despite this, these patients
required only standard dosages of narcotic analgesics to control
pain. Thus, any concept that supernormal dosages need be utilized
acutely to overcome "methadone blockade" is not supported. Only
3 patients in the study group would be considered to be receiving
"low dosage" maintenance (i.e., below 50 mgm/day). However, even
here repeated doses by various routes of narcotic analgesics did
not appear to increase methadone dosage requirements on discharge.
In our study, when a maintenance dosage of methadone was to be
given parenterally, the total dose was reduced by one-third to
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one-half with half the reduced dosage given at 12-hour intervals.
We feel this method more closely approximates a patient's oral
maintenance dosage and, as such, is unlikely to provide analgesia
in addition to the other drugs employed. We have used this method
of parentemal maintenance dose reduction extensively at Bellevue
Hospital with no clinical problems of oversedation or methadone
withdrawal symptoms being manifested.
In this study, drug interaction could obsure a patient's need
for an enhanced methadone dosage, Reviews of in-hospital medication
records revealed no medical use of interacting drugs during hospita-
lization in our patients. On hospital discharge, urine profiles
did not reveal any consistent abuse of sedatives or antidepressants
by the study patients. Indeed, urine profiles for the month
preceding hospitalization and the month after discharge show no
significant change in substance abuse patterns for the group
(Table IV) (N.U.C. Methadone Maintenance Treatment Program, 1979
Census Date, Bi-Weekly Report).
TABLE IV. URINE TESTS
STUDY GROUP CONTROL GROUP
Pre-Hospital (1 mo.) Post Hospital (1 mo.)
Total No. Urines
Analyzed 46 74 50
No. "Dirty" 9 17 12
% "Dirty" 19.6 22.9 24.0
Drugs Abused H  A  B C  V  P NM H A B C V P NM H A B C V P NM
No. of Mentions 0 1 1 1 2 0 4 5* 0 1 3 1 1 6 3 2 2 2 1 0 2
% Total Urines 0 2.2 2.2 2.2 4.4 0 8.7 6.8 0 1.4 4.0 1.4 1.4 2.1 6.0 4.0 4.0 4.0 2.0 0 4.0
* Accounted for by one patient
TOTAL N.Y.C. MMTP BI MONTHLY URINE TESTS
1976 1977 1978
% "Dirty" 24.0 26.0 30.0
% Drugs of Abuse H = 7.0 H = 9.0 H = 9.0
B = 4.0 B = 4.0 B = 4.0
A = 2.0 A = 1.0 A = 7.0
C = 9.0 C = 9.0 C = 6.0
D = 14.0 O = 6.0 O = 9.0
Because study patients were hospitalized in several different years, this Table is provided
to give a representative sample of substance pattern
A = Amphetamine O = Other (placidyn, alcohol, elavil, etc.)
CODES B = Barbiturates P = PhenothiazineC = Cocaine V = Valium
H = Heroin NM = Neg. Methadone
TABLE V. CLIENT OUTCOMES
Hospitalized N (%) Control N (%)
Stable Maintenance at Bellevue MMTP 15 (60) 15 (60)
Successfully Detoxified from Methadone 5 (20) 5 (20)
Transferred to Another MMTP 4 (16) 5 (20)
Deceased 1 ( 4) 0 ( 0)
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Thus, although the clinical response may vary, it seems prudent at
this time to utilize, when necessary, standard dosages of narcotic
drugs in methadone-maintained patients, increasing these dosages
only after careful clinical evaluation. It appears that these
agents may be used safely and effectively in this patient popula-
tion without fear of compromising further rehabilitation progress
(Table V).
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Plasma Levels of 
Tetrahydrocannabinol After
Intravenous, Oral, and Smoke
Administration
A. Ohlsson, J.-E. Lindgren, A. Wahlen, S. Agurell,
L. E. Hollister and H. K. Gillespie
In the Western countries -tetrahydrocannabinol (THC) - the
major psychoactive compound in Cannabis - is generally adminis-
tered by smoking marijuana (0.5-2 percent THC) or hashish (4-10
percent THC), but in Asia the oral intake of various Cannabis
preparations is usually preferred. The subjective effects of THC
in man after these routes of administration as well as after in-
fusion are well documented (Agurell et al. 1976, Domino et al.
1974, Hollister and Gillespie 1973, Hosko et al. 1973, Lemberger
et al. 1972, Lemberger and Rubin 1976 and Perez-Reyes et al.
1973a, 1973b).
The low doses of THC needed for behavioral effects and the rapid
distribution and metabolism of THC make it difficult to measure
the nonlabelled compound in biological fluids. However, during
the last decade various methods (e.g. mass spectrometry, radio-
immunoassay or other techniques) have been developed for this pur-
pose (Vinson 1979, Willette 1976). Still, the available informa-
tion on plasma level of THC is scanty and seldom related to clini-
cal effects.
The purpose of the present investigation was to estimate the sys-
temic availability - as evident from the plasma concentration pro-
files - after smoking and oral intake of THC in comparison with
intravenous administration of the drug and also to evaluate drug
effects in relation to the plasma levels of THC after all three
routes of administration.
METHODS
Subject and dosage procedure. Eleven men between 18 to 35 years
with previous experience with the drug volunteered to participate.
The following three forms of THC were administered to each subject
in randomized order:
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Smoking - Cigarettes were prepared from marijuana material con-
taining 1.64 percent THC and 0.23 percent cannabinol. Each ciga-
rette contained 14.9 to 16.1 mg THC.
Intravenous administration - Five mg of THC in 95 percent ethano-
lic solution (2 mg/ml) was slowly injected over a period of 2
minutes.
Oral administration - Each subject ate one chocolate cookie con-
taining 20 mg THC.
Blood specimens were drawn at periods indicated in figure 1. The
subjects, dosage and sampling procedures have been described in
detail elsewhere (Ohlsson et al. 1980).
Analysis of THC in plasma. The plasma levels of THC were deter-
mined by a mass fragmentographic method based on the use of deu-
terated internal standard as previously described (Agurell et al.
1979, Ohlsson et al, in Willette 1976, Ohlsson et al. 1980). The
detection limit has been estimated to be 60 pg/ml plasma.
The areas under the plasma concentration versus time curves (AUC)
for the time period 0 - 360 minutes were estimated using the
trapezoidal role as described earlier (Ohlsson et al. 1980).
Clinical evaluation of drug effects. The following clinical
evaluations were made:
a) Pulse rate was read constantly through an ear lobe monitor.
b) Conjunctival injection was rated on a 0 to 4 scale at the
same time periods as the blood samples were drawn.
c) A rating of the degree of high on a 0 to 10 scale was made by
subjects at periods indicated in figure 2.
RESULTS AND DISCUSSION
Injection. The mean (± SD) plasma concentration versus time
curves after injection, smoking and oral administration of THC for
the eleven subjects are shown in figure 1. Three minutes after
cessation of the 2-minute infusion of 5 mg THC, high plasma
levels ranging from 161 to 316 (mean 219) ng/ml were reached. The
THC levels in plasma fell rapidly to a few ng/ml during the first
hour after administration. The plasma levels decreased rather
uniformly with time with little interindividual variation (cf.
figure 1). Previously, THC levels have been measured after infu-
sion of 5 mg THC over 30 minutes resulting in initially lower
plasma levels (Wall et al. in Willette 1976). After one hour the
levels following the 30-minute infusion were similar to those
after 2-minute infusion as shown herein.
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Smoking. Smoking the marijuana cigarettes resulted in a delivery
of 11.6 to 15.6 (mean 13.0) mg of THC which produced peak plasma
levels in the range of 33 to 118 (mean 77) ng/ml plasma. As evi-
dent from figure 1, a fast absorption was followed by a biphasic
plasma decay curve during the first four hours. The similarities
to the intravenous curve are striking. The plasma levels determined
by us agree well with reported data for 14C-labelled (Lemberger
et al. 1972), nonlabelled THC (Valentine et al. in Vinson 1979,
and Williams et al. 1978) and also the -THC isomer (Agurell et
al. 1976).
Oral administration. Despite the higher dose (20 mg THC) by this
route, maximum plasma level of THC was between 4.4 and 11 ng/ml
(figure 1). In most subjects the peak plasma level was reached
at 60 or 90 minutes but in two subjects as late as 240 and 300
minutes. Also, in most subjects more than one plasma level peak
could be observed. However, a rapid absorption in a subject did
not necessarily confer a high oral systemic availability. Com-
pared to infused and inhaled THC the oral THC yielded low and
irregular plasma concentrations.
System availability. The mean AUC for the time 0 - 360 minutes
for the three routes of administration and the systemic avail-
ability for THC after smoking and oral administration are given
in table 1. The systemic availability for THC has been estimated
assuming linear pharmacokinetics, i.e. the fraction absorbed is
independent of the dose.
TABLE 1
Pharmacokinetic parameters for describing -THC
disposition following intravenous, smoke and oral
administration in eleven healthy volunteers.
Administration AUC0-360 minute s a
Systemic
Availability %
Route Dose
Mean ± SD
(range)
Mean ± SD
(range)
Infusion 5.0 mg 4.33 ± 0.62
(3.39 - 5.67)
Smoking 13.0 mgb 1.96 ± 0.65
(0.87 - 2.73)
Oral 20.0 mg 1.02 ± 0.32
(0.72 - 1.60)
a pg . ml-1 . min.
18 ± 6 (8 - 24)
6 ± 3 (4 - 12)
b Estimated after subtraction of the remaining THC in the butt
(Agurell and Leander 1971). The mean value is presented.
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FIGURE 1
Average (± SD) plasma levels of -THC in eleven healthy volun-
teers administered -THC intravenously (5 mg), orally (20 mg)
and by smoking (mean 13 mg).
FIGURE 2
Time-course of the subjective "high" after all three routes of
administration.
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An early assumption that THC is about three times as potent when
smoked as when taken orally (Hollister and Gillespie 1973) is
confirmed by our results. The systemic availability of THC was
estimated to 18 ± 6 (SD) percent following smoking and 6 ± 3
percent after oral ingestion (table 1). The 82 percent loss by
the pulmonary route is undoubtedly due mainly to pyrolysis and
the side stream smoke. The low systemic availability of oral THC
may not only depend on a high first pass effect but also to
chemical break-down in the gastric juice or to microbial trans-
formation in the gut flora.
Clinical effects in relation to plasma concentrations. Reddened
conjunctivae, one of the two most reliable signs of Cannabis in-
toxication, persisted for as long as levels of THC were above 5
ng/ml. Tachycardia, the other clinical sign, was a less reliable
measurement of prevailing levels of THC or "high."
The time-course of the average "high" after the three administra-
tion routes is shown in figure 2. After both infusion and
smoking, a prompt onset and steady decline of the effect occurred
over a four-hour period. Following oral ingestion, the onset of
the subjective "high" was much slower but lasted longer. Also,
the clinical effect occurred at lower plasma concentrations by
this route than after infusion and smoking. The appearance of
"high" lagged behind the plasma concentrations (cf. figures 1
and 2). The correlation between the degree of intoxication and
log concentrations of plasma THC were, therefore, not especially
strong.
In summary, the plasma levels may not necessarily reflect the
levels within the brain and one might surmise that a slow absorp-
tion of the drug permits a larger fraction to penetrate the blood-
brain-barrier. Also, after oral intake of THC the formation of
the psychoactive THC metabolite 11-hydroxy-THC is probably more
abundant than after infusion and smoking.
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Marijuana and Driving
A. J. McBay and S. M. Owens
Alcohol continues to be, and will most likely always be, the princi-
pal drug which causes deterioration of driving performance. In
North Carolina for over 10 years, the bloods of more than half of
the operators (57%) killed in single vehicle crashes contained more
than 0.09% alcohol. The effects of drugs other than alcohol on
driving are virtually unknown. Only recently have attempts been
made to see if other drugs have adverse effects that could lead to
accidents. The contribution of other drugs with and without alcohol
should be ascertained.
There is concern that the use of marijuana may increase the risk
of having an accident. In order to establish this scientifically,
it will be necessary to show that operators are being adversely
affected by the drug and that they are over-represented in the
group of drivers having accidents compared to a non-accident group.
To obtain such information it is necessary to analyze bloods from a
random sample of the non-accident driving population and also from
operators involved in crashes. It is becoming increasingly difficult
to obtain blood from living operators. This is not true of operators
killed in crashes. If a drug is rarely found or occurs at a non-
influencing concentration in the blood of those killed in crashes,
the drug is a relatively insignificant factor in crashes and it is
not necessary to establish the incidence of the drug in the general
driving population.
Information which may be of questionable value in evaluating the ef-
fects of drugs on driving is based on anecdotal or hearsay statements,
laboratory tests of physical or mental impairment, laboratory driver
simulators , test course performance, and actual street-driver perfor-
mance. A report published in 1977 reviews the literature up to that
time(1). Little has been added since that time. Regardless of the
results of the above methods of ascertaining impairment they do not
answer the question of whether the use of a certain drug has an ad-
verse effect on driving. This question may best be answered by
determining the concentrations of drugs in the bloods of a signifi-
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cant number of operators involved in crashes which are not attri-
butable to some other cause. Evidence of crashes which might be
attributable to operators adversely affected by marijuana is very
rare. Peripheral studies have indicated that marijuana may cause
problems but not-for a very significant number of operators.
An early and widely cited report on drivers allegedly under the in-
fluence of marijuana, who might have caused fatal accidents, was
based on hearsay. This is the report of Sterling-Smith et al. (1976).
They concluded that 43 out of 267 (16%) of the drivers were under
the influence of marijuana (2). The results were based on inter-
views of friends and relatives of the deceased. Only 13 (5%) were
said to have used only marijuana. The "risk taking behavior" of
marijuana smokers was rated as low and in the same category with
"driving without restraints" or "smoking more than 2 packages of
cigarettes daily." Since there was no evidence that there were
any marijuana constituents in the blood of any operators it is
doubtful that this report sheds any light on a possible safety
problem that might be due to the effects of smoking marijuana.
Teale (1977) reported on the examination of 66 bloods obtained from
fatally injured drivers (3). The bloods were analyzed by radio-
immunoassay for cross-reacting cannabinoids, which were found in
6 specimens. Three of the blood extracts were purified by high
pressure liquid chromatography to separate the tetrahydrocannabinol
(THC) from the other cannabinoids. Blood of one of the victims con-
tained 2.3 ug/L of THC and 0.34% of alcohol. The other two vic-
tims were motorcyclists who crashed into automobiles. Their bloods
contained low concentrations of THC, 1.5 and 4.4 ug/L. Because
cannabinoids persist in the blood for many hours, it is not possible
to assess the effects these low concentrations of marijuana had on
the operators. This is rather a small sample to draw any valid
conclusions.
Reeve in 1979 reported on the examination of bloods from 1792
people arrested for driving under the influence (4). Blood was
analyzed for THC by a radioimmunoassay. Unfortunately, the proce-
dure used was not adequately enough documented to establish its
sensitivity (5 ug/L). Of the 1792 operators, 281 (16%) had posi-
tive findings of THC in their blood, 111 of the 281 had blood al-
cohol concentrations exceeding 0.09%. Most specimens were not
analyzed for other drugs. A strong negative correlation was found
between the THC positive bloods and accidents. The value of this
study as an indication of the safety of driving under the influ-
ence of marijuana is questionable.
A Canadian study (1980) sought drugs in 401 fatally injured drivers
and THC was found in the bloods of 14 (3.5%) of the victims, but 7
of the 14 had more than 0.09% alcohol in their blood. The bloods
of 2 of the drivers contained 5 ug/L of THC; the rest had less than
3 ug/L of THC (5).
The literature does not reveal that marijuana is a factor in unsafe
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operation of a motor vehicle. Sparse as the reports may be, they
tend to show that if there are drivers who are unsafe because of
marijuana, their numbers are small and most are also influenced
by alcohol.
METHODS
The 100 cases chosen for this study were those where adequate and
suitable specimens of blood were obtained from dead operators who
were killed in single vehicle crashes. Specimens from those who
lived more than 1 hour or whose blood was unsuitable because of
decomposition or contamination by embalming fluid were excluded.
The blood specimens were analyzed by RIA for THC using an Iodine-125
tracer (6). Only 0.1 ml of plasma or blood was required. The sen-
sitivity was at least 0.3 ug/L for plasma and 1.1 ug/L for hemo-
lyzed blood. The antiserum cross reacted with 11-hydroxy THC about
20%, but, fortunately, this physiologically active metabolite is
present in blood in low concentrations (7) following marijuana
smoking. It may be a significant factor when marijuana is ingested
orally. The other major metabolite, 11-carboxy THC, which is phy-
siologically inactive, is present in blood in significant quantities
but fortunately cross reacted less than 0.1%. The analysis was
further tested by analyzing specimens obtained from controlled
smoking studies (Fig. 1). No specimen which contained less than
3 ug/L of THC was reported as positive.
RESULTS AND DISCUSSION
The safety of driving following the smoking of marijuana will have
to be established. In our opinion, this has not been done. Smoking
studies reveal that the concentration of THC peaks in the blood at
about 50 to 150 ug/L, depending on the dose, in minutes while still
smoking. The concentration drops to about half that in about 10
minutes, and to less than 10 ug/L in about an hour. The reported
high lasts about two hours (8). No reports were found which indi-
cated that during the time the person was "high" their driving
performance was affected.
The concentration of THC found in the victims in this study ranged
from 3 to 18 ug/L with a median of 5 ug/L. At this time we are
unable to assess the effects of such concentrations on driving
ability (Table 1).
We do not know the significance of 18 ug/L of THC combined with
0.11% of ethanol in one of the victims. Certainly that concen-
tration of alcohol alone has been blamed for adverse driving per-
formance. Practically nothing is known of the effects of combi-
nations of alcohol and marijuana or any other drugs on driving.
Intuition leads us to believe that the other drugs won't favor-
ably improve the ability of the driver influenced by alcohol.
THC was found in the bloods of 9 of the 100 dead operators tested.
In 6 of the 9 bloods, alcohol in sufficient concentration to influ-
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Figure 1. Each of 5 subjects smoked a marijuana cigarette
that contained 9 mg of THC. It  took 7 to 13 minutes to
finish smoking.
TABLE 1. INCIDENCE OF THC IN 100 OPERATORS KILLED IN SINGLE
VEHICLE CRASHES
A/R/Sa THC Ethanol
Ug/L %
Speed mphb Time
Est./Limit
25WM 18 0.11 50/55 6 am
34WM 3 0.18 100/55 11 pm
26WM 4 0.04 100/55 6 amC
18WM 8 0.30 60/30 9 pm
49BM 3 0.31 85/55 12 md
22WM 5 0.09 80/35 2 am
18WM 7 0.17 60/55
24WM 7 0.00 50/35
10 Pme
2 Pm
24WM 4 0.12 80/55 5 am
a. A/R/S = Age/Race/Sex. b. Est. = Estimated
c. Plus butalbital 0.06 mg/dL. d. Died in 1 hour.
e. Died in 25 minutes
Other drugs sought: Opiates, barbiturates, cocaine,
amphetamines, phencyclidine (P.C.P.)
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ence operation was also found. One blood which had a low concen-
tration of alcohol also had a low concentration of butalbital. No
opiate, amphetamine, or phencyclidine (P.C.P.) was found in any
victim. Thus marijuana might have added to the effects of alcohol
in 6 of the 100 cases (6%).
factor in 3 of 100 (3%).
Marijuana alone might have been a
The incidence of alcohol in concentra-
tion greater than 0.09% was 62% (62 of 100). The number of dri-
vers who had marijuana in their blood was very small compared to
the number of those who had alcohol in their blood. Marijuana
was not found in the bloods of 91% of the drivers tested.
It will be difficult to establish whether or not marijuana is a
significant factor in traffic safety.
smoking are subtle.
The effects of marijuana
It produces a pleasant state of relaxation,
euphoria (a sense of well-being), altered perception of distance
and time, impaired memory of recent events, and impaired physical
coordination. This state lasts about an hour or two. Obviously
some people will overindulge with marijuana as they do with alco-
hol and other drugs and their performance will suffer greatly.
Are there many such people, will they try to drive, and will they
have accidents? If marijuana has an adverse effect on operation,
how much does it affect safety, for how long, and can the effect
be correlated with THC blood concentrations? Is the marijuana-
influenced operator more or less aggressive, apt to speed, likely
to take fewer chances, able to compensate, etc.? Is driving
adversely affected by marijuana in the same way that it is by
alcohol and/or other drugs?
The presence of cannabinoids on the breath or in the saliva may be
an indication that someone has smoked marijuana in the past few
hours and that the oral cavity was directly exposed. Unless con-
centrations in the breath or saliva can be correlated with effect,
these specimens will only be useful to show that marijuana has
been smoked at some time recently. Cannabinoids persist in the
urine for several days, thus positive urine specimens only iden-
tify marijuana users. It does not appear to be possible to deve-
lop an instrument for the detection and quantitation of marijuana
that is as easy to use as alcohol breath testing equipment. Are
such devices really necessary before it has been established
that there is a significant risk associated with marijuana and
driving?
It is difficult because of legal and logistic problems to obtain
blood specimens from the general driving population so that the
number of non-accident drivers who smoke marijuana and the concen-
tration of cannabinoids in their blood can be determined. If
marijuana is found in a small number of drivers killed in crashes,
it would mean that it is not a significant problem regardless of
what is found in the driving population. If a greater percentage
of driving population had marijuana in their blood than the percen-
tage in the crash group, would that mean that it is safer to drive
after smoking marijuana? Probably the most meaningful answer
concerning the effect of marijuana on driving will come from ana-
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lyzing the bloods of operators killed in single vehicle crashes.
A recent Department of Transportation report to Congress emphasizes
the need for information to "support arguments either for or against
establishing marijuana as a high priority highway safety concern"(9).
More research should be undertaken before legislation and counter-
measures are proposed to counteract a presumed problem of driving
under the influence of marijuana. Until the time that marijuana
is shown to be a significant problem, erratic operators may still
be removed from the highway by arresting them for reckless driving.
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The Role of Endorphins During
Parturition
K. Csontos, M. Rust, and V. Höllt
Parturition in humans is generally associated with extreme physical
and psychological stress under normal conditions. During pregnancy,
parturition, and confinement several changes in the endocrinological
homeostasis of the women take place. The controlling factors in the
endocrinological regulation (the hypothalamic: hypophyseal peptide
hormones) suggest a possible analgesic role of endorphins during
delivery. Since -endorphin and ACTH are located in the same pre-
cursor molecule (Mains et al. 1977) and are released simultaneously
from the anterior pituitary in response to various stressful stimuli
(Guillemin et al. 1977b), we have estimated ACTH levels as well as
-endorphin levels in the plasma of normal human female subjects
undergoing labor and parturition.
METHODS
For the -endorphin radioimmunoassay (RIA), antiserum was generated
in rabbits using thyroglobulin-coupled synthetic human -endorphin
( -h-endorphin) as the immunogen. The antiserum displayed a high
avidity for human -endorphin, (detection limit 4-6 fmoles/assay
tube or 20-30 fmoles/ml plasma) (Höllt et al. 1975). Methionine-
enkephalin, and endorphin and several ACTH fragments displayed
no cross reactivity. Human -lipotropin ( -h-LPH), however, was
recognized on an equimolar basis. 100 µl of undiluted plasma per
0.5 ml assay volume was assayed for immunoreactive -endorphin.
Synthetic -endorphin was used as a standard and for iodination
with I125 to provide the radioactive component of the assay.
ACTH was assayed by a commercially available kit (adrenocortico-
tropic hormone RIA Kit-CEA SORIN, Salugia, Italy). In our labora-
tory we have established that this antiserum shows no cross-reac-
tivity to human -endorphin, -LPH and -MSH. 100 µl of undiluted
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plasma per 0.5 ml assay volume was assayed for immuno-reactive ACTH.
In order to separate the immunoreactive peptides, -endorphin and
-LPH, 20 ml plasma aliquots were extracted by the silicic acid
(50 mg/ml plasma) and subjected to gel chromatography on a 09 x 85
cm analytical column containing Sephadex G-50. The separate lobes
of the pituitary of a 22-week-old stillborn fetus were extracted
with 0.1N HCl and also subjected to gel chromatography. 10 ml ven-
ous blood samples from the mother were collected in the different
stages of labor and parturition and one day post partum, further-
more, from the umbilical artery and vein of the newborn. Venous
blood samples were withdrawn from 12 mothers undergoing parturition
with segmental epidural anesthesia, from pregnant women during
oxytocin-induced labor, registered labor without subsequent partu-
rition, from mothers during and after nursing and, from non-pregnant
women during several stages of diagnostic dilatation and curettages.
RESULTS
Fig. 1 illustrates that plasma levels of both immunoreactive -en-
dorphin and ACTH in pregnant women and their neonates are signifi-
cantly elevated above those seen in non-pregnant women. One day
post partum the elevated peptide levels in maternal plasma seen
during labor had significantly decreased, and there was no marked
difference from normal control levels. There was a slight decrease
Figure 1
Immunoreactive -endorphin (A) and ACTH (B) in the plasma of con-
trols and in several stages of labor and in umbilical vein.
Astericks indicate significant differences between control and
other values (p=<0.05 *; p<0.01 **)
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in plasma levels of immunoreactive ß-endorphin in the moment of
labor intervals as compared to the second stage of labor. Plasma
levels of immunoreactive ACTH were found to be significantly in-
creased in the second stage of labor as compared to the first stage.
When compared to nonpregnant women, elevated plasma levels of both
immunoreactive -endorphin and ACTH were found in the umbilical
vein of the new-borns.
To investigate the possible releasing activity of the routinely used
oxytocin infusion, labors were induced and registered in 8 women
in the 42nd week of pregnancy by a continuous infusion of orathin
(Fig. 2). Venous blood samples were collected before, during and
after the 20 min. long infusion period. There was no statistically
significant increase in the immunoreactive -endorphin ( -ELIR)
during the induced labors. There was a slight decrease in the
-ELIR in the plasma. Therefore, routinely administered oxytocin
infusion does not seem to be responsible for the increased endor-
phin release.
The highest levels of -endorphin/ -LPH in maternal plasma were
observed immediately after delivery and probably reflect the ex-
treme physiological stress of the birth process (Fig. 3). No
difference between umbilical, venous and arterial -endorphin con-
Figure 2 Figure 3
Immunoreactive -endorphin
in plasma of women before
(1), during (2) and 1 hour
after (3) oxytocin infusion
in induced labor
Immunoreactive -endorphin
in maternal plasma (1), um-
bilical venous (2) and ar-
terial (3) plasma immediately
after partition
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Figure 4
Separation of immunoreactive -endorphin into -lipotropin ( -LPH)
and -endorphin ( -E) by gel filtration on Sephadex G-50 after
silicic acid extraction from plasma. A= 10 non-pregnant women B=
10 pregnant women in second stage of labor, C= umbilical vein, D=
umbilical artery of 20 neonates, E= anterior lobe of pituitary,
F= intermediate/posterior lobe of 22-week-old fetus. Ordinate is
-endorphin-like immunoreactivity in fmoles/fraction.
tent could be detected. In Fig. 4, the chromatographic separation
of -ELIR into its components in plasma and tissue extracts of
humans is shown. The figure illustrates the elution profiles of
immunoreactive components of extracts of 30 ml plasma samples
pooled from non-pregnant women (A), from pregnant women during
second stage labor (B), from umbilical vein plasma (C), and from
umbilical artery plasma (D). In all cases the immunoreactive pep-
tides eluted from the columns showed fractions corresponding to
both -h-LPH and -h-endorphin. With the exception of the maternal
plasma during labor, -h-LPH appears to be the predominant peptide
in plasma. The fetal pituitary anterior and intermediate/posterior
lobes also contain equal amounts of both peptides.
Segmental epidural anesthesia during spontaneous delivery does not
seem to have an influence to the peptide plasma levels (Fig. 5).
High levels with little fluctuation were detected during the whole
observation period. In pregnant women plasma -endorphin content
was not influenced by the mechanical stimulus of dilation and
curettage (Fig. 6). Elevated level of -endorpin in the plasma
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Figure 5
Immunoreactive -endorphin in the plasma of women giving birth
under segmental epidural anesthesia. Plasma withdrawn at first
stages of labor (1-3), second stage of labor (4,5), umbilical vein
at delivery (6) and 1 day post partum (7).
during nursing was detected (Fig. 7). One hour after nursing only
12% of the peptide level during nursing was observed in the plasma
of a mother 6 days after parturition.
Figure 6 Figure 7
Immunoreactive -endorphin
in plasma of non-pregnant
women during dilatation and
curettage
Immunoreactive -endorphin
in maternal plasma during
(1) and after (2) nursing
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DISCUSSION
In comparison to non-pregnant female controls, significantly eleva-
ted plasma levels of both -endorphin and -LPH in maternal and
neonate plasma could be detected during labor and parturition.
ACTH levels rise also during parturition, reaching maximums in the
second stage of parturition. Our results confirm those of Kauppila
(1974). Between the phases of uterine contraction and dilatation no
significant difference in the ACTH levels was detected, whereas
there was such a difference in the content of -endorphin immuno-
reactive materials. A faster metabolic clearance rate for -LPH
than ACTH has been reported (Liotta et al. 1978).
Immediately after parturition very high levels of -endorphin/a-
LPH were also observed in plasma of the infant, although signifi-
cantly lower than in the maternal plasma. Possible sources for
these elevated peptide levels in the circulatory system of the neo-
nate are the maternal plasma, the placenta, (which has recently
been shown to contain high levels of -endorphin/ -LPH (Nakai et al.
1978) or the fetal pituitary (Nakao et al. 1978). If the major
source of -endorphin/ -LPH in the neonate plasma is the maternal
plasma, placental transfer by diffusion would depend largely on a
maternal-fetal concentration gradient and a tendency for equaliza-
tion of the respective concentrations should be noticed. But it
is well known that, when a drug has a molecular weight above 600,
placental transfer by diffusion does not occur. Since it has been
shown that ACTH (molecular weight 4500) can not readily penetrate
the placental barrier, it is unlikely that peptides such as -en-
dorphin (molecular weight about 3500) or -LPH (molecular weight
about 1000) could cross it to a major extent.
If the maternal plasma or the placenta were the major source of
-endorphin and B-LPH, higher concentrations of the peptides should
be expected in the umbilical vein than in the umbilical artery.
Although significant secretion of -endorphin/ -LPH from the pla-
centa cannot be excluded, our findings indicate that at least the
most of the peptides in the neonate plasma are secreted by the
neonate pituitary.
In view of the analgesic properties of opioids, one is tempted to
speculate about a possible physiological role of -endorphin in
human labor. The analgesic properties of -endorphin are well
known (Guillemin et al. 1977a). Thus an increase of this peptide
might help in rendering mother and infant less sensitive to the
pain of labor and parturition. It should be realized, however, that
the highest levels of -endorphin measured in maternal and fetal
plasma are very low (in the range of 40 to 150 fmole/ml or 40x10-11
to 1.5 x 10-1OM). Even if one assumes that the infant has not yet
a fully developed blood brain barrier and drugs like morphine pene-
trate the fetal nervous tissue more easily than its adult counter-
part, the amounts of plasma -endorphin appear too low to cause
any analgesic effect in test systems routinely used for analgesic
sensitivity. However, no exact data are available about the pain-
sensitivity of women undergoing parturition and their neonates.
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One can not exclude that at a decreased pain threshold these con-
centrations of -endorphin could be analgesically active in mother
or infant. Since functionally active opiate receptors are already
present in early stages of the fetal development (Cox and Pert
1976) ananalgesic action of endorphins in the fetal compartment
at parturition can be assumed.
Elimination of the painful component of parturition by segmental
epidural-anesthesia seems to have no effect on the elevated -en-
dorphin levels in the plasma. The emotional stress still remains
unaffected. In this case, the physical pain does not seem to be
responsible for the -endorphin release. The mechanical stimula-
tion of the cervix by dilatation and the irritation of the uterus
by curettages induces also no endorphin release, as shown by our
results.
The interaction of the endocrine system with opiates has been stud-
ied extensively. The synthesis and secretion of several pituitary
hormones (ACTH, GH, prolactin) are affected by the specific action
of both exogenous and endogenous opiates (Fishman 1977). In our
investigations the opiate-induced release of prolactin by PIF syn-
thesis inhibition is of great interest. This regulatory step occurs
on the hypothalamic level. Prolactin has an important role in in-
ducing labor and thereby in initiation of parturition. We can
assume that the -endorphin modifies the release of pituitary hor-
mones during and after birth. Our findings of highly elevated
-endorphin levels in plasma of mothers during nursing indicate a
pronounced interaction between the endocrine system and the endog-
enous opiates.
SUMMARY
The concomitant in vivo release of immunoreactive ACTH and -endor-
phin was investigated by measuring the plasma levels of both pep-
tides in the plasma collected during labor and parturition of fe-
male human subjects. Maternal and fetal -endorphin circulation
was investigated by estimating the plasma levels in umbilical vein
and artery and comparing them with the maternal plasma content of
the peptide. The peptides -LPH and -endorphin (which both react
with the -endorphin antiserum) were separated chromatographically
on Sephadex G-50.
In the first, and particularly the second stages of labor, levels
of both ACTH and -endorphin were significantly elevated. The 
endorphin-like innnunoreactivity was also elevated in the umbilical
vein and artery, although these values were not as high as in the
maternal vein.
Neither oxytocin nor the mechanical stress produced by dilatation
and curettage played a large role in releasing ACTH and -endorphin.
The normal pathways of releasing pituitary trophic hormones (dis-
inhibition of inhibitory control of releasing factors in the hypo-
thalamus) must be assumed for the mothers, while fetal production
of both -endorphin and -LPH was demonstrated.
270
REFERENCES
Cox, J.T. and C.B. Pert: Ontogenetic development of (3H) naloxone
binding at rat brain. Neuropharmacology 15, 555-560, 1976.
Fishman, J. The opiates and the endocrine system. In: The Bases
of Addiction. Life Sci. Research Report 8, Ed: Fishman, J.
1977. pp. 257-280.
Guillemin R., N. Ling, R. Burgus, F. Bloom, D. Segal. Characteriza-
tion of the endorphins, novel hypothalamic and neurohypophysi-
cal peptides with opiate like activity: Evidence, that they
induce profound behavioral changes. Psychoneuroendocrinology
2, 59-62 1977a.
Guillemin R., I. Vargo, J. Rossier, S. Minick, N. Ling. C. Rivier,
W. Wale, F. Bloom. -Endorphin and Adrenocorticotropin Are
Secreted Concomitantly by the Pituitary Gland. Science, 197,
1367-1369, 1977b.
Höllt, V., R. Przewlocki, A. Herz: Radioimmunoassay of -endorphin.
Basal and stimulated levels in extracted rat plasma.
Naunyn-Schmiedeberg's Arch. Pharmacol. 303, 171-174 1975.
Kauppila, A., R. Tuimala, J. Haapalahti: Maternal adrenocortico-
tropic hormone and cortisol during labor and vaginal delivery.
J. Obst. Gynaecol. 81, 691-694, 1974.
Liotta, A.S., C.H. Li, G.S. Schussler, D.T. Krieger. Comparative
metabolic clearance rate, volume of distribution and plasma
half-life of human -lipotropin and ACTH. Life Sci. 23,
2323-2330 1978.
Mains, R.B. Eipper, N. Ling. Common precursor to corticotropins
and endorphins. Proc. Nat. Acad. Sci, USA 74, 3014-3018, 1977.
Nakai, Y., K. Nakao, S. Oki, H. Imura: Presence of immunoreactive
-lipotropin and -endorphin in human placenta. Life Sci. 23,
2013-2018, 1978.
Nakao, K., Y. Nakai, S. Oki, K. Horri, H. Imura. Presence of
immunoreactive -endorphin in normal human plasma. J. Clin.
invest. 62, 1395-1398 1978.
AUTHORS
Katharina Csontos (Ph.D. candidate) Max Planck Institute of
Psychiatry, Department of Neuropharmacology, Kraepelinstr.2.
8000 Munich 40, Germany*
Meinhart, Rust, M.D., Institute für Anesthesiologie der Technischen
Universit, München Klinikum Rechts der Isar, Ismaningerstr.
22, 8000 München 80, Germany
Volker Höllt, Ph.D., Max Planck Institute of Psychiatry, Department
of Neuropharmacology Kraepelinstr. 2, 8000 München 40, Germany.
*Present address: State of New York Division of Substance Abuse
Services, Bureau of Laboratories and Testing, 80 Hanson Place
Brooklyn, New York, 11217
271
Regulation of Alcohol, Tobacco,
and Other Drugs: The Agenda for
Law Reform
R. J. Bonnie
INTRODUCTION: THE AGENDA FOR LAW REFORM
Let me begin by endorsing what I will call the public
health model of drug regulation. The model has two
predicates. The first is that it is desirable for
government to aim to prevent and minimize those pat-
terns of use--of any substance--which can result in
impairment of health and/or normal behavioral function-
ing. Little dissent is likely to be raised on this
point. However, the major implications of the public
health model derive from its second predicate--the
view that it is legitimate for government to discourage
and attempt to minimize any consumption of any poten-
tially harmful substance as a means of preventing the
patterns of use that can result in behavioral impair-
ment and/or adverse effects on health. This second
notion is empirically rooted in what the alcohol
literature refers to as the distribution hypothesis.
According to this hypothesis, the prevalence of alcohol
problems in a society is linked to the amount of alcohol
consumed in that society, and such problems can accord-
ingly be reduced by reducing aggregate (or per capita)
consumption.
Insofar as our current drug policy is rooted in the
logic of public health (rather than a moral authori-
tarianism), its very foundation is the distribution
hypothesis. Many hard questions can be raised about
the policy implications of the distribution hypothesis,
but I do not want to dwell on them now. I would just
like to assume that this is a legitimate way of think-
ing about drug abuse control. With this basic assump-
tion in mind, I want to focus my attention on how the
law is best used in the effort to implement a policy
which is built on the public health model.
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The critics of marijuana prohibition never fail to call
attention to the disparate governmental approaches to
alcohol and tobacco. They have consistently offered
the so-called alcohol model as a useful guide for en-
lightened marijuana control. Yet I think we will all
agree that this nation's experience with the alcohol
model is nothing to be proud of, certainly as it is
currently practiced. To the contrary, the laws now
regulating alcohol tend to be wholly inconsistent with
the logic of the public health model, reflecting in-
stead what I would call "affirmative libertarianism"--
that is, the current regulatory system often appears
to be designed to facilitate and encourage the use of
alcohol. The case of tobacco is even more disturbing
since the public health model has supposedly been the
basis for our policy since the mid 1960's when the
Surgeon General's report was issued (1964) and the first
Public Health and Smoking Act was passed (1965). Yet,
despite its rhetoric, government has taken only a few
very tentative steps to implement a public health
approach toward tobacco use.
The National Commission on Marihuana and Drug Abuse,
of which I was Associate Director, is remembered best,
whether fondly or not, for its recommendation that
marijuana use be decriminalized (National Commission,
1972). But what may be more important, I think, is the
Commission's unqualified endorsement of the public
health model. Not only did the Commission say that use
of marijuana and other illicit drugs should be dis-
couraged, but it also took the position that nonmedical
use of all drugs, including alcohol and tobacco, should
be discouraged as well. As this may suggest, the Mari-
huana Commission's Report is actually a very conserva-
tive document.
I thought when the Commission issued its final report--
and I still believe--that its most significant contri-
bution lies in its effort to lay the groundwork for a
more coherent and sensible legal policy toward all
drugs-- marijuana and other illicit drugs as well as
alcohol and tobacco. It should not be assumed, the
Commission emphasized, that the mere lawfulness of a
behavior, such as the use of alcohol and tobacco, means
that the government approves the behavior or is indif-
ferent to it. In fact, the Commission said, the govern-
ment should take affirmative action to erase any such
impressions and to influence even lawful behavior in
ways which would promote and protect the public health.
Laissez faire may well be a sound policy if it is rooted
in an ideological commitment to libertarianism, but it
is hardly a policy at all when government has simply
abandoned the field to the forces which have no in-
terest in the public health or welfare.
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On the other hand, the Commission also emphasized that
when government takes a stance of disapproval, even
strong disapproval, it does not follow that the be-
havior must be prohibited with all the coercive power
of the law. In short, the Commission said, the public
health model can be implemented by a variety of legal
strategies, and the assessment of the benefit and costs
of the various legal options requires a more subtle
analysis than is customarily offered.
These observations lead to a two-part agenda for law
reform. First, we need to develop creative regulatory
strategies--I use the word "regulatory" in a narrow
sense here, as opposed to "prohibitory"--for the imple-
mentation of discouragement policies. How can the law
be used most wisely and effectively to implement a
public health ideology towards tobacco and alcohol use?
(My point is not limited, by the way, to alcohol and
tobacco use; similar questions can be raised with re-
gard to automobile safety, for example.) What steps
should be taken to qualify what I regard as the mind-
less libertarianism of our alcohol and tobacco policy?
The second item on the law reform agenda is to fix the
appropriate role of the criminal law in implementing a
policy which aims to minimize the use of illicit drugs.
Even if a prohibitory model is adopted--rather than a
regulatory model which legitimizes availability--it
need not be an intolerant and oppressive policy. Pro-
hibition of commercial, nonmedical availability may be
a sensible policy in many respects, but it does not
follow that the user who chooses to ignore the pre-
scribed norms, and who is able to obtain the drug
despite society's best efforts to keep it from him,
should be punished. What we need, the Commission said,
is discouragement without criminalization. The Commis-
sion elaborated on this fundamental point:
In determining conditions of availability for
psychoactive substances, policymakers should
err in the direction of too much restriction
rather than too little. Philosophical and
constitutional concerns for individual pri-
vacy and freedom are touched only indirectly
by society's legitimate efforts to resist
the adverse consequences of drug availability.
Therefore a presumption exists in favor of
restriction and decisions limiting availabil-
may well be defended on speculative grounds.
"What would happen if there were widespread
availability?" is a perfectly valid inquiry.
Too often, however, policymakers have taken
the same perspective and employed a similar
line of reasoning in connection with an en-
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tirely distinct policy decision. That is
whether and under what circumstances society
should intervene in the life of an individual
who has chosen to consume a substance out-
side the legal channels of availability.
Here for philosophical, constitutional and
many practical reasons the presumption in
favor of control should be reversed. The
policymaking perspective must emphasize
personal freedom rather than the protec-
tion of society. In a free society, the
state is obliged to justify restraint on
individual liberty, and this justification
must rest on facts, not on speculation.
(National Commission, 1973, p. 242-43)
The Commission also went on to point out this society's
ambivalent attitudes toward drug use, the relative
ineffectiveness of the possession penalty as a deter-
rent to use, and the high social cost of its enforce-
ment, and concluded that the criminal law is not a
necessary symbol for a discouragement policy. Yet,
the Commission cautioned, "until society develops a
replacement symbol and other institutions assume their
share of responsibility for control and discouragement,
[the criminal law] may well be a necessary codifica-
tion of public policy. Unfortunately, sixty years of
coercive policy have so exaggerated the symbolic im-
portance of the criminal law that it has become inter-
woven with social attitudes regarding drug use. Re-
moving it suddenly would connote a change in values
rather than perhaps a shift in emphasis." (Id., p.255-
56)
The Commission's discomfort about the situation is
apparent:
Perpetuating the criminal law principally
through its symbolism does not comport well
with the fundamental purposes of the rule of
law. The Commission is strongly of the
opinion, however, that policymakers cannot
abruptly displace criminal law as a central
support for control of drug-using behavior.
The common reaction of those opposed to the
Commission's recommendations to remove the
criminal sanction from possession of mari-
juana for personal use illustrates the dif-
ficulty of rearranging even part of the
structure. We observed in our first Report
that a legal policy designed to curtail the
availability of cannabis could no more be
construed as neutrality toward or approval
of marijuana use than a similar legal scheme
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employed during alcohol prohibition. (During
alcohol prohibition possession for personal
use was an offense in only five states.)
Nevertheless, there has been a chorus of
objections that withdrawal of the criminal
sanctions would signify approval of use
and encourage more consumption of the drug.
(Id., p. 256)
The Commission went on to reaffirm its view that the
criminal proscription of marijuana use is self-defeat-
ing as a means of implementing a discouragement policy.
But the Commission was equivocal on the use of the
criminal law to proscribe and punish possession of
other drugs. "In the long run," the Commission said,
"a measure of success of this nation's drug policy will
be how much we have been able to disengage the criminal
law from concern with consumption. As long as the
legality of consuming legal drugs is a sign of approval
and the criminality of using prohibited drugs is the
major symbol of disapproval, the law will continue to
bear the sole burden of fulfilling public policy of
discouragement and most certainly will bear it badly."
(Id.). In the short run, however, the Commission con-
cluded-- and until replacement symbols are developed--
the possession penalty should probably remain in force
for other drugs. Even then, the Commission went on to
say, enforcement efforts should be selective and care-
fully chosen in order to minimize the adverse effects
of criminal intervention.
This, then, was the two-part agenda for law reform in
1973. The question that I would like to address today
is where we are seven years later. I will take up each
of these two items in turn--(l) regulatory implementa-
tion of discouragement strategies, and (2) "discourage-
ment without criminalization" under prohibitory policies.
Before going into the details, let me note in passing
that I am more sanguine about the likelihood of pro-
gress in the area of alcohol and tobacco regulation
than in the area of drug abuse control. In fact, I
will call attention to several recent signs of regres-
sion in drug policy.
IMPLEMENTING DISCOURAGEMENT POLICIES: REGULATION
OF ALCOHOL AND TOBACCO
Let me now take up tobacco and alcohol regulation.
Events during the last several years suggest that con-
siderable momentum is building for rethinking our legal
policies toward alcohol and tobacco. These policies
have become one of the targets of what the Surgeon
General has called the "second public health revolution."
The recruits in this revolution carry a banner sounding
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the call for "Primary Prevention," and their mani-
festos emphasize the need to engineer changes in col-
lective lifestyle as an essential component of the new
public health initiatives. The effort to prevent disease
and other health problems, it is said, must include
measures designed to discourage unhealthy personal
choices and to promote healthy ones. The target be-
haviors of this new public health revolution--what I
have elsewhere called the "new paternalism" (Bonnie,
1978) --always include alcohol abuse, tobacco smoking
and poor eating habits. Proponents of lifestyle modi-
fication strategies also always single out pregnant
women and adolescents as target populations in need of
special emphasis.
My sympathies lie with the "new paternalism." I even
support the use of regulatory measures . . . but only
if they appear to be essential components of an effec-
tive strategy for discouraging the use of tobacco and
for reducing the adverse health and social consequences
of alcohol abuse. In saying this, I stand somewhere
between the "health promoters" who want only to per-
suade, and the most vocal "preventors" who seem to want
health at almost any cost.
Organized social action aiming to generate mass changes
in lifestyle can, of course, be limited to health edu-
cation and to other efforts to influence collective
behavior in desired directions by reshaping attitudes
and social norms. Many contemporary advocates of life-
style modification strategies say that they want only
to promote the values of health, and therefore to
orchestrate voluntary behavioral change. Thus, they
accent the positive and frequently disclaim any in-
terest in seeking more potent regulatory initiatives.
Yet I am convinced that the new "public health revolu-
tion" will fail miserably to produce any measurable
result unless its leaders are prepared to sponsor regu-
latory initiatives. This is especially, true in connec-
tion with alcohol and tobacco use.
Tobacco Policy
Let us take a quick look at the chronology of the re-
cent Federal anti-smoking initiative. In early 1978,
Secretary Califano launched the anti-smoking campaign
with considerable fanfare, emphasizing the desirability
of curbing smoking as a means of reducing chronic
disease. Despite the speculation that Secretary Cali-
fano's dismissal was attributable, in part, to the
political fall-out from the anti-smoking campaign,
Secretary Harris promised to continue it.
in 1979,
A year later,
Dr. Richmond issued the Surgeon General's
Report on Smoking and Health, a 15-year follow-up to
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the famous 1964 Report. The smoking issue also re-
ceived considerable attention in the Surgeon General's
Report, entitled Healthy People, launching the Depart-
ment's health promotion, disease prevention initiative.
(DHEW, 1979)
But, let us ask, what is the goal of these Federal
initiatives? Listen to what an HEW Task Force on pre-
vention had to say about this in September 1978:
There are a number of significant gaps in
the Department's work on smoking: consi-
derable knowledge has been developed about
the health effects of smoking, but too little
about the behavioral factors associated with
smoking. . . . The Department has not spon-
sored a strong systematic campaign to pro-
vide information about the dangers of
smoking until January 11, 1978, when
Secretary Califano announced a major new
smoking reduction effort by HEW to increase
education, research and regulation. The
purpose of this renewed commitment is to
provide information to permit American
citizens to make a genuinely free choice
about smoking and their own health. (DHEW,
1978, p. 109-10) [Emphasis added.]
Is that really the goal--to promote a genuinely "free
choice"? Or is the nation's goal to promote the right
choice--not smoking--and to discourage and prevent the
wrong choice--smoking?
The Department of HHS will soon announce its long-
awaited specific Prevention Goals for the 1980's.
These Goals have been the product of a year-long pro-
cess involving 15 separate working groups producing
quantifiable objectives in 15 specific areas. One was
on smoking. Here the goal is clearly stated:
By 1990, the proportion of adult women who
smoke should be reduced to below 25 per-
cent. (In 1979, the share was 30 percent.)
By 1990, the proportion of adult men who
smoke should be reduced to below 25 percent.
(In 1979, the share was 38 percent.)
By 1990, the proportion of 12 to 18 year
old girls who smoke should be reduced to
below 6 percent. (In 1979, the share was
13 percent.)
By 1990, the proportion of 12 to 18 year old
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boys who smoke should be reduced to below
6 percent. (In 1979, the share was 11 per-
cent.) (DHHS 1980)
Once we acknowledge that reduced smoking is the goal,
we must confront the crucial question: How are we
going to go about achieving this goal, especially in
the face of data which suggest that cigarette smoking
is on the increase among teenagers and women? Specific
measures are recommended in the prevention goals docu-
ment, including stronger health warnings, bans on
smoking in places of public accommodation, and insur-
ance premiums which differentiate between people who
smoke and those who do not. But note that the industry
remains essentially untouched by these recommendations.
Nothing is said about the conditions of availability,
even though cigarettes are promiscuously available in
our society, especially to the young. One need not
walk very far in any part of this country in order to
find a vending machine, a convenience store or another
retail outlet for cigarettes. Meanwhile, the industry's
print advertising budgets continue to increase, and the
real price of cigarettes continues to fall, relative
to disposable income, in most parts of the country.
I simply do not believe that these smoking reduction
goals can be achieved while the conditions of avail-
ability are so carefully ignored. Again, without
endorsing any particular approach to regulatory policy,
I am convinced that serious consideration must be given
to possible regulatory initiatives as part of any major
prevention program.
To summarize, the Nation's tobacco policy is moving in
the right direction, but its focus should be clarified
and its pace increased. Let me make three specific
recommendations in this regard.
First, the objective of national tobacco policy should
be clearly and unequivocally stated. The goal is not,
as is sometimes said, to facilitate informed, or
genuinely free, personal choice. Instead, the goal is
to reduce cigarette consumption in the United States,
to reduce the number of people who smoke and how often
they smoke. The objective, simply put, is to discourage
consumption.
Secondly, Federal programming for prevention of ciga-
rette smoking should not be limited to the initiatives
of the Office of Smoking and Health. Nor should it be
subsumed within the generalized mandate of the re-
organized Center for Disease Control. Instead, HHS
should designate an identifiable "lead agency" for pre-
vention of tobacco-smoking, with a specific mandate.
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I do not have a concrete proposal to make, but one
possibility which seems to make conceptual sense--
whether it makes bureaucratic sense or not--would be
to give NIDA programmatic responsibility for preven-
tion of cigarette smoking and for implementing dis-
couragement policies with regard to use of tobacco as
well as the so-called illicit drugs.
Thirdly, the Federal Government should work with the
States to sponsor demonstration programs which aim to
reduce smoking by regulating the conditions of avail-
ability. Let me emphasize that I am not claiming that
the case can now be made, empirically, for various
types of regulatory initiatives. But I am arguing that,
despite all the fanfare about cigarette smoking pre-
vention, no systematic attention is now being given to
this area. Let me take the example of using taxing
policy as a means of reducing consumption by driving
the price up. Some available data suggest that a sig-
nificant price increase would reduce aggregate con-
sumption. The Federal Government should stand ready
to assist States who want to find out. Another possi-
bility is to reduce the accessibility of tobacco to
the consumer. Our drug abuse policies, and some State
ABC regulations, are predicated on the assumption that
aggregate consumption can be reduced and contained by
making access more costly and inconvenient. For drugs,
we drive the distribution system underground. For
alcohol, some States curtail the number of retail out-
lets. Meanwhile tobacco is available everywhere, even
to the young. We say it is illegal to distribute
tobacco to people under age, and yet vending machines
can be found in every building in the universe. A
vending machine ban in some locality which is committed
to the "new paternalism" would provide an opportunity
to study the impact of such a ban on consumption
patterns, especially among the underage.
Alcohol Policy
Recent concern about the fetal alcohol syndrome has
stimulated considerable interest in health warning
labels for alcoholic beverages. The leadership of
both the FDA and NIAAA are on record favoring such
warnings, although the Bureau of Alcohol,. Tobacco and
Firearms, which apparently has jurisdiction over the
matter, has been slow to act. In September of 1979,
Senator Thurmond of, South Carolina proposed to amend
the Comprehensive Alcohol Abuse and Alcohol Prevention
and Rehabilitation Act to require the following warn-
ing on any beverage container having more than 24 per-
cent alcohol: "Caution, Consumption of Alcoholic
Beverages may be Hazardous to your Health, May be Habit-
Forming and May Cause Serious Birth Defects when Con-
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sumed During Pregnancy." Senator Huddleston of
Kentucky argued that such a mandatory warning would be
somewhat precipitous in the absence of definitive data
concerning the effectiveness of such warnings when com-
pared with other devices such as public information
campaigns. Although Senator Huddleston's argument did
not carry the day in the Senate--which passed a warn-
ing provision--Senator Thurmond was persuaded to water
it down. As passed by the Senate the warning would
have stated: "Consumption of Alcoholic Beverages May
Be Hazardous To Your Health." Obviously, this is the
same warning required for cigarette packages and ad-
vertising since 1965; it says nothing about alcohol
dependence and nothing about the risk of fetal defects.
Although the House omitted any warning provision from
its bill, the House-Senate conferees agreed on the in-
evitable compromise--they directed the Secretaries of
HEW and Treasury to report to the Congress and the
President by June 1, 1980 concerning the health hazards
associated with alcohol use and the actions which
should be taken by the Federal Government to inform
the general public of such health hazards. (I under-
stand that the deadline has since been extended.)
During the Senate debate on the warning provision,
Senator Thurmond repeatedly insisted that the purpose
of the alcohol warning was not to regulate people's
lives but simply to provide the consumer with informa-
tion. Similarly, the Director of NIAAA testified that
he viewed the warning labels as one of the many forms
of public education, not as a regulation for control:
Such warnings may not have an immediate or
measurable impact on existing patterns of
consumption. This does not relieve us of
our obligation to inform the public of a
scientifically established health hazard.
I suppose that various portions of the public
may well be unaware of the risks that are
associated with alcohol use especially by
pregnant women and I suppose in this sense
package warnings may well be a useful supple-
ment to media information campaigns and edu-
cational programs.
But if this were the proponents' only purpose in seek-
ing such warnings, I think the industry might legiti-
mately claim--as its spokesman, Senator Huddleston,
did on the Senate floor--that package warnings are too
inspecific to provide the consumer with the necessary
information, and that there might be better ways of
accomplishing this objective. The simple fact is that
the industry resists the labeling requirement pre-
cisely because it fears that one consequence would be
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reduced consumption. It fears that the warning is
designed not to "promote informed choice" but rather
to push people in the direction of making the choice
that the government would prefer.
Again, the problem is that the Federal Government has
not yet come to terms with the need to formulate an
alcohol consumption policy. Since the repeal of Prohi-
bition, the goal of the nation's alcohol policy, if
there has been one at all, has surely not been to dis-
courage consumption. Indeed, the National Government
has carefully left the matter to State and local prero-
gatives. Meanwhile, the trend in Alcohol Beverage con-
trol has been to liberalize the conditions of access.
In fact, State ABC officials seem to assume that the
21st Amendment not only repealed the Volstead Act but
also established the illegitimacy of any governmental
effort to try to influence consumption.
The recent NIAAA Forward Plan for 1979-1983 minces no
words on the need for Federal leadership in planning
and implementing a Federal prevention effort and for
a concentrated attempt "to change social policy as it
defines alcohol use in the United States." To put it
succinctly, NIAAA, at least in 1978, did propose to
implement a national consumption policy. Even more
significant is the content of that policy. One of the
Institute's major goals over the next five years, it
said, would be to stabilize per capita consumption of
alcoholic beverages at the current level of 2.7 gallons
annually. And here the Forward Plan explicitly en-
dorses the so-called distribution hypothesis:
There is strong evidence that as consump-
tion rises, so do primary and secondary prob-
lems related to the use of alcohol. Since
the trend in this country during the last
decade has been toward ever increasing total
consumption, a major effort is required to
stabilize the increase which in view of the
population increase will in reality result
in a reduction of per capital consumption.
(NIAAA, 1978, p. 9)
Obviously, NIAAA's impending prevention initiative is
a significant departure from the national Government's
hands-off posture toward alcohol consumption which has
been in effect since the repeal of Prohibition. More-
over, it will be moving against the grain of public
opinion, will endanger vested economic interests and
will reverse current trends in ABC law reform. For
these reasons, the NIAAA Forward Plan listed among its
primary objectives the need "to work with the States to
consider the public health consequences of existing ABC
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laws." This year the NIAAA prevention plan charac-
terizes research in this area as a major priority.
(ADAMHA, 1980)
I applaud these efforts by NIAAA to overcome the momen-
tum of blind libertarianism. If we are ever to have a
fighting chance of reducing alcohol problems, we cannot
afford to ignore the norms of drinking behavior and the
relevance of the conditions under which alcohol is
available. By saying this, however, let me emphasize
that I am not endorsing any particular regulatory
approach; I am only emphasizing that some attention
to the regulatory system must be an essential ingredient
of a revived public health approach to alcohol problem
prevention.
DISCOURAGEMENT WITHOUT CRIMINALIZATION: ILLICIT DRUGS
I am less sanguine about recent trends in the area of
illicit drug use--where the nation has adopted a pro-
hibitory model toward availability. Considerable
progress was made in the mid-1970's in curbing the
oppressive excesses of the prohibition policy. Eleven
States decriminalized marijuana use between 1973 and
1978. A national treatment network was put in place,
and strongly supported, by the Federal Government, both
in principle and in terms of budgetary policy. Also
enforcement priorities were generally rearranged by
the Federal enforcement officials as well as by State
and local police--toward supply and away from prose-
cuting users. I generally thought we were in the
process of institutionalizing a policy of tolerant
discouragement, as the Commission had recommended--an
approach aiming to provide help where needed and to
avoid intervention otherwise.
I am not so sure any more. Unfortunately, the forces
of fear and authoritarianism have reemerged during the
last several years. The foot soldiers of a renewed
policy of oppression are the 400 parent groups which
have emerged all over the country. However well in-
tentioned they are, I am concerned that they are doing
the cause of enlightened drug abuse prevention a con-
siderable disservice.
Their central message is relatively simple, and I have
heard it many times: "If you are concerned about our
children and want to discourage them from using drugs,
you must be against decriminalization and in favor of
bans against head shops, and paraphernalia distribution.
Unless you support coercion, in short, you are in favor
of drug use."
But this is wrong and wrongheaded.
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I, too, am personally troubled by recent increases in
illicit drug use by our teenagers. I, too, am con-
cerned about our failure to develop effective and
meaningful approaches to discouraging teenagers from
using tobacco, alcohol and marijuana, as well as other
drugs. But I also know that criminal sanctions for
possession of marijuana make no measurable contribution
to our discouragement policy and cause a lot of harm
along the way. All the available data indicate clearly
that consumption patterns are substantially the same in
decriminalized and nondecriminalized jurisdictions.
Thus, the argument for retaining the criminal sanction
is essentially a symbolic one, and, as the Commission
noted as long ago as 1972, we pay an extraordinarily
high price for this ounce of symbolism.
I also know that the "head shop" bans--on advertising
and selling commodities whose "primary intended use"
is to facilitate the use of illicit drugs--are uncon-
stitutional, as virtually every court which has con-
fronted the question has concluded. As is the case
with the anti-decriminalization movement, the proponents
of these head shop bans really do not expect to suppress
consumption of illicit drugs through these ordinances.
Instead, I think the argument is primarily a symbolic
one.
The paraphernalia bans are really efforts at message
regulation. They serve the same purpose as proposed
bans on advertising by the liquor and tobacco industries.
That is to say, they are designed to purge the environ-
ment of those messages which are thought to encourage
the disapproved behavior--here the use of illicit drugs.
But I need not remind you that the cultural environ-
ment is replete with messages which can be seen or in-
terpreted as encouraging or "glorifying" the use of
illicit drugs. Styles of dress and music, and the atti-
tudes and behavior portrayed in contemporary movies and
literature reflect current social realities--and the
undeniable truth is that drug use is widespread in
Western culture. I am reminded in this connection of
the extraordinary scenes concerning use of opium during
the late 19th century in the movie called "McCabe and
Mrs. Miller."
I care nothing for the economic rights of the purveyors
of paraphernalia, any more than I care for the economic
rights of those who make and distribute X-rated movies
or pornographic magazines, but I do care for their
freedom of expression.
The point is this: a policy of "discouragement with-
out criminalization" is responsive to the behavioral
realities of drug use: the factors which influence deci-
sions to use or continue to use these drugs--or which
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affect the intensity or frequency with which they are
used--are too varied, and too subtle to be effectively
offset or neutralized by the blunt hand of authority,
especially the coercive hand of the criminal law.
However much we are committed to the public health
ideology of drug abuse control, we should remember that
health and conformity to majoritarian norms are not
universally regarded as the supreme values in our
society. I have rejected the blind libertarianism
which, in my opinion, obstructs rational regulation of
alcohol and tobacco. But I must now also reaffirm my
distaste for the blind paternalism which cares not for
liberty at all.
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Progress Reports
Annual Report: Biological
Evaluation of Compounds for
Their Dependence Liability. IV.
Drug Testing Program of the
Committee on Problems of Drug
Dependence, Inc. (1980)
A. E. Jacobson
INITIAL PROCEDURE
The procedures used to evaluate compounds for their dependence
liability, under the auspices of the Committee on Problems of Drug
Dependence, Inc., have changed, and are becoming formalized at the
Medical College of Virginia (MCV) and the University of Michigan
(UM). The roles played in the testing program by the National
Institute of Drug Abuse (NIDA), and the National Institutes of
Health (NIH) will be mentioned.
Compounds submitted to me are accepted for evaluation in our
initial screens if they are accompanied by data relating to the
identity and purity of the compound, and if the submitter is fully
aware of our policy on the release of obtained data (within 3
years of submission). To remain in compliance with the Good
Laboratory Practice Regulations of the FDA, we request thin layer
chromatographic (tlc) and infrared (ir) spectroscopic data. The
tlc is repeated at, for example, MCV before that group initiates
its work; the ir spectrum may be repeated at NIH. The compound is
initially examined at NIH for antinociceptive activity in the hot
plate and, occasionally, the Nilsen assay. The obtained data are
included in the reports submitted by MCV and UM. The hot plate
assay data are utilized to obtain a starting dose for the single
dose suppression (SDS) test at MCV or UM. Perhaps 10 percent of
the submitted compounds are evaluated at both MCV and UM in SDS,
for various reasons.
BIOLOGICAL EVALUATION -
The submitted sample is distributed to both groups for
testing. If MCV runs the SDS assay, UM will obtain biochemical
data (binding affinity to opiate receptors in rat brain
homogenates, electrically stimulated guinea pig ileum and vas
deferens assays). If UM runs the initial SDS test, MCV will run
rodent antinociceptive tests (tail flick (TF) and phenylquinone
writhing (PPQ)) and the tail flick antagonist assay (TFA). I
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combine, and compare, these reports and send a copy to the
submitter of the compound. Biochemical data, of course,
supplement tests on compounds sent to UM for SDS, and compounds
sent to MCV for SDS will have the TF, PPQ and TFA assays run on
them. Occasionally. UM and MCV will continue with a precipitated
withdrawal test in the rhesus monkey on compounds which obviously
warrant it.
FURTHER TESTING
At this stage, for the last few years, recommendations would be
made by an MCV/NIDA/NIH group as to whether the compound should
receive further testing at MCV. In the future. recommendations
for, or against, further work will also be made at the joint
conference of MCV/UM/NIDA/NIH. Individually initiated research
will continue as it has before and will be reviewed at the joint
conference. Further work could, theoretically, consist of a
primary addiction study in the monkey, rat infusion data.
self-administration tests, or drug-discrimination procedures in
monkey and/or pigeon. The data obtained by these procedures can
be observed in the Annual Report to the Committee from MCV and UM.
There is, both at MCV and UM, simultaneous with the attempt to
obtain sufficient biological and biochemical data to ascertain
whether we have an analgesic with or without dependence liability
and characteristics which might tend to lead to abuse by man, an
attempt to learn about some of the other fundamental actions of
the drug. The results from this work on selected compounds are the
subject of reports by both groups to the Committee at its
scientific session. I might note that the drug discrimination
procedure of UM is rather new and we hope to utilize it in the
future as an additional method for determining the likelihood of
abuse, by classification with subsets of compounds with documented
abuse potential in man. Dr. J. Woods has reported on the
procedure at Committee meetings.
SUPPORT
The Committee, to some extent, financially supports the work of UM
and MCV and also supports the-joint meetings which are held.
However, the bulk of the funds for these programs come from a NIDA
grant and contract. The World Health Organization (WHO) also
contributes to the drug testing program, through the Committee.
Although it is a rather circuitous method, the Federal Government
has supported, and continues to support, the work of the Committee
to a much greater extent than pharmaceutical industry. Over
two-thirds of the funds necessary for the work of the Committee
come from NIDA and NIH. The money, of course, does not come
directly to the Committee but to its testing units. Reports go to
the Committee, the Government, and to the submitter of the drug.
NUMBER OF TESTS PERFORMED AT MCV/UM
We are, once again, very much indebted to the researchers in the
Department of Pharmacology of the Medical College of Virginia and
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the University of Michigan for the work which I shall be
discussing. Among these are Drs. L. S. Harris, M. D. Aceto,
W. L. Dewey and E. L. May from MCV, and Drs. H. H. Swain, J. H.
Woods, A. Young, C. B. Smith and F. Medzihradsky from UM. The
program at UM suffered from the untimely death of Mr. C. L. Fly.
who ran part of the dependence testing program. An additional
researcher, Dr. John Katz, will soon join their program.
This report concerns compounds which I received between May 1,
1979, and April 30, 1980, a rather arbitrary period for what I
will denote as the "evaluation year." Of the ca. 118 compounds
which I received at NIH for various tests, 25 new compounds were
submitted to MCV and 23 new compounds to UM for evaluation in the
single dose suppression test in the rhesus monkey. About 15 older
compounds were evaluated in other tests (precipitated withdrawal,
rat infusion, primary addiction, self-administration, etc.) at MCV
and 8 older compounds were further evaluated at UM. Biochemical
studies (binding affinity to rat brain homogenates, electrically
stimulated guinea pig ileum and vas deferens preparations) on
another set of 12 or so compounds submitted for these studies
alone, were carried out at UM. Several compounds were sent to MCV
for rodent antinociceptive tests., and the TFA assay, which did not
receive further evaluation. Thus, about 80 compounds, altogether,
were examined during this "evaluation year. " If one counts the
number of "tests" run, where SDS. NW, PAS, self-administration,
rat infusion, biochemical tests and antinociceptive tests are
counted individually, about 90 such tests were carried out at MCV
and ca. 70 tests at UM. One compound can, obviously, have
multiple tests run on it and, thus, the number of reports
submitted by MCV and UM are less than the number of tests.
However, to compare the results of our testing units from year to
year, we can look at the number of tests completed at each
unit/year. Last year, UM completed ca. 73 tests, and MCV ca. 66.
The observed annual fluctuation is directly related to the
release, or non-release, of data from older compounds. This year,
for example, we have an additional ca. 20 reports completed, but
have not obtained consent from their submitter for release. Most
of these will, hopefully, be included in next year’s reports. My
previous estimate of the number of new compounds which would be
received appears reasonable, and there is a regular flow of
compounds.
ORIGIN OF SAMPLES -
We have seen an increased interest in analgesics by several
companies. Of the ca. 50 compounds which were new to the program
this year, about 62 percent came from pharmaceutical industry (28
percent foreign, and 34 percent domestic), 36 percent came from
U.S. universities, and 2 percent (one compound) came, more-or-less
directly, from the WHO. This is the inverse of last year's
figures of 40 percent from industry and 60 percent from
universities, perhaps reflecting the increased difficulty
university researchers are having at obtaining grants to
synthesize analgesics, and a resurgence of interest in analgesics
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by pharmaceutical companies. Although I have a feeling that these
conclusions are valid, there is sufficient annual variation to
allow the conclusion that submissions are evenly divided between
University and Industry, the observed deviation from 50 percent
being fortuitous.
STRUCTURE-ACTIVITY RELATIONSHIPS OF COMPOUNDS IN THE MCV/UM
REPORTS
The compounds in the MCV/UM reports can be classified as
"morphine-like" (table 1), "methadone-like" (table 2),
"morphinan-like" (table 3), "benzomorphan-like" (table 4),
"pethidine-like" (table 5), and miscellaneous structures (tables
6-9). These 9 tables contain ca. 50 compounds. I eliminated
compounds which presently appear to be of less interest, and those
which have been adequately discussed heretofore. The tables
contain excerpted data from the UM/MCV reports and thus could be
called a "readers digest" of the CPDD. The complete data on each
of the compounds can be found in the reports submitted by MCV and
UM.
290




DISCUSSION
In table 1 a quaternary ammonium compound is listed (NIH 9629)
which appears to have in vivo activity. We find this somewhat
surprising since SC injected quaternary analgesic salts are not
supposed to be able to traverse the blood brain barrier. A number
of C-14 substituted compounds are listed with substituents other
than the hydroxyl group, in table 1. No doubt, attempts will be
made, in the future, to produce antagonists from some of them.
Propoxyphene (table 2) was tested and found to have high physical
dependence capacity (PDC). This is the dextro enantiomer. A
methadone-like compound (NIH 9004) was found to have antagonist
activity in the TFA assay. The SDS did not show it to be a
particularly potent antagonist, if it is one in monkeys.
Considerable tinkering has been done to the morphinan skeleton
(table 3). Ring C was substituted with various substituents. NIH
9538 is particularly interesting in that it showed high PDC in the
SDS test, but did not maintain codeine-like rates of
self-administration. These tests might indicate that the compound
would produce physical dependence, but not be abused by man. A
comparable mono-oxygenated morphinan (NIH 9539) was reported last
year. It was a potent agonist-antagonist and was not
self-administered by monkeys. Peculiarly, NIH 9538 did not show
antagonist activity in monkeys. It is one of the few, or the
only, known N-cyclopropylmethyl substituted morphinan which does
not have antagonist properties in the monkey.
Benzomorphans with an extended C-9 beta side-chain continue to be
most interesting (table 4). Some are potent N-methyl
agonist-antagonists. One pair of enantiomers (NIH 9751 and 9752)
could conceivably serve as replacements for (+)- and (-)-naloxone,
until NIDA completes its program of producing sufficient
quantities of these enantiomers, based on the total synthesis of
the opium alkaloids by Dr. Kenner C. Rice (NIH) which is scheduled
to appear in the July issue of the Journal of Organic Chemistry.
Unfortunately, these enantiomeric benzomorphans are not completely
inert as agonists, although they do not show a dose-response
relationship in the hot plate assay. The C-homobenzomorphans (NIH
9612 - 9614. in table 4) have been of interest and further work is
continuing on one of them. Their hot plate ED50's have been
confirmed and, evidently, the depressant action of the molecules
caused the observed deviation from the expected relationship
between racemate and enantiomers. The first 9 pethidine-like
compounds noted in table 5 were part of a series in which it could
be noted that as the agonist activity increased, so did PDC.
However one compound (NIH 9729) appeared to be an exception to the
generalization and it is being further evaluated. Experiments
with clonidine (NIH 9571), a clonidine-like compound (NIH 9460)
and PCP (NIH 9580) are summarized in table 6. Work on clonidine
and PCP continued this year due to their interesting properties.
The peptide shown in table 7 is the first we have reported. It,
like others reported in the literature, was a potent agonist with
high PDC. We have not, as yet, seen a peptide with other than
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high PDC. The pyrindinyl compounds in table 8 appear to be
somewhat more interesting than the corresponding
decahydroisoquinolines, as a series. The azabicyclo[3.3.1]nonanes
in table 9 are. also, part of a series. Some of these may be
quite interesting in the future. Further evaluation of some of
the members of this series is contemplated if sufficient material
can be obtained. The sufentanil, shown in table 9, was sent to
the Committee at the instigation of WHO. It had high PDC, and is
a very potent agonist. Work on the enantiomeric nicotines is
continuing and will be the subject of a paper from MCV.
Once again we have seen compounds which resulted from modification
of well-known structures and those which represent wide variations
from known analgesics. Although it might have been assumed that
we could guess, more or less correctly. at the dependence
liability of variants of known structures, based on past
structure-activity studies, in fact we would tend to be inaccurate
a good bit of the time--sufficiently so as to warrant our
continued examination of compounds whose structures, a priori.
would not appear to be of much interest from a clinical viewpoint.
Thus, we note that medicinal chemists from universities and in
industry are continuing their attempts to obtain useful
analgesics. Some of the compounds which we have discussed may
have good clinical potential, or are of theoretical interest, and
are worthy of further study.
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Annual Report: Dependence
Studies of New Compounds in
the Rhesus Monkey (1980)
M. D. Aceto, L. S. Harris, W. L. Dewey, and E. L. May
All the test drugs were supplied by Dr. Arthur Jacobson, Medici-
nal Chemistry Section, NIAMDD, under the auspices of the Commit-
tee on Problems of Drug Dependence, Inc. Morphine was supplied
by Dr. Robert Willette, National Institute on Drug Abuse. The
chemical structures of the test compounds excluding yohimbine
were unknown to us when they were submitted.
Three mouse tests were used in our laboratory at the Medical
College of Virginia to provide a preliminary estimate of the
potency and profile of activity of each test compound. The
tests were the tail-flick agonist (TF) and the morphine antagonist
tests (TF vs M) and the phenylquinone test (PPQ) (Dewey et al.
1970; Dewey and Harris, 1971). Reference-standard data for
these tests are shown in table 1. In addition, Dr. Jacobson
supplemented these data and estimated starting doses which were
based on results obtained from the mouse hot plate (HP) (Eddy
and Leimbach, 1953; Jacobson and May, 1965; Atwell and Jacobson,
1978) and Nilsen (N) (Perrine et al. 1972) tests from his
laboratory. Reference data for these tests are shown in table 2.
This study was supported by a contract (#271-77-3404) from the
National Institute on Drug Abuse, Dr. Heinz Sorer, Contract
Officer. Technical assistance was provided by F. Tom Grove,
R.F. Jones, and S.M. Tucker, Medical College of Virginia, Depart-
ment of Pharmacology.
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A rat continuous-infusion method was reported by Teiger (1974)
and modified by Dewey and Patrick. Using this method, we can
determine whether or not a drug will substitute for morphine
in morphine-dependent rats or whether or not the drug per se
will produce physical dependence.
Table 1
Comparative Data-ED50 Mg/Kg/Sc (95% C.L.) of Selected
Standards in 3 Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail Flick An- Phenylquinone
Test tagonism Test Test
Pentazocine 15% at 10.0 18(12.4-26) 1.65(1.0-2.5)
Cyclazocine 17% at 1.0a 0.03(0.12-.78) 0.011(0.0046-03)
Nalorphine None at 10.0 2.6(0.69-9.75) 0.6(0.25-1.44)
.HCL
Naloxone None at 10.0 0.031(.010-0.93) No Activity
.HCL
Naltrexone None at 10.0 0.007(0.002- No Activity
.HCL 0.02)
Morphine 5.8(5.7-5.9) 0.23(0.20-0.25)
Sulfate
aMice were ataxic at 3.0 and 10.0 mg/kg but no further increase
in reaction time was seen.
For the most part, the procedures described by Seevers and his
colleagues (1936, 1963) and Deneau (1956) regarding the facili-
ties and training of the monkeys were used and a brief descrip-
tion follows. The monkeys were injected with 3 mg/kg/sc of
morphine sulfate every 6 hours for at least 90 days before being
used. This dose schedule was reported by Seevers and Deneau
(1963) to produce maximal physical dependence. Modified proce-
dures for the precipitated withdrawal test (PPt-Withdrawal) and
single dose suppression test (SDS) were reported by Aceto and co-
workers (1974, 1977 and 1978). The PPt-Withdrawal test was ini-
tiated by the injection of a test drug 2 1/2 hours after an in-
jection of morphine and the animals were observed for signs of
withdrawal. The SDS test was started approximately 15 hours after
the last dose of morphine at which time the animals were show-
ing withdrawal signs. The test compound was injected and the
animals were observed for the suppression of abstinence signs.
The onset and duration of action of the test drug were noted. In
both tests, a vehicle control and an appropriate positive con-
trol (naloxone 0.05 mg/kg or morphine sulfate 3.0 mg/kg) along
with 3 different treatments (doses) of a test compound were
randomly allocated to the 5 monkeys of a group. Occasionally 4
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monkeys comprised a group and 2 doses of test compound were stud-
ied. Usually, 3 or 4 groups per compound were used. All drugs
were given subcutaneously in a volume of 1 ml/kg and the vehicle
used is indicated for each compound. The observer was "blind"
with regard to the treatment given. A minimum 2 week washout
and recuperation period between tests was allowed. In the pri-
mary physical dependence test. the animals of a group received
the drug every 6 hours for 30-50 days. They were placed in
abrupt withdrawal and challenged with naloxone periodically, and
were observed for signs of physical dependence.
Table 2
Comparative Data (ED50 Mg/Kg) (95% S.E.) from the Hot Plate
and Nilsen Test
Compound
Morphine Sulfate
Codeine Phosphate
Levorphanol Tartrate
Meperidine .HCL
(-)-Metazocine.HBr
Dihydromorphinone
.HCL
Nalorphine .HCL
Cyclazocine
Pentazocine
Chlorpromazine .HCL
Hot Plate Test
Subcutaneous
Oral
0.98(0.83-1.1)
6.3(4.7-8.3)
6.8(4.5-10.2)
13.5(9.7-18.7)
0.2(0.1-0.3)
5.3(4.0-7.1)
0.6(0.5-0.9)
10.6(8.0-14.1)
0.19(0.15-0.25)
0.9(0.7-1.2)
9.9(5.7-17.1)
1.5(1.1-2.1)
9.3(6.7-12.8)
1.1(0.9-1.5)
Nilsen Test
Subcutaneous
Oral
1.3(1.0-1.7)
8.3(6.0-11.4)
7.4(4.9-11.0)
14.7(9.2-23.3)
0.2(0.16-0.3)
2.5(1.7-3.7)
0.5(0.3-0.7)
26.0(21.0-33.0)
0.2(0.15-0.3)
1.8(1.5-2.1)
23.0(16.2-32.7)
0.1(0.07-0.16)
6.5(4.4-8.8)
Naloxone .HCL and Naltrexone HCL No Dose Response
Phenobarbital, Amobarbital, Valium, Oxazepam, Flurazepam,
Meprobamate and Mescaline are inactive on the hot plate test.
The Self-administration studies on rhesus monkeys are presented in
a separate report in this monograph (Woolverton, et al,).
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MCV 4030-NIH 9004. alpha-6-Dimethylamino-4,4-diphenyl-3-(2,2-di-
chloroacetoxy)heptane hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-5% at 1.0, 7% at 3.0 and
3% at 10.0
2) TF vs M-4.6 (1.64-12.88)
3) PPQ-2% at 10.0
4) HP-Inactive to 100.0
MONKEY DATA #ANIMALS 2 , 4 , 4 , 4 , Vehicle-
(SDS) Doses (mg/kg/sc) 6.0 2.0 1.0 0.5 H2O
This compound did not substitute for morphine in the dose range
tested.
MCV 4041-NIH 9048-UM 1144. alpha-4,4-Diphenyl-6-dimethyl-amino-
3-heptanol phenylacetate
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-7% at 1.0, 19% at 3.0
and 17% at 10.0
2) TF vs M-0% at 1.0, 4% at 3.0
and 8% at 10.0
3) PPQ-1.76 (0.98-3.13)
4) HP-4.5 (3.2-6.4)
MONKEY DATA #ANIMALS 2 , 2 , 2 , Vehicle-H2O +
(SDS) Doses (mg/kg/sc) 16.0 8.0 . 4.0 lactic acid
This compound did not substitute for morphine in the dose range
tested.
MCV 4103-NIH 9343A-UM 1125A. m-(1,3-Dimethyl-4-propyl-4-piperi-
dyl)phenol hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at doses up to
30.0
2) TF vs M-11.2 (4.9-26.3)
3) PPQ-0.9 (0.1-5.9)
4) HP-5.3 (3.2-8.5)
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MONKEY DATA #ANIMALS 4 , 4 , 4 ,
(SDS) Doses (mg/kg/sc) 5.0 2.5 1.25
Vehicle-H2O
MCV 4103 did not substitute for morphine in the dose range
tested. The drug may have exacerbated withdrawal.
MCV 4126-NIH 9460. 1-(Cyclohex-3-enoic)-2-(2,6-dichlorophenyl
amino)-2-imidazoline
(95% C.L.)-
(mg/kg/sc)
MOUSE DATA-ED 5 0
1) TF-22.2 (5.6-87.7)
2) TF vs M-Inactive at 3.0,
10.0 and 30.0
3) PPQ-0.04 (0.02-0.10)
4) HP-13.0 (10.0-16.9)
MONKEY DATA #ANIMALS 4 , 4 , 4 , Vehicle-dil.
A. (SDS) Doses (mg/kg/sc) 16.0 8.0 4.0 HCL + H2O
In the dose range tested, MCV 4126 did not substitute for
morphine, In three of four monkeys receiving the highest
and lowest dose and in two of four monkeys receiving the
intermediate dose, ataxia was noted. Some monkeys re-
ceiving drug were noted to be depressed and moving very
slowly a day later.
B. (PPD)
Five non-dependent monkeys were given MCV 4126 suspended in
½% carboxymethylcellulose aqueous solution every 6 hours and
observed for signs as designated below:
Day
Dose
mg/kg/sc Comments
1-7 2.0-4.0
8-15 6.0-14.0
16 Abrupt Withdrawal and
PPt-withdrawal
12-24 18.0-38.0
25-29 42.0-56.0
30 Abrupt and PPt-withdrawal
The most common sign
noted after drug was
drowsiness. Fighting
and restlessness were
noted infrequently. Dur-
ing the first abrupt with-
drawal session (day 16),
drowsiness, restlessness,
and wet dogs were noted
13-15 hours after the
drug was discontinued.
A naloxone challenge (0.5 mg/kg/sc) was given and a few addi-
tional signs were seen. During the 30-day, abrupt-withdrawal
session drowsiness and wet dogs were seen and one monkey
301
vocalized when its abdomen was palpated. These animals were
challenged with 5.0 mg/kg/sc of naloxone (n=4) and saline (n=1)
the next day and only the signs designated as fighting, avoids
contact, and wet dogs were seen.
Conclusion: Administered as a suspension, the morphine-like
physical dependence liability of MCV 4126 appears to be very
low.
MCV 4132-NIH 9469. trans-N-(2-Dimethylaminocyclohexyl)-4-bromo-
benzamide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-14.7 (5.8-32.3)
2) TF vs M-15% at 3.0; 22% at
10.0 and 17% at 30.0
3) PPQ-3.3 (1.0-7.0)
4) HP-7.7 (5.7-10.4)
MONKEY DATA #ANIMALS 2 , 3 , 2 , 1 ,
(PPt-Withdrawal) Doses (mg/kg/sc) 6.0 48.0 24.0 12.0
(Vehicle-1/2% carboxymethylcellulose, aqueous suspension). In
the dose range tested, MCV 4132 did not precipitate withdrawal
signs. Drowsiness was the principal sign observed.
MCV 4147-NIH 9542. 1-(4-Methylphenyl)-3-azabicyclo(3.1.0)hexane
hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-30.9 (13.2-72.2)
2) TF vs M-Inactive at
and 80.0
3) PPQ-4.8 (1.6-13.8)
4) HP-Non-determinable
10.0, 30.0
MONKEY DATA #ANIMALS 4 , 4 , 4 ,
A. (SDS) Doses (mg/kg/sc) 24.0 12.0 6.0
Vehicle-H2O
The drug substituted partially and very briefly for morphine
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soon after it was injected. At the highest dose, the signs
designated as lying on side or abdomen, restless, wet dog shakes
and vomiting, vocalizes when abdomen palpated and rigid abdomen
were suppressed. However, tremors and myoclonic spasms were
much more prevalent, especially at the 2 higher doses. In addi-
tion, salivation was seen in 2 animals at the highest dose.
Partial substitution does not necessarily imply that the drug
has morphine-like dependence liability.
B. (PPD)
Five drug--naive monkeys were given MCV 4147 dissolved in
water every 6 hours as indicated below:
Day Doses mg/kg/sc Comments
1-7 2.0-17.0 The effects noted with this
drug included: Lying on
8-14 19.0-31.0 side or abdomen, wet dogs,
scratching, myoclonic jerks,
15-17 33.0-35.0 yawning, drowsiness, fight-
ing, salivation and vomit-
18 Abrupt & PPt-Withdrawal ing. During Day 18 abrupt
withdrawal, we saw rest-
19-25 35.0-30.0 lessness in all animals,
and myoclonic jerks be-
26-32 36.0-36.0 tween 14-17 hours after
drug was withdrawn. No
33-39 36.0-43.0 remarkable effects were
seen after naloxone. On
40 Abrupt & PPt-Withdrawal Day 23, one monkey was
found dead.
During withdrawal on day 40 at 12-18 hours after the last in-
jection, we noted fighting 2/4; restlessness 4/4; tremors 1/4;
wet dogs 1/4; retching 1/4; scratching 2/4. No remarkable
signs were seen during precipitated withdrawal with 2.0 mg/kg
naloxone.
Conclusion: MCV 4147 does not produce morphine-like physical
dependence. Relatively little tolerance was seen to develop
to this drug. All the animals bled from the site of in-
jection just after each injection beginning on day 8 to the
end of the study. One animal died during the study. Body
weights remained about the same throughout the experiment.
MCV 4148-NIH 9543. 1-(4-Chlorophenyl)-3-azabicyclo(3.1.0)hexane
hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 10.0 and
100.0
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339-844 0 - 81 - 21
MCV 4148-NIH 9543 (continued)
2) TF vs M-Inactive at 10.0
and 100.0
3) PPQ-16.4 (8.1-33.1)
4) HP-No dose response
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
Doses (mg/kg/sc) 24.0 12.0 6.0
Vehicle-H20
(SDS)
This compound did not substitute for morphine at any of the doses
tested. Myoclonic jerks were noted in 2 of the animals receiving
the intermediate dose.
MCV 4150-NIH 9544. 3-Methyl-1-(4-methylphenyl)-3-azabicyclo(3.1.0)
hexane hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 10.0 and 30.0
2) TF vs M-Inactive at 10.0
and 30.0
3) PPQ-4.3 (1.3-14.5)
4) HP-19.1 (13.5-27.0)
MONKEY DATA #ANIMALS 3 , 3 , 3 , Vehicle-H20
(SDS) Doses (mg/kg/sc) 24.0 12.0 6.0
MCV 4150 did not substitute for morphine. The drug appeared to
exacerbate withdrawal. Salivation was noted at 2 higher doses.
MCV 4156-NIH 9575. cis-(+)-3-(Octahydro-2-methyl-1H-2-pyrindin
4a-yl)phenol, (Z)-2-butenedioic acid salt
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-2.2 (0.7-7.2)
2) TF vs M-Inactive at 1.0,
3.0 and 10.0
3) PPQ-0.13 (0-05-0.4)
4) HP-0.46 (0.33-0.64)
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MONKEY DATA #ANIMALS 3 , 3 , 3 ,
A. (SDS) Doses (mg/kg/sc) 2.0 1.0 0.5
Vehicle-H20
The drug substituted partially for morphine. Partial substitu-
tion does not necessarily imply that the compound has morphine-
like properties. Initially, some restlessness (pacing) was seen
which was soon followed by drowsiness. A challenge dose of nalox-
one (0.1 mg/kg/sc) was given to the monkeys of another group re-
ceiving this drug or morphine and the animals promptly went into
withdrawal.
MONKEY DATA 2 , 3 , 3 , 1 ,
B. (PPt-Withdrawal) 8.0 4.0 2.0 1.0
Vehicle-H20
MCV 4156 elicited the symptoms designated: drowsiness, restless-
ness, wet dogs salivation and jaw sag. However, the animals did
not vocalize when their abdomens were palpated nor was retching
or vomiting observed after MCV 4156. The drug does not preci-
patate a typical withdrawal reaction in the dose range tested.
MCV 4157-NIH 9576-UM 1242. cis-(-)-3-(Octahydro-2-methyl-1H-2-
pyrindin-4a-yl)phenol, (Z)-2-butenedioic acid salt
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-10.4 (3.3-33.2)
2) TF vs M-60.5 (12.8-286.8)
3) PPQ-0.6 (0.3-1.9)
4) HP-2.4 (1.6-3.7)
MONKEY DATA #ANIMALS 3 , 3 , 2 ,
A. (SDS) Doses (mg/kg/sc) 32.0 16.0 8.0
Vehicle-H20
This drug substituted partially for morphine. Drowsiness was
noted at all doses tested. Partial substitution does not neces-
sarily imply that the compound has morphine-like properties.
MONKEY DATA 1 , 3 , 3 , 2 ,
B. (PPt-Withdrawal) 48.0 32.0 16.0
Vehicle-H20
8.0
At the highest dose, tremors, wet dogs, retching and convulsions
were observed within the first 30 minutes after drug. The animal
was given pentobarbital to terminate the convulsions. At the
32.0-mg dose, drowsiness, avoids contact, restlessness, tremors,
wet dogs, retching, vomiting and salivation were seen. However,
the animals did not vocalize when their abdomens were palpated.
Drowsiness was the principal sign noted at the two lower doses.
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The drug appears to elicit many withdrawal signs. It is consider-
ed to have weak antagonist properties.
MCV 4158-NIH 9580. 1-(1-Phenylcyclohexyl)piperidine hydrochloride
(Phencyclidine)
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1)
2)
3).
4)
TF-Inactive at 1.0,
3.0 and 10.0
TF vs M-0.3 (0.1-1.0)
PPQ-1.4 (0.5-4.1)
HP-Not Tested
MONKEY DATA
Primary Physical Dependence
Five drug-naive animals were given MCV 4158 every 6 hours or as
indicated below subcutaneously. The drug was dissolved in H2O.
The animals were observed for drug-behavioral effects approxl-
mately 1/2 hour after administration for 15 minutes. During
abrupt or precipitated withdrawal, the animals were observed as
indicated below:
Day
1-3
4-5
6
7
8-9
10-13
Dose mg/kg/sc
4 x day
0.1
0.2
0.3
0.4
0.5
0.4
14-15 0.5
16-17 0.55
18-19 0.6
20-21 0.65
22-23 0.7 6 x d a y
24 0.45 6 x day
25-26 0.7 6 x day
27-28 0.45 6 x day
29-30 0.5 6 x day
Day 31 Abrupt withdrawal
Hours in Withdrawal
12¼
Comments
Frequently noted signs were
slowing, ataxia, restlessness,
body sag, and staring. Some
were quite severe. Tolerance
developed to drowsiness.
Less frequently seen signs
were: lying on side, fight-
ing, avoids contact, lip-
licking, and jaw sag.
Comments
1/5 fighting, tremor, wet dogs,
2/5 avoids contact
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Hours in Withdrawal
13¼
14¼
15
18
24
Day Dose
32-34 0.7
35-36 0.6
37 Precipitated withdrawal
38-40 0.6
41-50 0.7
51 Abrupt withdrawal
Hours in Withdrawal
14
19
24
36
48
72
102-120
Comments
1/5 restless, 1/5 tremors, 2/5
fighting, 2/5 avoids contact
1/5 lying on side, tremors,
retching, restless, yawning;
215 fighting
1/5 lying on side, fighting,
crawling, tremors, yawning and
avoids contact; 2/5 restless,
wet dogs 3/5 myoclonic jerks;
5/5 Drowsy
1/5 fighting, avoids contact;
2/5 myoclonic jerks; 5/5 rest-
less
1/5 avoids contact
Little difference between the
naloxone (0.5 mg/kg/sc) and
saline-challenged animals.
Comments
1/5 avoids contact, vocalizes,
slowing, yawning, vocalizes
when abdomen palpated; 2/5
fighting; 4/5 tremors; 5/5
restless
1/5 avoids contact, slowing,
yawning, 2/5 fighting, tremors,
vocalizes when abdomen palpated;
5/5 restless
1/5 avoids contact; 2/5 slowing,
fighting, vocalizes when ab-
domen palpated; 5/5 restless
1/5 fighting, avoids contact,
restless; 2/5 wet dogs
No Signs
1/5 fighting, avoids contact
No Signs
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Conclusions: With the exception of drowsiness, MCV 4158 produces
many side effects to which little tolerance develops. The drug
has a rapid onset of action (15 to 30 minutes) and a short dura-
tion of action (1 to 2 hours).
The severity of withdrawal signs appears to increase when the
drug is given more frequently and there is some resemblence of
these signs to those seen when morphine is withdrawn in morphine-
dependent monkeys. Naloxone did not precipitate withdrawal.
When the body weights taken at the beginning of the experiment
are compared to those noted at the end, 2 animals lost weight
(0.4 to 0.5 Kg), 2 gained weight (0.3 Kg) and one showed no
difference.
This drug has a definite physical dependence liability and more
studies are recommended.
MCV 4159-NIH 9577. cis-(+)-3-(Decahydro-2-methyl-4a-isoquino-
linyl)phenol, (Z)-2-butenedioic acid salt
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-13.0 (4.3-39.3)
2) TF vs M-18.0 (7.9-40.5)
3) PPQ-0.23 (0.06-0.86)
4) HP-0.88 (0.66-1.2)
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
A. (SDS) Doses (mg/kg/sc) 4.0 2.0 1.0
Vehicle-H20
In the dose range tested, MCV 4159 substituted partially and
briefly for morphine. Partial substitution does not necessarily
imply that the compound has morphine-like properties.
MONKEY DATA #ANIMALS 1 , 2 , 3 , 2 ,
B. (PPt-With- Doses (mg/kg/sc) 32.0 16.0 8.0 4.0
drawal) 1 ,
2.0 Vehicle-H20
In the dose range studied, the drug did not precipitate with-
drawal. Drowsiness was the only sign seen consistently.
MCV 4160-NIH 9578. cis-(-)-3-(Decahydro-2-methyl-4a-isoquinolin-
yl)phenol, (Z)-2-butenedioic acid salt
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MCV 4160-NIH 9578 (continued)
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-62.6 (15.0-260.5)
2) TF vs M-40.0 (16.1-99.4)
3) PPQ-0.6 (0.2-2.1)
4) HP-2.9 (1.9-4.3)
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 32.0 16.0 8.0
Vehicle-H20
MCV 4160 substituted completely for morphine. At the highest
dose, 3/3 showed tremors, 2/3 were restless and 1/3 salivated.
MCV 4161-NIH 9596. (-)-trans-5,6,6a-beta,7,8,9,10,10a-alpha-
Octahydro-1-acetoxy-9-beta-hydroxy-6-beta-methyl-3-(5-phenyl-2-
pentyloxy)-phenanthridine hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1.7 (0.6-5.0)
2) TF vs M-Inactive at 3.0,
10.0, and 30.0
3) PPQ-0.1 (0.04-0.3)
4) HP-0.15 (0.13-0.19)
MONKEY DATA #ANIMALS 3 , 3 , 3 , Vehicle-
(SDS) Doses (mg/kg/sc) 0.5 0.25 0.125 Propylene
Glycol + H20
This compound substituted partially for morphine at all doses
tested. The signs drowsiness, eyelids ptosis were noted in
most of the animals and slowing was seen in one monkey at each
dose.
Partial substitution does not necessarily imply that the com-
pound has morphine-like properties.
MCV 4162-NIH 9597. (-)-trans-5,6,6a-beta,7,8,9,10,10a-alpha-
Octahydro-1-acetoxy-9-beta-hydroxy-5,6-beta-dimethyl-3-(5-phenyl-
2-pentyloxy-phenanthridine hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.1 (0.04-0.3)
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MCV 4162-NIH 9597. (continued)
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
2) TF vs M-Inactive at 0.03,
0.1, 0.3, and 30.0
3) PPQ-0.06 (0.02-0.2)
4) HP-0.016 (0.011-0.023)
MONKEY DATA #ANIMALS 1 , 3 , 3 ,1 ,
(SDS) Doses (mg/kg/sc) 0.16 0.08 0.04 0.02
3 , 1 , Vehicle-Propylene
0.01 0.005 Glycol + H2O
At the two higher doses, MCV 4162 substituted partially for mor-
phine. However, tremors were noted at these doses. In addition,
at the highest dose, ataxia was seen. Drowsiness was seen at all
doses tested. Partial substitution does not necessarily mean
that the drug has morphine-like properties.
MCV 4167-NIH 9612. dl-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan
hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1. 6.4 (3.9-10.5)
2. 15.5 (7.4-32.2)
2) TF vs M-l. 19.8 (10.5-37.2)
2. 24.9 (10.8-57.4)
3) PPQ-0.5 (0.2-1.3)
4) HP-1. 0.4 (0.25-0.6)
2. 0.49 (0.36-0.65)
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
(PPt-Withdrawal) Doses (mg/kg/sc) 18.0 9.0 4.5
Vehicle-
carboxyme-
thyl cellulose suspension
The principal signs noted at the highest dose were drowsiness,
lying on side or abdomen, ataxia, and for 30-45 minutes, the ani-
mals were unable to move about and appeared to be anesthetized.
One animals vocalized when its abdomen was palpated, 2 retched and
1 was restless. At the lowest dose, drowsiness was the principal
sign seen, 1 was fighting, 1 was restless, 1 showed tremors, and
1 salivated.
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This drug appears to have very weak antogonist and very strong
depressant properties.
MCV 4168-NIH 9613. (+)-9-hydroxy-4.7-dimethyl-C-homobenzomorphan
hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
2) TF vs M-1. Inactive at 3.0,
6.0, 10.0, and
30.0
2. Inactive at 3.0,
3.0, 10.0, and
30.0
1) TF-1. 8.2 (3.1-21.8)
2. 6.7 (2.5-18.4)
3) PPQ-1. 0.3 (0.1-1.0)
2. 0.9 (0.4-2.2)
4) HP-1. 2.6 (2.1-3.4)
2. 2.4 (1.4-4.0)
MONKEY DATA #ANIMALS 3 , 3 3 ,
(PPt-Withdrawal) Doses (mg/kg/sc) 10.0 5.0 2.5
Vehicle-H2O
Dose-related precipitated withdrawal was seen. All the animals
showed ataxia at the highest dose. At the 2 higher doses, it
seemed to the observer that some of the animals were unable to
vocalize when the abdomen was palpated.
MCV 4169-NIH 9614. (-)-9-Hydroxy-4.7-dimethyl-C-homobenzormorphan
hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1. Inactive at 3.0, 6.0,
10.0, and 30.0
2. Inactive at 3.0, 10.0,
and 30.0
2) TF vs M-1. 13.4 (5.7-31.3)
2. 5.5 (1.2-25.9)
3) PPQ-1. 0.5 (0.2-1.7)
2. 0.4 (0.1-.1.3)
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MONKEY DATA
(PPt-Withdrawal)
4) HP-l. 1.8 (1.3-2.4)
2. 2.5 (1.9-3.3)
#ANIMALS 3 , 3 , 3 ,
Doses (mg/kg/sc) 12.0 6.0 3.0
Vehicle-H2O
Certain signs designated as lying on side or abdomen, drowsiness,
ataxia, restlessness and tremors were seen. However, only one
animal retched, one salivated, and two vocalized when the abdomen
was palpated. This drug appeared to have very weak antagonist
and/or strong depressant properties.
MCV 4171-NIH 9622. 3-Hydroxy-6-0x0-7-alpha,8-beta-dimethyl B/C-cis
N-cyclobutyl-methylmorphinan
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
30.0
2) TF vs M-0.2 (0.1-0.8)
3) PPO-0.4 (0-1-1.9)
MONKEY DATA
(SDS)
4) HP-4.5 (3.4-5.9)
#ANIMALS 3 , 3 , 4 , 1 ,
Doses (mg/kg/sc) 3.0 1.5 0.75 0.16
1 , Vehicle-H20
0.04
MCV 4171 substituted completely for morphine in the dose range of
0.75-3.0. The drug has a prompt onset of action and a long dura-
tion of action. Two out of three monkeys receiving the highest
dose did not require morphine for approximately 6 hours and all
the monkeys receiving the 0.75 dose also did not require morphine
for approximately 6 hours. The drug appears to be much more po-
tent and longer acting than morphine.
MCV 4174-NIH 9623. 3-Hydroxy-6-oxo-7-alpha-methyl-B/C-tran s - N -
cyclopropylmethylmorphinan hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-17.3 (5.4-55.5)
2) TF vs M-0.6 (0.2-2.2)
3) PPO-0.7 (0.1-3.3)
4) HP-13.7 (9.6-19.5)
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MCV 4174 (continued)
MONKEY DATA #ANIMALS 2 , 2 ,
0 . 5
2 ,
A. (SDS) Doses (mg/kg/sc) 1.0 0.25' Vehicle -
1/2% carboxymethylcellulose aqueous suspension.
Because of the severe exacerbation of withdrawal signs, all the
animals were injected with morphine from 45 to 90 minutes after
receiving MCV 4174. Thirty minutes later, some of the animals
still vocalized during abdominal palpation and showed severe tre-
mors. Salivation and jaw sagging were noted in some animals.
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
B. (PPt-Withdrawal) Doses (mg/kg/sc) 1.0 0.5 0.25
Vehicle-H20
The drug promptly precipitated dose-related withdrawal signs in
all the monkeys. After 90 minutes all the animals were given mor-
phine to alleviate severe withdrawal. At the highest dose, one
monkey still vocalized during abdominal palpation; jaw sag and
salivation were also observed in most animals at the highest dose.
MCV 4175-NIH 9624-UM 1258. 1-[(2-alpha, 6-alpha, 11S)-d l-1-(1,2,3,
4,5,6-Hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benza-
zocin-11-yl]-3-octanone methanesulfonate.
MONKEY DATA
(Primary Physical Dependance)
A group of 5 monkeys which had not received any drug for at least
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
30.0
2) TF vs M-0.03 (0.08-0.07)
3) PPQ+0.2 (0.08-0.6)
4) HP-2.4 (1.7-3.3)
3 months was given MCV 4175 every 6 hours as indicated below and
observed for behavioral signs for approximately 15 minutes, 1/2
hour after drug was administered. The drug was dissolved in H2O.
During abrupt or precipitated withdrawal the animals were ob-
served as indicated below:
DAY DOSE mg/kg/sc COMMENTS
1 0.1 Drowsy
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DAY
2
3-4
5
6
7
DOSE mg/kg/sc
0.2
0.4
0.8
1.6
3.2
8-12 3.8
13-15
16 ABRUPT WITHDRAWAL
17 2.6
18 2.8
19
20
21
3.2
3.6
3.8
22-24 4.0
2.4
COMMENTS
Drowsy
Drowsy
Drowsy
Drowsy
Drowsy, slowing, some sedation; jaw
sag.
Lying on side, drowsy, slowing, some
vomiting and coughing, salivation, and
jaw sag. One animal convulsed. Sores
began developing at sites of injec-
tions. Weight loss in all animals.
Dose was reduced but animals were
drowsy and one was very depressed,
some salivation also noted. Some
animals convulsed on day 14.
One animal avoided contact, some
restlessness, wet dogs. Animals less
drowsy in withdrawal.
Drowsy, some salivation, tremors and
avoids contact.
Drowsy, fighting, coughing and sali-
vation.
Drowsy, some salivation, fighting,
coughing and scratching.
Drowsy, scratching, some avoided con-
tact, slowing, wet dogs, and salivation.
Drowsy, some fighting, wet dogs, ret-
ching, coughing, salivation, and
scratching. One animal developed
sores on back.
On day 22, drowsy, some lying on side,
severe tremors, wet dogs, salivation
and scratching. Three monkeys had
sores on backs. On day 23, drowsy,
some salivation, avoids contact, sag-
ging and scratching. On day 24,
drowsy, and scratching. One monkey
found dead at midnight; dose reduced.
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25 2.0
26 2.4
27 2.8
28-29 3.2
30
30
ABRUPT WITHDRAWAL
PPt-WITHDRAWAL
Drowsy, some lying on side, sagging,
wet dogs.
Drowsy, some avoid contact, ataxia,
restlessness, retching, coughing,
salivation and scratching.
Drowsy, some fighting,
scratching.
salivation and
Drowsy and scratching, some jaw sag,
and salivation. Sores on back.
Drowsy, scratching, and wet dog
Challenged with 2.0 mg/kg of maloxone
Lying on side or abdomen, restless,
scratching, wet dogs, retching, and
coughing were seen.
Another monkey died 11 days later.
CONCLUSION: MCV 4175 does not produce a significant degree of
morphine-like dependence. Little tolerance developed to the ef-
fects of the drug. Drowsiness was the principal side effect seen.
The drug does not appear to be well tolerated.
MCV 4176-NIH 9625. 1-[(2-alpha,6-alpha,11S)- dl-1-(1,2,3,4,5,6-
Hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-
yl]-6-methyl-3-heptanone methanesulfonate
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
30.0
2) TF vs M-14.8 (3.7-58.6)
3) PPQ-0.002 (0.0003-0.01)
4) HP-1.1 (0.8-1.3)
MONKEY DATA #ANIMALS
(SDS) Doses (mg/kg/sc) 20.0 10.0 5.0
Vehicle-H2O
MCV 4176 did not substitute for morphine. At the highest dose,
convulsions were noted in one animal 10 minutes after receiving
drug. The convulsions were terminated with a pentobarbital in-
jection. Severe tremors were also seen in one monkey receiving
the 10.0 mg/kg dose. MCV 4176 was tested previously in the SDS
test in the dose range 0-62-5.0 mg/kg/sc.
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MCV 4177-NIH 9538-UM 1167. (-)-17-Cyclopropylmethyl-7,7-dimethyl-
3-hydroxy-6,8-dioxamorphinan d-tartrate methanolate)
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
30.0
2) TF vs M-0.03 (0.01-0.08)
3) PPQ-0.04 (0.2-2.0)
4) HP-0.21 (0.18-0.26)
MONKEY DATA #ANIMALS 3 ,
0.5
4 , 3 , 1 ,
A. (SDS) Doses (mg/kg/sc) 0.25 0.125 0.016
Vehicle-H2O
More studies at lower doses will have to be done to state whether
or not the compound sustitutes completely for morphine. At the
higher doses, ataxia, slowing, jaw sag, ptosis and drowsiness were
noted and partial substitution for morphine was seen. Partial sub-
stitution does not necessarily mean that the drug is morphine-like.
MONKEY DATA #ANIMALS 2 2 , 2 , Vehicle-H2O
B. (PPt-Withdrawal) Doses (mg/kg/sc) 1.0 0.25 0.06
MCV 4177 did not precipitate withdrawal. The animals were drowsy
and slow, were salivating and showed jaw and body sag at all doses.
Some of the animals receiving drug did not require the noon injec-
tion of morphine and were given morphine 2 1/2 hours later.
EAT INFUSION (PPD)
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When given in the same dose regimen as morphine, MCV 4177 produces
substantial signs of physical withdrawal, but less than that of
morphine, as shown by the weight-on data above. Fewer withdrawal
signs were noted when compared to morphine.
MCV 4180-NIH 9653. 3-Allyl-9-beta-methoxy-9-phenyl-3-azabicyclo-
[3.3.1]nonane hydrochloride
3) PPQ-1.4 (0.6-3.3)
4) HP-3.6 (2.6-5.0)
1 , in one hour.MONKEY DATA #ANIMALS
Preliminary (SDS) Doses (mg/kg/sc) 22.0
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-25.0 (11.2-55.8)
2) TF vs M-0% at 3.0, 10% at 10.0,
and 34% at 30.0
Up to a cumulative dose of 22.0 mg/kg, (2.0, 4.0, 8.0, and 8.0
mg/kg every 15 minutes), MCV 4180 did not substitute for morphine.
Drug supply was exhausted.
MCV 4181-NIH 9654.
{3.3.1}
3-n-Amyl-9-beta-methoxy-9-phenyl-3-azabicyclo-
nonane hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-5.2 (2.1-32.2)
2) TF vs M-Inactive at 3.0, 10.0,
and 30.0
3) PPQ-0.2 (0.1-0.7)
4) HP-2.6 (1.9-3.5)
MONKEY DATA #ANIMALS 2 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 2.0 1.0 0.5
Vehicle-H2O
MCV 4181 substituted completely for morphine at the highest dose.
The drug had a prompt onset of action. The duration of action
was 2-3 hours.
MCV 4182-NIH 9655. 3-Methyl-9-beta-methoxy-9-phenyl-3-azabicyclo-
[3.3.1]nonane citrate hemihydrate
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-10.0 (3.2-31.0)
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MCV 4182-NIH 9655 (continued)
MOUSE DATA-ED50 (95% C.L.)-
2) TF vs M-0% at 3.0, 21% at
10.0, and 29% at 30.0
3) PPQ-0.3 (0.1-1.0)
4) HP-1.7 (1.3-2.2)
MONKEY DATA #ANIMALS 1 , 2 , 1 , 2 , 2
(SDS) Doses (mg/kg/sc) 32.0 24.0 16.0 12.0 6.0
Vehicle-H20 + Lactic Acid
This drug did not substitute for morphine in the dose range tested.
MCV 4184-NIH 9689. Yohimbine hydrocholoride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 3.0, 10.0, and
Text
2) TF vs M-5.6 (2.7-11.5)
3) PPQ-17.1 (6.6-44.1)
4) HP-Not Tested
MONKEY DATA # ANIMALS 1 , 1 , 1 , 1 , 2
(PPt-Withdrawal)Doses (mg/kg/sc) 0.25 0.06 0.01 0.001 0.002
2 , Vehicle-H2O
0.0005
MCV 4184 did not precipitate withdrawal in the dose range tested.
The only signs notedi especially in the dose range 0.01-0.002,
were salivation, avoids contact and jaw sag.
MCV 4185-NIH 8437, UM 774. N-Cyclopropylmethylnordesomorphine
hydrochloride
MOUSE DATA-ED50
(mg/kg/sc)
1) TF-Inactive
30.0
2) TF vs M-0.3
(95% C.L.)-
at 3.0, 10.0, and
(0.1-1.1)
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MCV 4185-NIH 8437, UM 774. (continued)
MOUSE DATA ED50 (95% C.L.)-
(mg/kg/sc)
3) PPQ-3.5 (1.7-7.4)
4) HP-4.5 (2.7-7.4)
MONKEY DATA #ANIMALS 2 , 2 , 2 ,
Doses (mg/kg/sc)(SDS) 0.1 0.05 0.025
Vehicle-H2O
A.
MCV 4185 did not substitute for morphine. Salivation was noted
at the 2 higher doses. One monkey at the highest dose ejaculated
3 times during the first 1/2 hour.
MONKEY DATA #ANIMALS 2 , 2 , 3 , 4 ,
B. (PPt Withdrawal) Doses (mg/kg/sc) 0.2 0.1 0.01 0.05
3 , 1 ,
0.003 0.008
Vehicle-H20
This compound precipitated withdrawal in doses as low as 0.003
mg/kg. The drug acts promptly and has a longer duration of ac-
tion than naloxone. MCV 4185 is approximately 10 times as potent
as naloxone. Salivation was noted occassionallv and was not dose-
related.
MCV 4188-NIH 9725, UM 1213. L-Tyrosyl-D-alanylglycyl-L-N-alpha-
ethylphenylalanine amide acetate.
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-1.2 (0.3-5.3)
2) TF vs M-Inactive at 0.01, 0.03.
0.1, 1.0 and 30.0
3) PPQ-0.064 (0.018-0.22)
4) HP-0.73 (0.59-0.90)
MCV 4189-NIH 8735A, UM 909. 2-(2-Methyl-3-furymethyl)-2'-hydroxy-
5,9-alpha-dimethyl-6,7-benzomorphan methanesulfonate.
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MCV 4189-NIH 8735A-UM 909.(continued)
MOUSE DATA ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-5.1 (1.9-13.7)
2) TF vs M-Inactive at 1.0, and
10.0
3) PPQ-0.72 (0.38-1.36)
4) HP-1.9 (1.5-2.5)
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
(SDS)
Vehicle-H20
Doses (mg/kg/sc) 8.0 4.0 2.0
This compound did not substitute for morphine although it sharply
reduced the incidence of retching and lying on side. The signs
designated ataxia and sagging were also noted at the highest dose.
MCV 4191-NIH 9726-UM 1214. N-[4-(Methoxymethyl)-1-(-2-(2-thienyl)
ethyl)-4-piperidinyl]-N-phenylpropanamide 2-hydroxy-1,2,3-propane-
tricarboxylate (1:1). (Sufentanil citrate)
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.011 (0.004-0.03)
2) TF vs M-Inactive at 30.0, 1.0,
0.03, 0.003 and 0.0003
3) PPQ-0.0004 (0.0001-0.0015)
4) HP-0.004 (0.003-0.005)
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
(SDS) Doses (mg/kg/sc) 0.004 0.002 0.001
Vehicle-H20
At the higher doses, MCV 4191 substituted completely for morphine.
The drug acts promptly and is approximately 1000 x as potent as
morphine. Its duration of action is at least as long as that of
morphine. Some of the animals receiving the drug also appeared
to be drowsy.
MCV 4194-NIH 9733-UM 1230. (-)-Nicotine di-l-tartrate
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-5.2 (2.7 10.0)
2) TF vs M-0.6 (0.03-15.0)
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MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
MONKEY DATA
A. (SDS)
3) PPQ-1.3 (0.5-3.2)
4) HP-2.2 (1.6-3.0)
#ANIMALS STUDY 1. 1 , 1 , 3 ,
Doses (mg/kg/sc) 0.03 0.06 0.125
4 5 , 3 ,
0.25 0.5 0.75
Vehicle-H2O
STUDY 2. 2 , 2 , 2 ,
0.125 0.25 0.5
Vehicle-H2O
MCV 4194 did not substitute for morphine in the dose range tested.
MONKEY DATA #ANIMALS 1 , 2 , 3 , 2 , 1 ,
B. PPt-Withdrawal) Doses (mg/kg/sc) 0.96 0.48 0.24 0.1 0.06
Vehicle-H2O
At the 3 higher doses, (-)-nicotine produced restlessness. Other
signs such as drowsiness, avoids contact and wet dogs were seen
but they were also observed in one monkey receiving H2O. (-)-
Nicotine does not appear to be a specific narcotic antogonist.
MCV 4195-NIH 9735. N-Cyclopropylmethyl-7 8-dihydronormorphinone
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0.04 (0.035-0.23)
2) TF vs M-0.14 (0.03-0.54)
3) PPQ-0.009 (0.001-0.06)
4) HP-Inactive
5) N-No dose-response
MONKEY DATA #ANIMALS 3 , 3 , 3 ,
A. (SDS) Doses (mg/kg/sc) 0.15 0.3
Vehicle-H2O +
0.6 dil, HCl
MCV 4195 did not substitute for morphine. The drug exacerbated
withdrawal at all doses tested. Severe tremors were noted in
one monkey receiving the highest dose.
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MONKEY DATA #ANIMALS
B.(PPt-Withdrawal) Dose (mg/kg/sc)
3 , 3 , 3 , Vehicle-H20
0.3 0.6 1.2 + dil. HCl
This drug precipitated withdrawal at all doses tested. In one
group of monkeys, all receiving MCV 4195 were given morphine to
terminate severe withdrawal.
MCV 4198-NIH 9734-UM 1219. dl-Spiro (1,3-diethyl-1-methyl-7-
hydroxy-1H-2-benzopyran)-4,4'(1-pentylpiperidine) hydrobromide
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 1.0 and 30.0
2) TF vs M-6% at 1.0; 32% at 10.0,
and 8% at 30.0
3) PPQ-2.5 (1.25-4.81)
4) HP-Inactive
MCV 4199-NIH 9738,2-Nitronaltrexone
MOUSE DATA-ED50
(mg/kg/sc)
(95% C.L.)-
1) TF-0% at 0.3; 14% at 3.0; 23%
at 10.0; lethal 4/6 at 30.0
2) TF vs M-21% at 10.0; 27% at
15.0; lethal 6/6 at 30.0
3) PPQ-3.5 (1.4-8.5)
4) HP-3.7 (2.3-5.7)
5) N-5.8 (4-1-8.4)
MCV 4200-NIH 9739 2-Nitronaloxone
MOUSE DATA-ED50
(mg/kg/sc)
(95% C.L.)-
1) TF-0% at 1.0, 17% at 10.0,
5/6 died at 30.0
2) TF vs M-3.6 (0.8-16.8)
3) PPQ-3.5 (1.8-6.8)
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MCV 4201-NIH 9740-UM 1220.
oxalate
4) HP-3.1 (2.0-4.8)
5) N-6.0 (4.5-8.0)
N-(2-Methoxyethyl)norketobemidone
MOUSE DATA-ED 5 0 (95% C.L.)-
(mg/kg/sc)
1) TF-2.1 (1.3-3.3)
2) TF vs M-0% at 1.0 and 30.0
3) PPQ-0.9 (0.55-1.53)
4) HP-0.73 (0.55-0.98)
5) N-2.1 (1.4-3.1)
MCV 4202-NIH 9751-UM 1228. (2-alpha, 6-alpha,11S)-(+)-1-Cyclo-
pentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3.6,11-trimethyl-2,6-
methano-3-benzazocin-11-yl)-3-pentanone methanesulfonate
MOUSE DATA-ED 5 0 (95% C.L.)-
(mg/kg/sc)
1) TF-Inactive at 0.1, 1.0, 10.0,
and 30.0
2) TF vs M-6% at 1.0, 4% at 3.0,
10.0 and 17% at 30.0
3) PPC-Inactive 1.0 and 30.0
4) HP-No dose-response
5) N-Inactive to 100.0
MONKEY DATA #ANIMALS 2 , 2 , 2 ,
A. (SDS) Doses (mg/kg/sc) 10.0 5.0 2.5
Vehicle-H2O
This drug did not substitute for morphine. It may have exacerbated
withdrawal. Severe tremors were noted and morphine was given to
the monkey in the preliminary study receiving a cumulative dose
of 10 mg/kg in 1/2 hour and to another receiving the highest dose
in this SDS study to terminate severe withdrawal.
MONKEY DATA #ANIMALS 1 , 2 , 2 , 1 , Vehicle-
B.(PPt-Withdrawal) Doses(mg/kg/sc) 20.0 10.0 5.0 2.5 H2O
At the two higher doses, MCV 4202 precipitated withdrawal. The
onset and duration of action was similar to that of naloxone. The
drug is about 400 x less potent than naloxone. Drug supply was
exhausted.
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MCV 4203-NIH 9752-UM 1229. (2-alpha,6-alpha,11S)-(-)-1-Cyclo-
pentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6
methano-3-benzazocin 11-yl)-3-pentanone methanesulfonate
MOUSE DATA-ED50 (95% C.L.)
(mg/kg/sc)
1) TF-Inactive at 1.0, 10.0 and
30.0
2) TF vs M-0.06 (0.01-0.39) ED
Time Course: 78% at 1 hour50
71% at 3 hours, 31% 10 hours
and 0% at 30 hours.
3) PPQ-44% at 0.001; 27% at 0.01;
33% at 0.1% at 1.0; 65% at
10.0 and 47% at 30.0
4) HP-No dose-response
5) N-Inactive to 100.0
MONKEY DATA #ANIMALS 1 , 1 , 1 , 1 , 2
A. (SDS) Doses (mg/kg/sc) 0.015 0.06 0.05 0.1 0.25
Vehicle-H2O
MCV 4203 did not substitute for morphine. The drug exacerbated
withdrawal. One monkey at the lowest dose had convulsions about
6 hours after the study was started. Another monkey receiving
the highest dose appeared sick. Morphine was given after 2 1/2
hours to terminate severe withdrawal but some of the monkeys still
vocalized when their abdomens were palpated and had rigid abdomens
9 hours after the start of the experiment in spite of the fact
that morphine was given.
MONKEY DATA #ANIMALS 2 , 3 , 3 , 1
B. (PPt-Withdrawal) Doses (mg/kg/sc) 0.008 0.03 0.1 0.125
1 , Vehicle-H2O
0.50
The drug precipitated withdrawal signs at all but the lowest dose.
The monkey receiving the highest dose was very sick and moved
about very slowly for 2 days in spite of repeated doses of mor-
phine. One monkey receiving 0.125 mg/kg and another receiving
0.03 mg/kg still showed withdrawal signs after 2 injections of
morphine (3.0 mg/kg). At this dose, morphine may not be an ade-
quate antidote.
MCV 4204-NIH 9757-UM 1231. Dextropropoxyphene hydrochloride
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
324
MCV 4204-NIH 9757-UM 1231. (continued) Mouse Data
1) TF--19.4 (15.5-24.5)
2) TF vs M-Inactive at 0.1, 1.0,
and 25.0
3) PPQ-2.2 (0.7-6.6)
4) HP-3.8 (2.8-5.2)
5) N-7.1 (5.3-9.4)
MONKEY DATA #ANIMALS 1 , 2 , 3 , 2 , 1 ,
(SDS) Doses (mg/kg/sc) 10.0 5.0 2.5 0.6 0.3
Vehicle-H2O
At the highest dose, MCV 4204 substituted completely and briefly
(1 hour) for morphine. The drug behaved similarly in 1 of 2
animals receiving 5.0 and 2 of 3 animals receiving 2.5 mg/kg.
MCV 4205-NIH 9771. 4-(1-Hydroxypropyl)-4-m-hydroxyphenyl-1-
methylpiperidine
MOUSE DATA-ED50 (95% C.L.)-
(mg/kg/sc)
1) TF-0% at 20.0 and 11% at 30.0
2) TF vs M-0% at 0.1; 20% at 1.0
and 12% at 30.0
3) PPQ-0% at 0.1; 29% at
11% at 30.0
4) HP-No dose-response
MONKEY DATA
(SDS)
#ANIMALS 1 , 3 , 2 , 2 ,
Doses (mg/kg/sc) 20.0 10.0 5.0 2.5
1.0 and
Vehicle-
Lactic Acid
and H20
In the dose range studied, MCV 4205 does not substitute for mor-
phine.
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Annual Report: Evaluation of New
Compounds for Opioid Activity
(1980)
J. H. Woods, F. Medzihradsky, C. B. Smith, A. M. Young,
and H. H. Swain
The flow of new compounds through the evaluation programs at The
University of Michigan (UM) and the Medical College of Virginia
(MCV) is coordinated by Dr. Arthur E. Jacobson, Medicinal Chem-
istry Section, NIAMDD, National Institutes of Health, Bethesda,
MD. The drugs, which come originally from pharmaceutical compan-
ies, universities and government laboratories, are submitted to
Dr. Jacobson, who performs the MOUSE ANALGESIA tests (see Table
I below).
At the UM and MCV laboratories, drug samples arrive from Dr. Jacobson
with only the following information: (1) an identifying NIH number,
(2) molecular weight, (3) solubility information, and (4) a recom-
mended starting dose. Only after the evaluation is complete and
the report submitted back to Dr. Jacobson are the chemical struc-
ture and the mouse-analgesia data released to the evaluating lab-
oratory.
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single dose suppression test (SDS) determines the ability of
a drug to suppress the signs of abstinence in monkeys which have
been made physically dependent by the chronic administration of
morphine (3 mg/kg every six hours). Compounds suspected of having
morphine-antagonist properties are tested for their ability to
precipitate the abstinence syndrome in non-withdrawn (NW) morphine-
dependent monkeys. Non-dependent monkeys (Normals) are used to
determine whether the acute effects of the test drug are reversible
by nalorphine or naloxone. In a primary addiction study (PAS) non-
dependent monkeys receive the test drug every six hours for 30 days
to determine whether abstinence signs will appear when the animals
are challenged with an antagonist or when drug administration is
discontinued.
Details of these techniques have been presented in the ANNUAL RE-
PORT to the Committee in 1963 (Minutes of the 25th Meeting).
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SELF-ADMINISTRATION BY MONKEYS
The compounds were examined in monkeys which had been conditioned
to self-inject codeine. Each of at least three monkeys was stud-
ied with saline as a negative control and a number of doses of
the test compound until a maximum rate of responding was obtained
or until, in the absence of evidence of a reinforcing effect, di-
rectly observable changes in behavior were elicited by the com-
pound.
The schedule of intravenous drug delivery is a fixed-ratio 30;
when a light above a lever is illuminated, the 30th response in
its presence turns off the fixed-ratio light and delivers a five-
second intravenous drug injection in the presence of another light
that is illuminated during drug delivery. After each injection,
a ten-minute timeout condition is in effect, during which responses
have no programmed consequence and no lights are illuminated. Each
of the two daily sessions consists of 13 injections or 130 minutes,
whichever occurs first. Other details of the procedure and initial
findings with a variety of narcotics are given in a previous report
(Woods, 1977, Committee Report, pages 420-437). Additional back-
ground material is available from Dr. Woods.
Doses of the drugs are described in terms of moles/kg/injection, to
facilitate direct comparisons among drugs. Duplicate observations
of codeine (7.5 x 10-5 mol/kg/injection; 0.32 mg/kg/injection) and
of saline are obtained for each monkey. A saline substitution is
conducted before and after the series of observations on a test
drug; the rates of codeine-reinforced responding are obtained by
a random sampling of two sessions interpolated between the drug-
substitution sessions. These data are represented in the following
graphs with individual symbols for each of the monkeys; in addition,
using the same symbols, the mean of duplicate observations is given
for the doses studied in each monkey. There are two additional
types of averaged data presented. The closed circles indicate the
averaged data for observations on the subset of monkeys used to
study each drug under each of the experimental conditions. The
open circles indicate the codeine and saline rates of responding of
20 monkeys studied under the same conditions. The brackets indicate
+3 standard errors of the mean for codeine and +3 standard errors
of the mean for saline. In all cases, the rates of responding given
are those calculated during the fixed-ratio portion of each session.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay were described in the 1978 ANNUAL RE-
PORT. Briefly, aliguots of a membrane preparation from rat cerebrum
are incubated with 3H-etorphine in the absence and presence of 150
mM NaCl, and in the presence of different concentrations of a given
opioid drug under investigation. Stereospecific, i.e., opioid-
receptor related, binding of etorphine is determined and the inhib-
itory potency of the drug is obtained from log-probit plots of the
data. Values obtained with this method for some representative
opioid drugs are as follows:
328
DRUG
Naltrexone
Naloxone
Nalorphine
Cyclazocine
Levallorphan
Dextrorphan
Levorphanol
Codeine
l-Pentazocine
d-Pentazocine
Morphine
+NaCl
2.0
9.1
20.0
3.6
5.5
18400
21.4
34700
174.0
6190
142.0
EC50 (nM)
-NaCl
7.9
31.6
51.3
6.4
7.0
14000
15.4
17800
85.1
8660
60.2
+Na/-Na
0.25
0.29
0.39
0.56
0.79
1.32
1.39
1.95
2.04
0.71
2.36
NOTE: Binding data for a number of other compounds are included
in the 1978 and 1979 ANNUAL REPORTS.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA PIG ILEUM AND
MOUSE VAS DEFERENS PREPARATIONS
Submitted drugs are evaluated on two smooth muscle preparations,
the details of which were described in the 1978 ANNUAL REPORT.
Shown in the following pages are the EC50's for the tested drug
alone, for the drug in the presence of naltrexone (a pure opioid
antagonist which is more effective against so-called "mu" agonists
than against so-called "kappa" agonists), and for the drug in the
presence of UM 979 (an antagonist which seems to be more effective
against "kappa" than against "mu" drugs). The maximum depression
of the electrically induced twitch in each of these preparations
is also indicated.
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at The University of Michigan
during the past year, and the individual tests which were performed
are shown in Table II.
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MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated for analgesic
activity by Dr. Arthur E. Jacobsord. Shown below are comparative data (ED50 mg/kg) (95% Confidence Inter-
val) from Hot PlateH-C and Nilsen assays. umo/lkg
Compound
NIH #
Morphine sulfate
NIH 0001
Codeine phosphate
NIH 0002
Levorphanol tartrate
NIH 4590
Meperidine.HCl
NIH 5221
(-)-Metazocine.HBr
NIH 7569
TABLE I
HOT PLATE
(sc, mg/kg)
(sc, umol/kg)
0.98 (0.83-1.1)
2.9 (2.5-3.3)
6.8 (4.5-10.2)
17.1 (11.3-25.7)
0.2 (0.1-0.3)
0.5 (0.2-0.7)
5.3 (4.0-7.1)
18.7 (14.1-25.0)
0.6 (0.5-0.9)
1.9 (1.4-2.8)
(oral, mg/kg)
(oral, umol/kg)
6.3 (4.7-8.3)
18.9 (14.1-24.9)
13.5 (9.7-18.7)
34.0 (24.4-47.1)
10.6 (8.0-14.1)
34.1 (25.7-45.3)
(SC, mg/kg)
(sc, umol/kg)
1.3 (1.0-1.7)
3.9 (3.0-5.1)
7.4 (4.9-11.0)
18.6 (12.3-27.7)
0.2 (0.16-0-3)
0.5 (0.4-0.7)
0.5 (0.3-0.7)
1.6 (1.0-2.3)
NILSEN
(oral, mg/kg)
(oral, umol/kg)
8.3 (6.0-11.4)
24.9 (18.0-34.1)
14.7 (9.2-23.3)
37.0 (23.2-58.7)
2.5 (1.7-3.7)
6.2 (4.2-9.1)
26.0 (21.0-33.0)
83.6 (67.5-106.1)
Dihydromorphinone.HCl
NIH 0123
Nalorphine.HCl
NIH 2105
Cyclazocine
NIH 7981
Pentazocine
NIH 7958
Naltrexone.HCl
NM 8503
Naloxone. HCl
NIH 7890
0.19 (0.15-0.25) 0.9 (0.7-1.2)
0.6 (0.5-0.8) 2.8 (2.2-3.7)
9.9 (5.7-17.1)
28.4 (16.4-49.1)
1.5 (1.1-2.1)
5.5 (4.1-7.7)
9.3 (6.7-12.8)
32.6 (23.5-44.9)
No dose response
No dose response
0.2 (0.15-0.3) 1.8 (1.5-2.1)
0.6 (0.5-0.9) 5.6 (4.7-6.5)
23.0 (16.2-32.7)
66.1 (46.6-94-0)
0.1 (0.07-0-16)
0.4 (0.3-0.6)
6.5 (4.4-8.8)
22.8 (15.4-30.9)
No antinociceptive activity in hot plate assay: Phenobarbital, amobarbital, diazepam, meprobamate,
mescaline, oxazepam, flurazepam.
Chlorpromazine.HCl 1.1 (0.9-1.5)
3.2 (2.4-4.2)
a) N.B. Eddy and D. Leimbach, J. Pharmacol. Exp Ther.,107: 385 (1953); b) AE Jacobson and E.L. May, J.
Med. Chem., 8: 563 (1965); c) L. Atwell and A.E. Jacobson, Lab Anim., 7: 42 (1978); d) T.D. Perriner, L.
Atwell, I.B. Tice, A.E. Jacobson and E.L. May, J. Pharm. Sci., 61: 86 (1972).
TABLE II
SUMMARY OF TESTS PERFORMED
COMPOUND NUMBER
UM NIH MCV
909 8735A 4189
941 8791
1125A 9343A 4103
1144 9048 4041
1151 9549 4155
(9571) (4183)
1159 9513
1167 9538 4177
1168 9539
1173 9550
1184 9629
1185 9630
1189 9463
1190 9627
CHEMICAL CLASS
Benzomorphan
Butorphanol
Phenylpiperidine
Miscellaneous
Clonidine
" "
Cannabinoid
Dioxamorphinan
Oxamorphinan
Miscellaneous
Naloxone quat.
Naltrexone quat.
Miscellaneous
Miscellaneous
1195 9637 sec-Butylnormorphine
1196 9648 Ketobemidone
1199 9673 Miscellaneous
SDS NW Nor-
mals
Self-
Adm.
GPI MVD Bind. PAS
TABLE II (cont.)
COMPOUND NUMBER
UM NIH MCV
1202 9701
1203 9702
1204 9703
1205 9704
1206 9705
1207 9706
1208 9707
1209 9708
1210 9709
1211 9712
(136) (7380)
1213 9725 4188
1214 9726 4171
1215 9729 4193
1218 9585
1219 9734 4194
1220 9740 4201
1221 9741
CHEMICAL CLASS
Mercaptomorphine
Mercaptocodeine
Amidocodeine
Amidocodeine
Amidomorphine
Aminocodeine
Chlorocodeinone
Chloromorphinone
Bromomorphinone
Galanthamine
Peptide
Sufentanil
Phenylpiperidine
Ketobemidone
Miscellaneous
Ketobemidone
Ketobemidone
SDS NW Nor-
mals
Self- GPI
Adm.
MVD Bind PAS
TABLE II (cont.)
CHEMICAL CLASS SDS NW Nor-
mals
Miscellaneous
Benzomorphan
Benzomorphan
Nicotine
Propoxyphene
Ketobemidone
Ketobemidone
Ketobemidone
Miscellaneous
Benzomorphan
COMPOUND NUMBER
UM NIH MGV
1222 9742
1228 9751 4202
1229 9752 4203
1230 9733 4194
1231 9757 4204
1232 9769
1233 9770
1237 9789
1242 9576A 4157
1258 9624 4175
Self- GPI
Adm.
MVD Bind. PAS
SDS = Single-dose suppression of abstinence signs in morphine-dependent monkeys
NW = Attempted precipitation of abstinence in non-withdrawn, morphine-dependent monkeys
Normals = Attempted reversal by nalorphine and naloxone of effects in non-dependent monkeys
Self-Adm. = Test of reinforcing properties in monkeys which normally self-administer codeine
GPI = Suppression of twitch in electrically driven guinea-pig ileum preparation
MVD = Suppression of twitch in electrically driven mouse vas deferens preparation
Bind. = Stereospecific displacement of 3H-etorphine in membrane preparation from rat cerebrum
PAS = Primary addiction study in monkeys
UM 909 NIH 8735A MCV 4189
PRIMARY ADDICTION STUDY
2-(2-Methyl-3-furylmethyl)-2' -hydroxy-5,9 alpha-dimethyl-6,7-
benzomorphan methanesulfonate
In single-dose-suppression studies (see 1972 ANNUAL REPORT), this
compound produced no suppression of abstinence signs in morphine-
dependent Rhesus monkeys, but it caused severe, short-lasting CNS
depression at a dose of 8.0 mg/kg. In mouse analgesia studies, it
had a potency approximately one-half that of morphine, with an
ED50 of 2.2 (1.7-2.8) mg/kg.
Animals. Rhesus monkeys numbered 115A, 205A and 1123 were used in
this sutdy. Throughout the study, the weights of these monkeys
remained essentially constant.
Dosage schedule. The initial dose of UM 909 was 2.0 mg/kg, given
subcutaneously every six hours. On the third day of the study,
this was raised to 4.0 mg/kg and on Day 8 it was raised again to
8.0 mg/kg every six hours. On Day 18, monkey number 1123 received
one dose of 16 mg/kg and, twenty minutes after the injection, the
animal convulsed and was treated with pentobarbital. Thereafter,
the dose for all three animals remained at 8.0 mg/kg/injection.
On the 23rd day, the injection interval was reduced from six hours
to three hours for the remainder of the study. On Day 36, the
administration of UM 909 was discontinued abruptly.
Acute effects. UM 909 caused signs of CNS depression. The monkeys
became moderately ataxic, showed muscle weakness and decreased body
movement. They had blank facial expressions and stared into space.
Their pupils were dilated; their respiration was not depressed.
All of these effects were relatively short-lasting. Initially
the signs were gone within three hours of the injection, but as
tolerance developed, they were hard to detect after two hours or
even less. Tolerance was also apparent from the decreasing severity
of the CNS depression as a dose was repeated.
The skin on the animals' backs became hardened and showed increased
bleeding at injection sites as the study progressed. (This local
effect has been observed previously with other benzomorphan drugs.)
Physical dependence. When UM 909 was injected every six hours, the
development of physical dependence was minimal. On the 15th day of
the study, the injection of nalorphine (2.0 mg/kg) reversed the
acute effects of the immediately preceding dose of UM 909 (ataxia
and CNS depression) but precipitated only the mildest of abstinence
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339-844 0 - 81 - 23
signs. On the 17th day, a challenge with 2.0 mg/kg of naloxone
produced only slightly more severe abstinence, characterized by
retching and vomiting, apprehension and irritability to handling.
On an every-three-hour injection schedule (initiated on Day 23)
the physical dependence became more marked, so that the nalorphine
challenge on Day 28 precipitated mild abstinence and the naloxone
challenge on Day 30 produced moderately severe signs. These latter
included vomiting, yawning, irritability, prostration and abdominal
tenderness but not the abdominal guarding and rigidity which would
have been seen in morphine-dependent animals.
An additional challenge was performed on Day 32 when the animals
were given a dose of an antagonist which structurally is almost
identical to the agonist DM 909. known variously as UM 979, NIH
8859 and Mr 1452-MS, this antagonist lacks the 2-methyl group
which is present on the furyl ring of UM 909, and in small doses it
precipitates abstinence signs in morphine-dependent monkeys. There
has been speculation that UM 979 is preferentially effective at so-
called "kappa" receptors, and therefore it might be especially
active in antagonizing the effects of UM 909, which behaves like a
kappa agonist. However, the abstinence signs precipitated by the
challenge with UM 979 were only mild in intensity.
Upon the abrupt discontinuation of UM 909 administration, mild absti-
nence signs appeared, with their peak intensity observed at 12 hours
after the last dose of the drug, and disappearing completely over a
period of 6 - 8 days. As was the case with precipitated abstinence,
abdominal guarding and rigidity were absent from the syndrome.
Summary. UM 909 is a drug which neither suppresses nor precipitates
the signs of abstinence in a morphine-dependent Rhesus monkey. It
produces CNS-depressant signs of relatively brief duration. Toler-
ance develops to these effects upon repeated administration of the
drug. In one animal, which had become partially tolerant to the
depressant effects of 8.0 mg/kg of UM 909, a single dose of 16
mg/kg produced convulsions. Physical dependence developed to only
a minimal degree when the drug was given every six hours, and to a
moderate degree when administered every three hours. A structurally
related antagonist, known as UM 979, was less effective than nalox-
one in precipitating the abstinence syndrome. The abstinence signs
which followed either antagonist administration or the abrupt with-
drawal of the drug differed somewhat from those seen during morphine
withdrawal -- in particular, abdominal guarding and rigidity were
not seen.
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UM 941,
PRIMARY ADDICTION STUDY
NIH 8791, Butorphanol
(-)-N-Cyclobutylmethyl-3,14-dihydroxymorphinan tartrate
In single-dose suppression studies (see 1973 ANNUAL REPORT), this
compound caused mild exacerbation of morphine abstinence signs,
when the drug was given in a dose of 6.4 or 12.8 mg/kg. However,
in the non-withdrawn, morphine-dependent monkeys, a dose of 6.4
mg/kg did not precipitate any abstinence signs. The highest dose
tested in withdrawn, dependent animals was 25.6 mg/kg, which caused
convulsions.
Animals. Rhesus monkeys numbered 1186, 1194 and 1195 were used in
this study. Throughout the investigation, the animals maintained
essentially constant weight and they suffered no apparent ill-
effects from the study.
Dosage schedule. The drug was administered subcutaneously every
six hours. The starting dose, given on Days 1 through 3, was 0.8
mg/kg. This was raised to 1.6 mg/kg for Days 4 through 11; it was
3.2 mg/kg on Days 12 through 18; finally, a dose of 6.4 mg/kg was
given to the animals every six hours from Day 19 through Day 42.
On the 43rd day of the study, drug administration was abruptly dis-
continued.
Acute effects. The starting dose of UM 941 caused marked CNS depres-
sion with muscle weakness, ataxia and body sag. When the animals
were handled, they showed little or no aggression or irritability.
When left alone, they tended to stay in one place, with little ten-
dency to move around in the cage. Pupil size was increased and,
likewise, respiration increased. Tolerance, as evidenced by the
effects of UM 941 becoming less intense and shorter in duration,
developed to the actions of the drug within a few days.
Physical dependence. On the 14th day of the study, the monkeys
were challenged with a dose of 2.0 mg/kg of nalorphine, which pro-
duced mild abstinence signs which included a general restlessness
and irritability, a decrease in pupil size, scratching, stretching,
peculiar postures, quarreling and salivation. Interestingly, the
animals did not show any abdominal tenderness or cramps, though they
did tend to hold their abdomens. On a scale of 1 (very mild) to
8 (very severe), these abstinence signs were graded as 1. A nal-
oxone challenge (2 mg/kg) on the 16th day produced essentially the
same withdrawal signs (including the absence of the usual abdominal
tenderness), but the withdrawal was more severe (grade = 4). The
nalorphine challenge was repeated on the 31st day, and the signs
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were at least as mild as those seen on the 14th day. The repeat
of the naloxone test on Day 36, on the other hand, produced signs
which were more severe than those of Day 16 (grade = 6); the  man-
keys were very irritable, had severe retching and vomiting and dis-
played the "half-retch/half-yawn" behavior which has been seen pre-
viously in animals withdrawing from cyclazocine-like drugs. Abrupt
withdrawal of the drug on the 43rd day of the study produced absti-
nance signs which were intermediate in severity between those seen
after nalorphine and those precipitated by naloxone; they were
rated as grade = 3. The withdrawal signs peaked in intensity at
30-36 hours after the last dose of UM 941 and had disappeared after
96 hours.
Summary. UM 941 behaves like an effective narcotic agonist, a weak
narcotic antagonist or a convulsant, depending upon the circumstan-
ces of its administration. In the 14-hour-withdrawn, morphine-
dependent monkey, the agonist activity of the drug is not apparent;
instead, its antagonist properties are shown by a mild exacerbation
in the severity of the abstinence syndrome. In the normal (non-
dependent) monkey, UM 941 produces narcotic-like CNS depression, and
tolerance and physical, dependence develop upon repeated administra-
tion of the drug. The unusual characteristics of this drug include
(1) the markedly greater severity of the naloxone-induced abstinence,
compared to the nalorphine-induced withdrawal signs, and (2) the
absence of abdominal tenderness during withdrawal.
UM 1125A, NIH 9343A
PRIMARY ADDICTION STUDY
m-(1,3-Dimethyl-4-propyl-4-piperidyl)phenol hydrobromide
In single-dose-suppression studies in morphine-dependent Rhesus
monkeys, this drug caused mild CNS depression in doses up to 40
mg/kg/; at 80 mg/kg it caused convulsions (see 1978 ANNUAL REPORT) -
It neither suppressed nor precipitated the signs of morphine absti-
nance. In the non-dependent monkey, the CNS depression which it
produced was not reversed by either nalorphine or naloxone.
Animals. Rhesus monkeys numbered 1126, 1127 and 1133 were used
in study. All three animals tolerated the procedures well
and maintained their body weights throughout. The animals developed
abscesses on their backs at the sites of subcutaneous injections.
Dosage schedule. The animals received 10 mg/kg of UM 1125A every
six hours for the first seven days of the study; 20 mg/kg four
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times each on Days 8 through 28, after which drug administration was
abruptly discontinued. There were problems in putting and keeping
the drug in solution. For the 10 mg/kg dose, it was dissolved in
1/3 propylene glycol and 2/3 water. When the dose was raised to
20 mg/kg, the higher concentration of drug would not stay in solu-
tion in the propylene glycol, even when the solution was kept warm,
and once it had come out of solution, it would not go back into
solution with rewarming. Emulphor EL 620 diluted with water to
1/3 strength proved to be more satisfactory. The drug would stay
in solution for 2-3 days, and would re-enter solution when rewarmed.
This 33% Emulphor solution was used as the vehicle for the remainder
of the study.
Acute effects. UM 1125A caused CNS depression. The animals showed
marked ataxia and motor incoordination. At times they would stare
wide-eyed, and at other times they would doze and appear to be mild-
ly stuporous. Strong stimuli were needed to produce any reaction on
the part of the animals. There were slight tremors and perhaps some
slight increase in respiratory rate. Upon repeated administration
of the drug, the signs became less prominent, suggesting development
of tolerance.
Physical dependence. On the 14th day of the study, the animals were
challenged with nalorphine, 2.0 mg/kg subcutaneously. No abstinence
signs were produced, although there may have been some slight in-
crease in the extent of CNS depression. Nalorphine challenge was
repeated on the 21st day, and again there was no precipitation of
abstinence signs of any consequence. Naloxone was used to challenge
the monkeys on the 16th and again on the 23rd days of the study. On
the former occasion, a dose of 2.0 mg/kg produced mild abstinence
signs, scored between grades 2 and 3 on the Seevers scale, and
consisting of generalized irritability, apprehension, restlessness
and nausea and retching. There was a slight increase in respiratory
rate. The second naloxone challenge produced similar but slightly
more severe signs, scored between grades 3 and 4. When the admin-
istration of UM 1125A was abruptly discontinued on the 28th day of
the study, as abstinence syndrome appeared which was not typical of
withdrawal from morphine and related drugs, though it had enough
signs in common with morphine abstinence that a Seevers score of
4 could be used to describe its-peak intensity. The peak occurred
between the 60th and 66th hours after the last dose of UM 1125A,
and signs were still visible for at least 210 hours. The withdrawal
syndrome was characterized by generalized irritability, restlessness
and apprehension. The animals held their abdomens and appeared to
be nauseated. They showed intention tremors or shivering. There
was questionable tenderness of the abdomen.
Summary. This is a drug which neither suppresses nor precipitates
abstinence in morphine-dependent monkeys, and whose direct effects
of CNS depression are not antagonized by nalorphine or naloxone.
Upon chronic administration, it produced CNS depression and upon
discontinuation there was mild-to-moderate abstinence, which was not
typical of a morphine-like drug. Withdrawal signs were precipitated
by naloxone, but not nalorphine, after 14-21 days of UM 1125A.
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UM 1144 NIH 9048 MCV 4041
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 4.5 (3.2-6.4)
Nilsen:
alpha-4,4-Diphenyl-6-dimethylamino-3-heptanol phenylacetate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
In the doses tested, the drug produced no behavioral effects on
the animals, but it causes lumps at the injection sites, and one
of these lumps developed into an abscess. Therefore, higher doses
were not tested. Doses tested: SDS, 2.0, 4.0, 8.0. Vehicle:
water, 33% propylene glycol for highest dose.
UM 1151 NIH 9549 & 9571 MCV 4155 & 4184 Clonidine
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.98 (0.66-1.46)
Nilsen:
2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
Clonidine neither suppresses nor precipitates morphine abstinence
signs in dependent monkeys. It causes a dose-dependent CNS depres-
sion, not like that of morphine, but characterized by muscle weak-
ness, ataxia and apparent dysphoria, which is not reversed by nal-
oxone and may actually be made more severe by nalorphine. Doses
tested: SDS, 0.005-0.16, Normals, 0.16 mg/kg. Vehicle: water.
DRUG DISCRIMINATION IN PIGEONS AND MONKEYS
In pigeons trained to discriminate morphine or pentobarbital from
saline, clonidine evoked drug-appropriate responding in one of four
birds at doses that reduced rates of responding that were maintained
by food delivery. In monkeys trained to ethylketazocine, clonidine
brought about intermediate responding in three of four animals, with
the fourth monkey placing all of its responding on the saline-appro-
priate key. Apparently, clonidine has some interoceptive components
that are somewhat similar to each of the above compounds, but not
enough for it to be classified as equivalent to any.
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SELF-ADMINISTRATION BY MONKEYS
Clonidine was studied over a range of doses from 0.0001-0.003
mg/kg/inj in monkeys trained to self-inject codeine (0.32 mg/kg/
inj). Clonidine maintained rates of self-injection no higher than
those maintained by saline in all three animals.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
Clonidine was inactive in concentrations of 2 µl in the presence
or absence of 150 nM NaCl.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
Clonidine is a potent agonist which is not blocked by either nal-
trexone or UM 979.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
The actions of clonidine are blocked by naltrexone but not by UM 979.
When the vasa deferentia were isolated from mice treated repeatedly
with morphine, there was tolerance to the effects of morphine and a
small degree of cross tolerance to those of clonidine.
SUMMARY
The data suggest that on the guinea-pig ileum clonidine does not
exert its effects through a morphine-like mechanism, while on the
mouse vas deferens there may be some interaction between clonidine
receptors and morphine receptors. The actions of clonidine in the
behavioral preparations point to non-morphine-like sedative proper-
ties which are not reversed by naloxone. Nevertheless, these data
show that the drug is very potent and has strong behavioral effects.
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UM 1159 NIH 9513
dl-trans-5,6,6a beta,7,8,9,10,10a alpha-Octahydro-1-acetoxy
-9 beta-hydroxy-6 beta-methyl-3-(5-phenyl-2-pentyloxy)-
phenanthridine hydrochloride
SELF-ADMINISTRATION BY MONKEYS
UM 1159
GRAND AVERAGE
AVERAGE
1261
1235
1086
UM 1159 was dissolved in a mixture of Emulphor and ethanol and
diluted with saline. It was studied over a dosage range of
0.001-0.1 mg/kg/injection. Thus, the highest dose tested was
close to that which would have produced directly observable behav-
ioral effects. The drug failed to maintain self-injection respon-
ding at rates above those of saline.
UM 1167 NIH 9538 MCV 4177
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.21 (0.18-0.26)
Nilsen:
(-)-17-Cyclopropylmethyl-7,7-dimethyl-3-hydroxy-6,8-dioxamorphinan
d-tartrate methanolate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
A potent narcotic agonist which, for any particular degree of abstin-
ence suppression, produces a remarkable amount of CNS depression.
There is no indication that this drug has any antagonist properties.
Doses tested: SDS, 0.025-0.20 mg/kg; NW, 0.1 mg/kg. Vehicle:
water.
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SELF-ADMINISTRATION BY RHESUS MONKEYS
Three doses of UM 1167 were studied (2.6 x 10-9 - 2.6 x 10-8 M/kg).
None of these doses maintained self-injection responding above saline.
A few observations were obtained at higher doses; these also pro-
duced very low self-injection rates. These higher doses reduced
subsequent codeine self-injection.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 0.87 1.17 0.75
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone 1.74 x 10
-9
After naltrexone, 10-7M 5.80 x 10-7
After UM 979, 10-7M 1.40 x 10-8
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone 8.6 x 10
-10
After naltrexone, 10-8M 2.4 x 10-9
After UM 979, 10-8M 6.3 x 10-10
SUMMARY
UM 1167 is an unusual drug in that it resembles morphine in some
respects but not in others. It is a potent agent for displacing
etorphine and for inhibiting the electrically induced twitch in the
guinea-pig ileum and mouse vas deferens preparations. Depending on
the preparation employed, the compound is 10 to 50 times as potent
as morphine. The ability of naltrexone and UM 979 to reverse the
actions of UM 1167 on the guinea-pig ileum suggests a morphine-like
action; however, the drug appears to have a different mechanism of
action in the mouse vas deferens, where these antagonists are in-
effective.
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The acute behavioral signs produced by UM 1167 were reversed by both
nalorphine and naloxone. The ataxia and sedation produced by the
compound suggest an ethylketazocine-like component in addition to
morphine-like actions. This is the first compound which we have
studied which was not self-injected by monkeys even though it com-
pletely suppressed the abstinence signs in morphine-dependent animals.
UM 1168 NIH 9539
PRIMARY ADDICTION STUDY
17-Cyclopropylmethyl-3-hydroxy-6-oxamorphinan tartrate
In single dose suppression studies, this drug behaved like an opioid
antagonist, approximately equal in potency to, but longer lasting
than nalorphine. It was not self-administered by monkeys which had
been trained to self-administer codeine. In competing for etorphine-
binding sites in a membrane preparation from rat brain, the drug
showed a high affinity and an intermediate sodium-response ratio.
UM 1168 depressed the twitch in electrically driven preparations of
the isolated guinea pig ileum and mouse vas deferens, and this de-
pressant activity was not greatly antagonized by naltrexone. The
drug is a potent analgesic in the mouse hot-plate test and the
phenylquinone-writhing test but not in the tail-flick test. (See
1979 ANNUAL REPORT of the Drug Abuse Basic Research Program of The
University of Michigan and the comparable report by the Medical
College of Virginia in the Proceedings of the Forty-first Annual
Scientific Meeting of the Committee on Problems of Drug Dependence.)
Animals. In this study, Rhesus monkeys numbered 234A, 279A and 392A
were used.
Dosage schedule. The initial dose of UM 1168 was 0.1 mg/kg subcutan-
eously, and because this produced prolonged effects, the dose was
given only every 12 hours (instead of every six hours, which is
usual in Primary Addiction Studies). On the eighth day, the dose
was doubled to 0.2 mg/kg every 12 hours. By this time the animals
had developed considerable tolerance to the effects of the drug, and
so the dosing interval was reduced to the normal six hours on the
eleventh day of the study. On the 17th day, the dose was doubled
again, to 0.4 mg/kg every six hours; 0.8 mg/kg every six hours
was begun on the 23rd day; and 1.6 mg/kg every six hours was given
from the 25th day on. Drug administration was discontinued abruptly
on the 32nd day of the study.
Acute effects. Initially, UM 1168 produced marked, long-lasting CNS
depression, characterized by body-sag, ataxia, dozing, pupil dila-
tation and very little in the way of facial expression. These signs
were maximal from the second to the eighth hour after drug injection
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and were still apparent at 12 hours. For the first day or two, the
monkeys ate very little food, presumably because of the continuous
CNS depression.
By the eighth day, the signs were significantly less prominent, even
when the dose had been doubled from 0.1 to 0.2 mg/kg every 12 hours.
There was still some body sag apparent when the animals were sitting
and very mild ataxia when they walked.
Subsequently, the dosage interval was reduced to six hours and the
dose was raised to 0.4, 0.8 and finally 1.6 mg/kg, but the signs
remained mild, with slight pupil dilatation and minimal body sag.
It was apparent that rather marked tolerance had developed to the
effects of UM 1168.
Physical dependence. On the 15th day, the monkeys were challenged
with nalorphine, 2 mg/kg, at a time when they were showing mild seda-
tion from the preceding UM 1168 dose. The antagonist reduced that
sedation somewhat and produced very mild abstinence signs (approxi-
mately Grade 1 on the Seevers scale) of yawning and slight irritab-
ility to handling but no abdominal tenderness. Naloxone challenge
(2 mg/kg) , performed on the 17th day, produced moderate abstinence
signs (approximately Seevers Grade 3). There was yawning, retching,
apprehension, restlessness, dyspnea, and the animals lay on their
sides. As with the nalorphine challenge, naloxone produced no ab-
dominal tenderness or rigidity.
Repeated challenges two weeks later produced milder abstinence signs.
The 29-day nalorphine produced restlessness and apprehension, which
was graded as less than 1 on the Seevers scale. The naloxone chal-
lenge on Day 31 produced Grade 2 signs including restlessness, ap-
prehension, increased respiration, nausea, yawning, retching and
the peculiar "half yawn-half retch" sign that has been seen in
withdrawal from nalorphine, cyclazocine and some of the so-called
"kappa" agonists.
Abrupt withdrawal began on the 32nd day, and once again the signs
were very mild, considering the magnitude of the tolerance which
had developed at UM 1168 at that time. The peak occurred at approx-
imately 18 hours after the last dose of UM 1168, and was no more
than Seevers Grade 1 in any of the three monkeys.
Summary. UM 1168 is a potent narcotic antagonist which has a sig-
nificant component of ethylketazocine-like agonist activity (kappa
activity). It produces marked, relatively prolonged CNS depression,
but tolerance develops rapidly to this action. The abstinence signs,
produced either by abrupt withdrawal or challenge with nalorphine
or naloxone, are much milder than might have been expected on the
basis of the marked tolerance development which this drug showed.
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UM 1173 NIH 9550
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 5.5 (3.6-8.2) SC
5.4 (3.9-7.5) oral
Nilsen:
dl-1-(2-(Dimethylamino)ethyl)-6,7-dihydro-3-methyl-4-oxo-6-
phenylindole-2-carboxylic acid ethyl ester (E) oxime
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This drug is a narcotic agonist, somewhat less potent and shorter-
acting than morphine. Doses tested: SDS, 1.5, 3.0, 6.0 mg/kg.
Vehicle: 50% dilute HCl, 50% propylene glycol, heated.
SELF-ADMINISTRATION BY MONKEYS
This drug was self-administered by all three monkeys. Higher doses
were not tested due to solubility problems.
UM 1184 NIH 9629
MOUSE ANALGESIA, ED50 (mg/kg)
Inactive to 100 mg/kg
PHYSICAL DEPENDENCE IN MONKEYS
Quaternary Naloxone
(Naloxone methobromide)
A morphine antagonist, less potent
and shorter acting than naloxone,
which probably has some agonist
properties. Doses tested: SDS,
1.0 mg/kg; NW, 1.0, 2.0, 4.0 mg/kg.
Vehicle: water
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SELF-ADMINISTRATION BY MONKEYS
No dose of the drug was self-administered.
UM 1185 NIH 9630
MOUSE ANALGESIA, ED50 (mg/kg)
Insufficiently active to assay
PHYSICAL DEPENDENCE IN MONKEYS
This compound was tested over a
wide range of doses, but it was
neither a narcotic agonist or a
narcotic antagonist. It caused
very slight CNS depression.
Doses tested: SDS, 1.0-16 mg/kg;
NW, 1.0-32 mg/kg; normals, 16 mg/kg.
Vehicle: water.
Quaternary naltrexone
(Naltrexone methobromide)
UM 1189 NIH 9463
MOUSE ANALGESIA, ED50 (mg/kg)
1,4-Dimethyl-4-piperidinol
(2,4,5-trimethylpyrrole-3-
carboxylate) hydrochloride
Hot Plate: 4.6 (3.3-6.4)
Nilsen: 6.0 (4.5-7.9)
PHYSICAL DEPENDENCE IN MONKEYS
It neither suppresses nor precipi-
tates the signs of morphine abstin-
ence, but at 10 mg/kg it caused
the monkeys to appear pre-convul-
sive, so higher doses were not
tested. Doses tested: SDS,
2.5-5.0 mg/kg; NW, 5.0-10 mg/kg.
Vehicle: water
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SELF-ADMINISTRATION BY MONKEYS
This drug was not self-injected at any tested dose.
UM 1190 NIH 9627
MOUSE ANALGESIA, ED50 (mg/kg)
Insufficiently active for assay
PHYSICAL DEPENDENCE IN MONKEYS
At the doses tested, the drug nei-
ther suppressed nor precipitated
the signs of morphine abstinence.
It caused slight CNS depression.
dl-Spiro ((1,1-dimethyl-3-ethyl-7- Doses tested: SDS, 2.5-10 mg/kg
hydroxy-1H-2-benzopyran)-4,4'- Vehicle: 66% propylene glycol
(1-pentylpiperidine)) hydrobromide
UM 1195 NIH 9637
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 15.0 (11.3-19.8)
Nilsen:
PHYSICAL DEPENDENCE IN MONKEYS
S-N-sec-Butylnormorphine At the doses tested, the compound
neither suppressed nor precipitated
the signs of morphine abstinence.
The highest dose tested caused
tremors and other pre-convulsive
signs, but otherwise the compound
had very little effect upon the
animals Doses tested: SDS, 5.0-
40 mg/kg. Vehicle: water, 33% PC
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 148.4 178.8 0.83
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone 1.15 x 10
-7
After naltrexone, 10-7M 4.00 x 10-6
After UM 979, 10-7M 1.25 x 10-6
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone 4.12 x 10
-7
After naltrexone, 10-8M 7.69 x 10-7
After UM 979, 10-7M 1.17 x 10-6
SUMMARY
This compound is not a typical morphine-like agonist. Its potency
in binding predicts in vivo activity at doses higher than morphine.
The intermediate sodium response ratio is not predictive of the
nature of the in vivo activity. In both smooth muscle preparations
the compound has agonist activity, which is morphine-like in the
guinea pig ileum and unlike morphine in the mouse vas deferens.
UM 1196 NIH 9648
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.29 (0.21-0.40)
PHYSICAL DEPENDENCE IN MONKEYS
A narcotic agonist, approximately
equal to morphine in potency but
shorter in duration. The reversal
N-3-Butenylnorketobemidone
of the drug's effects by nalorphine
hydrobromide and naloxone was somewhat atypical,
in that apparent recovery was fol-
Doses tested: SDS, 0.2-1.6 mg/ lowed by increased CNS depression
kg; normals 3.2 mg/kg.
which lasted for one hour or more.
UM 1199 NIH 9673
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.6 (0.45-0.80)
3-Phenethyl-9 beta-methoxy-9-
Nilsen:
phenyl-3-azabicyclo(3.3.1)-
nonane hydrochloride PHYSICAL DEPENDENCE IN MONKEYS
A narcotic agonist, more potent and
and longer lasting than morphine.
Doses tested: SDS, 0.04-0.6 mg/kg,
Normals, 0.6. Vehicle: water
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UM 1202 NIH 9701
SUMMARY
UM 1202 appears to have narcotic
agonist actions in these prepara-
tions with considerably less
potency than morphine.
14 beta-Mercaptomorphine hydrochloride hydrate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1412 693 2.04
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 approximately 1 x 10
-5M. Maximum depression was 60% at
3 x 10-5M. Naltrexone (10-7M) antagonized UM 1202, but EC50 not
determined because supply of drug was insufficient.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 approximately 1 x 10
-5M. Maximum depression was 100% at
1 x 10-4M. Naltrexone (10-8M) antagonized effects of UM 1202.
UM 1203 NIH 9702
SUMMARY
This compound has a low potency in
each of the preparations. The
results from the smooth muscle pre-
parations suggest a narcotic agonist
component of action due to the type
of response observed and by the
14 beta-Mercaptocodeine antagonism with naltrexone.
DISPLACEMENT OF STEREO SPECIFIC 3H-ETORPHINE BINDING
The EC50 was higher than 15 µM, which is the concentration at
which dextrorphan also displaces the ligand.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 approximately 8 x 10
-5M. Maximum decrease was 100%. Nal-
trexone antagonized the actions of UM 1203.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
In doses of 1 x 10-5M to 3 x 10-4M, the drug decreased the
twitch to a maximum of 88%. Naltrexone (10-8M) antagonized the
action of UM 1203. EC50 values were not determined because of
the limited supply of drug.
350
UM 1204 NIH 9703
SUMMARY
It is unlikely that UM 1204 has
either narcotic agonist or antag-
onist properties. Interestingly,
it enhances the twitch in the mouse
vas deferens preparation.
14 beta-Acetamidocodeine-6-acetate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
The EC50 value was higher than 2000 nM.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
Concentrations from 10-9 M to 10-4 M were tested. The maximum
decrease was 18.4% of the control twitch at 3 x 10-5 M. Naltrex-
one, 10-7 M, did not alter the response to UM 1204. EC50's
could not be determined and probably would have little signifi-
cance when the maximum response is so small.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Concentrations between 3 x 10 -6 M and 1 x 10-4 M increased the
magnitude of the twitch. Naltrexone had no effect on this action.
UM 1205 NIH 9704
SUMMARY
This drug does not have typical mor-
phine-like agonist actions in these
preparations. Like UM 1204, it
enhances the twitch in the electri-
cally driven mouse vas deferens.
14 beta-Chloroacetamidocodeine-6-acetate
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 13800 9970 1.38
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
Concentrations between 10-9 M and 10-4 M had no effect on the
magnitude of the twitch.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVE MOUSE VAS DEFERENS
Concentrations between 10-6 M and 10-4 M increased the twitch
magnitude (5.2 fold at 10-4M). The EC50 for this effect was
approximately 2 x 10-5 M.
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339-844 0 - 81 - 24
UM 1206 NIH 9705
SUMMARY
The compound is not a morphine-
like agonist. It has a very high
sodium response ratio and binds
with an affinity between those of
morphine and propoxyphene. It does
not inhibit the twitch in the
14 beta-Acetamidomorphine-6- guinea-pig ileum to the extent that
acetate hemihydrate morphine does, and it enhances the
twitch in the mouse vas deferens.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 848.8 167.1 5.08
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
UM 1206 decreased the twitch slightly in concentrations between
3 x 10-6 M and 10-4 M. The maximum decrease was 25.4% and occur-
red at the the highest concentration studied. Neither naltrexone
nor UM 979 affected the action of UM 1206.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
In concentrations between 10-6 M and 10-4 M it increased markedly
the magnitude of the twitch, to a maximum of 20 times the control.
UM 1207 NIH 9706
SUMMARY
Receptor binding suggests that UM
1207 is a narcotic agonist of low
potency. In the guinea-pig ileum
and mouse vas deferens preparations,
the pattern of effects produced by
the narcotic antagonists suggests
14 beta-Aminocodeine-6-acetate atypical agonist activity.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 5780 3500 1.65
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 78.9%)1.15 x 10
-9
After naltrexone, 10-7 M 1.28 x 10-9
After UM 979, 10-7M 1.65 x 10-8
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone (maximum depression 37.5%)2.41 x 10
-9
After naltrexone, 10 -8 M 2.03 x 10-9
After UM 979, 10-8 M 4.87 x 10-9
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UM 1208 NIH 9707
agonist. The transient increases
in magnitude of the twitch in the
mouse vas deferens are most unusual.
SUMMARY
This drug is not a morphine-like
14 beta-Chlorocodeinone
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
The EC50 was higher than 15000 nM, which is the value of dextror-
phan in displacing etorphine.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
The dose-response curve was biphasic. The initial decreases oc-
curred over the range of 3 x 10 -10 M to 10-7 M and were completely
abolished by naltrexone, 10-7 M and UM 979, 10-7 M. The second
phase occurred over a range of 3 x 10-7 M to 10-6 M and was not
affected by either antagonist.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At lower concentrations (10-9 M to 10-5 M), it caused slight
decreases in twitch which were not affected by naltrexone, 10-8M
or UM 979, 10 -8 M. At 10-5 M and higher concentrations, the drug
caused large, but very transient increases in the size of twitch.
UM 1209 NIH 9708
SUMMARY
In all three preparations, UM 1209
is a narcotic agonist, less potent
than morphine. It is antagonized
by naltrexone but not by UM 979,
suggesting that it is a "mu"
14 beta-Chloromorphinone
agonist.
DISPLANCEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 434 317 1.37
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 36.7%)1.12 x 10
-6
After naltrexone, 10-7 M 2.00 x 10-4
After UM 979, 10-7 M 1.75 x 10-6
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DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone (maximum depression 85.2%)1.04 x 10
-6
After naltrexone, 10-8 M 8.43 x 10-6
After UM 979, 10-8 M 1.44 x 10-6
UM 1210 NIH 9709
SUMMARY
UM 1210 behaved like a morphine-
type agonist in all three prepara-
tions.
14 beta-Bromomorphinone
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 759 460 1.65
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 48.5%)2.67 x 10
-6
After naltrexone, 10-7 M 3.63 x 10-5
After UM 979, 10-7 M 9.77 x 10-6
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone [maximum depression 89.4%)8.24 x 10
-7
After naltrexone, 10-8 M 1.97 x 10-5
After UM 979, 10-8 M 2.79 x 10-6
UM 1211 136 NIH 9712 7380
SUMMARY
This drug was without effects in
these three preparations.
(-)-Galanthamine hydrobromide
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
EC50 was greater than 20000 nM.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA PIG ILEUM
No depression in doses between 10-9 M and 10-4 M.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
No depression in doses between 10 -9 M and 10-4 M.
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UM 1213 NIH 9725 MCV 4188
L-Tyrosyl-D-alanylglycyl-L-N-alpha ethylphenylalanine amide acetate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.73 (0.59-0.90) Nilsen:
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This is a morphine-like narcotic agonist with a very flat dose-
response curve. Doses tested: SDS, 0.5-16 mg/kg. Vehicle: water
SELF-ADMINISTRATION BY MONKEYS
UM 1213 maintained drug self-injection responding at rates above
those of saline but only at 52 per cent of the maximum rate of
codeine self-injection (0.3 mg/kg/injection). The dose that main-
tained the maximum rates of responding was 5.5 x 10-7 mol/kg/injec-
tion (0.3 mg/kg/injection); higher and lower doses were less effec-
tive.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 8.17 4.92 1.66
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 27.3%)1.01 x 10
-8
After naltrexone, 10-7 M 7.72 x 10-8
After UM 979, 10-7 1.41 x 10-8
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DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone (maximum depression 98.3%)1.09 x 10
-8
After naltrexone, 10-8 M 1.42 x 10-7
After UM 979, 10-8 M 7.10 x 10-8
SUMMARY
UM 1213 appears to be a morphine-like agonist in all of our prepa-
rations. The drug is equal to or more potent than morphine on the
in vitro preparations but less potent than morphine on the in vivo
preparations.
UM 1214 NIH 9726 MCV 4191 Sufentanil citrate
MOUSE ANALGESIA, EC50 (mg/kg)
Hot Plate: 0.004 (0.003-0.005)
Nilsen:
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-
phenylpropanamide 2-hydroxy-1,2,3-propane-tricarboxylate (1:1)
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This is a very potent, short-acting narcotic agonist. Doses tested:
SDS, 0.0005-0.004 mg/kg. Vehicle: water.
SELF-ADMINISTRATION BY MONKEYS
UM 1214 maintained self-injection responding at rates comparable
to codeine in two of three monkeys at a dose of 5.2 x 10-9 mol/kg/
injection. In the third monkey, maximum rates were maintained at
the same dose, but the rates were lower than codeine. UM 1214 at
the two highest doses studied suppressed codeine self-injection
for a number of sessions after these doses were substituted. This
phenomenon has not been observed previously with other drugs that
have high potency (e.g., etorphine, fentanyl).
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 7.79 4.15 1.87
NOTE: In the absence of Na+,
3H
the drug exhibited a biphasic pattern
in inhibiting -etorphine binding. The cross-over point of the
two linear portions of the log-probit plot occurred at the E C 5 0
value, which was 4.15 nM. The biphasic response represents a
unusual phenomenon
 3H
hitherto not encountered in displacing opiate
receptor binding of -etorphine by various narcotic drugs.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone 5.9 x 10
-16
After naltrexone, 10-7M 5.0 x 10-12
After UM 979, 10-7 M 3.9 x 10-12
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 (M) Drug alone 4.4 x 10
-9
After
After
SUMMARY
UM 1214 resembles
was studied. Its
naltrexone, 10-8 M
UM 979, 10-8 M
9.2 x 10-8
1.3 x 10-8
morphine in each of the preparations in which it
sodium ratio is similar to that of narcotic agon-
ists. It suppresses electrically induced twitches in both smooth
muscle preparations and it is reversed by both narcotic antagonists
in these preparations. It suppresses narcotic withdrawal in morphine-
dependent Rhesus monkeys. It supports drug self-injection in these
monkeys.
UM 1215 NIH 9729 MCV 4193
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.49 (0.34-0.72)
Nilsen:
4-(m-Acetoxyphenyl)-4-(1-acetoxypropyl)-1- n -pentylpiperidine
oxaiate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
In the doses tested, UM 1215 neither precipitated nor suppressed the
signs of morphine abstinence, nor did it modify the monkeys' behavior
in any other detectable way. Doses tested: SDS, 0.3-4.8 mg/kg;
NW, 0.3, 0.6 mg/kg. Vehicle: water, 25% propylene glycol, heat
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DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 351.8 154.3 2.28
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 63%) 2.14 x 10
-8
After naltrexone, 10-7 M 1.84 x 10-5
After UM  979, 10-7 M 2.48 x 10-6
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
EC50 was 4.07 x 10
-8 M. Maximum depression was
Neither naltrexone (10-8 M) nor UM 979 (10-8 M)
actions of UM 1215.
50 per cent.
antagonized the
SUMMARY
Results from receptor binding and guinea pig ileum suggest a mor-
phine-like component of action for this drug. The inhibitory
actions on the mouse vas deferens are different in mechanism in
that there is only a half-maximal suppression of the twitch and
that is refractory to narcotic antagonism. These data, taken to-
gether with the information from the morphine-dependent monkey, are
interesting because UM 1215 was without effect in suppressing the
signs of morphine abstinence in doses that, on the basis of the
binding and guinea-pig-ileum data, would be expected to be effec-
tive.
UM 1218 NIH 9585
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: No dose response
Nilsen:
N-Cyclohexylmethylnorketobemidone hydrobromide
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
In the doses tested, this drug had no apparent effect upon the be-
havior of the monkeys. The supply of drug was depleted so that
higher doses could not be evaluated. Doses tested: SDS, 5.0-
10 mg/kg. Vehicle: water, 33% propylene glycol, heat
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UM 1219 NIH 9734 MCV 4194
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive to 100 mg/kg
Nilsen:
dl-Spiro ((1,3-diethyl-1-methyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(1-pentylpiperidine)) hydrobromide
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
At the doses tested, UM 1219 neither suppressed nor precipitated
the signs of morphine abstinence. Drug supply was depleted, so
higher doses were not tested. Doses tested: SDS, 5.0-20 mg/kg
Vehicle: ethanol + Emulphor
UM 1220 NIH 9740 MCV 4201
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 0.73 (0.55-0.98)
Nilsen: 2.1 (1.4-3.1)
N-(2-Methoxyethyl)-norketobemidone oxalate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This compound is a short-acting narcotic agonist, somewhat more
potent than morphine. Doses tested: SDS, 0.06-0.5 mg/kg., Nor-
mals, 0.5 mg/kg, Vehicle: water
UM 1221 NIH 9741
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: No dose response
Nilsen:
N-2-Hexylnorketobemidone hydrobromide
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PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
In the doses tested, this drug had no obvious effect upon the be-
havior of the animals. Drug supply was depleted so that higher
doses could not be tested. Doses tested: 5.0-20 mg/kg. Vehicle:
50% ethanol + 50% water
UM 1222 NIH 9742
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Insufficiently active
for assay
Nilsen: Inactive to 50 mg/kg
Spiro((1,1-Dimethyl-3-ethyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(1-allylpiperidine)) hydrobromide
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This drug neither suppressed nor precipitated abstinence signs in
the doses which were tested. Doses tested: SDS, 5.0-10 mg/kg.
Vehicle: 50% ethanol + 50% water, heat.
UM 1228 NIH 9751 MCV 4202 MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: No dose response
Nilsen: Inactive to 100 mg/kg
(2 alpha, 6 alpha, 11S)-(+)-1-Cyclopentyl-5-(1,2,3,4,5,6-hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-y1)-3-
pentanone methanesulfonate.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 290.4 471.2 0.62
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
UM 1228 suppressed the twitch at 10-5 M and this effect was
not prevented by naltrexone (10-7 M). The drug had no effect
upon responses to morphine when administered in concentrations
up to 10-6 M, 15 minutes before determining the morphine concen-
tration-effect curve.
SUMMARY
This is the essentially inactive dextro isomer of UM 1229.
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1229 NIH 9752 MCV 4203 MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: No dose response
Nilsen: Inactive to 100 mg/kg
(2 alpha, 6 alpha, 11S)-(-)-1-Cyclopentyl-5-(1,2,3,4,5,6-hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-y1)-3-
pentanone methanesulfonate
DISPLACEMENT OF STEROSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1.78 2.22 0.80
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
UM 1229 produced an unsurmountable (noncompetitive) inhibition
of the response to morphine when administered in concentrations
as low as 10-12 M. The drug inhibits the electrically induced
twitch at 10-5 M, and this effect is not prevented by naltrexone
(10-7 M).
SUMMARY
This drug, the active levo isomer of UM 1228, is a potent opioid
antagonist, comparable to or more potent than naltrexone. The un-
surmountable nature of the interaction of UM 1229 with morphine in
the guinea-pig ileum preparation suggests that the compound may have
a long duration of action.
UM 1230 NIH 9733 MCV 4194
MOUSE ANALGESIA, EC50 (mg/kg)
Hot Plate: 2.2 (1.6-3.0)
Nilsen: 19.6 (13.6-28.1)
(-)-Nicotine di-l-tartrate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
At the doses tested, this drug neither suppressed nor precipitated
the signs of morphine abstinence. Doses tested: SDS, 0.5-4.0 mg/kg
Vehicle: water
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
UM 1230 has an EC50 greater than 2000 nM.
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DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
No effect over the range from 10 -9 M to 10-4 M.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
No effect over the range from 1 0 - 9 M to 10-4 M.
SUMMARY
This compound was inactive in all of the tests performed.
UM 1231 NIH 9757 MCV 4204
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 3.8 (2.8-5.2)
Nilsen: 7.1 (5.3-9.4)
dextro-Propoxyphene hydrochloride
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
A narcotic agonist which is less potent than morphine. Doses
tested: SDS, 2.0-16 mg/kg. Normals, 12-16 mg/kg. Vehicle: water
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 10175 1795 5.67
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA PIG ILEUM
EC50 (M) Drug alone (maximum depression 92.4%)5.45 x 10
-6
After naltrexone, 10-7 M 7.62 x 10-6
After UM 979, 10-7 M 7.32 x 10-6
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
UM 1231 increased the magnitude of the twitch to a maximum of
2.4 fold at a drug concentration of 3 x 10 -5 M . In the presence
of naltrexone, 1 0 - 8 M, caused a greater enhancement to a maximum
of 5.6 fold. UM 979, 10-8 M, did not alter the response to
UM 1231.
SUMMARY
UM 1231 suppressed the withdrawal syndrome in the monkey with a
potency 1/5 that of morphine. In the in vitro preparations, it was
considerably less potent than morphine and had unusual properties.
In the binding assay it had a very large sodium response ratio.
On the mouse vas deferens, it produced enhancement which was poten-
tiated by naltrexone. Thus, while appearing to be a morphine-like
compound in the dependent monkey, UM 1231 has a variety of non-
morphine-like actions in the other preparations.
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UM 1232 NIH 9769
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 23.6 (17.7-31.5)
Nilsen:
N-Pentylacetate norketobemidone
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
At the doses tested, this compound had very little pharmacological
effect. At the highest dose, there was a slight suggestion of
antagonist activity, but the supply of drug was depleted and higher
doses could not be tested. Doses tested: SDS, 5.0-20 mg/kg.
Vehicle: 50% ethanol - 50% water, heated to put into solution.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1957 2200 0.89
SUMMARY
UM 1232 appears to be a narcotic antagonist of very low potency.
UM 1233 NIH 9770
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 1.8 (1.4-2.2)
Nilsen:
N-(2-Ethoxyethyl) norketobemidone oxalate
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
A narcotic agonist, approximately equal to morphine in potency and
duration of action. Doses tested, 0.8-6.4 mg/kg. Vehicle: 50%
ethanol-50% water, heated to put into solution.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1061 643 1.65
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DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA-PIG ILEUM
EC50 (M) Drug alone (maximum depression 38.6%)2.63 x 10
-6
After naltrexone, 10-7 M 3.27 x 10-5
After UM 979, 10-7 M 1.11 x 10-5
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
The responses of the mouse vas deferens to UM 1233 are complex.
At concentrations between 10-7 M and 10-5 M, the drug slightly
suppressed the twitch. At higher concentrations the magnitude
of the twitch increased greatly. UM 979, 10 -8 M, had no effect
on the responses to UM 1233. However, naltrexone, 1 0 - 8 M, com-
pletely antagonized the suppression of the twitch by UM 1233 and
consequently enhanced the increases in twitch magnitude produced
by higher concentrations.
SUMMARY
UM 1233 is morphine-like in the withdrawn Rhesus monkey. In dis-
placing etorphine, it is only 1/10 as potent as morphine. This
type of disparity is infrequent but has been seen with meperidine-
like drugs in the past. In the guinea-pig ileum, the compound was
considerably less potent than morphine. The morphine-like actions
of UM 1233 upon the mouse vas deferens are obscured by the increases
in twitch magnitude which are produced by this drug.
UM 1237 NIH 9789
MOUSE ANALGESIA, EC50 (mg/kg)
Hot Plate: Inactive
Nilsen:
5-Hydroxypentyl norketobemidone hydrobromide
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
The compound neither suppressed nor precipitated the signs of mor-
phine abstinence. Doses tested: 5.0-10 mg/kg. Vehicle: water
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1236 802 1.54
SUMMARY
If this is a narcotic agonist, it is a weak one.
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UM 1242 NIH 9576 MCV 4157
MOUSE ANALGESIA, EC50 (mg/kg)
Hot Plate: 2.4 (1.6-3.7)
Nilsen:
cis-(-)-3-(Octahydro-2-methyl-1H-1-2-pyridin-4a-yl)phenol, (Z)-2-
butenedioic acid salt
PHYSICAL DEPENDENCE EVALUATION IN RHESUS MONKEYS
This drug had no effect upon the progression of abstinence signs
in morphine-dependent monkeys. Doses tested: SDS, 4.0-32 mg/kg.
Vehicle: water.
DISPLACEMENT OF STEREOSPECIFIC 3H-ETORPHINE BINDING
+Na -Na +Na/-Na
EC50 (nM) 1077 497 2.17
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN GUINEA PIG ILEUM
Concentrations between 10 -6 M and 3 x 10-4 M increased the mag-
nitude of the twitch and also increased the baseline tension.
Neither naltrexone, 10-7 M, nor UM 979, 10 - 7 M altered the re-
sponse to UM 1242.
DEPRESSION OF TWITCH IN ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
This drug had no consistent effect upon the vas deferens prepa-
ration.
SUMMARY
UM 1242 appears to be devoid of narcotic activity at the doses
tested in the withdrawn monkeys; it also shows no narcotic agonist
activity on the smooth muscle preparations. In the binding assay,
it is approximately 1/10 as potent as morphine and has an agonist-
like sodium response ratio.
UM 1258 NIH 9624 MCV 4175
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: 2.4 (1.7-3.3)
Nilsen:
1-((2 alpha, 6 alpha, 11S)-dl-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl))-3-octanone
methanesulfonate
365
SELF-ADMINISTRATION BY MONKEYS
No injection dose of UM 1258 maintained rates of
behavior higher than those maintained by saline.
self-injection
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Dopamine and Serum Prolactin in
Methadone Withdrawal
M. S. Gold, A. L. C. Pottash, I. Extein, and H. D. Kleber
We have hypothesized that chronic exogenous opiate administration
might cause a decrease in endogenous opiate release and synthesis
as well as a decrease in opiate receptor sensitivity (1-4). Abrupt
discontinuation of chronic opiate administration would, according
to our model system, result in the absenceof exogenous opiate-
mediated inhibition of ascending norepinephrine (NE) activity. As
a result of this release from chronic exogenous inhibition and the
absence of adequate inhibitory neurotransmitters at the level of
the NE nucleus (4), there would be a resultant large increase in NE
activity, release, and turnover (1,5). Attempts to use endorphin
stores to autoregulate this profound locus coeruleus (LC) firing
increase would be too little too late, as the stores of available
endogenous opiates would be of insufficient quantity and the recep-
tor sensitivity would be too low to augment the available m-Enkepha-
lin. In addition, it is likely that other available inhibitory pre-
synaptic neuro transmitters such as epinephrine (E) and NE would be
of insufficient quantity and interact with receptors which are them-
selves abnormal to reverse the NE "rebound" release from opiate
mediated inhibition (4).
We tested the efficacy of clonidine in opiate withdrawal not only
to demonstrate that clonidine might be a new and important treat-
ment for addicts (6) but also to see which physiological and affect-
ive variables would be clonidine-reversible and thereby attributable
to clonidine's agonistic effects on presynaptic alpha-2 receptors on
the LC. We had speculated that clonidine would reverse in man the
behaviors and affective state produced by electrical or pharmaco-
logical activation of the IC as we had demonstrated in primates.
Our LC or NE hyperactivity hypothesis was supported by knowledge of
LC neuroanatomy. The known anatomical connections of the LC sug-
gested an important role for this structure in the wide variety of
behaviors and physiological changes which accompany drug-withdrawal
and spontaneous panic states. The LC also receives afferents from
serotonergic, adrenergic, peptidergic and noradrenergic neurons,
the hypothalamus, and may have transducer cells to receive and relay
hormonal messages (4,7,8). This LC neuroanatomy supports an
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important neuromodulatory or "tone" role for the LC and does not
necessitate the direct involvement of numerous brain systems in
the feeling state, cardiovascular, sympathetic, parasympathetic,
and many other manifestations of opiate withdrawal states (1,4).
After we administered 5 ug/kg of clonidine and placebo double-blind,
orally in matching vehicles to 5 male opiate (methadone) addicts (1)
we recognized that clonidine was effective for the full spectrum
of withdrawal signs, symptoms and affects. All of our clinical
data on the antiwithdrawal efficacy of clonidine in man (1-6) served
to offer strong support for an important Endorphin-LC interaction
and NE hyperactivity as the most critical event in the generation
of withdrawal symptom on the basis of clonidine's known effects on
the LC and NE activity when given in low doses. This NE hypothesis
could only be directly investigated in animal studies. In rodent
and primate studies it was demonstrated that clonidine decreased NE
activity, release and turnover as assessed by changes in the brain's
major NE metabolic MHPG (4,9-11). Morphine and endogenous opiates
were found to have a similar effect through interaction with LC
opiate receptors as assessed by naloxone reversal (12,13). Finally,
Aghajanian (14) demonstrated that chronic exogenous opiate admini-
stration produced tolerance of LC neurons to suppression. He also
demonstrated that tolerance develops in the LC inhibition response
to chronic opiates (in opiate addiction) and that naloxon-precipi-
tated withdrawal was accompanied the predicted noradrenergic
hyperactivity. He demonstrated in single neuronal electrophysio-
logical and microiontophoresis studies that this NE hyperactivity
could be reversed by clonidine (14). This study confirmed the
hypothesized LC hyperactivity (1,4) in withdrawal and supported our
notion that NE was the important neurotransmitter in the generation
of withdrawal symptoms. Our studies and the studies in the litera-
ture (15) did not exclude an important or at least significant role
for other brain monoamine nuclei and neurotransmitters in opiate
withdrawal. However, we did hypothesize that the NE hyperactivity
could be demonstrated directly in studies of animals and man and
that this hyperactivity was related to the signs and symptoms of
withdrawal (1,2).
This noradrenergic hypothesis can also explain the efficacy of
clonidine and other nonopiate treatments for opiate withdrawal (4).
However, a dopaminergic hyperactivity hypothesis has also been pro-
posed and supported by a large number of animal studies. This dopa-
mine hypothesis is also supported by a rodent study and a pilot
study in humans (16-19) reporting that opiate withdrawal is associa-
ted with decreases in serum prolactin (PRL).
Serum PRL is predominantly controlled in vivo and in vitro by an
inhibitory dopamimergic mechanism (20,21). Consistent with this
control mechanism, augmentation of dopamine activity results in a
decrease in serum PRL, whereas inhibitionof dopamine function
results in significant increases in serum PRL (20,21). Exogenous
and endogenous opiates produce increases in serum PRL (20,21) while
opiate antagonists produce decreases in serum PRL in some species
and some human studies (20,21).
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To evaluate the dopamine hyperactivity hypothesis in man and con-
firm the pilot data on decreased serum PRL in opiate withdrawal, we
measured serum PRL during significant opiate withdrawal in 21 male
opiate addicts and after clonidine suppression of opiate withdrawal
signs and symptoms. We also measured serum PRL in these addicts 4
weeks after they were free of clonidine and opiates.
METHODS
The subjects were 21 male opiate addicts who had been maintained on
15-80 mg of methadone for more than 6 months. All gave informed
consent to participate in a study that involved abrupt discontinua-
tion of methadone and administration of 6 ug/kg of clonidine after
at least 36 hours of total abstinence. A research nurse specialist
observed and rated the patients as described previously (11) with
the subjects at bed rest after an indwelling venous catheter had
been in place for 60 minutes. Ratings were done simultaneously with
blood samples taken 60 minutes before clonidine administration, at
the time of clonidine administration. PRL levels were not measured
while the patients were taking methadone because of the known stimu-
latory effects of methadone on serum PRL (20,21). Subjects had
venipuncture performad 4 weeks after clonidine discontinuation for
determination of an opiate-free PRL baseline. Urine toxicology was
performed weekly by T.L.C. to determine whether patients were drug-
free. All samples were placed on ice and centrifuged within 1 hour.
Serum was frozen at -20°C until radioimmnoassays were performed in
duplicate (20,21).
RESULTS
Clonidine caused a significant decrease in nurse-rated opiate
withdrawal signs and symptoms. Opiate withdrawal symptoms decreas-
ed from a mean (±SD) just before clonidine administration of 13.8 ±
6.9 to 1.8 ± 2.7 at 60 minutes after clonidine administration and to
0.7 ± 1.8 at 120 minutes after clonidine administration (paired t
test; P<0.01). Serum PRL was significantly decreased
from a mean during peak opiate withdrawal before clonidine (36-72
hours of total abstinence) of 5.3 ± 3.2 as compared to a drug-free
baseline of 14.1 ± 2.7. There were no significant changes or
effects of clonidine demonstrated as differences between the 0 and
120-minute serum PRL levels. Serum PRL was 4.7 ± 3.3 at 60 and 4.3
± 3.8 at 120 minutes (paired t, NS).
DISCUSSION
Significant decreases in serum PRL are normally attributable to the
administration of drugs or medications which stimulate dopamine re-
ceptors or augment dopamine release or neurotransmission, but other
neurotransmitters may also inhibit PRL release (20). The decreased
serum PRL reported here for patients in significant opiate withdraw-
al is in agreemant with our previous pilot study (19) and the rodent
study of Lal et al. (17). These data support the proposed dopaminer-
gic hyperactivity in opiate withdrawal (16,17,22). However, although
the signs and symptoms of opiate withdrawal were reversed by
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clonidine, the serum PRL did not return to the normal range or post-
addiction levels. This suggests that the dopaminergic hyperactivity
my continue for a prolonged period of time irrespective of the
symptoms or signs reported or observed. Further studies are neces-
sary with PRL samples taken throughout opiate withdrawal to evaluate
this hypothesis.
Clonidine in the doses used in this study is not known to stimulate
DA receptors or augment DA turnover. However, it is possible that
clonidine may prolong the decrease in serum PRL that accompanies
withdrawal through non-DA mechanisms (19).
On the basis of rodent and primate studies and the efficacy of low
doses of the presynaptic -2 agonist clonidine in withdrawal, we
have suggested that opiate withdrawal results from increased
neuronal activity in noradrenergic areas of the brain that are reg-
ulated by -2 and opiate receptors (1-4). We further suggested that
LC might have a rebound release from tonic exogenous opiate-
mediated inhibition and that clonidine reverses noradrenergic hyper-
activity by replacing opiate with -2 mediated inhibition of the LC
(1-6). Direct electrophysiological (14) and neurochemical (11)
investigations in rodents have supported noradrenergic hyperactivity
in withdrawal and its relationship to the efficacy of clonidine. Our
preliminary studies of plasma levels of 3-methoxy-4-hydroxy-phene-
thylene-glycol in acute withdrawal and after clonidine in man suggest
that noradrenergic hyperactivity is present, and may be related to
the symtoms of withdrawal the efficacy of clonidine in with-
drawal. Other neurotransmitter and neural peptides systems also
be involved in the data reported here and elsewhere.
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The Generality of Benefits From
Alcohol and Drug Abuse
Treatments
A. T. McLellan, L. Luborsky, G. E. Woody, and
C. P. O’Brien
INTRODUCTION
As part of a large treatment evaluation study (McLellan et al. 1980)
we collected data on the severity of chemical use, as well as five
other problem areas, from samples of alcoholics and drug addicts at
admission to treatment and at follow-up six months later. These data
provided a natural opportunity: (1) To examine the relationships
between the severity of alcohol/drug use and the status of the other
problem areas prior to and following treatment; (2) To determine if
improvement in alcohol/drug use was related to improvement in the
other problem areas.
METHOD
Subjects - Subjects were drawn from the 1035 male, service veterans
who were admitted to alcohol (n=671) or drug abuse (n=364) rehabili-
tation programs at the Coatesville or Philadelphia VA Hospitals
during 1978. We excluded patients who dropped out of treatment
prior to 5 inpatient days or 5 outpatient visits. We were able to
follow up approximately 85 percent of the remaining 879 patients six
months after admission to treatment, and complete data was therefore
available on 460 alcoholic and 282 drug addicted clients (total
n=742).
Data Collection
The admission and follow-up evaluations were based upon data from
the Addiction Severity Index (ASI) (McLellan et al. 1980). The
ASI is a structured 30-40 minute, clinical research interview de-
signed to assess problem severity in six areas commonly affected
by addiction: medical, legal, substance abuse, employment, family,
and psychological function.
In order to develop valid general measures of outcome in each of the
problem areas, and to overcome the inherent unreliability of single-
item criteria (Nunnally 1967), we constructed criterion composites
from sets of single items within each of the ASI problem areas.
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Several items from each problem area were intercorrelated to exclude
those which were unrelated. The remaining items were standardized
and tested for conjoint reliability using Cronbach's formula (Cron-
bath 1970). A set of 4 to 6 items from each area was selected using
this procedure, and each set showed a standardized reliability co-
efficient of .73 or higher. Seven composites [medical problems,
employment, drug use, alcohol use, legal status, family problems,
and psychological function) were constructed in this manner, and
scores on each composite were calculated for all patients at admis-
sion and follow-up, with higher scores indicating greater problem
severity.
RESULTS
Pre-Treatment Problem Status Correlations - Pearson product-moment
correlations were calculated among the seven
status composites as a means of determining
retreatment problem
the nature and extent
of the relationships among them. The results are presented for the
total population in the top portion of table 1. As can be seen, the
coefficients were generally quite low, including the relationships
between alcohol/drug use with the other problem areas. Although
four coefficients were large enough to be statistically significant
(p < .01) this was more a function of the population size than the
strength of the relationships, since even the largest coefficient
(.44) accounted for less than 19% of joint variation.
The significant negative correlations between alcohol use and drug
use, and between alcohol use and legal status, reflected the essen-
tial differences between the Alcoholic and Drug Addict samples with-
in our population. To test the possibility that extreme variation
between these samples was masking more robust relationships within
each group, we calculated the correlations separately, and these
results are presented in the lower portion of table 1. While the
separation of these samples did expose some differences, in general
the correlations remained low in both groups. The few significant
relationships were common to both samples and were not surprising.
For example, the severity of drug use was directly related to the
severity of the legal problem, and the severity of the family prob-
lem was directly related to the severity of the psychological prob-
lem.
These findings confirm our previous reports (McLellan et al. 1980)
with another set of measurements, and indicate the independence of
the separate problem areas and the lack of a general relationship
between the chemical abuse measures and the remaining problem areas
in this population at the time of admission.
Post-Treatment Problem Status Correlations
Although the correlations between the pretreatment measures were
generally low, it remained possible that the posttreatment status
of the problem areas would be generally related to the outcome
status of the chemical abuse problems. As a test of this possibility,
we again intercorrelated the problem status measures for the entire
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population and for the alcoholic and drug addict samples at the time
of followup. Again, generally low correlations were shown for the
total population and for the individual samples. Although more sig-
nificant relationships were seen in the followup data than were seen
in the pretreatment results, the magnitude of the relationships
remained low, and there did not appear to be a tendency toward a
general relationship between the chemical abuse measures and the
remaining problem areas. However, there was an indication of a
general relationship between the psychological problem status and
most of the other problem areas in the total population and in each
of the samples.
Correlation Among Improvement Scores
As a test of the generality of treatment effects, we calculated
residual change scores (which equated individuals for different
pretreatment scores) on each of the criterion measures and then
intercorrelated these residualized change measures. If treatment
for drug and alcohol abuse produced general effects, then there
should be generally significant relationships among the change
scores, especially between the change in chemical abuse and the
other scores. The results of these intercorrelations are presented
for the total population in the top portion of table 2, and again
the correlations were strikingly low, especially between the chemi-
cal abuse change scores and change in the other problem areas. As
in the case of the Posttreatment Status results, there appeared to
be a clear, if not large, relationship between change in psychologi-
cal status and change in the other areas.
When these intercorrelations were examined separately for the two
samples (lower portion, table 2), similar results were obtained.
Most correlations were quite low for both samples, yet four sig-
nificant relationships were seen in each sample between the psycho-
logical change score and the other change measures. Again, no
general relationships were seen between change in drug use and
change in the other areas.
SUMMARY AND DISCUSSION
We tested the relationships between severity of chemical abuse and
the status of several other problems commonly associated with ad-
diction, by intercorrelating highly reliable problem status mea-
sures in samples of male alcoholics and drug addicts before and
after substance abuse treatment. The results for the total popu-
lation and for each of the samples showed very low correlations
generally, and virtually no evidence of a general relationship
between the chemical abuse measures and the remaining problem areas.
We then tested the generality of treatment effects by calculating
residual change scores on each of the problem measures and inter-
correlating these scores. Again, the correlations were quite low
with no suggestion of a general relationship between improvement in
the chemical abuse problem and improvement in the other areas. While
no general relationships were found between chemical abuse and the
other problem areas, the posttreatment psychological status was
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TABLE 1
PRETREATMENT CORRELATIONS OF PROBLEM STATUS MEASURES
TOTAL  POPULATION (N=742)
EMPLOY ALCOHOL DRUG LEGAL FAMILY PSYCH
MED .09 .ll .07 -.06 .07 .12
EMP .O8 .04 .03 .05 .14
ALC -.22* -.24* .ll .09
DRG .44* .14 .08
LEG .09 .05
FAM .34*
ALCOHOLICS (N=460) 9
EMP ALC DRG LEG FAN PSY
MED .11 .15 .01 .00 .07 .10
EMP .17* .03 .00 .02 .10
ALC -.09 -.01 .11 .07
DRG .73* .12 .04
LEG .04 .15
FAM .33*
* = p< .01
DRUG ADDICTS (N=282) 10
EMP ALC DRG LEG FAM PSY
MED .05 .08 .07 -.09 .10 .18
EMP .08 .05 .02 .11 .22
ALC -.07 -.02 .08 .18
DRG .32* .18 .08
LEG .07 .05
FAM .36*
TABLE  2
CORRELATION OF RESIDUALIZED CHANGE SCORES OK PROBLEM STATUS MEASURES
TOTAL  POPULATION (N=742)
EMPLOY ALCOHOL
MED .05 .14*
EMP .03
ALC
DRG
LEG
FAM
ALCHOHOLICS (N=460)
EMP ALC DRC LEG FAM PSY
MED .06 .07 .04 .02 .07 .23*
EMP .16* -.03 -.06 .09 .19*
ALC .04 .03 .21* .21*
DRG .13 .02 -.01
LEG .01 .11
FAM .29*
* = p < .01
DRUG LEGAL FAMILY PSYCH
.02 .02 .07 .19*
.04 .11 .13 .09
.08 .02 .15* .22*
.19* .08 .23*
.10 .15*
DRUG ADDICTS (N=282)
EMP ALC DRG LEG FAM PSY
MED .04 -.05 -.03 -.05 .10 .24*
EMP -.01 .01 .15 .20* .09
ALC -.09 -.08 .08 .19*
DRG .21* .09 .17*
LEG .06 .16
FAM .31*
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generally related at a moderate level to the posttreatment status
of the other measures, and psychological improvement was generally
related to improvement in most of the other problem areas.
Generality of Treatment Benefits
The low intercorrelations among the problem status measures at
followup and among the residual change scores were surprising in
light of the many evaluation studies (Armor et al. 1976; Pattison
1976; Simpson et al. 1978) which have shown general population im-
provements in the areas of legal status, employment, and social re-
lationships following alcohol and drug abuse treatments. However,
the general improvements reported in these evaluation studies are
a function of population averages compared before and after treat-
ment. This does not mean that most patients presented with most
problems and that most improved. McLellan et al. have pointed out
how subgroups of patients within a population may show different
patterns of treatment problems, and extremely different patterns of
change. These different groups are not recognized when only popu-
lation statistics are reported.
Despite the low intercorrelations demonstrated between the improve-
ment scores, it would be rash to dismiss the potential importance
of improvement in the substance abuse problem for the long term
maintenance of treatment benefits. The followup interval employed
in this study was six months, which maximized the effects of treat-
ment. However, it is probable that while improvement in the sub-
stance abuse, medical, and even psychological problem areas is
possible within that time period, improvement in the employment,
family, and legal problem areas may have a longer latency. In
addition, improvement in these areas may depend upon continued con-
trol of the substance abuse problem. While this suggests the possi-
bility that greater relationships would be seen between the sub-
stance abuse measures and the other problem areas at a longer follow-
up period, the data also argue that the reduced substance abuse may
be necessary but not sufficient for improvement in these other
areas. In fact, two-year followup data on alcoholics by Finney
et al. (1980) support this conclusion, and point out the importance
of posttreatment family and social variables in maintaining post-
treatment gains.
Implications
The present data indicate that although it is tempting to ask whether
patients are generally improved following treatment, it seems more
reasonable to consider the specific treatment problems presented
at admission, and the particular areas that have (and have not)
shown improvement. In this regard, it seems clear that followup
evaluations which report only the proportion of patients who have
remained abstinent do not offer adequate information regarding the
total effects of rehabilitation treatment.
With regard to the clinical implications of these data, it seems
clear that the results support a move away from addiction-centered
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therapy toward the development of more comprehensive programs offer-
ing counseling, therapy, and referral in a variety of potential
problem areas. It may be that the general improvements reported
by many evaluation studies are due in part to the specific effects
of the associated services (e.g., job referral, family counseling)
provided by most treatment centers, on the particular problems of
their clients.
Importance of Psychological Dysfunction
Perhaps the most intriguing finding within the present results was
the moderate general relationship shown, in both improvement scores
and in outcome status measures, between the psychological area and
the other problem areas. This finding is important for two reasons.
First, the relationship between improvement in psychological adjust-
ment and improvement in drug and alcohol abuse, may have implica-
tions for the etiologies of addiction. It has long been speculated
that underlying psychological problems are the basis for many forms
of addiction, and that chemicals of abuse may serve as medications
for these underlying problems. Secondly, the general associations
shown between psychological improvement and improvement in the other
areas suggests that psychological interventions may be particularly
important to the total rehabilitation effort within drug and alcohol
programs. It may be that improvement in the psychological problems
of addicted individuals has more pervasive and powerful effects on
overall outcome than improvement in their substance abuse problems
alone.
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A Preliminary Evaluation of
Parenting, Depression, and
Violence Profiles in Methadone-
Maintained Women
S. M. Oehlberg, D. O’M. Regan, M. E. Rudrauff, and
L. P. Finnegan
INTRODUCTION
Family Center is an outpatient day program for pregnant drug
dependent women in the greater metropolitan area of Philadelphia.
It is involved in both research and treatment. The program pro-
vides comprehensive services including obstetrical, medical,
psychosocial, addictive, outreach, and aftercare.
The patients may be either self-referred or referred from other
local drug programs when it has been ascertained that the client
is pregnant. Clients maybe admitted to the program at any point
in their pregnancy. Once admitted, the client is scheduled to
be seen in the high-risk obstetrical clinic regularly until
delivery. Following delivery, the patient remains in the program
from three months to a year, depending on individual circumstances.
Women may be maintained on methadone, if opiate dependent, or
simply followed with respect to obtaining the best possible mental
and physical health of mother and infant.
The potential for improved treatment of both mother and infant,
especially prediction of problems, is extremely important. A
pilot study was devised to explore three factors which were felt
to be relevant to this: 1) degree of depression or abnormality
of mood; 2) exposure to physical and/or sexual abuse; and 3) po-
tential for child abuse or neglect.
Depression has been found to be a strong factor in the treatment
of drug abusers (Beck et al. 1974; Beck et al. 1961; DeLeon et
al. 1973; Weimann et al. 1978), and although a profile of person-
ality characteristics with which to predict drug abuse has not been
found, anxiety and depression were frequently present in addicts
(Craig 1979a; Craig 1979b). Many possible variables indicated by
previous studies and government publication of relevant demo-
graphics (Schneider et al. 1972; Smith et al. 1974; Spinetta and
Regler 1972) were incorporated in tests to determine parenting
ability and risk of child abuse.
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An effort has been made to identify specific variables which
would indicate, separately or in combination, those women who are
likely to abuse or neglect their infants. The presence of severe
depression, or abnormal mood states in the mother, and history of
subjection to physical violence were selected as sources of pos-
sible predictors. The interrelationship between these factors,
drug abuse, and parenting has also been considered.
METHOD
Subjects
Participants in the study were drawn from a population of clients
at the Family Center Program and included drug dependent women who
were abusing or had abused illicit drugs through the prenatal,
intrapartal, and postpartal periods.
For the purpose of this pilot study, a sample of 21 pregnant women
was drawn by consecutive presentation as new patients at the Center.
Prerequisite for inclusion was methadone maintenance.
The resulting group consisted of 7 white and 14 black women, mean
age 28.4 with a range of 20 to 39, mean age at first pregnancy
20.1 years. The mean number of living children was 3.0, with a
range of 1 to 7. Eight subjects had completed high school; two
had some college. Three subjects were currently employed part-
time. Seven lived with their families of origin, ten with partners/
husbands, two with both families of origin and partners/husbands,
and two lived alone.
Materials
1) Profile of Mood States (POMS) measures mood within the time-
frame of one week. There are six identifiable mood or affective
states: Tension-Anxiety: Depression-Dejection: Anger-Hostility;
Vigor-Activity: Fatigue-Inertia: and Confusion-Bewilderment. A
Total Mood Disturbance score (TMD) is obtained by summing the six
factor scores, weighting Vigor negatively (McNair et al. 1971).
2) Beck Depression Inventory consists of 13 items, rated on a four-
point scale, zero to three, indicating depression levels of none
to severe (Deck et al. 1974; Deck et al. 1961).
3) Violence Questionnaire quantifies violent events in the sub-
ject's past (e.g. beatings, rape). There are 23 items, yielding
a possible score from 0 to 35, with a high score indicating a
greater number of and/or more severe violent episodes. This
questionnaire was developed by the Family Center staff.
4) Profile of Abuse/Neglect Risk Factors (PAF) evaluates potential
for child abuse/neglect. It contains 90 questions, divided into
psychosocial, pregnancy data, and parenting sections. This test
was developed by the pediatric nurse practitioner with the help of
the Family Center staff.
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Procedure
The POMS, Deck, and Violence Questionnaire were completed by the
patient. The PAF was filled out by the primary social worker with
the patient in attendance. Tests were administered at the initial
interview or as soon thereafter as possible.
Weekly urine toxicologies were collected from all patients on a
once-a-week, random day schedule. Urines were screened for metha-
done, morphine, quinine, stimulants, depressants, diazepam, and
other contaminants.
RESULTS
In order to facilitate preliminary analysis of the data, certain
items were selected from the PAP and the violence Questionnaire and
used. to create a Life Event Scale (LES), Parenting Scale (PS), and
High Risk of Abuse Scale (PAS). The individual items in these
scales, total scores for the Violence Questionnaire, Peck, POMS,
POMS subscores, urine toxicology results, and demographic data
were compared by correlation [Table I].
Strong correlations were found to exist between the Deck and all of
the POMS scores except Anger and Tension. Total POMS scores also
correlated with the LES and presence of amphetamines in the urine,
while POMS Confusion and Fatigue scores correlated highly with
presence of depressants in the urine. POMS Tension scores also
correlated with the LES [Table I].
The prenatal clinic attendance was correlated at a significant
level with depression, parenting, total urine toxicologies, and
depressants in the urine, parity, and age. RAS scores correlated
only with presence of amphetamines in the urine. LES scores cor-
related with PS scores, which were also related to employment and
education, age, parity, and depressants in the urine [Table I].
An incidence of reported rape of 52 percent was noted, with 3 of
11 raped or molested by a relative. It is interesting to note
that these three subjects scored particularly high on the Total POMS
and the Beck [Table I].
Urine toxicologies throughout the pregnancy and postpartally re-
vealed that 50 percent of all the urines collected from these-
contained significant amounts of drugs other than methadone. De-
pressants (morphine, diazepam) accounted for 44 percent, and am-
phetamines for 8 percent of the total number of urinary contami-
nants [Table I].
DISCUSSION
Review of the findings reveals many ares which merit further study
and analysis. A larger sample would yield greater reliability;
while more informtion about the general character of drug abusers,
rather than only methadone maintained subjects, would be worthwhile.
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TABLE I
SIGNIFICANT CORRELATIONS
Parenting : Age
: Parity
: Employment/Education
: Depressants
: Life Events
: Prenatal Clinic
Attendant
Life Events : Urine Toxicology
POMS Total
POMS Tension
High Risk of Abuse : Amphetamines
Beck Depression : Prenatal Clinic
Attendance
: POMS Total
Depression
Vigor
Fatigue
Confusion
POMS Confusion : Depressants
POMS Fatigue : Depressants
Urine Toxicology : Prenatal Clinic
Attendance
: Employment/Education
Prenatal Clinic
Attendance : Depressants
: Parity
Employment : Age
-.53**
-.71***
.57**
-.61**
-.60**
.68***
.50**
.43*
.46*
.51*
-.57**
.61**
.62**
-.57**
.58**
.60
.47*
.57**
-.48*
-.61**
-.57**
-.55**
-.49*
* p < .05
** p < .01
*** p < .001
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Correlational comparisons are valuable in looking for relation-
ships, but multiple regression, principal component, and discrim-
inantanalyses are needed in order to determine whether the reare
indeed predictive qualities present.
Depression and Mood
In the total Family Center population, we have observed that high
depression scores on admission predispose a client to drop out,
continued drug use, and indications of poor attachment to the
infant. Depression scores correlated negatively with attendance
at prenatal clinic. This may be explained by its tendency to im-
mobilize and limit ability to follow through on activities.
The effects of chemical depressants or stimulants may well be con-
fusing the results with regard to depression and mood states. The
presence of depressants in the urine also correlated with the total
POMS scores.
Positive correlations between the Tension and Total POMS scores and
the LES scores are easily accepted as all the selected life events
are traumatic and would naturally produce tension and contribute to
raised levels in other POMS scales.
Exposure to Physical or Sexual Abuse
There seems to be an unusually high incidence of physical or sexual
abuse, especially rape, present in the lives of these subjects;
however, a comparable control group is needed.
Potential for Child Abuse or Neglect
The only correlation with the RAS scores was with presence of
amphetamines in the urine. These subjects, however, were not known
to abuse their other children.
Parenting
While parenting scores did not relate to child abuse, they did
correlate with some demographics: maternal age, number of children,
education, and employment. Higher age and number of children may
be confounding variables as well as independently limiting ability
to parent (in drug abusers). Both education and employment open
avenues for personal growth; spending time away from children; and
obtaining information pertaining to child care, development,
discipline, and other parenting behaviors.
The percentage of depressants in the urine correlated negatively
with total parenting scores. The effects of depressants would
logically interfere with most behaviors relating to parenting.
The negative relation of LES saxes and parenting scores suggests
that exposure to traumatic events makes it difficult, if not at
times impossible, to carry out the pervasive responsibility of
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parenting successfully.
Attendance at prenatal clinic correlated positively with total
parenting scores. This suggests that evidence of positive maternal
behaviors prenatally is indicative of strong potential for attach-
ment and good parenting behaviors following delivery.
CONTINUED INVESTIGATION
We are continuing to collect data as described in order to achieve
greater reliability. We need more methadone-maintained subjects,
as well as new groups of non-methadone-maintained drug abusers,
and non-drug abusers for comparison.
Addition of the Hamilton Rating System for Depression and The
Tennessee Self-Concept Scale will broaden the range of investiga-
tion into personality factors. Moreover, serial measurements
would assist us in picking up variations in individuals.
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Granting Dose Increases to
Methadone Maintenance
Patients: Effects on
Symptomatology and Drug Use
M. Stitzer, G. E. Bigelow, and I. Liebson
The goal of methadone maintenance treatment is to stabilize
patients on a daily dose of methadone which allows them to feel
comfortable and function adequately, while the cross tolerance
conferred by methadone reduces opiate-seeking behavior. Low
maintenance doses are generally considered desirable since these
provide fewer discriminable drug effects and may make it easier
for patients to ultimately detoxify and become drug free.
In practice, havever, there are few rational guidelines for
selection of a methadone stabilization dose for a given patient.
Treatment clinics generally select individual doses from a range
which is currently considered optimal (30-80 mg), but doses may
frequently be adjusted in response to patient complaints, and
negotiation for dosage adjustments can take up considerable time
and attention of treatment staff. A previous report (Stitzer and
Bigelow 1976), describing dosage alterations among methadone
maintenance patients enrolled in treatment for a full year, found
that only 12.1 percent of patients were maintained at a single
dose for the entire time, while the majority (63.6 percent) had
dose alterations (up and down) which cumulated to 30 mg or less of
dose change per patient per year. Dose increases of 5-10 mg were
common, and several of these might be granted to an individual
patient during a year of treatment.
The utility of small dose alterations in patients maintained on
and tolerant to methadone is questionable. Previous studies
(Berry 1972; Garbutt and Goldstein 1972; Goldstein and Judson 1973)
concluded that clinical outcomes were essentially indistinguishable
for patients maintained at widely disparate stabilization doses
between 30 and 160 mg. Assessment of the effects of chronic dose
alterations, however, is relevant to the clinical problem of dosage
selection for individual patients. In particular, it would be
useful to determine whether dose increases can effectively enhance
patient comfort. The present study examined the effects of blind
20 mg dose increases which were granted to patients with persistent
complaints about their methadone dose. The purpose of this study
was to determine whether a dose increase of this magnitude would
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have any detectable effect on symptomatic complaints or supple-
mental drug use.
METHODS
Clinic procedures. Maintenance patients report to the clinic
daily and ingest their daily dose of methadone at the clinic
dispensary under nursing supervision. Doses are dispensed as
Methadose in a cherry syrup drink made up to a volume of 60 cc.
Informed consent had been obtained from all patients for blind
dose adjustment procedures. Patients could formally request a
dose increase at any time by meeting with a staff member and
stating the specific physical symptoms or complaints which led to
the request for increase. Patients were told that any dose in-
creases granted would be blind, and they were encouraged to con-
tinue requesting increases if symptoms did not abate. Blind dose
increases which occurred during this study were made abruptly in
a single day with the volume of cherry syrup drink raining
constant.
Subject selection. A total of 99 increase requests were made by
50 patients enrolled in this treatment clinic during the first 15
months the procedure was in effect. Twenty-two patients (44 per-
cent) filled out at least one dose increase request: however 66.7
percent of all requests were made by only six patients, each of
whon trade six or more requests. These six patients were selected
for participation in the present study, as were two additional
patients (DJ, DZ) who were maintained at a relatively low methadone
dose (30 mg) and had a relatively high level of symptom complaints,
but who did not specifically request dose increases.
Subject characteristics. Participants in the present study, all
males, had an average age of 27.3 years (range 22-31 years) and
reported an average of 8.8 years of prior narcotic addiction. All
were Caucasian but one (DZ), who was black, and all but DZ were
recent program admissions, having been enrolled in treatment an
average of 5.9 weeks (range 1-17 weeks) prior to the start of data
collection for this study. Average methadone dose for study
participants was 46.3 mg (range 30-60 mg).
Measures. Symptom complaints were assessed using a 59-item symptom
checklist from which 56 items were scored. The checklist contained
symptoms specifically related to methadone withdrawal and methadone
side effects as well as items designating general psychological
and miscellaneous physical complaints. For each item, subjects
checked one of four possible answers according to the level at
which they experienced the symptan during the previous 24 hours:
0 = not at all; 1 = slight; 2 = moderate; 3 = severe. The total
score reported represents the sum of scores on each item. Patients
completed symptom reports twice weekly on Monday and Friday or
daily if they wished following a dose increase request until they
felt their dose was adequate.
Supplemental drug use was assessed from TLC analysis of urine
samples collected twice weekly on Monday and Friday. All samples
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were routinely analyzed for methadone, opiates (heroin, morphine,
codeine, meperidine, hydranorphone), barbiturates (phenobarbital,
unspecified barbiturates), nonbarbiturate sedatives (meprobamate,
methaqualone, glutethimide, ethchlorvynol), stimulants (cocaine,
amphetamine, methamphetamine, phenmetrazine) and phenothiazines,
phenytoin and propoxyphene.
RESULTS
Symptom complaints. As shown in Fig. 1, total symptom complaint
scores were suppressed following the dose increase in 6 of 8 sub-
jects (DZ, DJ, BB, HD, DH, BH), while two others (KM, VC) did not
show any clear alterations in symptom complaints. A matched pairs
t-test was used to compare average symptomatology scores obtained
for each study participant during three weeks before and three
weeks following the dose increase. The test revealed a significant
reduction in symptomatology scores for the group as a whole
(p<0.01).
Although reductions in symptcmatology were noted within one week
following a dose increase, these effects did not always persist.
For some patients (e.g., subjects DH, BB in Fig. 1), complaints
tended to return to previous levels within three weeks following
the dose increase. The tendency for recurrence of high levels of
symptom complaints can be seen more dramatically in Fig. 2, which
shows symptomatology data for subjects BB and HD over several
months time. Symptomatology scores repeatedly returned to high
levels following dose increases, and these patients continued to
make occasional dose increase requests. Reduced symptomatology
scores did persist, on the other hand, for subjects DZ and DJ,
whose doses were increased from 30 to 50 mg.
Urinalysis reports. Urinalysis results shown in Table 1 reveal
that all subjects except DZ habitually used a variety of supple-
mental drugs in addition to their methadone. Table 1 also shows
that there were no systematic changes in urinalysis results for
the barbiturate, benzodiazepine or other drug categories during
the three weeks after the dose change compared to the three weeks
prior. Of the three patients who had been abusing supplemental
opiates, however, two (HD, DZ) had substantial reductions in
opiate positive tests after the dose increase.
DISCUSSION
Results of the present study suggest that dose increases may have
at least short-term beneficial effects on symptomatology (Fig. 1)
and opiate drug use (Table 1) in methadone maintenance patients
who complain about their dose. On the other hand, the long-term
benefit of dose increases is questionable since the effects on
symptomatology tended to be transitory in many subjects, with
high levels of complaints recurring over time even after repeated
dose increases (Fig. 2). Furthermore, use of supplemental sedatives
and tranquilizers was unaffected by the dose increase procedure.
The results of this experiment confirm and extend to a within-
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FIGURE 1
SUCCESSIVE DAYS
Symptomatology scores in eight individual methadone
maintenance patients are shown before (left-hand panel)
and after (right-hand panel) an abrupt 20 mg dose
increase. Methadone dose (mg) is indicated within
each panel. Vertical arrows indicate days on which
the patients requested a dose increase. Derivation
of total symptomatology scores is described under
Methods.
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FIGURE 2
SUCCESSIVE DAYS
Symptomatology scores are shown for two individual
patients maintained at three successively higher
methadone doses. Methadone dose (mg) is indicated
within each panel of the figure. Vertical arrows
indicate days on which the patient requested a dose
increase.
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TABLE 1
Percent Positive Urines
Subject
Before Dose
Increase
DZ
DJ
BB
HD
DH
BH
KM
VC
O p 1 Barb2 Other
3 Benzo4
50.0 0 0 0
83.3 0 0 66.7
0 0 100.1* 100.0
66.7 33.3 66.7 100.0
0 0 33.3 100.0
0 16.7 33.3 100.0
0 0 0 100.0
16.7 33.3 16.7 100.0
After Dose
Increase
Op Barb Other Denzo
0 0 0 0
66.7 0 0 100.0
33.3 0 83.3* 100.0
0 0 83.3 100.0
0 50.0 33.3 100.0
0 50.0 66.7 100.0
0 0 16.7 66.7
0 0 33.3 100.0
1 Opiates include morphine and demerol.
2Barbiturates (unspecified)
3Except as noted, other drugs include methaqualone,
ethchlorvynol and phenothiazines.
4Benzodiazepine tranquilizers
*Propoxyphene
subject analysis reports (Berry 1972; Berry and Kuhn 1973; Garbutt
and Goldstein 1972; Goldstein and Judson 1973) of no differences
in clinical outcomes for methadone patients maintained on widely
different methadone doses, except for reduced opiate use at higher
doses.
It could be argued that continued use of supplemental drugs,
including sedatives and minor tranquilizers, would make these
particular methadone patients relatively insensitive to alterations
in their methadone dose. This argument may have merit. Neverthe-
less, these particular patients were considered appropriate for
evaluation of the dose increase procedure because of their per-
sistent requests for dose increases. The association of supple-
mental drug use and requests for dose increases in these patients
suggests that the latter may be part of a generally high level of
drug seeking behavior in these particular patients.
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Findings from the present study are relevant to current clinical
practice regarding dosage selection and adjustment. They suggest
that raising doses which are already above 30 mg may have at best
a temporary effect on complaints and may have no effect on
supplemental polydrug use. If dose increases of 20 mg have little
effect, the common practice of granting smaller dose increases on
the order of 5-10 mg may have even more questionable utility.
Furthermore, to the extent that dose increases are detectable,
they may serve to reinforce persistent complaints and continued
requests for dosage adjustments, thus exacerbating the problem
they are meant to correct.
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The Effect of Heroin and
Naloxone on the Growth of
Neuroblastoma Tumors in Mice
I. S. Zagon
INTRODUCTION
Although narcotic drugs are best-known for their analgesic and
behavioral effects, these agents have also been reported to be
cytotoxic (Roizin and Liu, 1977), antimitotic (Andersen, 1966),
and to retard growth and development in many diverse organisms and
cell types (Willson et al., 1976; Zagon and McLaughlin, 1977a, b,
1978).
In view of the growth-impeding properties of opiates in normal tis-
sues undergoing proliferation and development, we were prompted to
examine whether these compounds are also effective in inhibiting
the growth of tumors. In the present study we have determined the
effects of heroin on C1300 murine neuroblastoma, a well-character-
ized tumor system that resembles human neuroblastoma in many
respects (Finkelstein et al., 1973). Drug injections were initiated
prior to tumor cell inoculation in order to assess whether animals
exposed to heroin before tumor induction exhibit alterations in
their capacity to develop tumors, as well as in tumor growth and
survival time.
METHOD
Animals. Male syngeneic A/Jax mice (6-8 weeks of age)were obtained
from The Jackson Laboratories, Bar Harbour, ME. Groups of 5 male
mice were housed in stainless-steel cages and given water and Purina
laboratory chow ad libitum.
Tumors. The murine tumor cells, S20Y neuroblastorna, cloned from the
A/Jax mouse C1300 neuroblastoma, were obtained from Dr. M. Nirenberg,
(NIH, Bethesda, MD). Cells were grown in Dulbecco's medium con-
taining 10% fetal calf serum and 0.225% sodium bicarbonate in an
atmosphere of 5% CO2/95% air at 37°C. Cell viability was deter-
mined by the trypan blue exclusion test.
To induce tumor formation, 106 cells in 0.05 ml growth medium were
injected S.C. just posterior to the dorsal surface of the right
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foreleg; this area had been shaved previously with electric clip-
pers. The day of tumor cell inoculation was considered Day 0.
Body weights of mice were recorded on a weekly basis. Tumor size
was measured in 2 dimension with vernier calipers (accuracy, 0.05
mm) on a biweekly basis (every 3rd and 7th days). Since tumors
grew in somewhat irregular shapes, the largest dimensions perpen-
dicular to one another were always chosen; an approximtion of
tumor diameter was obtained by averaging the two measurements for
each animals. The time of "initial appearance" of a tumor was con-
sidered the day at which tumor diameter was 5 mm or larger. At
death, a random sampling of mice from each treatment schedule was
autopsied for metastases.
Drug Treament. Forty mice were divided into 4 groups of 10 animals
each. Some mice received daily s.c. injections of either 6 mg/kg
heroin (diacetylmorphine; National Institute on Drug Abuse,
Bethesda, MD) or 0.1 ml sterile saline (= heroin-tumor and saline-
tumor groups, respectively). In addition, another group of mice
received daily s.c. injections of naloxone (10 mg/kg; Endo Labor-
atories, Garden City, NY) simultaneous with the heroin injections
(= heroin-naloxme-tumor group). Two weeks after the initiation of
drug injections, these groups of mice received tumor cell inocula-
tions. Inorderto control for the effect of heroin on bodyweight
and mortality, another group of mice that had receiving heroin
was injected with only growth medium (= heroin only group). Drug
or saline injections were continued until the death of all tumor-
bearing animals.
Statistics. Tumor size was analyzed at 3- or 4-day intervals an
post-inoculation days 10-31 using an analysis of variance with the
7 measurement points analyzed as a repeated measure. This time
period corresponded to one in which 50% of all mice were alive.
Tumor size on the day of death, as well as survival times of tumor-
bearing mice, were also analyzed using an analysis of variance;
subsequent analyses to determine differences between Treatment
schedules were performed with the Newman-Keuls test. P values less
than 0.05 were considered significant.
Body weights of mice were compared a two-factor analysis of
variance. Treatment Schedule was considered to be a between-group
variable and Days (10-31) was a within-group variable.
RESULTS
General Observations. Within three weeks after the injection of
neuroblastma cells, all mice in the saline-tumor and heroine-
naloxone-tumor group had developed measurable tumors. In contrast
to these results, 2 of the 10 mice in the heroine-tumor group did
not develop tumors within the 62 days after cell inoculation.
Metastases were not observed in drug- or saline-treated mice inoc-
ulated with neuroblastma. Body weights did not differ between
any group of mice.
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Survival Time. Mean survival time of mice in the heroin-tumor
group was extended 35% in comparison to controls, and mediam sur-
vival time for tumor-bearing mice receiving heroin was extended
18%. Although mice in the saline-tumor group began to die in the
4th post-inoculation week and 100% of these mice had died by the
6th week, the first death in turmor-bearing mice treated with heroin
occurred on day 34 and some of these mice lived more than 3 weeks
beyond any of the mice in the saline-tumor group. Animals receiv-
ing simultaneous injections of heroin and naloxone did not differ
significantly from saline-tumor mice in mean survival time, nor
were major differences noted in either the median or range of
survival time.
Tumor Growth. In contrast to saline-tumor mice,the mean time for
the initial appearance of measurable tumor was delayed by 45% in
mice of the heroin-tumor group. The median time of tumor appearance
was comparable for heroin-tumor and saline-tumor groups. Whereas
100% of saline-tumor animals had measurable tumors by day 10,
tumors in all of the heroin-tumor mice were not observed until day
24. Tumor growth between days 10 and 31 was significantly retarded
in mice of the heroin-tumor group, with marked reductions found on
days 17, 21, 24, 28, and 31. At the time of death, animals in the
heroine-tumor group also had smaller tumors than mice in the saline-
tumor group, with a mean reduction of 21% being recorded for tumor-
bearing animals receiving heroin.
A 23% delay in the mean time for the initial appearance of tumors
was observed for mice in the heroin-naloxone-tumor group, but the
median day for initial tumor appearanace, tumor growth between days
10 and 31, and tumor size at death were comparable to controls.
DISCUSSION
The results of this investigation show that administration of
heroin, beginning 2 weeks prior to tumor cell inoculation, delays
the initial appearance of measurable tumors, retards tumor growth
and prolongs survival time in mice with transplanted neuroblastoma
tumors. Moreover, despite inoculation with 106 cells, which was
found in this study and others (Shuffler, Repman, and Schengrund,
1979) to induce neuroblastoma in 100% of the controls, sane heroin-
injected animals never developed tumors within the 62-day post-
inoculation period; this would suggest that heroin may also suppress
the formation of tumors.
The dosage of heroin utilized in this study was not exceedingly
high, being above the analgesic dose of 1 mg/kg, but well below
the LD50 level of 190 mg/kg (Brands, Hirst, and Gowdey, 1975) in
mice. Tumor-bearing animals receiving heroin also did not lose
bodyweight, incontrast to the cachexia observed with many of the
antitumor agents, again reflecting the low general toxicity of the
dosages employed.
The mechanisms underlying heroin's ability to retard tumor growth
and prolong survival are presently unclear. Heroin's action does
appear to be related to certain physiological properties of opiates
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since administration of naloxone, a well-known opiate antagonist,
blocked heroin's antitumor activity. Opiates have been reported
to suppress cell division, alter polyamine, nucleic acid and
protein biosnythetic systems, and retard growth (Andersen, 1966;
Roizin and Liu, 1977; Slotkin, Seidler, and Whitmore, 1980; Willson
et al., 1976; Zagon and Mclaughlin, 1977a, b, 1978). One or me
of these actions may be responsible for heroin's effects on neo-
plasia.
Narcotic analgesics such as heroin are commonly used in the control
of pain in patients with advanced stages of malignancy (Ettinger,
Vitale, and Trump, 1979; Twycross, 1974). In view of the present
data, it appears that some opiates, in addition to their analgesic
and behavioral properties my also alter cell function and response
associated with oncogenesis.
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Quantum Chemical Studies of
the Origin of Agonist and
Antagonist Activity in 3- and
4- Piperidines
G. H. Loew, S. K. Burt, and G. M. Hashimoto
A number of 3-arylpiperidine compounds are now known which
possess potent opiate narcotic analgesic activity and which
exhibit antagonistic activity (Kugita et al. 1965, Iorio and
Casy 1978, Jacoby et al. 1974). All compounds with a 2-CH3 sub-
stituent and ,a mOH group on the phenyl ring are potent, pure
antagonists, regardless of their N-substituent. In contrast,
the few compounds reported without a 2-CH3 group are mixed
agonist/antagonists. Thus this class of opiates exhibit
structure-activity profiles markedly different from the rigid
opiates.
TABLE I: CALCULATED LOW-ENERGY ISOMERS AND
OBSERVED PHARMACOLOGICAL ACTIVITY FOR 3-0PIPERIDINES
3-R 2-R LOW-ENERGY ISOMERS
ACTIVITY (AGONIST/ANTAGONIST)
NO OH mOH pOH
CH3 H 0EQ, N-REQ; 0AX, N-REQ ND WK AG/ND ND
-CH3 0EQ, N-REQ; 0AX N-REQ ND INACT/ANT ND
-CH3 0EQ, N-REQ ND INACT/ANT ND
COOET H 0EQ, N-REQ AG/INACT AG/ANT WK AG/INACT
-CH3 ND0EQ, N-REQ
-CH3 OEQ, N-REQ
ND
Recently potent pure antagonists with a mOH-0 in the 1,3,4-
trialkyl-4-phenylpiperidine series were prepared (Zimmerman et
al. 1978a, Zimmerman et al. 1978b). In this series, antagonism
was not found to be modulated by N-substituent variation. The
structure-activity profile for a number of these analogs indi-
cates that the 4-R group, the 3-CH3 substituent, as well as the
position and presence of a phenolic hydroxyl are all modulators
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of agonist/antagonist potency. These compounds, then, also have
a very different structure-activity profile from the rigid opi-
ates. The study of molecular features of opiates that regulate
the extent of agonism/antagonism in a given opiate are particu-
larly suited to quantum mechanical calculations since the ratio
of agonism to antagonism should be a receptor-related event and
should be reflected in molecular indices obtained from conforma-
tional calculations and electronic properties.
TABLE II: CALCULATED LOW-ENERGY ISOMERS AND
OBSERVED  PHARMCOLOGICAL  ACTIVITY FOR  4-0PIPERIDINES
4-R 3-R LOW-ENERGY ISOMERS
ACTIVITY (AGONIST/ANTAGONIST)
NO OH mOH
CH3 H
a-CH3
-CH3
n -C3H7 H
-CH3
-CH3
OCOC2H5 H
-CH3
-CH3
0EQ, N-REQ; 0AX, N-RAX; 0EQ, N-RAX
0EQ, N-REQ 0AX, N-REQ ;0EQ, N-RAX
0EQ, N-REQ
0AX, N-REQ
0AX, N-REQ
0EQ, N-REQ
0EQ, N-REQ; 0EQ, N-RAX
0EQ, N-REQ; 0EQ, N-RAX
0EQ, N-REQ
WK AG/lNACT
INACT/INACT
INACT/WK ANT
AG/INACT
INACT/INACT
AG/INACT
AG/INACT
AG/INACT
AG/INACT
AG/INACT
WK AG/WK ANT
INACT/ANT
AG/INACT
AG/INACT
WK AG
N D
ND
INACT/ANT
In order to understand their unusual structure-activity profile,
determine their molecular requirements for agonism and antagonism,
and to suggest new, potentially useful analogs for synthesis and
testing, we have calculated the energy-conformation behavior of
the series of 3- and 4-0piperidines given in Tables I and II,
using the semiempirical quantum mechanical method called PCILO
(Diner et al. 1969).
For each possible geometric isomer, nested rotations were per-
formed around all torsional axes and local geometry optimizations
made for minimum rotational conformers. The conformational
results obtained should be essentially the same for m- and p-OH,
but not necessarily o-OH, substituents on the phenyl ring.
The low-energy isomers obtained for all analogs studied are sum-
marized in Tables I and II. While some isomers of the des-CH3
compounds had conformational flexibility, all eight isomers of
the 2-CH3, 3-R, 3-hiperidines and 3-CH3, 4-R, 4-0peridines had
only one low-energy conformation. As shown in these tables, for
both the 3- and 4-0piperidines, the same low-energy isomers were
found for the des-CH3 and a-CH3 analogs; while the -CH3 compounds
have different conformational behavior. Surprisingly, for the
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des-3-CH3, and -3-CH3, 4-n-propyl analogs, unlike any other
known 4-0piperidines, an isomer with an axial phenyl ring is pre-
dicted to be the unique, low-energy form. An X-ray structure
determination of these analogs should help verify these results.
The results of the energy-conformation studies, together with the
known activity profile, allows the selection of 3-0 and 4-0 opiate
pharmacophores--i.e., conformations and orientations at the recep-
tor site--responsible for agonist and antagonist activity.
All of the 3-0piperidines studied have antagonist activity with a
mOH group, and all have one and only one common low-energy isomer:
0EQ, N-REQ. This isomer, in an orientation at the receptor site
allowing interaction of the phenyl ring similar to rigid opiates,
is thus proposed as the universal antagonist pharmacophore (Fig-
ure 1A, Pharmacophore I) for 3-0piperidines. The fact that a mOH
creates the most potent antagonists reinforces this hypothesis.
Figure 1: Proposed Antagonist Pharmacophores for A) 3-0piperi-
dines and B) 4-0piperidines (shown against morphine for comparison)
The ß-isomers of all 4-0piperidine analogs studied also have only
one low-energy isomer, 0EQ, N-CH3EQ. Moreover, for all of these
compounds, a g-isomer is a pure antagonist when a mOH group is
present. These combined results also clearly indicate a univer-
sal antagonist pharmacophore for 4-0piperidines: a 0EQ, N-CH3EQ
isomer interacting at the receptor with a mOH-0 overlap similar
to the rigid opiates (Pharmacophore II, Figure 1B). In these
similar pharmacophores, the postulated role of the mOH group is
to anchor a low-energy 0EQ, N-REQ isomer in a phenyl overlap
(antagonist) orientation at the receptor site.
Our results have thus allowed the selection of a universal ant-
agonist pharmacophore for the 3-0piperidines and for the 4-
0piperidines. The -3-CH3 isomers of both 3- and 4-0piperidines
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with a mOH would all be pure antagonists, and the behavior of des-
CH3 and -CH3 isomers in general should be different from the B-
isomers and similar to each other. These results are consistent
with the observation of agonism in the des-CH3 and -CH3 analogs
but not in the -CH3 compounds.
Two remaining questions are: What is the origin of agonist activ-
ity in 3- and 4-0piperidines with a mOH? What is the role of the
mOH in modulating agonism and antagonism? Unlike the single an
tagonist mode postulated for the 3- and 4-0piperidines (Figure 1A,
B), there are a number of possible pharmacophores for each of
these classes of opiates which could account for their agonist
activity.
From our results for the 3-0piperidines, two different agonist
modes seem possible (Figure 2A,B), one common to all 3-0piperidines
(Pharmacophore III, Figure 2A) and one involving a boat conformer
(Figure 2B) which our calculations indicate is possible only for
des-2-CH3 and a-2-CH3, 3-CH3, 3-0piperidines and not for any
3-COOC2H5, 3-0piperidines. Each proposed pharmacophore has an
amine group interaction at the receptor site similar to fused ring
opiates--a postulated key requirement for agonism.
Figure 2: Proposed Agonist Phamacophores for 3-0piperidines
The agonist Pharmacophore III (Figure 2A) is proposed in addition
to the antagonist mode as an alternative mode of interaction of the
single low-energy conformer of the des-2-CH3 betameperidines with
the receptor site as a plausible explanation of its mixed agonist/
antagonist behavior.
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This same pharmacophore could also be responsible for the agonist
activity observed in 2-des-methyl, 1,3-diCH3, 3-0piperidines, since
the axial phenyl group of the low-energy 0AX, N-CH3EQ isomer of
this analog would occupy a similar position to the axial ester
chain in Figure 2A. In this pharmacophore, the ester chain, or
0 group, is in the position of the C14-OH group in oxymorphones
or the C9 extended group of the recently synthesized benzomorphans,
substituents which appear to be interacting at a newly-delineated
subsite of the opiate receptor which also modulates their relative
agonist/antagonist activity.
If Pharmacophore III (Figure 2A) is responsible for agonism in
the des-2-CH3 analogs, the effect of adding a 2-CH3 group on ago-
nism can be predicted. The -2-CH3 isomer of betameperidine (2R,
3R) should retain agonism since the axial 2-CH3 group in this
position should not interfere with agonist-type binding if there
is a receptor pocket available to them. The B- (2S, 3S) and
isomers, which have an equatorial 2-CH3 group in the position of a
C9 or C16 substituent in morphine, should not bind in the agonist
mode (Pharmacophore III) and would be pure antagonist (Pharmaco-
phore I). Synthesis and testing of 2-CH3 analogs of betameperi-
dines would verify this prediction.
For the des-2-CH3, 3-CH3, 3-0piperidines, both the chair and boat
forms (Figures 2A,B) are possible conformers. Each predicts a
different effect of addition of a 2-CH3 group. If the chair form
is a relevant one, the -2-CH3 isomers could retain agonism, since
axial 2-CH3 groups in these positions should not interfere with
this agonist-type binding if there is a receptor pocket available
for them; while B-isomers would not bind in this mode. If the
boat form is the agonist, addition of a -2-CH3 group does not
allow it and would result in a lack of agonist activity. For the
a-isomer, while a boat form is possible, the 2-methyl group is in
the position of the C9 or Cl6 substituent as in morphine, blocking
activity.
For the 3-CH3-3-(mOH)-0 analogs, both - and -2-CH3 compounds have
been synthesized. No agonism has been reported for either isomer.
A piperidine boat conformer is then more consistent with the known
effect of a 2-CH3 group than the piperidine chair conformer. In
this pharmacophore there is simultaneous overlap with both the
amine nitrogen and the mOH-0 group of rigid opiates, suggesting
agonist/antagonist potency ratios should be modulated by N-
substituents--a hypothesis that could be tested by the synthesis
and testing of analogs with varying N-substituents.
From our results, agonist activity in the 4-0piperidines could be
due to three types of pharmacophores, shown in Figure 3A,B,C.
Figure 3A shows a 4-0piperidine in a low-energy @EQ, N-REQ conformer.
This conformer with a mOH substituent is the postulated antagonist
mode. However, without a mOH; it could orient at the receptor with
piperidine ring overlap with rigid opiates leading to agonism pro-
vided the 4-R group can serve as an effective binding site. This
condition seems to be fulfilled when 4-R is an ester chain (meperi-
dine or prodine) or the -3-CH3 isomer of a long alkyl chain
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(4-R = n-CH3H7), all of which are pure agonists without a mOH,
but not when 4-R = CH3. This latter analog can interact only in
the antagonist mode (Figure 2B) with or without a mOH and does
not require a mOH for antagonism, while all the prodines, meperi-
dines, and the -3-CH3, 4-n-C3H7 analogs require a mOH group to
change from an agonist (Figure 3A) to antagonist orientation
(Figure 1B).
Figure 3: Proposed Agonist Pharmacophores for 4-0piperidines
Figure 3B shows a 4-0piperidine analog in a low-energy 0AX, N-REQ
conformer. This conformer is the unique low-energy form for
4-R = n-C3H7 and probably for longer alkyl chain substituents with
an -3-CH3 or no 3-CH3 group. Thus this class of 4-0piperidines
is predicted to have a similar structure-activity profile to rigid
opiates; i.e., N-substituent variations should lead to potentially
useful analogs with mixed agonist/antagonist behavior. This pre-
diction is consistent with the observation that N-CH3, -3-CH3,
4-n-C3H7, 4-0piperidine is a pure agonist, while the -3-CH3 analog
(which can only be in Pharmacophore II conformation) is a pure
antagonist.
The remaining des-3-CH3 and -3-CH3, 4-R, 4-0piperidine analogs,
in contrast to -CH3 compounds, are also predicted to have agonist
as well as antagonist activity. However, the mixed agonist/
antagonist activity when 4-R = ester chain is predicted to arise
from interaction of another low-energy isomer, 0EQ, N-RAX, at the
receptor site oriented as shown in Figure 3C (Pharmacophore VII).
While these prodines have not been measured, the presence of two
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low-energy isomers could explain the mixed agonist/antagonist
behavior in the - but not the -isomers of 3-CH3 ketobemidone.
Since the pharmacophore shown in Figure 3C has some overlap with
both the amine and phenyl group of rigid opiates, it is suggested
that if agonism is observed in the des-CH3 and -CH3 mOH prodines,
it should be lessened by change of N-substituents from N-CH3 to
N-ally1 of N-methylcyclopropyl.
For the 4-CH3, 4-0piperidines, the des-CH3 and -3-CH3 isomers
have three low energy conformers. One, in common with most 4-
0piperidines, could be responsible for antagonist activity (Phar-
macophore II, Figure 1B), while either of the other two could
lead to agonist activity. The 0AX, N-REQ conformer could bind in
a Pharmacophore VI mode in common with the 4-n-propyl analogs
(Figure 3B), while the 0EQ, N-RAX isomer can bind in a Pharmaco-
phore VII mode (Figure 3C), in common with one proposed for the
prodines. In either of these pharmacophores there can be nearly
simultaneous overlap with both the mOH-0 and amine groups of
rigid opiates. If the observed agonism of the -analog of 1,2,3-
trimethyl-3-(mOH)0piperidine is due to binding in either mode,
then variation in N-substituents should lead to mixed agonist/
antagonist activity.
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Levallorphan
inhibition of 3H-etorphine stereospecific binding, 329
Levorphanol
analgesic activity in the mouse, 299-330
correlations among certain behavioral, physiological and biochemi-
cal effects, 46-57
drug discrimination studies in the rhesus monkey, 176
inhibition of 3H-etorphine stereospecific binding, 329
Levoxadrol
drug discrimination studies in the rhesus monkey, 176
-Lipotropin
plasma levels during parturition, 264-271
See also -endorphin
Loperamide
abuse potential in humans, 232-240
Marijuana
driving, 257-263
MCV 4030 (NIH 9004)
See alpha-6-Dimthylamino-4,4-diphenyl-3-(2,2-dichloracetoxy)
heptane hydrochloride
MCV 4041 (NIH 9048, UM 1144)
See alpha-4,4-Diphenyl-5-dimethylamino-3-heptanol phenylacetate
MCV
MCV
MCV
MCV
MCV
MCV
4103 (NIH 9343A, UM 1125A)
See m-(1,3-Dimethyl-4-propyl-4-piperidyl)phenol hydrobromide
4126 (NIH 9460)
See 1-Cyclohex-3-enoic-2-(2,6-dichlorophenylamino)-2-imidazoline
4132 (NIH 9469)
See trans-N-(2-Dimethylaminocyclohexyl)-4-bromobenzadine
4147 (N(H 9542)
See 1-(4-Methylphenyl)-3-azabicyclo(3.l.O)hexane hydrochloride
4148 (NIH 9543)
See 1-(4-Chlorophenyl)-2-azabicyclo(3.l.-0)hexane hydrochloride
4150 (NIH 9544)
See 3-Methyl-1-(4-methylphenyl)-2-azabicyclo(3.1O)hexane hydro-
chloride
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MCV 4155 (Clonidine, NIH 9549, NIH 9571, MCV 4183, UM 1151)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
MCV 4156 (NIH 9575)
See cis-(+)-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)phenol,(Z)-
2-butenedioic acid salt
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
MCV
4157 (NIH 9576, UM 1242)
See cis-(-)-3-(Octahydro-2-methyl-1H-2-pyrindin-4a-yl)phenol,(Z)-
2-butenedioic acid salt
4158 (NIH 9580)
See 1-(1-Phenylcyclohexyl) piperidine hydrochloride
4159 (NIH 9577)
See cis-(+)-3-(Decahydro-2-methyl-4a-isoquinolinyl)phenol,(Z)-2-
butenedioic acid salt
4160 (NIH 9578)
See cis-(-)-3-(Decahydro-2-methyl-4a-isoquinolinyl)phenyl,(Z)-2-
butenedioic acid salt
4161 (NIH 9596)
See (-)-trans-5,6,6a-beta,7,8,9a,lO,lO-alpha-Octahydro-1-acetoxy-9-
beta-hydroxy-6-beta-methyl-3-(5-phenyl-
thridine hydrochloride
2-pentyloxy)-phenan-
4162 (NIH 9597)
See (-)-trans-5,6,6a-beta,7,8,9,1O,1Oa-alpha-Octahydro-1-acetoxy-
9-beta-hydroxy-5,6-beta-dimethyl-3- (5-phenyl-2-pentyloxy)-phen-
anthridine hydrochloride
4167 (NIH 9612)
See dl-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
4168 (NIH 9613)
See (+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
4169 (NIH 9614)
See (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
4171 (NIH 9622)
See 3-Hydroxy-6-oxo-7-alpha,8-beta-dimethyl-B/B-cis-N-cyclobutyl-
methylmorphinan
4174 (NIH 9623)
See 3-Hydroxy-6-oxo-7-alpha-methyl-B/C-trans-N-cyclopropylmethyl-
morphinan hydrobromide
4175 (NIH 9624, UM 1258)
See 1-[(2-alpha,6-alpha,11S)-d1-1(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-3-octanone
methanesulfonate
417
MCV 4176 (NIH 9625)
See 1-[(2-alpha,6-alpha,11S)-dl-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methane-3-benzazocin-11-yl)]-6-methyl-3-
heptanone methanesulfonate
MCV 4177 (NIH 9538, UM 1167)
See (-)-17-Cyclopropylmethyl-7,7-dimethyl-3-hydroxy-6,8-dioxamorphi-
nan d-tartrate methanolate
MCV 4180 (NIH 9653)
See 3-Allyl-9- beta-methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
hydrochloride
MCV 4181 (NIH 9654)
See 3-n-Amyl-9- beta-methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
hydrochloride
MCV 4182 (NIH 9655)
See 3-Methyl-9-beta-methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
citrate hemihydrate
MCV 4183 (Clonidine, NIH 9549, NIH 9571, MCV 4155, UM 1151)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
MCV 4184 (NIH 9689)
See Yohimbine hydrochloride
MCV 4185 (NIH 8437, UM 774)
See N-Cyclopropylmethylnordesmorphine hydrochloride
MCV 4188 (NIH 9725, UM 1213)
See L-Tyrosyl-D-alanylglycyl-L-N- alpha-ethylphenylalanine amide
acetate
MCV 4189 (NIH 8735A, UM 909)
See 2-(2,Methyl-3-furymethyl)-2'hydroxy-5,9-alpha-dimethyl-6,7
benzomorphan methanesulfonate
MCV 4191 (NIH 9726, UM 1214)
See N-[4-(Methoxymethyl)-1-(-2-(2-thienyl)ethyl-4-piperidinyl]-N-
phenylpropanamide:2-hydroxy-1,2,3-propane-tricarboxylate(1:1)
MCV 4193 (NIH 9729, UM 1215)
See 4-(m-Acetoxyphenyl)-4-(1-acetoxypropyl)-1-n-pentylpiperidine
oxaiate
MCV 4194 (NIH 9733, UM 1230)
See (-)-Nicotine di-1-tartrate
MCV 4195 (NIH 9735)
See N-Cyclopropylmethyl-7,8-dihydronormorphinone
MCV 4198 (NIH 9734, UM 1219)
See dl-Spiro-(1,3-diethl-1-1-methyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(1-pentylpiperidine hydrobromide
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MCV
MCV
MCV
MCV
MCV
MCV
MCV
4199 (NIH 9738)
See 2-Nitronaltrexone
4200 (NIH 9739)
See 2-Nitronaloxone
4201 (NIH 9740, UM 1220)
See N-(2-Methoxyethyl)norketobemidone oxalate
4202 (NIH 9751, UM 1228)
See (2-alpha,6-alpha,11S)-(+)-1-Cyclopentyl-5-(1,2,3,5,6-hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-3
pentanone methanesulfonate
4203 (NIH 9752, UM 1229)
See (2-alpha,6-alpha,11S)-(-)-1-Cyclopentyl-5-(1,2,3,4,5,6-hexa-
hydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazodcin-11-yl)-
3-pentanone methanesulfonate
4204 (NIH 9757, UM 1231)
See d-Propoxyphene hydrochloride
4205 (NIH 9771)
See 4-(1-Hydroxypropyl)-4-m-hydroxyphenyl-1-methylpiperidine
Meperidine
analgesic activity in the mouse, 299, 330
correlations among certain behavioral, physiological and bio-
chemical effects, 46-57
Meprobamate
hot plate test, 299
14-beta-Mercaptocodeine (NIH 9702, UM 1203)
biological evaluation for dependence liability, 290
depression of smooth muscle twitch, 350
displacement of stereospecific 3H-etorphine binding, 350
14-beta-Mercaptomorphine hydrochloride hydrate (NIH 9701, UM 1201)
biological evaluation for dependence liability, 290
depression of smooth muscle twitch, 350
displacement of stereospecific 3H etorphine binding, 350
Mescaline
hot plate test, 299
(-)-Metazocine
analgesic activity in the mouse, 299, 330
Methadone
correlation among certain behavioral, physiological and biochemi-
cal effects, 46-57
detoxification with clonidine, 101-108
dopamine and serum prolactin during withdrawal, 367-372
419
dose increases in methadone maintenance patients: effects on
symptomatology and drug use, 387-393
effects of route of administration of methadone disoosition in
the rat, 145-151
maintenance in hospitalized surgical patients, 242-248
mean terminal half-life in chronically treated rats, 148
opiate detoxification, 89-94
parenting, depression and violence profiles in maintained women,
380-386
relationship between pre-treatment income and methadone main-
tenance, 116-122
total amounts in organs following drug administration, 147
N-(2-Methoxyethyl)norketobemidone oxalate (NIH 9740, MCV 4201, UM 1220)
biological evaluation for dependence liability, 292
correlation among certain behavioral, physiological and biochemi-
cal effects, 46-57
mouse analgesia, 323
N-(2-Methoxyethyl)-norketobemidone oxalate (NIH 9740, MCV 4201, UM 1220)
mouse analgesia, 359
physical dependence in monkeys, 359
N-(4-Methoxymethyl)-1-[(2-(2-thienyl)ethyl)-4-piperdinyl]-N-phenylpro-
panamide:2-hydroxy-1,2,3-propane-tricarboxylate(1:1) (NIH 9726, MCV 4194,
UM 1214)
biological evaluation for dependence liability, 294
dependence studies in monkeys, 320
depression of smooth muscle twitch, 356
displacement of stereospecific 3H-etorphine binding, 356
mouse analgesia, 320, 356
self-administration by monkeys, 356
4-beta-(m-Methoxyphenyl)-1,3,dimethyl-4- alpha-piperidinol propionate
hydrochloride (UM 1170)
correlation among certain behavioral, physiological and biochemi-
cal effects, 46-57
d-Methylamphetamine
behavioral reaction times, auditory and visual thresholds in baboons,
226-231
2-(2-Methyl-3-furymethyl)-2'-hydroxy-5,9-alpha-dimethyl-6,7-benzomor-
phan methanesulfonate (NIH 8735A, MCV 4189, UM 909)
correlation among certain behavioral, physiological and biochemi-
cal effects, 46-57
dependence studies in monkeys, 320, 335
mouse analgesia, 319-320
2-(3-Methylfurfuryl)-2'-hydroxy-5,9-alpha-dimethyl-6,7-benzomorphan
methanesulfonate (UM 911)
correlation among certain behavioral, physiological and biochemi-
cal effects, 46-57
420
3-Methyl-9- beta-methoxy-9-phenyl-3-azabicyclo-1[3.3.1]nonane citrate
hemihydrate(NIH 9655, MCV 4182)
biological evaluation for dependence liability, 294
dependence studies in monkeys, 318
mouse analgesia, 317-318
3-Methyl-1-(4-methylphenyl)-3-azabicyclo(3.1.0)hexane hydrochloride
(NIH 9544, MCV 4150)
dependence studies in monkeys, 304
mouse analgesia, 304
1-(4-Methylphenyl)-3-azabicyclo(3.1.0)hexane hydrochloride (NIH 9542,
MCV 4147)
dependence studies in monkeys, 302-303
mouse analgesia, 302
Morphine
analgesia, 73, 298, 299, 330
analgesic potency in cancer patients, 213-219
androgenic-like effects in the male rat, 152-158
correlations among certain behavioral, physiological and biochemi-
cal effects, 46-57
effects on hypothalmic LH-RH levels in the castrated male rat, 155
effects on serum LH levels in the castrated male rat, 154
inhibition of 3H-etorphine stereospecific binding, 329
mu agonists, morphine-like drugs, 43
nalbuphine and butorphanol vs. pentazocine: relapse and substi-
tution in morphine-addict rats, 138-144
T cell depression, 163
Nalbuphine
vs. pentazocine: relapse and substitution in morphine-addict rats
138-144
Nalorphine
analgesia, mouse agonist-antagonist tests, 298, 299, 331
inhibition of 3H-etorphine stereospecific binding, 329
Naloxone
analoesia, mouse aoonist-antaoonist tests, 298-299
effect on the
inhibition of
growth of neuroblastoma tumors in mice, 394-398
3H-etorohine stereospecific binding, 329
reversal of opiate-induced inhibition of sheep erythrocytes to T
lymphocyte, 159-165
Naloxone methobromide (Quarternary naloxone) (NIH 9629, UM 1184)
biological evaluation for dependence liability, 290
mouse analgesia, 346-347
physical dependence in monkeys, 366-367
self-administration by monkeys, 346-347
421
Naltrexone
analgesia, mouse, agonist-antagonist tests, 298-299
inhibition of 3H-etorphine stereospecific binding, 329
opiate dependence, 109-115
use after clonidine detoxification, 101-108
Naltrexone methobromide (Quarternary naltrexone)(NIH 9630, UM 1185)
biological evaluation for dependence liability, 290
mouse analgesia, 347
physical dependence in monkeys, 387
Narcotic addiction
changes during rapid social change, 206-212
Narcotic agonists
correlations among certain behavioral, physiological and biochemi-
cal effects, 46=57
kappa agonists, ethylketazocine-like drugs, 43
mu agonists, morphine-like drugs, 43
Nathan B. Eddy Memorial Award
"Dynorphin", Avram Goldstein, 1-10
Neuroblastoma
effect of heroin and naloxone on the growth of neuroblastoma
tumors in mice, 394-398
(-)-Nicotine di-1-tartrate (NIH 9733, MCV 4194, UM 1230)
biological evaluation for dependence liability, 294
dependence studies in monkeys, 321, 361
depression of smooth muscle twitch, 361
displacement of stereospecific 3H-etorphine binding, 361
mouse analgesia, 320-321, 361
NIH
NIH
NIH
NIH
NIH
NIH
7380 (NIH 9712, UM 1211, UM 9712)
See (-)-Galanthamine hydrobromide, 354
8437 (MCV 4185, UM 774)
See N-Cyclopropylmethylnordesmorphine hydrochloride
8735A (MCV 4189, UM 909)
See 2-(2-Methyl-3-furymthyl)-2'-hydroxy-5,6-alpha-dimethyl-6,7
benzomorphan methanesulfonate
8791 (UM 941)
See(-)-N-Cyclobutylmethyl-3,14-dihydroxymorphinan tartrate
9004 (MCV 4043)
See alpha-6-Dimethylamino-4,4-diphenyl-3-(2,2-dichloroacetoxy)
heptane hydrochloride
9048 (MCV 4041, UM 1144)
See alpha-4,4-Diphenyl-6-dimethylamino-3-heptanol phenylacetate
422
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
9343A (MCV 4103, UM 1125A)
See m-(1,3-Dimethyl-4-propyl-4-piperidyl)phenol hydrobromide
9460 (MCV 4126)
See 1-Cyclohex-3-enoic-2-(2,6-dichlorophenylamino)-2-imidazoline
9463 (UM 1189)
See 1,4-Dimethyl-4-piperidinol-4-(2,4,5-trimethylpyrrole-3-carboxy-
late hydrochloride
9469 (MCV 4132)
See trans-N-(2-Dimethylaminocyclohexyl)-4-bromobenzamide
9513 (UM 1159)
See dl-trans-5,6,6a-beta,7,8,9,1O,1Oa alpha-Octahydro-1-acetoxy-9-
beta-hydroxy-6-beta-methyl-3-(5-phenyl-2-pentyloxy)-phenanthri-
dine hydrochloride
9538 (MCV 4177, UM 1167)
See (-)-17-Cyclopropylmethyl-7,7-dimethyl-3-hydroxy-6,8-
dioxamorphinan d-tartrate methanolate
9539 (UM 1168)
See 17-Cyclopropylmethyl-3-hydroxy-6-oxamorphinan tartrate
9542 (MCV 4147)
See 1-(4-Methylphenyl)-3-azabicyclo(3.1.O)hexane hydrochloride
9543 (MCV 4148)
See 1-(4-Chlorophenyl)-3-azabicyclo(3.1.0)hexane hydrochloride
9544 (MCV 4150)
See 3-Methyl-1-(4-Methylphenyl)-3-azabicyclo(3.1.0)hexane hydro-
chloride
9549 (Clonidine, NIH 9571, MCV 4155, MCV 4183, UM 1151)
See 2-(2,6-Dichloroanilino)-2-imidazoline hydrochloride
NIH 9550 (UM 1173)
See dl-1-(2-(Dimethylamino)ethyl)-6,7-dihydro-3-methyl-4-oxo-6-
phenylindole-2-carboxylic acid ethyl ester (E)oxine
NIH 9571 (Clonidine, NIH 9549, MCV 4155, MCV 4183, UM 1151)
See 2-(2,6-Dichloroanilinoc)-2-imidazoline hydrochloride
NIH 9575 (MCV 4156)
See cis-(+)-3-(Octahydro-2-methyl-1H-2-pyridin-4a-yl)phenol,(Z)-
2-butenedoic acid salt
NIH 9576 (MCV 4157, UM 1242)
See cis-(-)-3-(Octahydro-2-methyl-1H-2-pyridin-4a-yl)phenol,(Z)-
2-butenedoic acid salt
423
NIH 9577 (MCV 4159)
See cis-(+)-3(Decahydro-2-methy1-4a-isoquinolinyl)phenol,
butenedoic acid salt
(Z)-2-
NIH 9578 (MCV 4163)
See cis -(-)-3-(Decahydro-2-methyl-4a-isoquinolinyl)phenyl,
butenedoic acid salt
(Z)-2-
NIH 9580 (MCV 4158)
See 1-(1-Phenylcyclohexyl)piperidine hydrochloride
NIH 9585 (MCV 1218)
See N-Cyclohexylmethylnorketobemidone hydrobromide
NIH 9596 (MCV 4161)
See (-)-trans -5,6,6a- beta,7,8,9,10,1Oa-alpha-0ctahydro-1-acetoxy-
9-beta-hydroxy-6-beta-methyl-3-(5-phenyl-2-pentyloxy)-phenan-
thridine hydrochloride
NIH 9597 (MCV 4162)
See (-)-trans-5,6,6a-beta,7,8,9,1O,1Oa-alpha-Octahydro-l-acetoxy-
9-beta-hydroxy-5,6-beta-dimethyl-3-
phenanthridine hydrochloride
(5-phenyl-2-pentyloxy)-
NIH 9612 (MCV 4167)
See dl-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
NIH 9613 (MCV 4168)
See (+)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
NIH 9614 (MCV 4169)
See (-)-9-Hydroxy-4,7-dimethyl-C-homobenzomorphan hydrobromide
NIH 9622 (MCV 4174)
See 3-Hydroxy-6-oxo-7- alpha ,8-beta-dimethyl-B/C-cis-N-cyclobutyl-
methylmorphinan
NIH 9623 (MCV 4174)
See 3-Hydroxy-6-oxo-7-alpha-methyl-B/C-trans-N-cyclopropylmethyl-
morphinan hydrobromide
NIH 9624 (MCV 4175, UM 1258)
See 1-[(2- alpha,6-alpha,11S)-dl-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-3,6-methano-3-benzazocin-11-yl)]-3-octanone
methanesulfonate
NIH 9625 (MCV 4176)
See 1-[(2-alpha,6-alpha,11S)-dl-1-(1,2,3,4,5,6-Hexahydro-8-hydroxy-
3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)]-5-methyl-3-
heptanone methanesulfonate
NIH 9627 (UM 1190)
See dl-Spiro((11,1-dimethyl-3-ethyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(pentylpiperidine))hydrobromide
NIH 9629 (UM 1184)
See Naloxone methobromide
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NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
9630 (UM 1185)
See Naltrexone  methobromide
9637 (UM 1195)
See S-N-sec-Butylnormorphine
9648
biological evaluation for dependence liability, 292
9653 (MCV 4180)
See 3-Allyl-9- beta-methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
hydrochloride
9654 (MCV 4184)
See 3- n-Amyl-9- beta -methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
hydrochloride
9655 (MCV 4182)
See 3-Methyl-9-beta-methoxy-9-phenyl-3-azabicyclo-[3.3.1]nonane
citrate hemihydrate
9673
biological evaluation for dependence liability, 294
9689 (MCV 4184)
See Yohimbine hydrochloride
9701 (UM 1202)
See 14-beta-Mercaptomorphine hydrochloride hydrate
9702 (UM 1203)
See 14-beta-Mercaptocodeine
9703 (UM 1205)
See 14-beta-Acetamidocodeine-6-acetate
9704 (UM 1205)
See 14-beta-Chloroacetamidocodeine-6-acetate
NIH 9705 (UM 1206)
See 14-beta-Acetamidomorphine-6-acetate hemihydrate
NIH 9706 (UM 1207)
See 14-beta-Aminocodeine-6-acetate
NIH 9707 (UM 1208)
See 14-beta-Chlorocodeinone
NIH 9708 (UM 1209)
See 14-beta-Chloromorphinone
NIH 9709 (UM 1210)
See 14-beta-Bromomorphinone
NIH 9712 (NIH 7380, UM 136, UM 1211)
See (-)-Galanthamine hydrobromide
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NIH 9725 (MCV 4188, UM 1213)
See L-Tyrosyl-D-alanylglycyl-L-N- alpha-ethylphenylalanine  amide
acetate
NIH 9726 (MCV 4191, UM 1214)
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
NIH
See N-[4-(Methoxymethyl)-1-2-(2-thienyl)ethyl-4-piperidinyl]-N-
phenylpropanamide: 2-hydroxy-1,2,3-propane-tricarboxylate (1:1)
9729 (UM 1215, MCV 4193)
See 4-(Acetoxyphennyl)-4-(1-acetoxypropyl)-1- n-pentylpiperaine oxalate
9733 (MCV 4194, UM 1230)
See (-)-Nicotine di-1-tartrate
9734 (MCV 4198, UM 1219)
See dl-Spiro-(1,3-diethyl-1-methyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(1-pentylpiperidine) hydrobromide
9735 (MCV 4195)
See N-Cyclopropylmethyl-7,8-dihydronormorphinone
9738 (MCV 4199)
See 2-Nitronaltrexone
9739 (MCV 4200)
See 2-Nitronaloxone
9740 (MCV 4201, UM 1220)
See N-(2-Methoxyethyl)norketobemidone oxalate
9741 (UM 1221.)
See N-2-Hexylnorketobemidone hydrobromide
9742 (UM 1222)
See Spiro-(1,1-dimethyl-3-ethyl-7-hydroxy-1H-2-benzopyran)-4,4'-
(1-allylpiperidine) hydrobromide
9743A
biological evaluation for dependence liability, 292
9751 (MCV 4202, UM 1228)
See (2-alpha,6-alpha,11S)-(+)-1-Cyclopentyl-5-(1,2,3,4,5,6-hexahydro-
8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-y1)-
3-pentanone methanesulfonate
9752 (MCV 4203, UM 1229)
See (2-alpha,6-alpha,11S)-(-)-1-Cyclopentyl-5-(1,2,3,4,5,6-hexa-
hydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-
yl)-3-pentanone methanesulfonate
9757 (MCV 4204, UM 1231)
See d-Propoxyphene hydrochloride
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NIH 9769 (UM 1232)
See N-Pentylacetate norketobemidone
NIH 9770 (UM 1233)
See N-(2-Ethoxyethyl)norketobemidone oxalate
NIH 9771 (MCV 4205)
See 4-(1-Hydroxypropyl)-4-m-hydroxyphenyl-1-methylpiperidine
NIH 9772
biological evaluation for dependence liability, 292
NIH 9789 (UM 1237)
See 5-Hydroxypentylnorketobemidone hydrobromide
2-Nitronaloxone (NIH 9739, MCV 4200)
mouse analgesia, 322-323
2-Nitronaltrexone (NIH 9738, MCV 4199)
mouse analgesia, 322
dl-trans-5,6,6a-beta,7,8,9,1O,1Oa-alpha-Octahydro-1-acetoxy-9- beta-
hydroxy-6- beta-methy1-3-(5-phenyl-2-pentyloxy)-phenanthridine hydro-
chloride (NIH 9513, UM 1159)
biological evaluation for dependence liability, 293
self-administration by monkeys, 342
(-)-trans-5,6,6a-beta,7,8,9,1O,1Oa-alpha-Octahydro-1-acetoxy-9- beta-
hydroxy-6-beta-methy1-3-(5-phenyl-2-pentyloxy)-phenanthridine hydro-
chloride (NIH 9596, MCV 4161)
biological evaluation for dependence liability, 293
dependence studies in monkeys, 309
mouse analgesia, 309
(-)-trans-5,6,6a-beta,7,8,9,1O,1Oa-alpha-Octahydro-1-acetoxy-9- beta-
hydroxy-5,6- beta-dimethyl-3-(5-phenyl-2- pentyloxy)-phenanthridi hydro-
chloride (NIH 9597, MCV 4162)
biological evaluation for dependence liability, 293
dependence studies in monkeys, 310
mouse analgesia, 309-310
cis-(-)-3-(Octahydro-2-methyl-1H-2-pyridin-4a-yl)phenol,(Z)-2-
butenedioic acid salt (NIH 9576, MCV 4157, UM 1242)
biological evaluation for dependence liability, 294
dependence studies in monkeys, 305-306
depression of smooth muscle twitch, 365
displacement of stereospecific 3H-etorphine binding, 365
mouse analgesia, 305, 365
cis-(+)-3-(Octahydro-2-methyl-1H-2-pyridin-4a-yl)phenol,(Z)-2-
butenedioic acid salt (NIH 9575, MCV 4156)
biological evaluation for dependence liability, 294
dependence studies in monkeys, 305
mouse analgesia, 304
427
Opiate abuses
effects of law enforcement activity, 199-204
Opiate detoxification
clonidine vs. methadone, 89-94
Opiate receptors
Nathan B. Eddy Memorial Award lecture, 1-10
doxpicodin affinity for, 79
Oxazepam
hot plate test, 299
Pain
treatment in cancer patients with heroin and morphine, 213-219
Parenting
in methadone-maintained women, 380-386
Parturition
role of endorphins, 264-271
Pentazocine
analaesia, 73, 298-299, 331
vs. nalbuphine and butorphanol: relapse and substitution in
morphine-addict rats, 138-144
d-Pentazocine
inhibition of 3H-etorphine stereospecific binding, 329
l-Pentazocine
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